Life Science in Sweden

research invest innovate develop

othic

% black

care

global

health

Life Science in Sweden

science

Life Science in Sweden

Published by Horn Forlag AS/Horn Publishing Ole Deviksvei 4, NO-0666 Oslo, Norway Tel.: +47 22 88 19 30 Fax: +47 22 65 40 40 mail@hornonline.com www.hornonline.com Managing Director and Publisher Espen Edvardsen General Manager Anders Moe (anders@hornonline.com) Life Science in Sweden © Copyright 2013/2014 Horn Forlag AS All Rights Reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording or any other information storage and retrieval system, without prior permission in writing from the publisher.

Disclaimer Horn Forlag AS assumes no responsibility for material sent to us by the companies presented in this book. The companies themselves are responsible for ensuring that the text and pictures comply with national and international law.

Managing Editor Hege Solberg Design and Layout Cecilie H. Haugfos Written by Totaltekst DA Profile Reservation Chelsea Ranger (chelsea@hornonline.com) Jenna Peaty (jenna@hornonline.com) Thomas Bjällhag (thomas@hornonline.com) Cameron Leslie (cameron@hornonline.com) Printed by Livonia print SIA, Latvia

2

Special thanks to SwedenBIO, Swedish Medtech, Swedish Labtech, Swecare, LIF, Business Region Sweden, Lund University, Invest in Skåne, Medicon Village, Det Medicinska Malmö, Business Region Göteborg, GU Holding, Lansstyrelsen, Uppsala University, Business Region Stockholm, Biotech Umeå, CMTF, New Tools for Health, Business Region East Sweden, Bio Partner UK, EBD Group, Venture Valuation, shutterstock.com

Life Science in Sweden

Espen Edvardsen Managing Director Horn Publishing

H o r n P ublishing S e r ving busine ss wo rldw ide This publication pays tribute to the inspiring history of the life science industry in Sweden and to the technological innovations that have shaped it.

We sincerely hope you will find the editorials and forewords interesting and useful. More importantly, we hope you will take note of the wealth of information on companies offering products and services that may be relevant to your needs.

The book is distributed free of charge throughout the world, and is available at a number of important trade fairs and conferences related to the industry, such as Bio-Europe, Nordic Life Science Days, BIO International, and more.

Additional copies are available on request from Horn Publishing, which also publishes similar books on a range of business sectors and industries in several countries.

This is truly an inspiring and challenging industry to work with, and Horn Publishing wishes to thank all our clients for participating in the book!

For further information, see www.hornonline.com Enjoy the book!

3

Contents Focus on Sweden

6

Forewords: Business Sweden ............................................ 8 SwedenBIO .................................................... 10 SwedenBIO Award 2013 ............................... 12 Swecare ......................................................... 14 Swedish Medtech .......................................... 16 LIF ................................................................... 18 Swedish Labtech ........................................... 20 Editorial ............................................................... 22 Companies .......................................................... 32

Focus on Umeå

74

Forewords: Biotech Umeå ................................................

CMTF ...............................................................

Editorial ...............................................................

Companies ..........................................................

76 80 82 86

Focus on Stockholm-Uppsala 92 Forewords: Länsstyrelsen Stockholm .............................. 94 Stockholm Business Region Development .. 96 Uppsala University ........................................ 98 Editorial ............................................................. 100 Companies ........................................................ 106

co nte nts

Indexes

4

Alphabetical index ............................................ 266 Categorical index................................................ 274

Focus on East Sweden

148

Forewords: East Sweden Region . ..................................

New Tools for Health ..................................

Editorial .............................................................

Companies ........................................................

Focus on Gothenburg

166

Forewords: Business Region Göteborg ..........................

GU Holding . .................................................

Editorial .............................................................

Companies ........................................................

Focus on Skåne

150 152 154 158

168 170 172 176

192

Forewords: Invest in Skåne ............................................ 194 Lund University ............................................ 196 Det Medicinska Malmö ............................... 198 Medicon Village AB ..................................... 200 Editorial ............................................................. 202 Companies ........................................................ 206

Focus on Europe

236

Forewords: EBD Group ....................................................

Venture Valuation ........................................

BioPartner UK ...............................................

Companies ........................................................

238 240 242 245

Fo c u s on S wed e n: Addtech AB.....................................................................................32 Agilent Technologies Sweden AB..................................................34 AkzoNobel.......................................................................................36 Alkit Communications....................................................................38 Arthur D. Little AB...........................................................................40 AstraZeneca ...................................................................................41 Avena Partners...............................................................................42 Brann AB.........................................................................................44 Etteplan . ........................................................................................45 FOI Swedish Defence Research Agency.........................................47 KOMMUNICERA COMMUNICATIONS.................................................48 Late Phase Solutions Europe AB....................................................50 Linde Healthcare.............................................................................52 Milton Medtech AB.........................................................................53 Nanomed North..............................................................................55 NDA Group......................................................................................56 Pall Norden AB...............................................................................58 Proffice Life Science AB..................................................................60 QIAGEN AB......................................................................................62 Silentia AB.......................................................................................65 Symbioteq Kvalitet AB....................................................................66 TFS Trial Form Support....................................................................68 Unimedic AB...................................................................................71 World Courier ............................................................................... 72

Fo c u s on U m eå: Medicvent AB.................................................................................86 Techtum Lab AB..............................................................................87 Umetrics AB....................................................................................89 Umeå Care......................................................................................90

Fo c u s on Stock ho lm -U p p sala: Abera Bioscience AB.................................................................... 106 AlphaHelix Technologies AB....................................................... 107 AlzeCure....................................................................................... 108 AroCell AB.................................................................................... 109 Axcentua Pharmaceuticals AB.................................................... 111 Biomotif AB.................................................................................. 112 BioThema AB............................................................................... 114 Bluefish Pharmaceuticals AB...................................................... 115 CMA Microdialysis AB.................................................................. 116 Cobra Biologics............................................................................ 117 Corline Systems AB...................................................................... 118 Diamyd Medical AB..................................................................... 119 Elekta AB...................................................................................... 120 Episurf Medical AB....................................................................... 121 GE Healthcare Bio-Sciences AB................................................... 123 Karolinska Development ............................................................ 124 Karolinska Institutet Science Park............................................... 126 LINK arkitektur AB....................................................................... 127 Medivir......................................................................................... 128 ModPro AB................................................................................... 129 Premune...................................................................................... 130 Q-linea AB.................................................................................... 131 Ridgeview Instruments AB......................................................... 132 Senzime AB.................................................................................. 133 Sigolis AB..................................................................................... 134 Thurne Teknik AB......................................................................... 137 Uppsala Cancer Clinic................................................................... 138 Uppsala Care................................................................................ 140 Vironova AB................................................................................. 142 Vironova Biosafety AB................................................................. 143

Viscogel AB.................................................................................. 144 Xbrane Bioscience AB.................................................................. 145 XSpray Microparticles AB .......................................................... 146 Zula Diagnostics AB ................................................................... 113

Foc us on East Sweden: CMIV ........................................................................................... 158 New Tools For Health.................................................................. 160 NovaMedTech.............................................................................. 161 Phil Med Alliance AB................................................................... 162 Wolfram MathCore .................................................................... 165

Foc us on Gothenburg: ABIGO Medical AB....................................................................... 176 Bellman & Symfon AB................................................................. 178 Biognos AB................................................................................... 180 Business Region Göteborg AB..................................................... 181 CRC medical AB............................................................................ 182 Getinge Infection Control AB...................................................... 184 GU Holding AB............................................................................. 187 Medfield Diagnostics .................................................................. 188 Meducati AB................................................................................. 189 Unfors Raysafe............................................................................. 190

Foc us on Skåne: Aventure AB................................................................................. 206 Det Medicinska Malmö............................................................... 207 Fagerström Pharma Systems AB................................................. 209 Genovis AB................................................................................... 210 ImaGene-iT AB............................................................................. 212 ImmuneBiotech AB..................................................................... 213 Invest in Skåne............................................................................ 214 Labjoy AB..................................................................................... 216 LifeAssays AB............................................................................... 217 Medeon AB.................................................................................. 218 Medicon Village AB..................................................................... 219 Mercan AB.................................................................................... 220 Ori Medical................................................................................... 221 PolyPeptide Laboratories (Sweden) AB..................................... 223 Promech Lab AB.......................................................................... 224 Redoxis AB................................................................................... 226 Science And Innovation AB......................................................... 227 Skåne Care AB............................................................................. 228 SPAGO Imaging AB...................................................................... 230 The Faculty of Medicine at Lund University............................... 232 Truly Translational Sweden AB.................................................... 233 Zelmic AB..................................................................................... 235

Foc us on Europe: Almac........................................................................................... 245 Aqua Bio Technology ASA........................................................... 246 beòcarta Ltd................................................................................. 248 Biolink Group AS.......................................................................... 249 Biotechpharma UAB.................................................................... 250 CytoVac A/S................................................................................. 251 Dako Denmark A/S..................................................................... 252 Ergolet . ....................................................................................... 253 Iduron........................................................................................... 255 Niels Clauson-Kaas A/S............................................................... 256 Scottish Development International...................................259/261 SIRION Biotech GmbH.................................................................. 263 Vetter Pharma International....................................................... 264

5

Focus on Sweden

Focus on Sweden

6

Focus on Sweden

7

Focus on Sweden

Foreword by Anders Hallersjö, Vice President Business Sweden

Sweden has adopted a very successful approach to make our healthcare system effective, which I would like to tell you about. This approach is being put to use by hospitals and care providers, by regulatory authorities, by the Swedish industry, and by research and education institutes.

foreword

Drawing on years of trial and error and step-by-step improvements we have forged a common understanding and built a fund of intellectual and structural capital based on four core values that define the Swedish approach.

8

1. Providing quality care - means focusing on the patient’s needs. Every action in the healthcare system must be for the patient’s good.

2. Being efficient - means mixing the right skills and resources throughout the healthcare system, so that we can deliver the right care at the right time.

3. Being generous - means that we strongly believe that people will be healthier if the healthcare system is generous and includes everyone. The right to treatment applies to all individuals. No patient is more important than another. Funding is allocated centrally, but healthcare providers are both public and private.

4. Being curious - means that we never stop searching for knowledge. The Swedish healthcare is very technologyintensive and innovation-based.

The Swedish approach strives to combine all stakeholders in a larger system that forges mutually beneficial partnerships.

But as we all know, an approach must also transfer into

clinical practice to make a real difference. In Sweden this transition is handled efficiently with excellent outcomes, which show that Swedish healthcare produces some of the best results in the world.

But these results must come at a high price, you may think?

Looking at our experience, the answer is “no”. Actually, it is the other way around. Sweden spends ONLY 9% of our GDP on healthcare. In relation to the results, this is low compared to most other countries in the EU, as well as to the USA. We know that comparing healthcare systems is not easy, yet these figures tell us we must be doing something right.

The innovative climate surrounding Sweden’s healthcare system is in part due to one person whose name will sound familiar: Alfred Nobel. The Nobel Prize is the foundation on which the Swedish innovation model stands, including health and medicine. A great example is Karolinska Institutet – one of Europe’s leading universities and a major contributor to all medical research and development in Sweden – as well as numerous initiatives worldwide. Karolinska Institutet is in fact the foremost medical institute outside the US. Every year it appoints the Nobel Prizes in Physiology and Medicine.

The Nobel Prize has created a collaborative innovation climate in Sweden where all parties act responsibly with an open-minded and boundary-spanning approach. Working in symbiosis, you might say. We have a long tradition of close cooperation between academia, clinical practice and industry. This means that industry takes responsibility for research – and that academics work as entrepreneurs.

Focus on Sweden

An attitude that has fostered many innovations: • The Leksell Gamma Knife has made it possible to treat brain tumors without having to actually enter the brain.

• The catheter coating has reduced the risk of bacteria spread on hospitals by more than 50%.

• The world’s first virtual autopsy table provides a digital medical visualization, making it possible to perform a full autopsy without invasive procedures.

• The Turbuhaler has improved the lives of people who suffer from asthma and allergies.

• Professor Brånemark’s invention - the titanium screw integrates with bone and has transformed dental surgery (as well as the chances of patients being able to eat ”an apple a day” once again).

In many ways our nation has become a greenhouse for innovation and discovery. Sweden files a comparatively high ratio of approved patents. We are among the world’s top five countries in the number of patents related to pharmaceuticals, medical technology and biotechnology per capita. When it comes to publishing scientific articles in medicine and bioscience, we are in top three in the world per capita.

Business Sweden is a merger of the Swedish Trade Council and Invest Sweden. With offices in 57 countries and in every region in Sweden, we facilitate for Swedish companies to grow internationally and for foreign actors to invest in Sweden.

Our aim is to strengthen and promote Sweden as an attractive, innovative and competitive business partner.

We support Swedish companies in reaching export markets and create business opportunities for small- and mediumsized enterprises to grow internationally. We also facilitate for foreign companies to invest in Sweden. Our innovationfriendly climate offers excellent investment opportunities in manufacturing, transport, science, technology, health care, music, design, tourism and other industries.

Business Sweden is owned by the Swedish Government and the industry, represented by the Ministry for Foreign Affairs and the Swedish Foreign Trade Association.

fo rewo rd

We believe the best possible healthcare can be available to more and more people. We believe that it can be done – if we invest in generosity, curiosity, quality and efficiency. And learn how to get more from less. We believe this approach has made our healthcare system world leading. But more importantly, we believe this approach has improved our

chances of living long and healthy lives – being with our friends and loved ones and seeing our kids grow up. Sweden has a name for this approach. We call it SymbioCare - Health

by Sweden™. (www.symbiocare.org)

9

Focus on Sweden

Foreword by Jonas Esktrand, Acting CEO SwedenBIO

foreword

Sweden – the countr y of L ife Scie nce

10

As a destination, Sweden is a country rich in both Life Science history and opportunities. With its strong innovative power and innovation-driven economy, Sweden is highly suitable for knowledge-intensive industry sectors such as the Life Sciences. Being home to the inventor Alfred Nobel and his Nobel Prizes, as well as Carl von Linné and his innovative cataloguing of the world’s flora and fauna, invention is part of our heritage and an important part of our future. Sweden’s life science-friendly environment has fostered innovations that include the ventilator, L-dopa, the pacemaker, gel filtration chromatography, hemodialysis, Losec®, and Xylocain® to name a few, as well as leading companies including Astra, Pharmacia and Kabi. This dynamic environment has attracted international projects like the European Spallation Source and the Human Proteome Atlas.

Many leading global Life Science companies are attracted to Sweden for our expertise and know-how.

For AstraZeneca, Sweden is one of three global R&D centres. The levels of research and high-quality projects among a several hundred small but highly innovative enterprises have led many international companies to establish commercial partnerships with Swedish companies. Today, more than 40,000 people work in the Swedish Life Science sector, at more than 1000 companies, ranging from international Big Pharma, Biotech and Medtech to sole entrepreneurs. A strong innovative drive has enabled many companies to spin off from academia, where entrepreneurship is seen as natural, encouraged by the Researcher Exemption that enables visiting researchers to work without a permit.

The close cooperation between industry, academia and health care is another key success factor.

The numbers speak for themselves: Swedes are successful! Consider the following facts. The Life Sciences industry in Sweden is one of the country’s largest exports. Sweden is ranked number six by the

Focus on Sweden

2013 Scientific American Worldview in terms of overall scores and as the world’s leading country for innovation (Innovation Union Scoreboard report 2013).

With more than 300 ongoing clinical trials (356, according to IFPMA), the Swedish pipeline for drug discovery is robust, diverse, and in all phases, dominated by infectious diseases, cancer and diseases related to the central nervous system.

Without doubt, we will continue to be one of the world’s leading countries in the Life Sciences.

Välkommen!

www.swedenbio.com

fo rewo rd

Welcome to the country where the spirit of Nobel is still going strong. The Life Sciences in Sweden have a lot to offer.

SwedenBIO helps innovative companies succeed!

SwedenBIO is the national organisation working for the benefit of the entire life science sector in Sweden. SwedenBIO is a member-driven, private, non-profit organisation. The main objective is to improve and maintain industry conditions which will support prosperous growth and business development among our 200 member companies. Our members are active in the fields of pharmaceuticals, biotech, medtech and diagnostics. Our mission is to create visibility and interest for the Swedish life sciences and thus support a successful life science industry. A successful industry can heal and help those patients still suffering from unmet medical needs. A successful industry creates jobs and welfare and creates opportunities for a healthier and brighter future. We’ve been doing this successfully for 10 years.

11

Focus on Sweden

12

Focus on Sweden

SwedenBIO Award 2013

Swed is h L i fe S c i e n c e I ndust r y Honor s Role Mod e l s t h ro u g h A n nua l P r i ze The trade association for 200 Swedish life science industry members, SwedenBIO, has for seven years rewarded a prize to highlight a successful company. At the association’s annual general meeting, the 2013 prize was awarded to Affibody. Affibody was awarded the top prize for their long-term work which has established a well-functioning, successful business model where capital is invested in research and development of products based on top world class research. The jury sees this business as a model for other promising companies in the life science industry.

SwedenBIO Award is for companies who can contribute to an increased interest in the industry and can show examples and inspiration of accomplishments and successes beyond normal in the life science industry in the past year. The nominee company should have acted to attract positive publicity for the industry and improving the recognition and image of the life science industry among decision makers and the public in Sweden.

The jury consists of renowned individuals with strong interest in entrepreneurship, enterprise and life science in media, investment, and academia.

SwedenBIO Award is the industry’s own price and include honor, a trophy and an opportunity to present the winners achievements at CEO Summit, a meeting for decision makers in the life science industry.

Previous winners are Vitrolife, Gyros, Aerocrine, BioInvent, CellaVision and Medivir.

13

Focus on Sweden

Foreword by Maria Helling, VD Swecare

foreword

Swe ca re

14

International comparisons put the Swedish health care system in a leading position. The country’s commitment to readily available medical resources has resulted in one of the healthiest populations in the world. Sweden is the home of many world leading companies and also the home of the Nobel Prize, a symbol of our longstanding tradition within research and development. The pacemaker, gamma knife, respirator, artificial kidney, Xylocain, and Losec are just some of the examples of Swedish innovations which have contributed to improving the quality of life for millions of people around the world. Through continuous investments in innovation and improvement across the full range of the health care chain, Sweden strives to further develop as a health care and life science nation. The international interest in the Swedish welfare model is great and has exploded in recent years when issues related to access to health, lifestyle related diseases, a rapidly aging population, antibiotic resistance etc. ended up high on the agenda in most countries.

Focus on Sweden

Finding solutions to the major health care challenges that we face, requires collaboration across the health care sector. Swecare provides a platform where academia, public sector and private sector meet and work together. Joining forces and addressing problems from multiple angles in turn increases collaboration and the international competitiveness of Swedish health care.

fo rewo rd

Swecare acts as a door opener for companies and organizations looking to access ministerial discussion partners, business contacts or collaborators.

Swecare assists ministries and official agencies in their international contacts, and receives foreign delegations visiting Sweden. Through a demand driven approach Swecare also arranges seminars, network meetings, and runs projects within identified focus areas. In its role as a partner to Sida, Swecare’s unique platform is used to enhance and further develop collaboration between stakeholders in Sweden and on developing markets.

Swecare was founded in 1978 jointly by the Swedish government and the health care industry as a semigovernmental non-profit organization. Today, the network of Swecare comprises some 350 Swedish companies and organizations. The members represent the entire health care spectrum – from the small startup company to universities, county councils, and global corporations, working with everything from biotech to medical technology, pharmaceuticals, and health care services.

15

Focus on Sweden

Foreword by Anna Lefevre SkjĂśldebrand, Chief Executive Swedish Medtech

M ed i ca l Tec hnology – the key to sust a ina ble h e a lt h ca re

foreword

For many years Sweden has been a leading country of innovative medical technology solutions.

The pacemaker, stereotactic radiosurgery, the ultrasound, the incubator, the haemodialysis and many other innovations have increased the prospect for healthcare to save, prolong and improve the quality of life of many. Behind these success stories lie a profound cooperation between medtech innovators and healthcare personnel.

16

Medical technology is a broad field that contains everything from large equipment, such as linear accelerators and MR-cameras to smaller products, like syringes, band-aids and incontinent products. IT software and systems used within healthcare and assistive

Focus on Sweden

fo rewo rd

technology, such as wheelchairs, are other Swedish Medtech is the Association for Medical examples of medical technology.

Technology in Sweden. Today we have around 170 member companies, which represent nearly Sweden has around 590 medtech companies 90 per cent of the total turnover of the medical (with five or more employees and a turnover of technology market in Sweden. We continuously minimum 110 000 Euro) that employs around work to ensure that patients will have access 22 000 people. Significant for this industry is to the technology delivering the best possible that a large majority of these companies are treatment and care. In order to achieve this we small. However, it is a prosperous industry strive to foster a good innovative climate for with an export of Swedish medical devices of the medtech industry. We work together with approximately 2,8 billion Euro (2012). Over 90 healthcare providers to further increase patient percent of all production of medical technology safety, encourage innovations and through in Sweden is exported. The domestic market in this create the foundation for a sustainable Sweden is almost 2,1 billion Euro (2009). Among healthcare. the largest Swedish medtech companies you find Getinge, Gambro, Mรถlnlycke Health Care, Permobil and Elekta.

17

Focus on Sweden

Foreword by Anders Blanck, Director-General LIF

T h e researc h- base d phar ma ce ut ica l indust ry

foreword

Sweden is a small country, but it is big in Life Science.

The pharmaceutical industry has a proud history and tradition in this country, with many companies that have been started here, many eminent researchers, including Nobel Prize laureates, big breakthroughs - and important research clusters as well as world renowned universities such as the Karolinska Institutet.

18

The research-based pharmaceutical industry is today one of Sweden’s most important industrial sectors, both for its role in high-quality R&D, but also for production. The trade surplus for pharmaceuticals is among the highest of all Swedish sectors.

Universities and the big pharmaceutical companies spawn startup pharmaceutical and biotech companies, which are important as incubators for cutting-edge technology.

Focus on Sweden

The institutional and regulatory framework for the pharmaceutical industry has several traits that make Sweden stand out. The regulatory authority, Läkemedelsverket (Medical Product Agency), is highly regarded in Europe and one of the allEuropean agency EMA’s most frequent rapporteurs.

The reimbursement authority TLV take a societal perspective of the costs and benefits that a new pharmaceutical brings when deciding whether a given new pharmaceutical will be reimbursed.

Although Sweden is a comparatively high-cost country, many clinical trials have traditionally been conducted here. The reasons include a

As a trade organization, LIF brings together both well-known big multinational firms and the new entrants. We represent our members on a broad number of issues important for the companies.

fo rewo rd

This has meant both savings for the payer and an innovation-friendly climate where new innovative pharmaceuticals can be used to the benefit of patients.

well-functioning healthcare system and unique possibilities for recruitment of patients through an extremely transparent national registration of citizens. Quality registers for different therapeutic areas play an ever growing role for follow-up of therapeutic outcome.

19

Focus on Sweden

Foreword by Ghazal Voghoui, VD Swedish Labtech

Diagnostics - the bridge between healthcare and pharmaceuticals

foreword

The Life Science industry plays an essential role in a well-functioning healthcare system and has an economic importance for the entire society. The diagnostics industry in Sweden has a long history of innovative solutions and with the recent years of rapid technological development we can measure faster using smaller volumes, with increased automation and precision. IgE allergy testing, the first European automated cell counter and point-of-care testing, are some of many Swedish innovations that has modernized today’s healthcare and helped improve many lives.

20

The diagnostics industry can be described as the bridge between healthcare and pharmaceuticals.

A comparatively small cost for diagnostics gives a high quality of life.

Focus on Sweden

Hemocue, GE Healthcare Bio-Sciences, Boule Diagnostics, and Thermo Fisher Scientific (former Phadia) are examples of world leading Swedish diagnostic companies.

As an organization we strive to emphasize the importance of analysis in medical care, research and industry, which we believe is vital for a quality healthcare and prosperous industry.

This life science-friendly climate also enables many innovative companies to grow such as Gyros, PHI and Lundonia Biotech.

fo rewo rd

Swedish Labtech is the trade association for laboratory suppliers. Our around 80 member companies represent the main part of the diagnostic market in Sweden and supply tools to a vast range of customer segments, from healthcare to research institutions and process industry. The cooperation between the industry, the authorities and healthcare providers is the key for a continued successful development.

21

Focus on Sweden

Life Science in Sweden:

innovation plus collaboration

According to a report issued in February 2012 by life science organisation SwedenBIO, Sweden invests more in the life sciences than any other OECD country. Sweden has the third highest number of registered patents per capita in the world and the world’s second highest R&D expenditure after Israel.

Sweden’s innovation leadership was confirmed again with the highest ranking for the third time in a row on the Innovation Union Scoreboard report 2013.

Life science companies are important employers in Sweden.

According to SwedenBIO, the sector in Sweden accounts for 20 per cent of the country’s net exports. SwedenBIO has 200 member companies, which together have more than 15,000 employees, so the total employed in the sector will be even greater. Life science employees are involved in manufacturing, consultancy, product development and/or research and development. State innovation agency VINNOVA put the number of companies in the sector at 1,025 companies with just under 41,000 employees in 2009. Between 1997 and 2010 total employment in the Swedish life science sector increased by more than 40 per cent, which makes it the most rapidly growing business in Sweden.

Roughly 40 per cent of the employees in the Swedish life sciences work in research and development activities. Together with academic researchers and scientists, R&D departments in Sweden produce a large number of reports on clinical research and innovations, including both products and therapies. All major universities are open for clinical research and a large number of spin-offs have been established in science parks in the vicinity of the colleges.

The Swedish life science clusters have a strong international position in clinical research. Sweden is the 12th largest producer of research results in the field of the life sciences and number six in terms of the most cited publications. The country has gained a strong international position in certain fields of research, such as cancer, cardiovascular diseases, stem cell research, implants and IT medicine and the disciplines of molecular biology, neurosciences, immunology and pharmacology. Other areas in which Swedish academic researchers possess outstanding expertise include diabetes, obesity, insulin resistance, atherosclerosis, Alzheimer’s and Parkinson’s.

22

Some outstanding examples of Swedish medical breakthroughs during in the 20th century serve to illustrate the long Swedish tradition of excellence in medical research: the gamma knife, the implantation of the cardiac pacemaker, the artificial kidney, igE allergy diagnosis methods, the Brånemark titanium implant systems and gel filtration chromatography.

Proud traditions Sweden has proud traditions in the life science sector. One reason is the Nobel Prize, which has placed Sweden in the limelight of the global scientific community. In 1895, Alfred Nobel’s testament bequeathed Karolinska Institutet the right to select the Nobel Prize Laureate in Physiology or Medicine.

The first Nobel Prize Award ceremony was held in 1901. Today the Nobel Prize in Physiology or Medicine is awarded by the Nobel Assembly, which consists of 50 professors at Karolinska Institutet. Thanks to this assignment KI has been able to create a global network in the life science field and to supply the Swedish pharmaceutical and medical technology industries with skilled scientists. International publicity has been a benefit in the development of research laboratories and funding scientific programmes.

Focus on Sweden The Royal Swedish Academy of Sciences (Kungliga Vetenskapsakademien) is an independent organisation founded with the aim “to promote the sciences and to strengthen their influence in society”. The Academy awards the annual Nobel Prize in Physics and Chemistry and the renowned Crafoord Prize in Biosciences. The Academy also organises international meetings for researchers and funds grants and scholarships for researchers within all fields of natural science, including medicine.

Investment Year Sweden’s life science sector has a long tradition and an extremely modern outlook. Over the years it has been responsible for the introduction of innovations that are known the world over, but part of the reason for its success has been its practicality and willingness to cooperate, across academic disciplines and across the sectors. 17 Swedish life science organisations joined forces to market Sweden Life Science Investment Year 2013, a year of exposure for partners and partnerships in the areas of pharmaceuticals, biotechnology, diagnostics and medical technology. Major events are held throughout Sweden and the Nordic countries, culminating in Nordic Life Science Days in Stockholm in October.

Their aim is to attract international investors to the sector, demonstrating its investment opportunities and the fruitful collaboration between academia, industry and healthcare. The organisations involved are: Biotech Umeå, Det Medicinska Malmö, Flemingsberg Science, HealthCap, Innovativa Mindre Life Science Bolag (IML), Invest Sweden,

Läkemedelsindustriföreningen (LIF), Medicon Valley Alliance, Stockholm Business Region, Stockholm Science City Foundation, Stockholm-Uppsala Life Science, SwedenBIO, Swedish American Life Science Summit, Swedish Medtech, SwedNanoTech and UppsalaBIO. Exporting expertise Although the life science sector represents a lower value in terms of production and exports than the traditional engineering and forest industries, the Swedish government and governmental organisations have focused strongly on promoting the life sciences, for example through the concept of “SymbioCare”.

Interaction and mutual benefit are some of the key concepts behind the SymbioCare project, which is administered by Business Sweden, the Swedish Trade Council, and strongly supported by the government. The idea is based on an approach to health and medicine which has an interface that is cross-border, integrated and combines all stakeholders in a larger system to stimulate and utilise the resulting synergies.

The goal is to export expertise about how healthcare processes can be integrated between private and public service providers, tax-based funding and the patient as the client, who should get the right treatment at the right cost.

International connections Foreign ownership is very common in the life science sector.

The USA, Switzerland and the UK dominate among the pharmaceutical companies, while many biotech companies

23

Focus on Sweden

have Dutch, German or other foreign owners, for example Chinese or Spanish. International connections are crucial since the size of the Swedish market is limited. The Nordic market is a natural co-operation area. According to the magazine Nordic Life Science, a co-operative project between the Nordic life science organisations, the Nordic countries have started to market the entire region as a single centre of excellence and the regional clusters have initiated a number of joint research and other co-operation projects. One obstacle is a lack of venture capital. The number of life science companies on the Nordic stock markets is very limited, and the interest from investors is rather low. Attempts have been made to attract foreign venture capital firms, for example from Switzerland, but there are still bottlenecks in the financing process.

Instead, international and Swedish investment companies such as IK Investment Partners, Triton, Nordic Capital and KKR have made substantial acquisitions in the field of healthcare and life science services. The yield over time is good and the exit conditions and potential profit are excellent. According to public statistics, 16 healthcare groups with a turnover of SEK 30 billion are owned by private venture capital investors, which corresponds to around 15 per cent of the total turnover.

Examples of venture capital firms that specialise in the life science business are ISEA, Karolinska Development and Teknoseed.

24

A good example for international co-operation is the close collaboration between Sweden and its Nordic neighbours.

This is best symbolised by the Medicon Valley concept in the Øresund region, a cooperative venture between life science companies in Denmark and Sweden. A key element of the internationalisation work is attracting large, global conferences about health-related issues. Sweden is also working actively to increase the number of international clinical studies that are

carried out. Swedish hospitals are also active partners in EUfunded life science projects and a number of researchers from countries outside Europe work at the major university hospitals.

Ethical decision-making Whether at a corporate, academic or public level, Swedish culture is founded on a strong sense of integrity, honesty and ethics. There is extensive experience of integrating ethical aspects in decision-making. With regard to clinical trials, for example, Swedish ethics reviews committees apply very exacting standards.

The Swedish Research Council, Vetenskapsrådet, monitors ethical guidelines, especially for medical research, which is highly regulated. The subject of research ethics also touches on topics such as how to behave towards colleagues, responsibilities to financial partners, the researcher’s role in society (e.g. as an expert) and which subjects should be studied. To avoid fraud and misconduct, a code has been drawn up to guide researchers in their ethics discussions.

On 1 January 2004 the Swedish Act regulating the Ethical Review of Research Involving Humans (SFS 2003:460) was introduced. The law applies to situations such as research that involves physical encroachment on a subject or that is conducted according to a method that may affect the subject physically or psychologically, as well as studies on biological material traceable to specific individuals. It is fundamental that research only be approved if it can be conducted with respect for human dignity and if human rights and fundamental freedoms are constantly safeguarded. A person’s welfare should be prioritised over the needs of society and science.

Research that clearly involves a risk of having an impact on subjects, for example interviews or surveys, should also be examined from the ethical point of view.

Focus on Sweden

A social contract

The role of private companies has grown since the early 1990s.

A number of private hospitals and clinics have been established and parts of the public services have been outsourced. The interchange between private and public-service providers has been supported by the present government. Many local healthcare centres are operated by limited companies or former employees. However, the most advanced medical treatment remains concentrated at the large university and regional hospitals.

The project was nicknamed “Folkhemmet”, a social network covering citizens’ lifespan from the cradle to the grave. The results were stunning and in the 1960s Sweden had reached a level of welfare superior to most European countries. In the early 1970s the oil crisis and globalisation made the model crack and ever since then Sweden has been more or less a country like most others.

The National Board of Health and Welfare sets the goals for the Swedish healthcare system by issuing provisions, guidelines and other general advice. The authority also monitors the actions of service providers and can withdraw their operating licence if necessary. The Medical Product Authority (Läkemedelsverket) in Uppsala is responsible for the pharmaceutical sector, including research and development, approval of new drugs, and monitoring manufacturing. The Dental and Pharmaceutical Benefits Agency (Tandvårds- och Läkemedelsförmånsverket) decides whether a product or dental care procedure should be subsidised or not.

Equality and quality are the key words in the Swedish national healthcare system. A fundamental principle is that all citizens have the right to good healthcare on equal terms, regardless of place of residence or their social or economic standing.

The cornerstone of the Swedish welfare society is the mutual agreement between politicians, employers and the trade unions – a social contract to develop society towards equal opportunities in education, healthcare and social welfare.

The national healthcare system under the Ministry of Health and Social Affairs is governed by the National Board of Health and Welfare (Socialstyrelsen). Tax-financed public healthcare is decentralised into 20 county councils (Landsting), which have taxation powers in their regions. The services are divided into three levels: Hospital care, primary healthcare and psychiatric care. Both private and public-service providers can offer healthcare services.

Financial transfers from the social insurance system to healthcare service providers are administered by Försäkringskassan, a state-governed public insurance company responsible for transfers of funds from the social security system to individuals and service providers. Private healthcare centres and specialist doctors connected to Försäkringskassan can offer subsidised services to all citizens.

Private healthcare insurance is still relatively rare in Sweden.

Around 460,000 Swedes have private insurance. Managers and companies’ key workers or their families are the main customers and the main benefit is faster treatment or operations at private clinics. The public insurance system covers all citizens and ordinary treatment fees are neutral if the private clinic or hospital is linked to Försäkringskassan.

A key test market Over the past six or seven years Sweden has participated in around 11 per cent of all clinical trials carried out within the European Union. In recent years Sweden has represented some 3.5 per cent of all clinical trials performed in the world

25

Focus on Sweden (clinicaltrials.gov). Thanks to various background factors, Sweden is particularly suitable for advanced and complex trials in phase I-II. The population records and health databases are extremely well developed and cover a long period. Personal Identification Numbers (PINs) were introduced in Sweden more than 60 years ago. Tracking a particular population group is easy. The Swedish Medical Products Agency is well regarded and one of the most frequently consulted authorities within the EU.

The Swedish medical birth register was established in 1973 and contains data about the parents and the child. The causes of death register dates back to 1749 and it contains information about the underlying cause of death, for example, smoking, drug abuse, etc. The Swedish cancer register collects information about all newly detected cases of cancer. The National Healthcare Quality Register covers a number of main diseases or groups of diseases. These high quality databases form the basis for a significant amount of life science research.

The availability of epidemiological and quality records qualifies Sweden as one of the best targets for clinical research for developing new therapies. For private life science companies, the Swedish healthcare authorities offer excellent conditions for phase I-III studies. In order to perform a phase I study only registration with the Medical Products Agency is required, for phase IIa limited third-party assessment is needed, while this is mandatory for classes IIb and III. The relationship between costs and quality is extremely favourable, making Sweden a very attractive test market.

Patented procedures The Swedish national patent register was introduced in 1964 and the medical data includes main and secondary diagnoses and surgical procedures. Patents for life science-related inventions can be obtained in Sweden in the same way as in any other European Union member state. The application, which is filed with the Swedish Patent and Registration Office (PRV), may also be made in English to prepare for further international patents.

The alternative is to protect a design, which gives exclusive rights, for example for a dental chair or a tablet shape. This has been successfully applied by AstraZeneca.

The Swedish healthcare providers, medical faculties and the pharmaceutical industry have jointly agreed on a national strategy to promote Sweden as an attractive location for clinical trials and non-interventional studies. The main agreement signed by the Swedish Association of the Pharmaceutical Industry and SKL, the Swedish Association of Local Authorities and Regions, establishes a number of common objectives to be reached. These relate, for example, to the quality, timeliness, ethical standards and costs of conducting clinical trials and noninterventional studies.

26

One famous Swedish patent covers the “Steel kidney” by Dr. Nils Alwall, who invented a dialysis machine which proved a huge international success and the driving force behind the company Gambro, which was founded by Holger Crafoord in 1964. Other famous Swedish medical patents are the “Brånemark” titanium screw together with the osseointegration method, which are used for fixing limbs and teeth, and the blood rocker, a device for preventing blood from clotting in the clinical laboratory, which was invented by nurse Barbro Hjalmarson.

Focus on Sweden Centres of excellence Healthcare services have become one of Sweden’s most contemporary export commodities. The value of services offered to foreign citizens and professional institutions is rapidly increasing, but it is still far from the traditional export blockbusters within the pharmaceutical industry.

All major Swedish university hospitals have opened their doors to patients from abroad. The Sahlgrenska Hospital in Gothenburg offers post-graduate specialist training and healthcare services in co-operation with the public dental services. To organise marketing of the treatment, a company named Sahlgrenska International Care AB has been formed by the county council.

The company also has a subsidiary in Uppsala. One speciality is advanced bone implant systems.

Stockholm Care is owned by Stockholm County Council. The core units are the Karolinska Hospital and the Karolinska Institute, in addition to a number of independent clinics. Among the services offered to global patients are neurosurgery, gamma knife surgery and robotic surgery, organ transplantations, paediatric care, cochlear implants, etc. Stockholm Care also administers the Tobias Registry, which is Sweden’s national stem cell archive.

Medical care, training and the transfer of knowledge to international customers are also offered by the International Care units in Lund (Skåne Care). Uppsala Care and Umeå Care also offer specialised healthcare services. The Swedish government supports their development through the network Cross Border Care, a subdivision of Swecare.

IT for health The term ‘IT for health’ covers a large number of research areas: medical informatics, system development and information access for systems within the healthcare sector. The aim is to improve medical care by meeting the need for IT systems at various levels, from county councils and hospitals to small mobile units for the elderly and nursing homes. IT for health also covers question-and-answer systems for health sites, analysis of search logs on general health websites for the detection of illnesses and the spread of infectious diseases, and automatic e-mail answering systems within health and insurance medicine. IT for health can cover everything from data mining and information access in large databases, consisting of millions of patient records containing symptoms, diagnoses, medication and discharge letters, to advanced medical decision support for risk assessment.

The national strategy for IT Health in Sweden was launched by government innovation agency VINNOVA in 2010. One of the cornerstones of the strategy is to increase the availability of advanced healthcare services in all parts of Sweden thanks to IT medicine. Northern Sweden is a sparsely populated area which cannot maintain the specialist network of the large life science clusters in Sweden. The concept, also called M Health or Mobile Health, is a solution for developing appropriate healthcare services that will be available to all citizens. The investments in IT equipment and structure are huge and new strategic alliances have been formed to guide the development.

In addition, ICT is an increasingly common element of everyday high-tech healthcare. For example, computers are used to monitor critically ill patients in intensive care units. And, when a body scanner is used to detect conditions such as tumours in the early stages, the data from the scanner passes to a computer, where a picture of the inside of the patient’s body is built up.

The latest developments in visualisation have raised this kind of technique to an entirely new level of accuracy. Computing power is vital for such medical advances as the sequencing of genomes – this kind of work poses particular challenges related to the massive size of the data sets involved. In the field of ICT, Swedish ICT provides a link between academia and industry, developing research results into innovations that contribute both to increased competitiveness and business development and to improved quality of life.

Procurement The life science sector is one of Sweden’s major public procurement areas. The government recognises the importance of the segment and in the 2012-2013 budget it allocated SEK 133 million for the years 2012-2015. Of this total, SEK 24 million was earmarked for public procurement innovation, in order to increase the use of public procurement to create better solutions for the public taxpayer-funded healthcare sector.

The public procurement system in Sweden is very transparent.

The county councils are responsible for buying pharmaceutical products, medical appliances and durables through specialised buyers. The county councils have their own distribution centres where durables and non-durables are stored. Most products are bought via general agreements: all interested suppliers are invited to a pre-qualification. The suppliers, who qualify on the basis of an evaluation of technical and financial requirements, are asked to deliver their products or services as sub-orders or on a regular basis.

27

Focus on Sweden E-procurement is becoming increasingly popular. At present well over 50 per cent of the Swedish county councils and a majority of the municipalities have introduced tools for electronic procurement.

Läkemedelsverket, the Medical Products Agency, is responsible for the trade in drugs and medical products. Pharmaceutical companies can apply for pharmaceutical pricing and reimbursement or search the database for pricing and other information from TLV, the Dental and Pharmaceutical Benefits Agency, the authority which determines whether a drug should be subsidised or not. TLV is also responsible for determining retail margins and monitoring profitability in the reformed pharmacy market. Pharmacies are responsible for offering customers the most inexpensive medicinal product when different versions of equal effectiveness are available.

The growth of the private sector Privatisation and outsourcing of healthcare is a process that started in the 1980s and which accelerated in the following decade. Venture capitalists entered the healthcare business in 2000. One example is St Göran’s Hospital in Stockholm, which is owned by Capio, a private European healthcare company. In 2009, the government introduced the concept of private health centres. By the end of 2011, around 284 private centres had been established and new companies have entered the market, for example Aleris, Carema and Attendo. In total 14,400 private companies are active in the healthcare and life science sectors and this number is still growing.

28

The present trend is for the public sector outsourcing of further medical services such as specialist operations, laboratory analyses, etc., to the private sector. Healthcare has proved to be an attractive area for venture capital investments. Insurance companies have also increased their range of private health insurance solutions to match the more diversified offers of private and public healthcare services.

Staying healthier longer Preventive healthcare is also a big issue in Sweden. The word ‘långtidsfrisk’ means ‘long-term healthy’ – rather than long-term treatment of patients, the goal should be to avoid illness and injuries for as long as possible. Services intended to improve the physical and mental status of citizens will be promoted together with traditional healthcare. Sustainability is another emerging issue. Materials and products should be recyclable and environmentally sustainable wherever possible.

In the same way, low consumption of electricity, water and chemicals is desirable.

Another pressing issue is what is known as “the age timebomb”, which is now just around the corner. Sweden was the first country in Europe to experience a baby boom in 1943-44. The resulting demand for health and age-related care services is expected to reach a peak in the period 2022-25. A lack of resources and workforce will push up the age-related care share of the country’s GDP from 4 per cent to 9 per cent and a number of private and public initiatives have been established to meet this threat to the healthcare system.

Focus on Sweden An organised industry

were around SEK 25 billion. Sweden accounts for 0.7 per cent of global pharmaceutical production, with only 0.14 per cent of the world’s population. Still, its healthcare expenditure corresponds to only 9 per cent of total GDP in Sweden, which is clearly below average and indicates highly efficient operations.

The heathcare sector is represented by the semi-governmental non-profit organisation Swecare. It represent the entire spectrum – from small start-up companies to universities, county councils, and global corporations, working with everything from biotech to medical technology, pharmaceuticals and healthcare services. Swecare was jointly founded in 1978 by the Swedish government and the healthcare industry and today around 350 Swedish companies and organisations are part of its network.

LIF, the Swedish pharmaceutical industry organisation, is a member organisation of for the research-based pharmaceutical industry in Sweden, including both importers and domestic producers. According to LIF, the pharmaceutical companies in Sweden invest around SEK 13 billion annually in the research and development of new drugs and therapies. In total more than 200 companies are active in the pharmaceutical field.

The Swedish life science sector can be divided into several main areas: the pharmaceutical industry, the medical technology segment and the biotech segment. Each of these has its own sectoral organisations.

Through the Swecare platform member organisations can access counterparts across the globe. Swecare also arranges international delegation trips, often accompanied by Swedish ministers, offering great collaboration and business opportunities for participating organisations. Other sources of funding are government innovation agency VINNOVA and the Healthcare Technology Alliance (supports innovative investment in new products and services in medical technology).

VINNOVA says that only a few Swedish pharmaceutical companies develop new drugs without using biotechnological tools. “However, not all companies have the development of biopharmaceuticals, i.e. drugs based on large biological molecules such as proteins, as their goal. Rather, the large biological molecules are targets for the drugs developed. The drugs can be small molecules produced by organic chemical synthesis. In some cases, manufacturing, sales and marketing are also performed by the individual company.”

Pharmaceuticals The life sciences in Sweden are dominated by the pharmaceutical industry. The total domestic sales of pharmaceutical products including imported products exceeded SEK 36.7 billion in 2011. Total domestic sales of medical technology products

Two examples, one early, one modern, serve to demonstrate the global reach of the Swedish pharmaceuticals industry. Astra Hässle, now the AstraZeneca Group, introduced the heart drug Seloken ZOC in 1975, which became the world’s most popular beta blocker. In modern times, Nicorette, the leading tool

29

Focus on Sweden for stopping smoking, is also a Swedish invention, produced in Helsingborg by McNeil AB (a Johnson & Johnson Group company).

Medical technology The second largest sector of the Swedish life science industry focuses on medical technology: electromechanical medical devices, anaesthetic and respiratory devices, diagnostic and therapeutic radiation devices, dental and ophthalmic devices and computer-aided diagnostic and care solutions. Implantable devices, medical instruments and electromechanical medical devices dominate the industry. Swedish Labtech is the membership organisation for the instrument and diagnostics area of the medical techology market.

There are currently about 590 medical technology companies with at least 5 employees and net sales of over EUR 1 million (SEK 8.69 million). Some 180 of these companies are engaged in research and development in Sweden. There are also a large number of companies with 0-4 employees, according to Swedish Medtech, the joint organisation for promoting development, research and marketing in the medical technology sector.

Swedish Medtech says that the diversity of the Swedish medical technology industry is reflected in the wide selection of products offered by the production companies. Their range includes X-ray equipment, orthodontic implants, stents, minimal invasive

30

surgery products, pacemakers, equipment for the physically disabled, haemodialysis and disposables. Implantable devices, medical instruments and electromechanical medical devices continue to dominate the medical technology industry.

As the majority of all medtech products on the Swedish market are subject to public procurement, it represents a central business process for the medical technology industry, as it does in the defence products industry. In addition, spin-offs from existing research and development projects mean that the medtech companies face challenges in their internationalisation process. In 2011 Vinnova launched a SEK 600 million programme, “Innovations for Future Health”, to promote innovation and market-driven commercialisation in a number of key areas: preventive healthcare, diagnostics and treatment. The aim is to forecast general and specific needs for healthcare in the decade from 2015-25.

The Triple Helix model might offer a way forward. The threeway collaboration between academia, industry, and the public sector could be a key way of working for the future. “Everything we do should be based on real needs, lead to changes in people’s lives or be motivated by the demand to improve or replace healthcare processes or systems,” commented Magnus Hållander of the Medical Technology Centre in Halland.

Focus on Sweden Biotechnology Biotechnology is the most heterogeneous part of the Swedish life science sector. It is estimated to employ almost 16,000 people in more than 200 companies in the country. Industry organisation SwedenBIO has more than 200 members in all fields of the life science industry. The majority of biotech sector employees are involved in identifying and developing drugs, biotech medical technology, biotech tools and supplies or bioproduction. Other areas are agrobiotechnology, food-related biotechnology and biotech tools and supplies. Numerically the biotechnology sector is dominated by the R&D and manufacturing categories.

The rise of the life science cluster Clusters specialising in the life sciences have grown up in various regions of Sweden. They are based on close-knit networks of organisations, clinical and academic institutions and companies, all with unique skills, which work together across the disciplines, sometimes with national or regional funding support, to create a fertile environment for growth, and an environment where life science research and business go hand-in-hand. Their success relates to their focus on and commitment to excellence in R&D and drug discovery.

Sweden’s per capita spending on life science research is the highest in Europe.

In 2010, SwedenBIO initiated an analysis and benchmarking project about the life science sector in Sweden entitled “International comparison of the Life Science industry climate in Sweden”. The objective was to investigate conditions for the industry in Sweden on an annual basis in order to generate a baseline for monitoring the development of the sector. According to SwedenBIO, its analysis conducted clearly shows that the country has strong innovative power and is an innovationdriven economy with conditions suited to knowledge-intensive industry sectors such as the life science sector. Nevertheless, there are a number of indicators and structural changes which need to be taken into consideration to prevent Sweden having a declining life science industry for its SMEs.

Swedish universities have specialist expertise in most of the segments of life sciences: discovery, research, development and manufacture of therapeutics; diagnostics; medical devices and platform technologies. Each of the regional clusters also includes specialist suppliers of products and services which support or are related to that centre’s particular specialism.

Unique specialist expertise can cover areas ranging from cancer and diabetes research to medical devices and stem cell therapies, drug discovery in infections and metabolic diseases, immunology and neuroscience, as well as advanced tools for diagnostics and bio production. Sweden’s life science centres of excellence are famed for the high standards of their clinical trials and, in addition, they have built up world-class biobanks, including the world’s largest twin registry at Stockholm’s Karolinska Institute.

31

Focus on Sweden

Addtech Life Science

Li fe Sc i en c e Com m erci a l iz at i on

Diagnostics, Medical and Process Technology and Research.

32

”We owe our success to the combination of each individual company’s smallscale, niched knowledge and to our collective wisdom as one of the biggest Life Science businesses in the Nordic Region” Artur Aira, CEO Addtech Life Science

Focus on Sweden

Added Value through knowledge Addtech Life Science is one of four business areas in the Addtech technology trading group, and consists of more than 30 operating companies.

The Life Science business area accounts for approximately 25% of the Groups total annual sales; about SEK 5 billion.

Addtech Life Science is one of the biggest independent companies within Life Sciences business in the Nordic Region  with a turnover of around 1,4 billion SEK and more than 500 employees The companies within Addtech Life Science enjoy strong market positions in their respective areas of operation and, thanks to the ever increasing knowledge and technology content of their products; they are key partners for customers and suppliers. Being part of the Addtech technology trading group allows the individual companies to focus and further enhance their core business, while enjoying all the benefits of being part of a great network of cutting-edge companies in the industry.

Divided into four business units; Diagnostics, Process Technology, Biomedical &Research and Medical Technology, the companies in the Addtech Life Science area offer a broad range of products and services and are able to create added value for the customers by providing knowledge-intensive services such as technology and application knowledge, consulting, training, support and maintenance.

Addtech Life Science companies

BioMedical & Research: BioNordika Group Holm & Halby AS Bergman Labora AB LabRobot Products AB

Process Technology: Norsk Analyse OmniProcess AB Insatech AS Kouvo OY Medical Technology: Active Care AB

Addtech AB Sturegatan 38, SE-11436 Stockholm Tel.: +46 8 54 54 14 00 Fax: +46 8 470 49 01 info@addtech.com www.addtech.com

Li fe S ci e n ce Co mm e rci a l iz at i on

Diagnostics Triolab Group ImmunoDiagnostics OY Electra-Box Group

33

Focus on Sweden

Agilent Technologies

Bi ote ch n o l ogy

Advance Your Life Science Research

34 2

bIOThERApEuTICS

LIquID ChROMATOgRAphy

CLINICAL RESEARCh

LC/MS

METAbOLOMICS

MICROARRAyS

INFORMATICS

ATOMIC SpECTROSCOpy

pROTEOMICS

X-RAy CRySTALLOgRAphy

INTEgRATED bIOLOgy

gC/MS

ELECTROphORESIS

MATERIALS

MOLECuLAR SpECTROSCOpy

FORENSICS & TOXICOLOgy

AuTOMATION SOLuTIONS

FOOD SAFETy

COLuMNS

phARMACEuTICALS

gAS ChROMATOgRAphy

ENvIRONMENTAL

NMR

gENOMICS

Focus on Sweden

achieve greater

results

Life Sciences laboratories worldwide benefit every day from Agilent’s solutions. Researchers use Agilent tools along the entire discovery value chain, from basic biological research to uncover possible causes of diseases, through discovery, development and manufacturing of drugs..

Agilent’s Life Sciences portfolio is one of the broadest available, with world-leading products that help solve any scientific problem – from routine to complex. Our innovations in biotechnology, genomics, metabolomics, proteomics and cellular and systems biology drive new understanding of living systems. Agilent systems and accessories include automation, liquid and gas chromatography, mass and NMR spectrometers, X-ray Crystallography, molecular and atomic spectroscopy as well as DNA microarrays and scanners, thermal cyclers, reagents and software.

To see more, visit www.agilent.com/chem/info.

© Agilent Technologies, Inc. 2013

Bi otec h n ol o gy

Agilent Technologies Sweden AB P. O. 52, BoxKronborgsgränd 52, Kronborgsgränd Box 23 23 SE-164 Kista, Sverige 164 94 94 Kista, Sverige Tel.: +46 (0)8-506 489 50 Fax: +46 (0)8-506 489 51 customercare_sweden@agilent.com www.agilent.com/chem/info

35 3

Focus on Sweden

Bi ote ch n o l ogy

Kromasil by AkzoNobel

36

Focus on Sweden

Kromasil – At the service of the pharmaceutical industry Kromasil is a totally spherical, high performance silica for HPLC purification of many substances, from the smallest organic compound to multi kDa proteins, in analytical up to industrial process scale separation.

Kromasil is offered with various surface chemistries to be used in most chromatographic modes, including reversed phase, normal phase, supercritical fluid chromatography or chiral chromatography. For all chemistries and column sizes available, check our website.

We care about your process For over 25 years, our business concept has been to provide the industry with superior HPLC silica for the best performance and economy in the purification of pharmaceuticals. We know how dramatically the economy of your total process can be improved by using the right silica under the right conditions.

Kromasil has founded its reputation on an outstanding mechanical stability that allow it to withstand repetitive repacking in DAC systems without loss of efficiency or back pressure increase. Also, its chemical stability will allow you to run many injections cycles on the same packing material.

Furthermore the specially engineered silica particles provide a very high available surface that ensures a high selectivity and loadability. These are the major properties that will help you leverage your process economy.

With Kromasil comes a dedicated partner that will assist you in all matters from the packing of DAC columns to all aspects of silica utilization, as well as process development and optimization.

The production of Kromasil is ISO 9001 certified and we are proud of the batch-to-batch reproducibility that has been achieved for decades.

We care about your lab Kromasil has also its place in your lab. Not only for lab-scale process development but also for all-purpose analysis. Kromasil columns are well known for their robustness and long lifetime.

That is why, with diameters from 2.1 mm to 50 mm, they are popular as analytical and semi-prep columns.

With a particle size down to 1.8 μm, small-sized Kromasil columns will comfortably fit in UHPLC instruments for extremely fast methods.

As we usually say, some things are too important to let anybody pack.

Therefore, all Kromasil columns are prepared by our care; individually packed and tested with full traceability.

Contact us!

Find out more by yourself: information about our products and distribution channels can be found on our website. Or tell us your needs and we’ll be glad to provide answers and suggestions!

AkzoNobel Separation Products SE-445 80 Bohus Tel.: +46 31 58 70 00 Fax: +46 31 58 77 27 Kromasil@akzonobel.com www.kromasil.com

Bi otec h n ol o gy

Kromasil is a brand of AkzoNobel, the largest global paint and coatings company and a major producer of specialty chemicals with headquarters in Amsterdam, the Netherlands. With 50 000 people in more than 80 countries around the world, we are committed to sustainability, excellence and delivering Tomorrow’s Answers TodayTM.

37

Focus on Sweden

Alkit Communications Life Science and Information Technology by Alkit Communications

Innovative applications of information and communication technology are becoming increasingly important for the advancement of life science. The ability to use and manage information and communication resources in new ways is a significant and critical part of many of the breakthrough results of life science.

Alkit Communications is a research and development company aiming at the creation of advanced information and communication solutions for life science.

Well organized information, based on well defined information structures, are critical to draw the right conclusions to reach new knowledge. This is achieved by developing conceptual models capturing the semantics of information. One example of this is the individual oriented

patient process in health care, where different specialist units, primary care units, municipality units, the individual and relatives have to cooperate to deliver a goal oriented and high quality care. In this context, the possibility to draw correct conclusions from the treatment of large numbers of patients is a source for new knowledge. This is an example of how well defined and structured information makes it possible to interpret and draw conclusions from large amounts of data. Alkit Communications has been an important player in developing the first version of the Swedish information structure for care and nursing commissioned by the National Board of Health and Welfare.

Different types of medical equipment produce a lot of different kinds of data which must be collected, represented, stored and communicated between different systems in order to compile a coherent view of a patient’ complete situation. This is needed to get a relevant information overview and an overall picture, to define adequate activities to influence the condition for the patient.

Well defined information structures and components, supporting the entire health care process of the patient, have been developed by Alkit Communications in order to manage situations with patients having multiple diseases.

The dramatic improvements of computer networks over the last few years have made it possible to design completely new solutions for life science, based on video mediated components and e-health services for home cared patients. One example of this, explored by Alkit Communications, is in the area of neurorehabilitation of stroke patients in the home. Based on Alkit’s technology, a therapist can remotely support patients carrying out rehabilitation activities at home, using real time videomediated communication in combination with specialized video games components based on depth camera technology designed for rehabilitation training. Data about the patient’s performance can be continuously collected and analyzed by the therapist, to monitor the progress of the rehabilitation. The therapist can also remotely participate in the training to give advice and study the patient’s condition directly.

E -H e al t h

Photo: shutterstock

38

Focus on Sweden

Alkit Communications develops advanced solutions for teleconsultations and remote diagnostics over large geographical distances, for patients with different medical conditions, involving both primary care units and specialist units in hospitals. The solutions developed by Alkit are based on high quality video-mediated communication in combination with medical data sharing and collaboration support. Key issues in the design of these systems are integration with different kinds of medical equipment and the ability to customize the systems to the work processes of each telemedical application.

Alkit has for many years delivered solutions to support collaboration between major hospitals in Sweden in the area of pediatric cardiology. This includes multipoint face-to-face communication support in combination with ultrasound and angiography in real time with high quality.

Alkit Communications is also helping cardiology heart centers, such as the Wallenberg Laboratory for Cardiovascular and Metabolic Research, Sahlgrenska Academy, to build tools to train cardiologists in collecting high quality information for the so called Quality Registries.

The Quality Registries store structured information of what treatments have been given to large numbers of patients.

The aim is to create new knowledge about treatment strategies of new and existing methods.

Alkit Communications has developed computer based training tools in the neuroscience field for patients with neurological damages of the brain. The patient can practice compensation strategies to improve everyday functions and abilities after brain damages caused for instance by accidents. The tools can be adapted to the specific brain damages of a specific individual to optimize the training performed by the individual. Based on this work, Alkit Communications is now creating new applications that can support individuals who have diagnoses related to neuropsychiatric disabilities like Asperger’s syndrome to manage the everyday activities of the individual. The tools can also support actors around the individual to improve the management of different kinds of activities, and provide support strategies for unexpected situations.

Actors around the individual can for instance be relatives, teachers, employers, coaches, doctors or therapists, who can support the individual both in the professional life and privately.

Alkit is currently also heavily involved in the development of applications and collaboration solutions supporting industrial development and manufacturing processes of life science equipment for infection control.

Altogether, the different research and development endeavors outlined above promise many new and exciting opportunities for the future advancement of information and communication support for life science applications.

Photo: shutterstock

E - He a lt h

Alkit Communications Aurorum 2, SE-977 75 Luleå Sallarängsbacken 2, SE-431 37 Mölndal Tel.: +46 31 67 55 41 www.alkit.se

39

Focus on Sweden

Arthur D. Little Linking strategy, technology and innovation

Dedicated to the success of our clients Arhtur D. Little is one of the world’s premier management consulting firms with offices in more than 30 countries. To the Healthcare and Life Science industry, we provide management consulting services in: n

Strategy development and implementation

n

Transformation change management

n

Innovation management

n

Performance improvement

n

Opportunity assessment

We offer our clients sustainable solutions to their most complex business problems. We help clients achieve accelerated growth, strong financial performance and sustainable innovation.

Arthur D. Little works with organizations in various phases, from early start-ups to mature companies. We have extensive experience in providing our advice to: n

Biotech companeis

n

Medtech companeis

n

Pharmaceutical companies

n

Healthcare service providers

n

Investors

Many of our clients return to us for guidance year after year, and they continue to rely on us for integrity, insight and lasting value.

For more information, please contact:

Co n s u lt a nt s

Nils Bohlin: Tel: +46 (0)85030 6524. Email: bohlin.nils@adlittle.com Petter Kilefors: Tel: +46 (0)8 5030 6542. Email: kilefors. petter@adlittle.com Anders Johansson: Tel: +46 (0)31 758 1018. Email: johansson.anders@adlittle.com Dr. Ulrica Sehlstedt: Tel: +46 (0)8 5030 6539. Email: sehlstedt.ulrica@adlittle.com Rasmus Jostrup: Tel: +46 (0)8 5030 6505. Email: jostrup.rasmus@adlittle.com

40

Arthur D. Little AB P.O. Box 70434, Kungsgatan 12-14 SE-107 25 Stockholm Tel: +46 (0)8 5030 6500 Fax: +46 (0)8 5030 6502 www.adlittle.com

Focus on Sweden

AstraZeneca

P h a rm a ce u t i ca l

AstraZeneca SE-151 85 Södertälje, Sweden Tel.: +46 8 553 260 00 Fax: +46 8 553 290 00 kontakt@astrazeneca.com www.astrazeneca.com

41

Focus on Sweden

Avena Partners – Building Bridges Avena Partners As three former colleagues (at one time or another), with a wealth of academic and business experience between us, we sat down one afternoon and said – “Lets do this together”. And so it was that Avena Partners was born, from a humble beginning holding meetings and telephone conferences with potential future customers in a car (“Con-in-car” was our first running name). Now we are a successful consultancy with our own office at Medicon Village in Lund.

The Mission Avena’s mission is to help our clients to make the right decisions in order that they can reach their goals reliably, at a lower cost and in less time.

Making the right decisions In life science business, making the right decision requires a full understanding and effective integration of several components. Avena offers a broad knowledge in bridging all the important issues of a commercially successful venture.

In order to be effective and to achieve commercial goals, departments like R&D, business development, internal/external patents and legal must all communicate and coordinate their activities. Inevitably, perhaps, such coordination sometimes involves challenges, not least because different departments have different “languages”.

At Avena, we understand these different “languages” and have a long-standing experience in handling complicated programs. By taking advantage of our strategic skills, you can reduce the risk of misunderstandings between departments, enabling your company to work together in a more integrated and efficient manner. This reduces costs and allows you to reach your goals faster.

Co n s u lt a nt s

Examples on Avena Partners expertise and offer Management of small companies Project leadership Intellectual property guidance (including patent strategies) Business strategies Funding guidance Project evaluations Assistance when starting up new businesses

42

Focus on Sweden

Avenue – Education Avena partners have a long experience in presenting and educating peers, colleagues and students. Avena offers education programs such as; Innovation – what is that To be an Entrepreneur Project evaluation Business – How to start and how to run What is intellectual property?

These are offered as single lectures, half-day or full-day programs.

We also run an entrepreneur program for high school teachers and have provided lectures in basic intellectual property for students at the Faculty of Engineering at Lund University.

Karin Bryder Karin holds a PhD in Medical Science with a focus on Immunology. Her academic work also includes studies of DNA vaccines, virus genetics and protein engineering. She has worked as lab director at Statens Serum Institut, Virology Department, Project manager and IP manager at Alligator Bioscience AB and as CEO of ProNoxis AB. With a special interest and experience in method development and quality assurance, she excels at well-performed analysis. Her extensive experience in the development of routine diagnostics, large and small molecule pharmaceuticals and with patent strategies has given her an appreciation and understanding of the importance of high quality knowledge at every decision point.

Anki Malmborg Hager Anki holds an M. Sc. in Chemical Engineering, a Ph.D. in Immunotechnology and a Pharma-MBA from Falconbury. She is the author of about 30 scientific papers and book chapters, and the inventor on a number of patents.

Being an inventor herself of a technology that forms the basis of a successful biotech company, Anki has the deep insight and invaluable experience in starting up small businesses. From her work for several small biotech companies, both as CEO and board member, and as an investment director, she understands the challenges these businesses face better than anyone.

Eskil Söderlind Eskil´s formal education includes a PhD in molecular biology from Uppsala and an associate professorship at Lund University; he also has an executive Master of Business Administration (MBA) diploma. He is author of several scientific publications and is also named inventor on several commercially successful patents.

Avena Partners Scheelevägen 2, SE-223 81 Lund Tel.: +46 70 683 0858 info@avenapartners.com www.avenapartners.com

Con s u l t a nt s

Eskil has more than 25 years of experience in the life science business area. He has been instrumental in the incorporation of more than 10 different companies and has past and present experience as an Investment Director, CEO and board member. Eskil has broad experience and can help to analyze, structure and comprehensively communicate complex business ideas.

43

Focus on Sweden

Brann – the IP Law Firm that Means Business for the Customers Intellectual Property Law firm Brann helps customers protect their most important competitive advantage: their ideas and innovations. Brann is a key partner throughout the entire lifecycle - from concept formation to commercially viable product or service, as well as valuation and transactions of patents, trademarks, and even complete companies. Relevant business consulting, patents, trademarks, protection of design and Intellectual Property Management are examples of services offered by Brann. In fact, the company is often acting as an intermediary between researchers from academia and companies that are willing to provide funding towards the development of new innovations.

Intellectual property is a very complex area today. Companies as well as inventors compete on a global level and competition is tougher today than ever before. Brann’s consultants are specialists in the field and contribute vital advice; therefore, the company should be contacted as early as possible in the innovation cycle.

“We combine business expertise and extensive industrial experience with in-depth knowledge of how innovations are developed. We usually say that we are the link between researchers and the industry”, states Brann CEO Anders Tangen.

I nte ll e c t u al P rop e r t y & Le ga l S er vi ces

The importance of patents “The patent portfolio is often the most valuable asset that a company has. The greatest wealth rests here, and without it the company would, in most cases, not survive. Protecting the patent portfolio content is the most important thing, and that is exactly what we do”, explains Tangen.

Patents are business tools. By extension, it is important to build a strong brand and a trademark that are well-recognized. When exclusive rights for a specified period expire, such as design protection and patents, the trademark and all that is associated with it still remains.

44

Full-service Intellectual Property Law firm Brann is a full-service Intellectual Property Law firm covering patents, legal advice and business consulting. These are three very different things, but the areas are often combined in the real world which means that expertise in all three is required when protecting a new innovation, for example.

Since Brann’s consultants stem from the industry, they have the essential skills and experience necessary to determine what is realistic and viable in terms of commercialization of innovations. If an innovation is not commercially viable, it must be adapted. Brann can communicate with industrial partners and convey knowledge between academia and industry.

“We have very talented consultants. We recruit regularly and make sure to be updated in terms of expertise. We have about 60 employees today, a close-knit team of colleagues eager to discuss common interests in law, patents, and business development. We secure the most important thing that a company has, i.e. their innovations. Therefore it is important that we maintain a high level of expertise”, Anders Tangen continues.

Strong in Life Science Since the company was established in 1949 innovations within Life Science has been one of the most important areas. Brann initiated

the industrial network “Life Science and Medtech” which has about 500 members in the Stockholm region. It was actually Anders Tangen who started the network in 2006 on behalf of the Chamber of Commerce in Stockholm.

Expanding Business In 2012, Brann opened a branch in Gothenburg, close to western Sweden’s strong life science cluster. “We are expanding all the time and the Gothenburg region is a very interesting area to operate in with many strong and viable businesses, for example in the Life Sciences. We have a growing customer base in the Gothenburg area that we want to serve even better”, Anders Tangen concludes.

Listen to our Customers Brann’s goal is to have the most skilled co-workers and the most satisfied customers in the industry. In a recent survey including more than 200 customers, all customers stated that they were happy or very happy about Brann’s services. Here is a comment from one of our customers: “I have been in the Technology Transfer business since 2004 and during this period worked with several IP law firms from different countries. There has always been a gap between a required level of IP management and protection process and the actual service and understanding provided by the IP law firms. I am very glad to work with Brann AB; the commercial results show that our technologies are very well handled by Brann AB because of the uniqueness and quality of service. I’ve previously worked with several IP law firms providing a decent quality patent draft and follow ups on office actions, understanding the regulations, finding opportunities and being up to date. Unfortunately, in the tech transfer business, this is not enough, we do not “just” need a patent BUT we need a valuable, transferable IP. Therefore it is necessary that the company providing IP related services is able to understand not just the technology but the business and commercial opportunities too. Working with Brann AB this criterion is completely fulfilled, our portfolio started to include accurately and properly managed patents, our IP strategies are not only based on generalities but case specific and business knowledge. We receive very well timed and outstanding quality additional services such as Freedom-tooperate search and analysis, technology / patent valuation and strategic decision support.

Based on all our experiences, we do recommend Brann AB for its outstanding service portfolio.

Brann AB Fleminggatan 7, P. O. Box 12246, SE-102 26 Stockholm Tel.: +46 08 429 10 00 Fax: +46 08 429 10 70 brann@brann.se www.brann.se

Focus on Sweden

Etteplan Smart way to smart products Etteplan provides design and development services for Life Science companies.

Etteplan’s experts have the know-how and expertise to help you along the entire product life cycle from idea generation to product development and production of profitable commercial products. Based on an understanding of your end-user needs and requirements together with our solid business insight, our experts can help make sound and successful development decisions with you.

You get faster results using our Medtech engineering teams. Discover the flexibility you get when developing products with dedicated in-house teams and on-site specialists.For more than two decades, Scandinavian companies have been commissioning our team of experienced engineers to innovate, develop and deliver breakthrough products.

Skills and process Whether you are a start-up company or a large corporation, you can engage our team to provide the skills you need to develop medical devices in MDD Classes I-III EU and FDA. You can be confident that your products’ development will meet the quality management standard for medical devices with our cross disciplinary engineering teams. Etteplan’s ISO 13485 certified operations give you access to dedicated medtech experts and in-house facilities

SUPPORTING FACILITIES

• Project Management • Usability Engineering • Innovation Workshops • Industrial Design • Mechanical Engineering • Hardware/Software Development • Packaging, sterilization, labeling, IFU • Documentation • Quality Management • Regulatory Affairs • Product Registrations

• Innovation Rooms for new ideas • Mechanical and electronic workshops • Rapid prototyping services • Test labs and facilities • Secure in-house project

Etteplan Industry AB Kålsängsgränd 10D, 3tr SE-753 19 Uppsala

Etteplan Industry AB Sperlingsgatan 5A, SE-802 48 Halmstad

Etteplan Industry AB Ideon Science Park Scheelevägen 17, SE-223 70 Lund

Etteplan Gävlegatan 22, SE-113 30 Stockholm Tel.: +46 10 722 40 00 www.etteplan.com

Con s u l t a nt s

OUR SERVICES INCLUDE

45

Focus on Sweden

46

Focus on Sweden

FOI Research for a safer world

FOI, the Swedish Defence Research Agency, has built up a unique competence that can serve as a one stop shop for support of early drug development Some examples of the in-house capabilities available: • Protein characterization and assay development • Macromolecular structure determination and modeling • Quantitative and qualitative analysis of bioactive compounds • In vivo infection models for preclinical evaluation of antimicrobial compounds and vaccines • Models for lung diseases • Models for skin penetration studies • Synthesis of bioactive compounds for preclinical testing and reference compounds for analytical use • Pharmacokinetic studies

At our facility in Umeå we host more than 100 scientists, of which approximately 60 are at PhD-level, who can support you in solving the issues you may have in your project.

Don´t hesitate to contact us!

Mats Strömqvist, Director mats.stromqvist@foi.se +46-90-106600

FOI, Swedish Defence Research Agency SE-164 90 Stockholm Tel.: +46 8 555 030 00 registrator@foi.se www.foi.se

CRO - Co nt ra ct Re se arch O rga n i z at io n

Our techniques include: · IVIS · LC-MS · LC-MS/MS · GC-HRMS · MALDI-MS · NMR · Biological (BSL-3) and chemical safety laboratories

47

Focus on Sweden

KOMMUNICERA COMMUNICATIONS Your natural choice for language services

A language services provider you can trust, with extensive experience in the industry

Members of the Medicon Valley Alliance

About Kommunicera Kommunicera Communications Group is a leading provider of language and content development services to the European business community. We translate, refine and manage content in more than 40 languages.

Kommunicera have been supplying specialised translations and other services to the life science industry for over 15 years. Kommunicera Communications Group works with a comprehensive range of documents and content including protocols, product brochures , SOPs, IFU, patents , websites, reports and internal and external communications for pharmaceutical companies, medical device companies and others in the industry.

We provide European businesses with optimised solutions that best suit their needs and resources, using effective technology integration.

Tra n s l at i o n Se rv i ce s

We work hard to establish long-term relationships with our customers, so we can

48

grow together and work proactively to generate added value.

Focus on Sweden

Quality assurance and standards European Language Industry Association

Kommunicera is one of the founding members of the European Language Industry Association (ELIA), a long-standing member of Eulogia, the European Consortium of translation companies, and a member of the Globalization and Localization Association (GALA).

Kommunicera Communications is ISO 9001 certified and was instrumental in developing the translation industry standard, EN 15038.

specialising in life sciences, manufacturing, power transmission and e-commerce.

KOMMUNICERA COMMUNICATIONS Sockerbruket 17, SE-41451 Gรถteborg Tel.: +46 31 346 15 00 medical@kommunicera.se www.kommunicera.se

Tra n s l at i on Se r v i ce s

We provide translation services for clients in Sweden and around the world,

49

Focus on Sweden

Late Phase Solutions Europe AB Expert in Real World Data and Late Phase Development of Orphan Drugs Increased focus on Orphan Drugs Orphan drug legislation has been in place since 1983 in the USA and since 2000 in Europe. The objective of introducing the legislation was to stimulate and motivate the pharmaceutical industry to develop treatment for patient with rare diseases.

Many companies from small biotech companies to big pharma are today showing a growing interest in developing drugs for rare diseases. Before the legislation was put into place there were only a handful drugs approved for patients with rare diseases. Today almost 450 indications have been approved by FDA in US and about 80 by EMA in Europe.

Challenges related to developing Orphan Drugs There are several challenges involved in developing orphan drugs. The clinical trial design are often one of the most prominent depending e.g. on;

• few available patients

• lack of knowledge of the natural history of the disease and optimal study endpoints.

Many orphan drugs are approved conditionally or under exceptional circumstances with post-marketing obligations for the manufacturer to further establish the safety and long-term benefit of the new treatment and therefore; Real World Data is a fundamental for developing Orphan Drugs;

Co n s u lt a nt s

• Typically safety and effectiveness of orphan drug in the post-marketing phase is demonstrated through registries.

By collecting data into patient registries not only the post-approval commitments can be fulfilled but also increasing knowledge about the rare disease and its optimal treatment

• With so few available patients as for rare diseases it is important to avoid duplication in data collection and a public private partnership is strongly encouraged within the rare disease community.

50

Focus on Sweden

Late Phase Solutions Europe; an Independent International Expert in Real World Data and Orphan Drugs Late Phase Solutions Europe AB provides you with strategic and operational guidance on Late Phase Drug Development with a focus on Real World Data on orphan drugs both from an international as well as national perspective.

Late Phase Solutions Europe has an in-depth expertise in orphan diseases and drugs as well as designing and managing patient registries within the orphan drug area and has a proven track record of successful collaboration with patient registry stakeholders (patient organizations, treating physicians, authorities, payers) by assuring registry output fulfills their different needs as well as the ability to connect pharma business opportunities with patient registry design, management and outcome.

Our offer includes strategic advice, guidance and project management on processes and activities related to Orphan Drug Development and Market Access.

Our Customers Our customers are big pharma companies as well as small startup pharma and biotech companies all with a focus on patients with rare diseases and the high degree on unmet medical needs within this area.

Our Services We provide you with more than thirty years of experience from International Biotech and Pharmaceutical Industry; whereof near twenty in the orphan drug sector and late phase drug development. We have a broad network of international expertise and key stakeholders within the global orphan drug community and can therefore tailor the solution for you by e.g. partnering with relevant stakeholders and an optimal EDC provider/CRO for your specific needs.

Examples on assignments are • Observational studies/ patient registries to collect real world data to fulfill the requirement of conditional market authorization or reimbursements of orphan drugs.

• Guidance and support in establishing data collection frameworks for internationally interoperable multi-purpose usage;

– post approval commitments

– supporting clinical research

– increase knowledge of the natural history of rare disease

– improve diagnosis, treatment and care of patients with rare diseases • Guidance and support in the process of developing and implementing patient registry charters and governance principles in partnership with registry stakeholders as e.g. academia and patient advocacy groups.

The founder of Late Phase Solution Europe AB Elizabeth Hernberg-Ståhl has published numerous scientific papers, contributed to books related to orphan drugs. Soon (October 2013) the book “Orphan drugs: Understanding the rare disease market and its dynamics” (Woodhead Publishing Series in Biomedicine ISBN 1 907568 09 3 ISBN-13: 978 1 907568 09 1 authors Elizabeth Hernberg-Stahl, Miroslav Reljanovic) will be released.

Elizabeth is also a frequent speaker and trainer at many international venues, organized by the industry, patient organization or other stakeholders within the field of rare diseases and orphan drugs.

Con s u l t a nt s

Late Phase Solutions Europe AB Sommarvägen 6, SE-183 60 Täby, Sweden Tel.: +46 703200 117 elizabeth@latephasesolutions.com www.latephasesolutions.com

51

Focus on Sweden

Linde Healthcare – your partner for inspired healthcare. Your assurance. Our understanding.

Working closely with customers for over 125 years, we have always risen to challenges in our pursuit of excellence. Our insight into the issues that shape the reality of our customers drives us to deliver breakthrough products and outstanding services.

Innovating for customers Our customers are the reason we exist and are central to our current and future success. Linde Healthcare aims to innovate in every area of our business in order to retain existing customers, attract new customers and enter new markets.

A passion to excel We have the commitment and drive to pursue everhigher standards through continuous improvement and commitment. Linde Healthcare strives for excellence, with the aim of improving every aspect of our organisation, processes and operations.

Empowering people Our people are given the space to contribute and grow. Linde Healthcare believes in empowering our staff because capable and responsible people create success, both for our customers and our company.

Thriving through diversity

Ph ar m ac e u t ic al

Diversity results in enriched collaboration and enhanced solutions. Linde Healthcare strongly believes that the diversity of our employees, their capabilities, our global footprint and our range of activities help us to understand the issues and pressures within healthcare, and to meet our customers’ evolving needs.

52

Quote: Our aim at Linde Healthcare is always to help our customers to achieve and maintain the highest standards in healthcare.

Linde Healthcare AGA Gas AB, SE-181 81 Lidingö Tel.: +46 8 731 10 00 healthcare@se.aga.com www.linde-healthcare.se

Focus on Sweden

Milton Medtech AB ”Medical technologies from ideas to products” We develop medical devices - and offer: • Project Management • Development of medical device innovations • Patentability investigations • Electronic Designs • Assemblies for research purposes • Risk analysis • Selection of suppliers and production strategy • Packaging, symbols and labels

Services to established medical device companies: • Technical education and training for the sales force • Service of medical equipment • User manuals and service manuals • Translations (English / Swedish)

About us

Operations began in Linköping in 1980 with technical support to researchers at the University Hospital of Linköping. Today, we are four employees with customers throughout Sweden.

We are experts in medical device technologies and have contributed with several patents to our clients. The majority of our commitment is to help innovators and emerging companies on the right track.

Our production has recently moved to new premises: To the former rail station building in Vikingstad. Here we will launch manufacturing in a cleanroom in 2014.

All products are manufactured on assignment.

Contact

sven@medtech.se eva@medtech.se kenneth@medtech.se melki@medtech.se

070 729 7724 070 253 5825 070 022 8730 070 938 1452

Manager Sven G Milton Milton Medtech AB Visiting address: Backgårdsgatan 15, SE-590 49 Vikingstad Tel.: +46 13 83 202 info@medtech.se www.medtech.se

Me d ic al Dev i ce

Manager Sven G Milton Administration Eva Milton Production Kenneth Holmgren Development Melki Karlsson

53

Focus on Sweden

54

Focus on Sweden

NanoMed North A Nanomedicine Consortium

Nanomedicine is one of the most important emerging areas of health research and is understood to be one of the 21st century’s distinctive areas—also from a commercial point of view.

NanoMed North is a platform designed to support networking, communication and unique events within nanomedicine.

Apply for membership

Welcome!

Ulf G Andersson Chairman NanoMed North

NANOMEDNORTH

NANOMEDNORTH

www@nanomednorth.com

NanoMed North c/o Det Medicinska Malmö SE-205 12 Malmö Tel.: +46 721 827 583 info@nanomednorth.com www.nanomednorth.com

No n -p rofi t S u ppo r t O rga n i z at i o n

Members have an interest in, and through dedication and expertise work for a positive development of, nanomedicine.

Please join us, send an e-mail to info@nanomednorth.com

55

Focus on Sweden

NDA Group Europe’s leading drug development consultancy

The NDA Group is a Swedish founded consultancy organisation with offices across Europe. NDA’s sole commitment is to make sure that the best possible medicines reach patients in need without unnecessary delay. With an extensive knowledge of regulatory and pricing requirements NDA has guided its clients to ensure efficient drug development since 1997.

A wide range of competence NDA’s expertise stretches across all therapeutic areas and encompasses small molecules as well as biological and advanced therapies. This enables the quick provision of tailor-made teams and services to meet all of the client’s strategic requirements.

Increasing the chances to reach the market NDA’s services range from operational activities to ensure the efficient introduction of good medicines into the market as well as the further maintenance of the products once they are there, to regulatory strategies, creating and maintaining efficient agency interfaces and putting together task forces to address particular and pressing development problems.

Unmatched advice – straight from the horse’s mouth In addition to NDA’s consultancy services NDA fields a service that is completely unique - the NDA Advisory Board.

Co n s u lt a nt s

The NDA Advisory Board provides top level advice, second opinions and input into development plans and strategies. The NDA Advisory Board comprises the leading experts in Europe within the areas of Regulatory Affairs and Health Technology Assessment. With track records from leading agencies in Europe, academia as well as from successful drug development in the pharmaceutical industry, this unique group not only reflects current opinions and decision making practices within the European

56

Focus on Sweden

authorities, but are in fact the people who implemented these requirements in the first place. Getting the advice of NDA’s Advisory Board is a certain way of ensuring that you are headed in the right direction, or a safe way to learn where changes are necessary.

Bridging the gaps NDA strives to bridge the communication gap between the regulated and the regulators to the ultimate benefit of patients. Although we support 90% of the world’s largest pharmaceutical companies, the vast majority of our clients are small to medium sized organisations. In 2012 NDA supported over 40% of the products recommended for approval by the EMA.

Our advice is unbiased, our capabilities unmatched.

Let’s bring medicines to the world.

Con s u l t a nt s

NDA Group Johanneslundsvägen 2, SE-194 81 Upplands Väsby Tel.: +46 8 590 778 00 info@ndareg.com www.ndareg.com

57

Focus on Sweden

Pall Norden AB Lund, Medicon Village, Sweden

Pall Corporation is a materials science and engineering company with the broadest filtration, separation and purification capabilities experience in the world. Pall Corporation has been partnering with customers for over 60 years helping them to solve their most critical and difficult fluid management challenges.

One of the earliest partnerships came from the fledging commercial aviation industry after landing gear failures grounded a fleet of new jets in the 1940s. Pall Corporation’s founder, David B. Pall developed the filter units to solve a crippling problem and get the aircraft flying and landing safely again. Some years later Dr Pall developed the Life Sciences component of Pall Corporation’s business when, after his wife had endured a long illness, he turned his attention to the development of filters which were capable of removing white blood cells from donor blood.

Bi ote ch n o l ogy

Since then Pall Corporation has become much more than a filter company with a truly global footprint supporting both industrial and life science customers. Pall Life

58

Pall Biopharmaceuticals design customised single-use systems for biopharmaceutical manufacturing. Automated systems can be applied to manage and control process steps or generate data for use in batch records. In this case a Palltronic Flowstar IV integrity test instrument provides process critical data to verify filter installation and integrity.

Sciences provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. Within biopharmaceuticals, our media and laboratory products are used in drug research, environmental monitoring and molecular diagnostics. Pall products are used extensively in drug production to ensure process consistency and product quality. Increasingly, we are leveraging technologies and experience gained from Pall Industrial to help drug companies reduce their energy and water use and to minimize their environmental impact.

Pall has become a trusted partner to the life sciences market by meeting exacting standards for innovation, product performance and global service.

Pall Life Sciences capabilities in the biopharmaceutical industry encompasses all aspects of manufacturing.

From cell culture, product capture and purification to formulation, filling and terminal or sterilising grade filters, Pall provides highly specified products that can be used in research, process development and cGMP manufacturing environments.

The BioPharmaceutical portfolio has genuine depth and breadth. It includes chromatography media with mixed-mode chemistries that bind and purify monoclonal antibodies or therapeutic proteins even in the presence of salts and ions used in the upstream bioreactor.

Pall provides systems capable of automating and managing fluid paths through tangential flow filters, chromatography columns, and virus or sterilising grade filters – all in highly regulated cGMP environments. Our Scientific Laboratory Services provide validation data to prove the safety and effectiveness of our products in the biopharmaceutical manufacturing environment - our customers rely on us to produce this credible and compelling data for their own regulatory submissions.

Focus on Sweden

In Scandinavia Pall Corporation has been represented both through partners and direct sales. However, significant investments have been made in the past 10 years to serve the advancing biopharmaceutical market more effectively.

One of the major steps in this process took place in 2007 when Pall BioPharmaceuticals created a direct sales organisation and technical support team serving the whole Nordic market. The Nordic headquarters began operations from Lund in the south of Sweden. The presence of offices in Sweden meant that customers could get faster support in their local language through the Nordic organisation, giving greater support to customers in Norway, Denmark and Sweden and also providing a stronger base for our technical specialists. In 2012 the Pall Life Sciences organisation relocated into the heart of Scandinavia’s biotechnology innovation at Medicon Village. This move provided improved services offered by our technical support and biopurification specialist team members in the form of a training facility.

The Lund training facility is used by customers to learn about key aspects of bioprocessing, including normal and tangential flow filtration, chromatography, integrity testing and other key principles in the field of separation technologies.

bioprocesses. Numerous single-use products such as disposable filling needles which make biomanufacturing operations safer, more economic, and quicker and easier to apply have also been developed. In 2011 Pall acquired ForteBio, a cutting edge technology which expanded our capabilities in analysis of cell culture, process monitoring and research analytics. With greater applications come the need for further expertise, and our Scandinavian customers are supported by regional and global teams of technical specialists and product managers. These highly qualified, experienced team members take responsibility for various elements of our portfolio: we have experts in the application of sterile filtration, chromatography, tangential flow filtration, process automation, single-use systems, cell culture, formulation and filling, and bioanalysis. In addition to this our Pall Advanced Separation Systems (PASS) team apply high quality engineering solutions to the design, manufacture, installation and validation of biomanufacturing unit operations at any scale on a global basis.

As Pall Life Sciences continues to establish itself in Scandinavia we look forward to working closely with the innovative and progressive companies that are operating and growing with us in the Nordic region.

As a technically innovative company, Pall Corporation continues to develop new products which better serve its customers. With the introduction of the Micro-24 MicroReactor System and the XRS 20 Bioreactor, our BioPharmaceutical division has developed new technologies in cell culture which bring clear benefits to its users. These include increasing research output and enhancing cell culture conditions. The recently launched Supor EX Grade ECV membrane filter is a class-leading sterilising filter offering exceptional flow rates for diverse applications throughout

Pall Norden AB Medicon Village, Scheelevägen 2, SE-22381 Lund Tel.: +46 46 198400 Fax: +46 198 423 pall_norden@pall.com www.pall.com

Bi otec h n ol o gy

BioLayer-Interferometry technology (BLI) simplifies drug development by providing rapid quantitation and functional characterization of a variety of protein-based therapeutics like monoclonal antibodies, antibody fragments, receptor proteins and growth factors. Pall’s ForteBio Octet and BLItz range are now widely used in Scandinavia and globally to expedite drug development programs.

59

Focus on Sweden

Proffice Life Science The Nordic specialist in recruiting and staffing within the biotech and chemtech industries

Proffice Life Science is not like other staffing and recruitment companies.

Our philosophy is that the right person should be in the right place, allowing both people and companies to develop and grow. It sounds so simple, but anyone who has ever looked for personnel or a new job knows that it is time consuming and difficult to find good solutions. Our colleagues are scientists with industry experience. This, along with our quality-assured recruitment processes, make us convinced that we can help you, irrespective of whether you are looking for a new job or new colleagues.

Consult Proffice Life Science We know how difficult it is to assess how a company will develop over the next few years. With this comes the challenge to dare to take on personnel. We will give you rapid, flexible and appropriate solutions to meet your needs for competent colleagues, regardless of whether you need competence for a time-defined project, or for the future. We will give you the courage to open the door when the next major client comes knocking on your door.

St aff i n g & Re c ru i t me nt

We also know how the recruitment process can consume a large quantity of one’s personnel resources. Many look for new competence in people they already know, but there is a risk of missing out on many suitable candidates. We look for candidates in our own networks, through adverts, social networks, and in our substantial candidate bank that contains everything from laboratory assistants to senior researchers. We also conduct the time consuming task of reading applications, making selections, carrying out tests and interviews, and checking references in accordance with our quality-assured recruitment process. When you consult Proffice Life Science, you can concentrate on your business and be confident that we will find the best possible colleague for you.

60

Then we would like to get to know more about you. Working as a consultant for Proffice will give you the opportunity to develop, meet new people, and see new environments.

Your every day workplace will be at one of our customers who range from major companies and public authorities to smaller businesses. You will get a number of new career opportunities and experiences while making your CV all the more attractive. Where do you want to take your career?

You can always find our current career opportunities on www.profficelifescience.se, irrespective of whether you want to work for us as a consultant or work directly for one of our customers.

The Nordic specialist Proffice Life Science is the Nordic specialist in recruiting and staffing within the biotech and chemtech industries. It is no coincidence. With more than 50 years in the industry, we comprise specialists that place and recruit specialists.

With local presence in the Nordic countries, we have the knowledge and experience to ensure each individual placement and recruitment. In addition, we are specialized in the Nordic labour market, its work conditions, and applicable laws. You will know the difference when you consult us.

Working for Proffice Life Science Are you so good at what you do that you can call yourself a specialist without shaking in your boots? Do you also have a keen sense of awareness, are you committed and are you solution-orientated?

We look forward to hearing from you.

Focus on Sweden

Pharmaceuticals

Examples: pharmacologists, laboratory workers, geneticists, immunologists, clinical trial leaders, registration executives, chemists, engineers, product developers

Pharmacy

Examples: pharmacy managers, pharmacists, pharmaceuticals managers, dispensers, pharmacy technicians

Foods

Examples: product developers, designers, registration executives, chemists, technical salespeople, application engineers, quality managers

Chemical Engineering

Examples: quality engineers, product developers, chemists, laboratory workers, laboratory engineers, environmental coordinators, process engineers

Environment and quality

Examples: quality engineers, environmental safety officers, environmental coordinators, registration executives, inspectors

Proffice is one of the largest specialist companies within staffing and recruitment in the Nordic region, with more than 10,000 employees. We contribute to the growth and development of people and business through our high degree of attentiveness and our passionate commitment.

Proffice Life Science AB M채ster Samuelsgatan 60, P. O. Box 70368, SE-107 24 Stockholm Tel.: +46 8 787 17 00 lifescience@proffice.se www.profficelifescience.se

St af fi n g & Re cr u it me nt

Examples: quality engineers, food chemists, microbiologists, clean rooms technicians, laboratory workers, laboratory engineers

Medicine and biotechnology

61

Focus on Sweden

QIAGEN Making improvements in life possible

Rotor-Gene Q - For outstanding performance in real-time PCR • Outstanding thermal and optical performance due to rotary format • An unmatched optical range spanning UV to infrared wavelengths • State-of-the art analyses supported by user-friendly software • Low maintenance and maximum convenience due to robust design • High performance in multiple applications with QIAGEN assays A range of QIAGEN kits for the Rotor-Gene Q enables reliable quantification in all your real-time PCR applications without the need for optimization of reaction and cycling conditions. Kits for real-time PCR and HRM applications are available for: • Gene expression analysis • Pathogen detection • DNA methylation analysis • Genotyping and gene scanning • miRNA research

PyroMark Q24 Advanced - For advanced methylation and mutation quantification in long sequence runs using Pyrosequencing

Li fe Sc i en c e I n st r u m e nt s

• Advanced technology, software, and chemistry for long sequence runs • Quantitative methylation analysis at consecutive CpG or CpN sites • Improved quantification of sequence variations at any sequence position • Easy and improved base calling functionality • Assay versatility on the same instrument and in the same run

62

PyroMark Q24 Advanced has improved Pyrosequencing technology to provide even better real-time sequence-based detection and quantification than before. PyroMark Q24 Advanced features advanced technology, software, and chemistry, and is highly suited for analyzing any kind of sequence variation, particularly DNA methylation at CpG or CpN sites, complex mutations, or for de novo sequencing applications such as microbial typing.

Focus on Sweden

QIAcube - For fully automated sample prep using QIAGEN spin-column kits • Automation of trusted QIAGEN spin-column kits • Elimination of manual processing steps • Purification of DNA, RNA, or proteins • More free time with affordable automated processing • Standardized results and increased productivity The innovative QIAcube uses advanced technology to process QIAGEN spin columns, enabling seamless integration of automated, low-throughput sample prep into the laboratory workflow. No change of purification chemistry is required, assuring fast startup and immediate results. All steps in the purification procedure are fully automated — up to 12 samples can be processed per run.

QIAsymphony SP/AS instruments For fully integrated automation of complete workflows, from sample preparation to assay setup • Innovative, easy-to-use modular system with built-in touchscreen • Purification of DNA, RNA, and protein from a wide range of samples • Automatic transfer of eluates to the QIAsymphony AS for assay setup • Continuous sample loading, with bar code reading for sample tracking • Import of sample lists and export of sample sheets

QIAGEN AB P. O. Box 461 SE-191 24 SOLLENTUNA Tel.: +46 8 594 704 00 Fax: +46 8 594 704 99 www.qiagen.com

Li fe Sc i en c e I n st r u m e nt s

With a dedicated range of QIAsymphony Kits, the QIAsymphony SP enables sample preparation of DNA, RNA, bacterial and viral nucleic acids, and 6xHis-tagged protein from a wide range of starting materials. The QIAsymphony AS extends the capabilities of the QIAsymphony SP by integrating automated PCR assay setup, which, in combination with the Rotor-Gene Q and QIAGEN real-time and end-point PCR kits, enables you to complete your automated PCR workflow and maximize your efficiency.

63

Focus on Sweden

64

Focus on Sweden

Silentia AB

The Silentia Screen System Silentia AB

The Silentia Screen System

Clean and flexible design Maximum hygiene combined with practical designs

EasyClean

EasyReturn

EasyClick

Silentia Screens are a patented screening system that has been designed to make your work easier in hospitals and other care situations, for the benefit of patients and staff. The Swedishmade system has been very successful since it was introduced in 1990 and now helps provide fast and effective screening in care situations all over the world. Silentia Screens satisfy a variety of needs. They can be installed without getting in the way of ceiling hoists or other equipment; they are always on hand and they let the daylight flood in. Simplicity is another benefit, as underlined

by EasyClean™, EasyReturn™ and EasyClick™ – three features that contribute to maximum hygiene, versatility and ease of use. Their clever design and wide range of heights, lengths and colours also ensure that our screens fit in well in most care environments.

P.O. Box 108, SE-311 22 Falkenberg, Sweden Tel.: +46 346 485 80 Fax: +46 346 485 89 info@silentia.se www.silentia.eu

I nte r io r

Silentia AB P.O. Box 108, SE-311 22 Falkenberg, Sweden Tel.: +46 346 485 80 Fax: +46 346 485 89 Silentia info@silentia.se AB www.silentia.eu

65

Focus on Sweden

Symbioteq Your partner in Quality Assurance & Regulatory Affairs for Medical Devices

Symbioteq is a consultancy company within the Medtech field (IVD (in vitro diagnostic) as well as Medical Devices) and was founded back in 1994 by Tomas Camnell. We have offices in Gothenburg and Stockholm for the time being. Core value for Symbioteq is patient safety, which of course also in most cases is of highest importance for companies producing medical devices.

Thanks to our wide experience and various in-depth competences in the regulatory and quality environment we can guide you to a fast and cost-efficient market entry.

Co n s u lt a nt s

Our services cover the entire development process from concept creation of new products to post-production activities, the services can roughly be divided into main areas consultancy services and education. We prefer to be involved early in the development to set the RA/QA-strategy together with the company, since late implementation of these issues often renders costly delays before market entry. The consultancy can be done on site as well as in Symbioteq facilities.

66

Examples of Consultancy services that Symbioteq provides: • Regulatory strategy, including Product Classification • Development of management systems (ISO 13485, QSR, ISO 9001 etc.)

• Internal audits • Issue Technical file • Product Registration USA, Canada, Australia etc.

• Development of or guidance in Risk Management process (ISO 14971) • Development of or guidance in Usability engineering process (ISO 62366) • Standard guidance, such as gap analysis and interpretation (IEC 60601-series, IEC 61010-series etc etc) • Establishing requirements, product and process (EU, USA and others.)

• Development of product documentation (labels, manual, etc.)

• Project management • Regulatory expertise • Act as QA / RA-staff and /or managers • Regulatory due diligence • Etc etc

Focus on Sweden

Regarding education we can more or less tailor make any education according to our customers’ needs within the medical field, we also have partners (Intertek and key2compliance) where we have open educations.

Symbioteq have unique certification programs for individual persons (“QA/RA Leader Medical Devices” and “Auditor/ Lead Auditor Pharmaceuticals/Medical Devices”) and offers separate education programs to prepare the participants in necessary skills to achieve the individual certification.

For further information regarding Symbioteq, see www.symbioteq.com

Contacts:

Symbioteq Kvalitet AB Augustendalsvägen 32, SE-131 52 Nacka Strand, Sweden Tel.: +46 8 621 05 02 info@symbioteq.se www.symbioteq.com

Con s u l t a nt s

Micael Johansson: +46 (0) 70 561 02 11 (mobile) micael.johansson@symbioteq.se Tomas Camnell: +46 (0) 70 561 25 88 (mobile) tomas.camnell@symbioteq.se Åsa Runnäs: +46 (0) 70 561 25 40 (mobile) asa.runnas@symbioteq.se

67

Focus on Sweden

TFS Trial Form Support Your trusted partner in clinical research

From Lund to the World Did you know that a Swedish CRO which started in 1996 is now among the 10 largest CROs in the world?

And do you know why?

TFS was started in 1996 in the city of Lund in southern Sweden by Daniel Spasic. Daniel saw a need in the market that was not filled and he acted on that. The first business area in TFS was TFS People. TFS People™ is our insourcing services where our customers can rent a Consultant on both short and long term assignments; full time or part time. We offer all types of Consultants in Clinical Development from Medical Advisors, Medical Writers, Global Project Leaders to Clinical Research Assistants and more.

Since then the Company has grown both in the number of business areas and in the geographical coverage.

We work with both large, mid-size and small pharmaceutical companies, we have unique expertise in Medical Devices and Functional Foods and even run trials with Cosmetics. Our strategy is to have a stronger local presence and a higher flexibility than the larger CROs. “Global in Mind but Local at Heart” is the culture we nurture. We also aim to always give our Customers the best value for their investments no matter if it is a big pharmaceutical customer or a small research group that has received some EU funding for their project adaptability and flexibility are key here.

Today TFS offers four business areas, including TFS People™

C RO - C l in i ca l Re s e a rc h O rg a n i z at i on

TFS Explore™ is our business area where we take on early clinical development. We are the leading CRO in the Nordic area and we perform anything from micro dosing, Phase I trials, to Phase IIa trials - in close cooperation with the Phase I clinics at the leading University Hospitals in the Nordic region. We work with both big pharmaceutical companies and small virtual customers, and we provide all services from scientific and medical input on the synopsis to final report and publication.

68

In the business area TFS Develop™ we take on the outsourced responsibility to run everything from Phase IIb trials to Phase IV trials, observational research and registry trials. Clinical Development is a global activity and we can supply our clients with a Global Project Leader and a senior Statistician that speak their own language, if that is a preference. TFS is currently running trials in more than 30 Countries - in all European Countries, the United States and Canada - with our own staff. We use three different eCRF systems and the choice depends on the customer and nature of the project. We have received a lot of positive feedback from customers that had previously wasted time talking to CROs located in the US - now we handle that communication and leadership for our customers.

Our fourth business area is unique to TFS and that is TFS Academy™. This is our education and training area.

We offer many highly-regarded face to face courses and are looking at developing more web based trainings in the future.

We at TFS look forward to working with you in the future!

Focus on Sweden

CRO - C l i n i ca l Re s e a rch Org an i z at i on

TFS Trial Form Support Ruben Rausings gata 11 A, P. O. Box 165, SE-221 00 Lund Tel.: +46 46 280 18 00 Fax: +46 46 280 18 01 tfs.international@tfscro.com www.tfscro.com

69

Focus on Sweden

70

Focus on Sweden

Unimedic AB About UniMedic: • Unimedic AB is one of Scandinavia’s largest contract manufacturers of liquid pharmaceutical drugs.

• Unimedic offers rational GMP-manufacturing and control in well-equipped laboratories.

• We take responsibility for the total manufacturing chain, from the purchase of input materials to the release of the end product.

• We are known for high flexibility and effectiveness, both for small and large manufacturing series.

• Among our current clients are some of the foremost pharmaceutical companies in Scandinavia.

Production Our services are adapted to both the pharmaceutical industries and to health care. Unimedic offers contract manufacturing of liquid products such as mouthwash fluids, mixtures as well as sterile medicines in the form of injection ampoules and vials. We are able to take care of everything from the purchase of input materials to the release of the end product.

Production lines Manufacturing takes place in modern production lines offering effective and secure production which fulfil EU-GMP. Batch sizes Our production is very flexible and can be adapted to manufacturing batches of up to 20 000 litres.

Services Quality control In our modernly equipped laboratories, we perform a number of large chemical and microbial analyses. We analyse active raw materials (API), excipients, WFI as well as end products.

We use both pharmacopoeia methods as well as our own developed methods to perform these analyses.

Stability studies We perform stability studies according to ICH-guidelines and have climate controlled cabinets for storage of samples.

Product development We work with the development and improvement of products for our clients.

(Visit the Phil Med Alliance page for more information : www.philmedalliance.com)

Unimedic AB Storjordenvägen 2, SE-864 31 Matfors Tel.: +46 60 515000 www.unimedic.se

P h a rm a ce u t i ca l

We are also A valuable part of the Swedish Healthcare Alliance, in cooperation with Phil Med Alliance

71

Focus on Sweden

World Courier Quality Research Deserves Quality Logistics Please Let Us Help You Succeed World Courier Profile

we offer an unparalleled service.

World Courier delivers its specialized logistics services across

We are strategically located in Australia, China, India, Latin

the full “life cycle� of the clinical trial process, beginning with

America, Russia, Japan, Singapore and South Africa to help in

pre-trial coordination between biopharmaceutical companies,

the most demanding regulatory environments.

CTSs, CROs and Central Labs.

World Courier Ground Europe: The company then manages the logistics and transport of all

Specialists in intra-European temperature-controlled ground

trial materials, packaging, scheduling and routing. Once a trial

transport for the pharmaceutical, biotech and healthcare

is underway, World Courier assists with regulatory and permit

industries.

issues and manages the import of bulk drugs and supplies into centralized storage depots.

Utilising state-of-the-art refrigerated vehicles, highly trained drivers and staff, continent-wide SOPs and advanced telema-

We also handle the intra-country distribution from investi-

tics including real-time satellite tracking, WCGE also provides

gational drug storage depots to clinical trial research sites,

customers with the added assurance of complying with all

coordinate patient sample logistics, and manage drug return

relevant GDP/GMP guidelines as required by EU regulatory

and destruction procedures. Reptresented in more than 50

agencies.

countries with 152 owned offices, we maintain a 24/7 support for our clients.

Core service offerings focus exclusively on premium on-demand 24/7 transport services within Europe for the distribution of temperature-sensitive clinical trial bulk product and finished product shipments at all critical temperatures ranges.

GxP compliance - QMS The basis of World Courier’s GxP Policy rests largely with established precepts of Good Distribution Practice (GDP), Good Storage Practice (GSP), Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) as they relate to each business individually (transport and storage) and follows all relevant guidance documents supporting these practices.

World Courier has also put in place an independent Quality

S pe ci a l ize d Tra n sp or t

Management System that complements its GxP policy and

72

Clinical Trial Supply Depot Network:

conforms to leading international quality management and

With company owned GMP compliant facilities, comprehensi-

oversight programs. World Courier also complies with other

ve SOPs and a proprietary CTM management software system,

quality systems such as the ISO 9000 series.

swedish_life_sciences_STO.indd 1

Focus on Sweden

GLOBAL THERMAL CONTAINER PACKAGING SYSTEM

Experts in Temperature Control The new GTC packaging system: ■ Is qualified to ISTA standards and available in sizes ranging from 4 to 96 liters of product capacity and for product temperatures of: +2°C to +8°C

|

+15°C to +25°C |

–25°C to –15°C

■ Utilizes vacuum-insulated panels and specific phase change material gel-packs for superior performance over extended periods of time ■ Accommodates an increased payload, generally lowering freight costs and resulting in overall cost reductions ■ Is a multi-use system significantly reducing our environmental footprint

Exterior: damage

Temperature Control Media: keeps temperature on a constant level

Insulation: protects from extreme ambient temperatures

please contact your local World Courier office.

World Courier Denmark A/S Avedoereholmen 96–98, DK 2650 Hvidovre Tel.: +45 3246 0680 ops@worldcourier.dk www.worldcourier.com

World Courier (Finland) Oy Puutarhatie 20, 01300 Vantaa Tel.: +358 9 8700 3300 Fax: +358 9 8700 3350 info@worldcourier.fi

World Courier (Norway) AS Industriveien 20, 2050 Jessheim Tel.: +47 6394 6200 Fax: +47 6394 6201 ops@worldcourier.no

2013-07-03 10:54:29

World Courier (Sweden) AB Soderbyvagen 1A, 195 25 Arlandastad Tel.: +46 8 594 414 80 Fax: +46 8 594 414 99 ops@worldcourier.se

S pe c ia l i ze d Tran s p or t

For further information

73

Focus on Ume책

Focus on Ume책

74

Focus on Ume책

75

Focus on Umeå

Foreword by Kurt Strömgren, Manager Biotech Umeå

– Northern Sweden’s growing life science cluster is firmly on the map Located at the northern end of the Baltic Sea, the university town of Umeå has doubled its population since the mid-sixties and is one of Sweden’s youngest and fastest growing cities. Umeå offers world-class art, drama, films, industries, music and research. It aims to attract more companies, break new construction records and has been nominated as European Capital of Culture 2014.

foreword

The life sciences sector, both in terms of academia and business, numbers as one of the fastest growth sectors in this fast developing town. The sector is contributing a lot to the expansion of Umeå both as city, but also to it being classed as a truly representative cluster within Sweden’s acknowledged world class life science environment.

76

The Umeå region, with its cutting-edge research, has become an exceptionally productive source of companies, many of which are international leaders within their fields. The Biotech Umeå cluster is well recognised as excelling in infectious disease and new antibiotics

research, and has leveraged this expertise to generate several exciting new companies active in developing anti-infectives with novel modes of action.

Umeå is also home to both UCMR – Umeå Center for Microbial Research with research in infection and pathogenicity and MIMS – Laboratory for Molecular Infection Medicine, the Swedish node of the Nordic EMBL Partnership for Molecular Medicine.

Other areas in which the Umeå cluster excels include medtech and diagnostics, plant and forest biotechnology at Umeå Plant Science Centre, metabolic diseases and neurodegenerative diseases.

Strong and systematic interplay of research and commerce A strong and systematic interplay of life science research and commerce is at the heart of the life science growth process in Umeå. Fuelled by innovative work and ideas stemming from Umeå’s two universities, the university hospital and local arm of the Swedish Defence Research

Focus on Umeå

Agency, a well-oiled and innovative tech transfer system supports the process of taking an idea from the lab bench to marketable, money-making product.

Located across the road from each other on the Umeå University campus, Biotech Umeå, the cluster initiative headed by Kurt Strömgren, and the Umeå Biotech Incubator (UBI), headed by Jennie Ekbeck, and Uminova Innovation with CEO Nils-Olof Forsgren, are major drivers within this process. They are all part of a cooperating framework responsible for identifying, funding, and supporting research projects and new business ideas on their way to the market.

UBI and Uminova Innovation- important players in the innovation process Uminova Innovation is a business incubator, which offers an extensive range of services to entrepreneurs and is the main counterpart when it comes to commercialisation of innovations from Umeå’s scientific, technical and IT communities. Uminova Innovation handles all new ideas originating from the research communities, including ideas within the medical technology and bioenergy sectors.

fo rewo rd

Biotech Umeå is a cluster initiative created in order to support growth of the biotech and medical technology industry in the Umeå region. Biotech Umeå’s goals are threefold: • to promote the cluster in order to create growth in existing companies • to attract both foreign and national interest and finance and • the creation of new ventures

The cluster is now home to over 70 life science companies, an increase of 100 % since 2005, and about 3000 people are employed in life science research and companies. The companies present in the cluster span all stages of size and maturity – from newly founded fledgling companies right through to major international players. The spread is wide but it is encouraging to see new projects entering the “research pipeline” and others moving towards greater maturity.

77

Focus on Umeå

foreword

In 2004, it was decided to create a separate entity to meet the specific requirements of the biomedical sectors where extensive and expensive laboratory equipment is usually needed to develop products to a marketable stage.

Umeå Biotech Incubator (UBI) was therefore formed, and it is now fully owned by Uminova Innovation. UBI, under the leadership of CEO Jennie Ekbeck, is located in very functional facilities at the Uminova Science Park, namely the old refurbished control labs relinquished by Astra Zeneca. Here UBI provides many services for fledgling companies – not least the all important infrastructure of lab facilities, offices and proximity to other like-minded individuals.

78

Sustained cluster growth UBI is Umeå’s biosciences business incubator. It offers an extensive range of services to entrepreneurs and is the main vehicle for commercialisation of innovations from Umeå’s life science research community. Projects usually come to UBI at the proof-of-concept stage, before forming into a company to attract first round financing and investment partners. UBI can host up to 20 projects

or companies in their facilities. UBI offers researchers and entrepreneurs a host of facilities and services including: • Facilities and infrastructure for biotechnology development activities.

• Pre-seed financing to verify the business idea before starting a company.

• Business development knowledge to start-up biotech companies in the incubator.

“UBI has a model whereby we do not take a stake in the company although we do provide early stage capital – pre-seed proof of principle financial support to these projects” explains Jennie Ekbeck.

Both Jennie Ekbeck and Nils-Olof Forsgren stress how important it is that UBI and Uminova Innovation become involved early enough in a project to make sure that intellectual property is secured before results are published. “There are several sources of innovation and business ideas here in Umeå” says Kurt Strömgren.

“On the one hand, we have Umeå University and the University Hospital, but we also have branches of the

Focus on Umeå

Swedish Agricultural University and the Swedish Defence Research Agency, which are additional sources of innovation and ideas”. Employees in these government owned institutions fall under the Swedish “Teacher’s Exemption” principle allowing inventors to own their own intellectual property, rather than it belonging the organisation where they work. This principle fosters interest in scientists to think about and make efforts to commercialise their research. The teacher’s exemption rule is generally not applied to innovations coming out of hospitals in Sweden since they are owned by the regional government, but in the Västerbotten region (where Umeå is situated), a pioneering decision has been made to apply this exemption principle to innovations and ideas originating from the hospital research environment as well.

Meanwhile, research at the university is attracting healthy levels of funding which can only serve to increase the number of new innovations, projects and companies that will turn to UBI and Uminova Innovation for support and competence in the future, and give the cluster an even broader platform of life science companies and technologies.

fo rewo rd

Uminova Innovation and UBI have between themselves evaluated close to 500 life science business ideas since 2005, and in that time they have also supported the creation of over 45 exciting life science companies.

Support from Uminova Innovation and UBI means, among

other things, that the companies and projects get access to project management and business development professionals, databases, experienced consultants, and a network of suppliers and business contacts.

79

Focus on Umeå

Foreword by Olof A. Lindahl, Professor in Biomedical Engineering, Director CMTF, Head of the Hospital Department for Biomedical Engineering R&D

Research and deve lopme nt in B io m e dica l Eng ine e ring b oosts i n dustr ial growth i n N o rt h e rn Swe de n

foreword

Scientific research and development at the Centre for biomedical Engineering and Physics (CMTF) has resulted in new medtech companies and strengthened healthcare in Northern Sweden. CMTF has generated growth both in academia, at the universities and in the industry in Northern Sweden. Furthermore, cooperation has been built up between the 26 research projects and more than 20 established companies in the field of biomedical engineering. A company for business development of the research results from the CMTF, called CMTF Business Development Co Ltd (CMTF BD), was formed by the researchers. It has launched three spinoff companies since autumn 2009. It has also increased the interest in commercial and entrepreneurship issues among the scientists and engineers in the centre. So far nine spin-off companies have resulted from the research in CMTF.

80

The process of commercialising scientific research results is very well established in Northern Sweden. The CMTF was established in order to form an organisation for triple-helix cooperation between scientific research, biomedical industry and healthcare. The aims were to produce intensive co-operation with the healthcare industry and create an excellent milieu for growing new innovations and starting spin-off companies, to the benefit of the patient. Financially, the CMTF activities were financed through local support from regional foundations and the EU structural foundation of Northern Sweden. CMTF had a turnover of EUR 6 million during the years 2000-2007, and it has a budget of EUR12 million for 2008-2014.

The two northernmost universities in Sweden, Umeå University (UmU) and Luleå University of Technology (LTU) have joined forces, combining the strong technical research at LTU with the strong medical/biomedical research at UmU. In addition, since

1982 a special division has been established at the University Hospital in Umeå within the County council organisation for biomedical engineering in Västerbotten that carries out research and development in the area of biomedical engineering and radiation physics, and is known as MT-FoU. This division is located inside the hospital area and works very closely with the clinical specialisms and is therefore of greatest importance for the success of the CMTF. The work at CMTF is organised into 26 research projects and one management company that takes care of the administration and joint conferences. A company, CMTF Business Development (CMTF BD) Co. Ltd., owned by the scientific leaders in CMTF and the local innovation system represented by Uminova Innovation Co. Ltd. and LTU Holding Co. Ltd., was inaugurated in 2007 to help with the business development of the scientific research results from the centre. The CMTF was established to create a strong, sustainable and virtual organisation for scientific research and business development in Northern Sweden. A further goal was to create a model for developing new, viable biomedical spin-off companies from the research results of the centre, boosting industrial growth in Northern Sweden.

CMTF is organised with a board of directors and one director, all assigned by the two universities UmU and LTU. The board was chosen to give the CMTF a stable leadership and to ensure effective cooperation between the two universities as well as with industry and healthcare. The broad expertise collected in the board members guaranteed a high degree of competence to make decisions on industrial and healthcare questions, as well as scientific matters, as representatives of the users. Before joining the CMTF, all 26 research projects were evaluated by the board, based on three criteria: scientific

Focus on Ume책

Centre for Biomedical Engineering and Physics, Ume책 University and Lule책 University of Technology, and Centre for Biomedical Engineering and Radiation Physics, Ume책 University Hospital.

excellence, clinical and industrial relevance and finally scientific research management. Approved projects may use the CMTF logotype and refer to CMTF as their research milieu. About 175 researchers and supporting staff have been engaged in this work. Almost all of the projects in CMTF have both scientific and industrial cooperation with international partners both outside the EU, e.g. Japan and the USA, and within the EU, e.g.

Norway, Finland and Italy.

The CMTF BD company is completing the existing innovation system in Northern Sweden through its special emphasis on launching the biomedical engineering research results on the commercial market. In Sweden, the scientific researchers own the rights to their patentable research results and therefore the scientific leaders could sign over the intellectual property rights (IPR) to the CMTF BD company through an agreement.

For identified business ideas, a contract that covered the sharing of future profit from the innovation, which is known as an incentive agreement, was signed with the scientists The company operators have links to expertise in venture capital, business development, regulatory issues and other skills necessary for business development in healthcare. The setting up of CMTF BD made it possible to separate the nonprofit research centre, CMTF, and the business facilitator, CMTF BD Co Ltd.

Year/Activity Spin-off companies Senior scientists Sc publications PhD/Lic exams Graduation works Projects Patents Workshops/conferences New employments Industry cooperation

2000-2012 9 30 300 30 >100 26 15 24 40 20

Twenty-four workshops have been arranged together with the healthcare industry and established spin-off companies, with an average of 60 participants, except for one workshop, the Nordic Baltic Conference on Biomedical Engineering and Physics in the year 2005, NBC2005, which had about 200 participants, and the National Biomedical Engineering conference 2010 which had 350 participants. The CMTF research network and CMTF BD have stimulated the setting up of spin-off companies in the area of biomedical engineering in Northern Sweden. This has resulted in increased growth in biomedical engineering activities, both in academia and in the industry in Northern Sweden.

fo rewo rd

Nine companies have so far been established from the research results from CMTF (Table 1). Eight of them were based on patents and one is the CMTF Business Development Co. Ltd. (CMTF BD). Since its establishment in 2007 the CMTF BD has started three new companies for the healthcare market in Northern Sweden and has 15 on-going business projects.

Fifteen patents have been filed from the research in CMTF.

Table 1. Twelve years of work with the CMTF, the number of spin-off companies and related activities.

81

Focus on Umeå

Umeå:

Fast-growing and close-knit

The life science cluster that has grown up in the Umeå region is Sweden’s most northerly. It is one of the fastest-growing groups of life science companies and academic research centres in the country, with more than 3,000 people, of whom two-thirds are in academia and one-third in industry. They are producing cutting-edge research, generating innovations and building companies to commercialise them. It has a strong entrepreneurial culture and over the last five years the number of life science companies in Umeå has doubled. A key element in the development of the cluster has been the close working relationships established across the disciplines and across the entire life science community. This collaboration involves national bodies such as innovation agency VINNOVA, regional and municipal bodies, academic organisations, research bodies and researchers, companies both brand new and well-established, and financial investors from substantial venture capital firms down to individual entrepreneurs.

In addition, the Umeå region has the infrastructure necessary to support the cluster and to attract other life science companies looking for a new operations base. It is very well connected, both geographically, with frequent international and domestic flights every day and excellent rail services to and from Stockholm, but also in the communications sense, with state-of-the-art broadband access via one of the world’s most extensive networks. The objectives of the cluster and the region are very much in tune.

Umeå’s centre of life science excellence is home to two major universities – Umeå University, the biggest in northern Sweden, and a campus of the Swedish University of Agricultural Sciences – plus a university hospital, sited next to the campus shared by the two universities. The Umeå life science cluster has significant strengths, particularly - but not only - in biotech and medtech. Its specialist expertise covers the areas of research into infectious diseases, neurological diseases and metabolic diseases and diagnostics and medical technology. Research is also carried out into plant and forest biotechnology at Umeå Plant Science Centre, established jointly by the department of Plant Physiology, Umeå University, and the Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences. There are also centres for Molecular Pathogenesis, Molecular Medicine and Microbial Research, for example, as well as Sweden’s national Laboratory for Molecular Infection Medicine, which are all parts of Umeå University. The city of Umeå is also the location for a department of the Swedish Defence Research Agency (FOI), which is one of Europe’s leading institutes for defence and security research. Its CBRN division in Umeå has leading experts on chemical and biological issues.

82

Focus on Umeå

Umeå’s academic world Umeå’s two universities and university hospital work closely together and have several joint venture operations, such as the Chemical Biological Center and the Umeå Plant Science Centre. A further example is UCMR, Umeå Centre for Microbial Research. It is an interdisciplinary research centre for medical and molecular microbiology, molecular and structural biology plus chemistry and physics, devoted to research and applications in the fields of microbial pathogenesis.

Founded in 1965, Umeå University was placed top in Sweden and highest ranked in the Nordic countries by the Times Higher Education’s 100 Under 50 annual listings (2013) for higher educational institutions less than 50 years old. With some 34,000 students, full- and part-time, and 4,500 employees, it is a base for world-leading research in a number of fields. It has four faculties: Arts, Medicine, Science and Technology and Social Sciences. Umeå University cooperates with more than 600 international universities throughout the world. It places a high priority on biotechnology/life science research. A total of ten institutions and units at the technology, natural sciences and medical faculties are involved in carrying out advanced research in biotechnology and related areas. Altogether the university has some 25 research centres.

The university’s Grants Office focuses on supporting its international research cooperation. It provides information and assistance to the university’s researchers about applying for funding from the Structural Funds of the European Union and the European Union Framework Programmes for Research and Development. A key element of its work is matching companies, organisations and individual to partners that they can collaborate with on R&D or joint ventures of other sorts. Its International Office oversees the university’s participation in the Nordic Centre in India – a cooperative venture between Nordic research and higher education institutions and Indian partners -- and the Erasmus, Nordplus and Linnaeus-Palme international exchange programmes.

The university also has an Innovation Office, which serves as the first point of contact for researchers, staff and students who want to see their ideas realised. Its role is described as operating “in the interface between Uminova Innovation, the Grants Office, the Office for External Relations and Umeå Biotech Incubator”. Innovationskontor north is one of the eight innovation offices selected by the Swedish government to work on innovation and collaboration.

CMTF, the Centre for Biomedical Engineering and Physics, is a network of research groups from several departments at Umeå University and Luleå University of Technology. It works in three-way collaborations with the county councils

in Norrbotten and Västerbotten and with industry. The aim is to coordinate and strengthen high-quality research so as to produce methods, products and services for more efficient, better and safer healthcare.

Computational Life science Cluster (CLiC) is Umeå University’s bioinformatics platform. It is based at one of the joint centres that are a hallmark of the life science clusters, the large interdisciplinary Chemical Biological Center (KBC), a collaborative venture between Umeå University and the Swedish University of Agricultural Sciences. CLiC researchers work on bioinformatics research, genomics, proteomics including protein modelling and metabolomics, in close contact with experimentalists and the analytical platforms.

Bioinformatics courses are run there for PhD students and postdoctoral researchers and there is also bioinformatics support and service provided through the core units, Genomics core and Metabolomics core.

The Swedish University of Agricultural Sciences (SLU) has several campuses in different parts of Sweden. Its head office is in Ultuna, Uppsala, but it has other main facilities in Alnarp, in Lomma Municipality, Skara, and Umeå. In Umeå it carries out biotechnology-related research, primarily in the field of forest genetics and plant physiology at its faculty of forest sciences. The research focuses on hormone physiology and population genetics and a significant success story has been the mapping of tree genomes. SLU describes the ethos of its research and education as its “comprehensive view, interdisciplinary studies and applicability ... and its contacts with industry and society”. Typical of its interdisciplinary outlook is the joint research platform, Umeå Plant Science Centre, it has with Umeå University.

University Hospital of Umeå (UMU) is responsible for providing quality medical care to the Västerbotten region.

As a major teaching hospital, it is also the location for most of the activities of Umeå University’s Faculty of Medicine. Its staff also carry out research, often in cooperation with those from Umeå University’s clinical institutions. This focuses primarily on a number of particular diseases and how they are treated, such as cancer, stroke, familial amyloidosis with polyneuropathy (Skellefteå disease) and amyotrophic lateral sclerosis.

Umeå Care is the commercial organisation for international patients having treatment at the University Hospital of Umeå in the specialised fields of neurosurgery, cardiac surgery and radiotherapy. It manages all the practical arrangements in terms of planning and administration for the trip. Both during and after the treatment the patient will be supported by Umeå Care until his or her safe return home.

83

Life Science cluster organisations

Focus on Umeå

Biotech Umeå is a project managed by the non-profit incubator Uminova Innovation and its role is to support growth of the biotech and medical technology industry in the Umeå region. It is financed by the University of Umeå, Municipality of Umeå, Uminova Innovation, FOI (Swedish Defence Research Agency), county council of Västerbotten, county administration of Västerbotten and EU Structural Funds. Biotech Umeå works to create growth and better prospects for the region’s life science companies, in collaboration with regional, national and international partners. It promotes the region’s businesses and the life science cluster’s research in the media and towards investors and partners. It also assists both companies and researchers to commercialise and develop life science sector business concepts, using Uminova Innovation’s processes.

Hatching new ventures: incubators and finance-providers Two key players in the Umeå life science cluster are Uminova Innovation and Umeå Biotech Incubator (UBI).

Their roles are complementary. Both assist entrepreneurs and start-up companies with advice, business know-how, office premises, and laboratory facilities in the case of UBI, plus seed capital. In addition, Uminova Invest is the cluster’s own venture capital company, providing early stage funding to start-up companies. It is partially supported

by Umeå Biotech Incubator.

The aims of Uminova Innovation are two-fold: to stimulate an exchange of knowledge, ideas and experience between the university and industry, and to develop innovative business ideas into commercial concerns. It sees itself as a gateway: to the research resources available at the university for industry and venture capitalists and to industry for researchers. It catalogues, investigates and evaluates research results from the point of view of commercial viability.

When research work is considered to be of commercial interest, Uminova Innovation can assist the researcher through all the necessary steps to establishing a company. Located in Uminova Science Park, Uminova Innovation has more than 40 years’ experience of developing ideas into businesses and processes, models, tools and strategic contacts. It also runs initiatives to strengthen Umeå and Västerbotten as a life science region (Biotech Umeå) and as an IT region (Infotech Umeå). Founded in 2003 to focus on entrepreneurship and spin-offs from academia, Uminova Innovation receives financing from Umeå municipality, Umeå University, the region of Västerbotten, Västerbotten County Council and European Union structural funds.

Uminova Innovation will help researchers and companies in the Västerbotten region to find international partners through the Enterprise Europe Network, an EU project to help small businesses to make the most of the European marketplace. Infotech Umeå is Uminova Innovation’s strategic initiative aimed at marketing and improving the IT innovation environment in the Umeå region. Using the parent organisation’s successful processes, models, tools and networks but adapting them for IT requirements, it provides support to people, companies and organisations in Västerbotten with developing their ideas – many of which are likely to have life science sector applications – into innovations and successful companies.

Umeå Biotech Incubator is a subsidiary of Biotech Umeå, offering business know-how to innovators who have ideas that could potentially stimulate the development and growth of companies in the region. It says its vision is “to develop great life science research into big global business”. UBI focuses on research organisations in the Umeå area made up of Umeå University, the Swedish University of Agricultural Sciences, Umeå University Hospital and the Swedish Defence Research Agency. It may support researchers and innovations outside that area, though only on condition that the development is done in Umeå at UBI. It offers the following: • Facilities and infrastructure in the form of specially equipped laboratories for biotechnology development activities; • Pre-seed financing to verify the business idea before starting a company; • Business development knowledge to start-up biotech companies in the incubator.

Almi Företagspartner is owned by the state together with the region, and runs programmes to support start-ups and SMEs with advice, loans, venture capital and incubation. As of 1 January 2013 it owns Innovationsbron, the national incubator that provided seed funding to researchers in achieving proof of concept.

84

Focus on Umeå Umeå scores significant R&D successes Why does the Christmas tree have ‘fat’ genes?

Researchers from Umeå Plant Science Centre (UPSC) and SciLifeLab, Stockholm, spearheaded the work to sequence the genome of the Norway spruce, the largest and most complex genome ever sequenced, seven times larger than that of humans. The results were published in the May issue of Nature.

The Norway spruce, known as the Christmas tree, is a species with huge economic and ecological importance. The new genetic information is of interest scientifically, botanically and also commercially, for the forest industry and its tree breeding programme. The question the researchers set out to answer was why the Norway spruce has such a very large genome, the biggest in the world so far.

According to their study, one explanation is “genome obesity” caused by extensive repetitive DNA sequences, building up for several hundred million years of evolution. Other plant and animal species have efficient mechanisms to eliminate such DNA repetition, but these do not seem to work well in conifers.

The project was funded by the Knut and Alice Wallenberg Foundation with the Swedish University of Agricultural Sciences as the lead applicant. Scientists from UPSC (Umeå University and Swedish University of Agricultural Sciences) and Science for Life Laboratory, Stockholm, participated, with several leading international scientists as collaborative partners. The budget for the project was SEK 75 million SEK, which the researchers point out compares favourably with the budget for mapping the human genome at SEK 20 billion.

Dutch order Likvor dementia test Umeå-based medical technology company Likvor recently received a prestigious order from Radboud University Nijmegen, in the Netherlands, for the patented Likvor CELDA® System that it has developed. This system offers those dementia patients suffering from treatable dementia a way back to life. The neurosurgical department of the Radboud University Nijmegen Medical Center has leased the Likvor CELDA® System for three years.

One in ten dementia patients is estimated, in fact, to be suffering from treatable dementia (NPH), a hidden and often difficult diagnosed disease, but one which can be treated by a relatively simple operation, the insertion of a shunt. However when an NPH patient with a shunt deteriorates, it can be difficult for the clinician to distinguish between a progression of the disease and a malfunctioning shunt. By using the Likvor CELDA® System infusion test to verify shunt function, unnecessary shunt revisions can be avoided.

Early stage innovations win funding A Umeå microdialysis diagnosis project has been awarded funding by government innovation agency Vinnova. Pernilla Abrahamsson’s unique microdialysis technique, developed as part of her PhD studies, may enable faster, easier, and more accurate diagnostics of severely ill patients. Known as Surface MD, it uses a unique MD catheter which can be placed on the surface of an organ rather than inserted into it, so reducing the risk of complications such as bleeding caused by the procedure. The project has been granted VINNOVA financing for the first in a series of milestones and if it reaches all of them, it is in line to receive a total of SEK 2 million. Pernilla Abrahamsson works partly as a project manager for her microdialysis project at Umeå Biotech Incubator, UBI, and also as a project leader for innovationssluss Västerbotten Umeå University Professor Mikael Elofsson and his collaborators from the Karolinska Institute, Stockholm, will receive a grant of SEK 25 million from the Swedish Foundation for Strategic Research for their work on antibiotic-resistant bacteria, specifically the virulent bacterial pathogen Pseudomonas aeruginosa. Its incidence is part of an urgent worldwide problem of increasing numbers of bacteria resistant to current pharmaceuticals and it can cause severe disease among patients with a compromised immune system. The researchers hope that the results from this study can be used to develop drugs against other pathogenic bacteria and diseases as well. Professor Elofsson runs an antiviral project at Umeå BIotech Incubator.

85

Focus on Umeå

Medicvent AB develop and manufacture a comprehensive range of products for the scavenging of air pollution

We clear the air in the operating room Clean air is about health, safety and mental acuity, for both staff and patients. We have many years of experience in minimizing gases, odours, vapours and particulates – right at the point of leakage.

Efficient extraction Medicvent offers a modular, central fan system – with accessories such as double masks and larynx covers – which effectively extracts the leaking gas and particles, and integrated extraction of fumes during e.g. laser and diathermy surgery, complete with on-off valve.

Better air quality Our system sucks the air out of the room, which is simpler and minimizes the problem of unpleasant odours. During laser and diathermy procedures air quality is significantly improved compared with charcoal filter fans.

“We chose Medicvent’s system

because it is a simple, smooth and very effective way to eliminate embarrassing odours and particles in laser and diathermy surgery. ”

In addition, our equipment occupies less space and is less noisy.

M e di ca l D ev ice

www.medicvent.se Learn more about our products on the web.

86

Others using our laser and diathermy evacuation system include Central Hospital in Växjö, University Hospital in Örebro, Sunderby Hospital, Central Hospital in Karlstad, and University Hospital in Malmö.

Medicvent AB Pendelgatan 3, SE-904 22 Umeå Tel.: +46 90 12 75 00 Fax: +46 90 77 23 61 info@medicvent.se www.medicvent.se

Ingela Häggström, Head of Operations Södra Älvsborgs Hospital, Borås

Focus on Umeå

Techtum Lab AB Personal support and service

Techtum Lab AB focus on two areas, QPCR/PCR and liquid handling/storage products. Techtum are continuously looking for new innovative products that will provide unique advantages for our customers. Our sales team knows the importance of personal support to provide with an optimal solution for every application. It is important that we give our potential customers best possible support when buying a new product. In order to accomplish that Techtum provides with free evaluation of instruments and consumables. Our customers are also free to return the products if they not work satisfying. Techtum is well known for a high level of support and service among clinical and research customers throughout Scandinavia since many years.

“Techtum is far more than a distributor. The capability to develop a low cost and high throughput screening system for MRSA according to demands by Karolinska Hospital as well as several other successful product developments is unique for us as being a distribution company. “ Håkan Evefors, VP sales and Marketing

Li fe Sc i en c e I n st r u m e nt s

Techtum Lab AB Yrkesvägen 5, SE-904 20 Umeå Tel.: +46 090 77 88 80 info@techtum.se www.techtum.se

87

Focus on Ume책

88

Focus on Umeå

Umetrics Value from Data®

World leading user friendly solutions for Design of Experiments and Multivariate Data Analysis Umetrics is the preferred partner for multivariate technology in QbD and PAT. We offer complete solutions ranging from software and training to implementation and support.

World leading graphically driven software solutions - #1 in ease of use Umetrics solutions deliver far more than sets of numbers you will need to interpret. Unique visualization of data, extensive wizard functionality and customizable plots maximize usability and versatility.

World leading consulting, support and training services No matter where you are, Umetrics is always nearby offering support, consulting and training. So you can rest assured that your solution will always be up and running.

Soft w a re

Umetrics AB P. O. Box 7960, SE-907 19 Umeå Tel.: +46 90 18 48 00 Fax: +46 90 18 48 99 info.se@umetrics.com www.umetrics.com

89

Focus on Umeå

Umeå Care

I nte r n at i on a l C a re

UMEÅ, SWEDEN

90

Focus on Ume책

STEREOTACTIC FUNCTIONAL NEUROSURGERY

I nte rn at i o n al C a re

University Hospital of Umea Ume책 Care SE-901 85 Ume책 Tel.: +46 90 78 59950 Mobile phone: + 46 72 575 08 86 umeacare@vll.se www.umeacare.vll.se

91

Focus on Stockholm-Uppsala

Focus on Stockholm-Uppsala

92

Focus on Stockholm-Uppsala

93

Focus on Stockholm-Uppsala

Foreword by Chris Heister, County Governor, Head of the County Administrative Board of Stockholm

Christ Heister has been the Governor of Stockholm County since 2012.

She has been appointed as Member of Parliament and also as Chairman of the County Executive Board of Stockholm.

Chris Heister is involved in life sciences in a number of different ways. Among other things, she is the chairman of the foundations Stockholm Science City, Flemingsberg Science, and Swecare. During 2012-13, she is the chairman of the steering committee for SILS (Sweden as International Centre for Life Science) - a strategic partnership between Sweden’s leading life science regions.

Stockh ol m – a life sc ie nc e re g io n of t h e f ut ure

foreword

It is well known that the life science sector, with its high added value, is important to Sweden and is currently the source of a fifth of export revenues. The industry is undergoing a rapid structural shift and proactive work is necessary in order to take advantage of the new opportunities that arise. In this way, increased global competition can be met and responded to.

94

In this respect, the Stockholm Region has an excellent starting point. Large public and private research investments have come to the region, and many companies in the region have adapted their business models based on the new situation. For example, one of the world’s leading medical universities, Karolinska Institutet, is located in the county, as well as a significant part of the substantial national initiative Science for Life Laboratory (SciLifeLab).

The cluster initiatives in the region have focused on both pharmaceuticals and medical technology. In recent

years, they have met with increasing success, and enjoy increasing levels of interaction with the world class IT cluster centred around Kista. The cluster of the moment is Stockholm Life – at the hub of Hagastaden, where the universities, companies, and healthcare are provided with the best opportunities possible to cooperate.

In order to better take advantage of the favourable situation in regions and in the country as a whole, the Stockholm / Uppsala region, along with Västra Götaland, Skåne, Linköping / Norrköping, and the Umeå Region has commenced a collaboration that will strengthen the sector both nationally and regionally - Sweden as International Centre for Life Science (SILS). Within the collaboration, we have concluded that Sweden’s greatest opportunity in the global arena is if we use our unique expertise and resources as well as utilising our relative small size. Through out joint efforts, we want SILS to ensure that:

Focus on Stockholm-Uppsala

• companies have better access to research facilities and are more quickly able to reach the global market, • investors have the opportunity to invest in quality assured product concepts with great potential for international success, • researchers have access to world class research opportunities, • health care personnel play an active role in the knowledge and innovation system, • patients receive better, safer, and quicker treatment.

We have agreed what must be done in order to achieve this:

Chris Heister

fo rewo rd

In order to strengthen the collaboration between ongoing large national and regional initiatives in life science, we see a need for a national delegation for collaboration.

It is also important to identify which measures that can and should be implemented, both in the short and long term. Other suggestions concern how to create better

ways to disseminate best practise in order to tie together industry, academia, and health care. New methods are also needed in order to make available large infrastructure investments such as SciLifeLab, European Spallation Source, and Max IV for companies. We are determined to improve the opportunities for clinical studies, to truly utilise the great opportunities that Sweden has to be a world leader in this area. We have also agreed to highlight, in a number of different ways, the need for new financial solutions for life science.

Initially, the sector needs to ensure that the early research and development stages are overcome, during which a lack of risk capital is palpable (valley of death).

Now that we are taking action at SILS, the Stockholm Region will continue to be strongly committed!

95

Focus on Stockholm-Uppsala

Foreword by Ylva Hultman-Erlandsson, Business Development Manager Stockholm Business Region Development

Geari ng up

foreword

Momentum is building for Stockholm’s life sciences. One of the world’s leading knowledge regions has been a life science stronghold for decades. Now Stockholm-Uppsala invests to strengthen that position with one of Europe’s largest urban development projects, Hagastaden.

96

It’s about synergy, and a considerable bit of spirit. Clusters cannot be created, but they can be helped to evolve. A new city district takes shape in central Stockholm, from a foundation of decades of academic research. With Karolinska Institutet of Nobel fame as the most prominent stakeholder, Hagastaden is a unique project, already a center for academic research in central Stockholm. It is now the stage for one of Europe’s largest urban

development projects. The area is emerging to a new powerhouse for life science companies, scholars and citizens. 5,000 residents, 50,000 workplaces and EUR 7 billion in investments is in the stake.

By 2025, Hagastaden in the heart of Stockholm will be an entirely new neighborhood with a mixture of apartments, workplaces, cultural attractions, green areas, world-leading research institutions and highly specialized medical care. A vibrant life science community.

The dynamics of leading research will be incorporated in daily life and work. That is the idea. It is secured by the direct proximity to Karolinska Institutet, one of the world’s leading medical universities,

Focus on Stockholm-Uppsala

research facility center SciLifeLab, the head office for European Centre for Disease Prevention and Control and a myriad of companies.

For an investor, Stockholm offers more possibilities than ever before. The region has a long innovative tradition, from big pharma like Pharmacia and Astra, and breakthroughs from the Pacemaker to

How to start? Begin with Stockholm-Uppsala Life Science Investment Hotlist. It is a carefully selected top list of investment cases from the region. Curated

by Stockholm Business Region Development, the list is a tool for investors focusing on innovation and commercial breakthroughs from the most promising new companies. Visit www.investstockholm.com for more information. Stay tuned and welcome to Stockholm.

fo rewo rd

A new state-of-the-art university hospital – New Karolinska Solna – will be the epicenter. Currently under construction, and focusing on highly specialized medical care, it will become a natural hub of healthcare, research and academia, due to open in 2016. Of course a unique advantage for the area’s stakeholders. Just imagine the business environment.

the Gamma knife and Pulmicort. But the time when a few giants dominated is now gone. With 630 life science companies and counting, the region is of growing interest from an investor’s perspective.

This is where you will find the next big thing.

97

Focus on Stockholm-Uppsala

Foreword by Göran Alderborn, Dean of faculty of Pharmacy Uppsala University

Photo: Jim Elfving

M ed i ci n e and Phar mac y at U ppsa la U nive rsit y

foreword

Medicine and Pharmacy is one of three disciplinary domains of Uppsala University and represents a major research and teaching unit in the Uppsala-Stockholm region in the life sciences. The disciplinary domain consists of two faculties, the faculty of Medicine and the faculty of Pharmacy. The domain is organised in twelve departments that are located at three research and teaching centers at Uppsala University, i.e. the Biomedical Centre (BMC), the Rudbeck laboratory and the Uppsala university hospital. In addition, the domain hosts four clinical research centres localized outside Uppsala in the cities Gävle, Falun, Västerås and Eskilstuna and a number of multi-disciplinary research centers.

98

The domain conduct research in preclinical and clinical medicine and in pharmaceutical and caring sciences and about 150 professors and 600 teachers and research scientist are active in developing the research program.

The research program of the two faculties is broad dealing with fundamental and applied projects, including some profile areas, namely cancer, neuroscience, infection

biology and antibiotic resistance and, finally, drug development. As a part of the research infrastructure, the faculties are running a series of high-class service facilities focused on imaging, gene and protein analysis and drug development. In addition, researchers of the faculties are strongly involved in developing and running front-line technology platforms within the Uppsala node of the Science for Life laboratory, a national infrastructure for life science.

The faculty of Medicine, which consists of 9 departments, has a long-term tradition in medical and biomedical science. Over the years the research output from the faculty has led to several innovations and close contacts with industry both within the Uppsala area and abroad.

Particular strong research areas of international top class, based on recent external evaluations, are basic and clinical cancer research, genomics, epidemiology, inflammation including angiogenesis, organ and cell transplantation, metabolism, functional pharmacology, development of neuronal circuits, biomaterials and

Focus on Stockholm-Uppsala

Foreword by Stellan Sandler, Dean of faculty of Medicine Uppsala University

regenerative medicine as well as research psychosocial and supportive care and bioethics.

The domain offers about 20 teaching programs, educating professionals for key positions within the health care and pharmacy sectors, the life science

Read more about education and research at the Disciplinary Domain of Medicine and Pharmacy of Uppsala university at www.medfarm.uu.se.

fo rewo rd

The faculty of Pharmacy is devoted to teaching and research related to the development and use of medicines. It is recognized as a top-class faculty in Europe and the pharmacology and pharmacy disciplines at Uppsala University are rated as internationally prominent disciplines. The research groups of the faculty represent a unique cluster of academic competences in pharmaceutical sciences in Sweden with broad contacts to the industrial life science sector and the faculty has thus a key role in the development of Swedish pharmaceutical research. Particularly strong areas of research are drug design and imaging, drug absorption and formulation, pharmacometrics and drug dependency, within which the faculty hosts international top-class research groups.

industry and authorities. Major teaching programs educate physicians, nurses, midwives, pharmacists and biomedical analysts and about 6 500 students are active within the programs and other courses. After graduation, students can continue to study on two PhD programs of the domain, i.e. in medical science and in pharmaceutical science. The faculties put great emphasis on running broad and extensive PhD programs with the ambition to educate PhDs that will contribute to the development of a high quality health care and industrial sector and that represent the frontline academic researchers of tomorrow. Today, about 800 PhD students are pursuing research studies within the domain.

99

Focus on Stockholm-Uppsala

Stockholm-Uppsala:

The hub of Sweden’s life science sector

Stockholm is not just the business capital of Sweden; it is the capital of the Swedish life sciences sector. It offers an extremely competitive business environment that is up-to-date, open, business orientated and globally connected.

Stockholm is a major Northern European financial hub and the business hub of Scandinavia, with an advanced financial market. More financial decision-makers and company headquarters are located there than anywhere else in Scandinavia.

The numbers of multi-national companies that have chosen a base in the capital testify to the calibre of local advisors and business partners. Stockholm, together with its northern neighbour Uppsala, is the location for one of Europe’s largest and most productive life science clusters, The Stockholm-Uppsala region benefits from excellent supporting expertise in IT, telecommunications, clean technology and energy. Stockholm-Uppsala is home to five universities with world-leading research, several hundred companies, university hospitals with top quality medical care, innovation support functions, and major government agencies, such as the Swedish Medical Products Agency.

Who’s who The Karolinska Institute The Karolinska Institute is a medical university with a thoroughly modern outlook. Originally established by King Karl XIII in 1810 as an “academy for the training of skilled army surgeons”, it is now responsible for over 40 per cent of the medical academic research conducted in Sweden. It offers the country’s broadest range of education in medicine and health sciences.

KTH Royal Institute of Technology Founded in 1827 as the Kungliga Tekniska högskolan, KTH moved to its central Stockholm campus in 1917. Including its four satellites, KTH have 14,500 students and an academic staff of more than 2,900, who are responsible for a third of all higher technical and engineering research and teaching in Sweden. It is the premier technical university in Sweden, with world-class research in a number of areas, designed in such a way as to break down traditional barriers between academic disciplines.

Stockholm University Stockholm University is the state university in the capital, which was founded in 1878 as “an alternative to the traditional universities in Sweden”. Now the largest university in Sweden, it has more than 60,000 students and 5,000 staff. It has nationally leading research in several segments of the life sciences.

Uppsala University Established in 1477, Uppsala University is the oldest in the Nordic countries. A research-focused organisation, 67 per cent of its turnover of SEK 5.5 billion SEK in 2012 was spent on research and research, while 29% went on education. Carolus Linnaeus, Olof Rudbeck, Anders Celsius, and Erik Gustaf Geijer are some of the famous figures associated with the university over the years. Uppsala University has no fewer than 11 campus areas – 10 in Uppsala and one in Visby, Gotland.

Stockholm Life is a hub for life science research and development in the Norra Station/Karolinska area of Stockholm, now known as Hagastaden. This area, where the cities of Solna and Stockholm overlap, contains academic institutions, life science companies, clinical healthcare facilities and government authorities in the medical field. It produces internationally recognised research.

100

The role of Stockholm Science City Foundation is to bring academic institutions and businesses in the life science field to Stockholm Life. The aim is to create a world-leading science city – a society with a mixture of academia, industry, hospitals, residential areas, culture, service and recreation – and a world class knowledge hub for the life sciences. Stockholm Science City Foundation is a joint venture between the three leading universities that make up the Stockholm Life hub – Karolinska Institute, Royal Institute of Technology and Stockholm University -- together with the cities of Stockholm and Solna, Stockholm county and the region’s business sector.

Focus on Stockholm-Uppsala Looking north

The life science sector in Uppsala, 70 km north of the capital, also has a long tradition of strong academic research and of translating research into life science products which have global market and range.

Uppsala BIO is an independent, not-for-profit organisation that describes itself as building “new ways to make life science flourish in Uppsala, in close collaboration with industry, academia, society and healthcare”. Its activities are decided upon jointly by the life science industry, universities, the healthcare sector, and the municipal authorities, which also provide funding, together with Sweden’s innovation agency VINNOVA. Uppsala BIO offers programmes and other assistance to strengthen the long-term competitiveness of life science in Uppsala.

STUNS (Foundation for Collaboration between the Universities of Uppsala, the Business Sector, and Society) works actively for sustainable regional growth and enhanced regional attractiveness, particularly in terms of long-term value. Its strategic areas include life science operations involving the open innovation program BIO-X, with Uppsala BIO. Its innovation and business activities are collaborations with other innovation players and the region’s business incubator Uppsala Innovation Centre (UIC).

Looking south

Uppsal a Stockh Flemin olm gsberg

The Flemingsberg Science Foundation is a part of Stockholm Life. Its point of departure is the strong clinical and academic life science base in Flemingsberg -- a southern suburb of Stockholm – which has a focus on medtech. The Science Foundation addresses the challenges in healthcare by combining clinical insight, academic knowledge from the universities in the area, with business competence from industry and entrepreneurs, and thus leading to innovations and the creation of new business. Flemingsberg is home to a number of Sweden’s leading universities and research institutes: the Royal Institute of Technology, Karolinska Institute, Karolinska University Hospital and Södertörn University. Each year, these four educate 16,000 students and researchers.

Unique medtech projects have made Flemingsberg the place for new partnerships that lead to discovery and innovation. The framework of the Center for Technology in Medicine and Health (CTMH) and Karolinska Institute Science Park provides invaluable support to successful researchers as they work towards establishing companies that can be internationally competitive in the export markets.

Flemingsberg, forward-looking and focused, describes itself as “a place where knowledge drives business”.

101

Focus on Stockholm-Uppsala

Bringing innovations to development

Karolinska Institute Science Park provides a bridge between academic researchers and entrepreneurs and support companies, encouraging new ideas and discoveries to eventual development. It is a commercial enterprise founded by the Karolinska Institute with the aim of offering an attractive and creative environment where innovative companies can grow, right beside the academic research and education facilities. The science park offers modern office premises, first class laboratory facilities and services for both newly created and mature companies in the fields of life science, medical technology and service production.

It occupies two different sites - four buildings in Solna and one Flemingsberg. Altogether 65 companies are based in the park, which has a close collaboration with the Royal Institute of Technology and Södertörn University.

health and medical care, according to project company Swedish Hospital Partners, and there is a greater focus on the patient’s needs, faster provision of care, and increased patient safety, with single rooms for all inpatients.

The Science Park says that “adequate infrastructure and a fruitful interaction between the commercial and the academic world is necessary to ensure that the public will benefit from research.” To help provide this profitable collaboration, the Karolinska Institute created a system to secure financing for the many innovations coming from its researchers. This led to the setting up of Karolinska Development, which “develops innovations from worldclass science into products that can be sold or out-licensed with high returns.” Its portfolio, currently of 36 projects, is particularly strong in the areas of cancer, infections and wound healing, inflammation, cardiovascular disease, women’s health and diseases that affect the central nervous system.

The new building will be considerably more concentrated.

There will also be close relationships and effective transportation and logistics between the care and research facilities and the Karolinska Institute. The New Karolinska Solna hospital is intended to create the conditions for rapid knowledge transfer between basic research, clinical research and specialised care, and translational research.

The increasingly important connection between these areas requires a concentration of resources and expertise.

Much of the equipment and multi-disciplinary expertise must be used jointly in order to obtain higher efficiency.

New development in Stockholm-Uppsala There is a great deal of investment being made in infrastructure to support the Stockholm-Uppsala life science cluster and in the surrounding urban environment.

Stockholm Life is part of the new area of Hagastaden, where capital expenditure on infrastructure is expected to exceed EUR 5 bn (SEK 43.35 bn) over the next 10 years, the largest such investment in Stockholm’s history.

The single largest new development in the cluster is the New Karolinska Solna Hospital, designed by White Architects and Tengbom Architects, two of the country’s leading practices, which formed a joint team for the project. It is a state-of-the-art new university hospital which is expected to open in 2016. It is the biggest project ever undertaken by Stockholm County Council, as well as one of the largest and most innovative healthcare projects in the world. The new hospital, with Karolinska Institute as its closest neighbour, will provide specialised healthcare in close collaboration with education and research and its facilities will cover an area of approximately 320,000 sq m in total. It is being built to meet future demands for

102

The present Karolinska University Hospital has two major sites, in the municipalities of Huddinge and Solna, and has about 15,000 employees and 1,700 patient beds. However, the facilities of the Karolinska Hospital in Solna are being replaced by the New Karolinska Solna University Hospital, which is its project name. The present campus, much of which dates back to the 1930s, is spread over a large area and more than 40 buildings. Major changes are needed to adapt the hospital to modern methods and systems of integrated healthcare.

Flemingsberg: ‘where companies are born and grow’ Currently new premises totalling over 1.6 million sq ft are being planned for Flemingsberg where, at present, a number of well-known life science companies, such as Medivir and KaroBio, exist side-by-side with the Karolinska Institute Science Park. A new tramline, known as Spårväg Syd, is planned in preparation for the future expansion.

The new Södertörnsleden roadway and the new bypass around Stockholm will also improve transport to and from Flemingsberg. It is already the location of one of Sweden’s largest train stations and close to Stockholm’s three international airports..

New clinic for Uppsala Uppsala is not missing out on the development spending, as it is the location for the new Skandion Clinic that is being constructed. It is the first Scandinavian clinic for advanced treatment of cancer using proton therapy. Due to open in 2015, the clinic is designed at present for the treatment of 1000 patients per year, but it also has the option for expansion in the future. Uppsala already has a very advanced cancer clinic at the University Hospital, where for the last ten years patients with peritoneal cancer have been treated. The clinic says proudly: “Our treatment outcomes are among the seven best in the world.”

Focus on Stockholm-Uppsala Science for Life The Science for Life Laboratory, or SciLifeLab Stockholm, was set up in 2011 with the aim of becoming the leading centre for large-scale biosciences in the world, with a focus on health and environmental research. The inspiration for it came from Stockholm University, the Karolinska Institute, the Royal Institute of Technology and Uppsala University. A key strength of SciLifeLab is its focus on finding cross-disciplinary synergies. Researchers in biology and medicine, for example, are working with innovators from the Royal Institute of Technology. A great deal of the organisation’s work is carried out in partnership with industry.

SciLifeLab combines advanced technical expertise and state-of-the-art equipment with wide knowledge in translational medicine and molecular bioscience. Platforms in genomics, comparative genetics, proteomics, functional biology, bioimaging and functional genomics are complemented by research programmes in biology, medicine and environmental sciences. SciLifeLab makes available the technology to provide optimal use of resources that are unique to Sweden and Scandinavia, among them clinical material in the form of biobanks and high quality medical records.

Stockholm-Uppsala region leads the world with its life science research There seems to be a constant flow of world-first research news from the Stockholm-Uppsala life science cluster, so much so that the discoveries are too numerous to list. Here are just a few recent examples, all stemming directly from years of planning and data-gathering, cooperation, hard work and high standards.

Twins of different birth weight prone to different problems

Risk of developing dementia has declined since 1990s

Novel proteins could distinguish between MS patients

Recent research, using data from the twin register at Karolinska Institute, shows that twins of different birth weights are prone to different problems. Dr Catarina Almqvist Malmros, Associate Professor at the Astrid Lindgren Children’s Hospital, which is part of Karolinska Institute, analysed data from a questionnaire completed by the parents of nine to 12 year-old low birth weight twins. She observed that where the twins were different weights at birth, the lighter twin was more likely to develop asthma than the heavier one, while atopic eczema was more likely in the heavier twin.

Another recent Swedish study that produced unexpected results was based on research going back to the 1980s.

It suggests that the risk of developing dementia may have declined over the past 20 years.

Scientists from Royal Institute of Technology at SciLifeLab have identified a set of novel proteins that could distinguish between groups of patients suffering from multiple sclerosis, based on the severity of disease and how the disease will develop over time. Their study was based on the Protein and Peptide Array facility in the Biobank Profiling research group at SciLifeLab in Stockholm.

The study included information on more than 10,000 twins born at weights under 2000g (4.4lbs) and more than 3500g (7.7lbs). The Swedish Twin Registry holds information on around 85,000 twin pairs, both monozygotic (identical) and dizygotic (non-identical).

The study found that the prevalence of dementia was stable in both men and women across all age groups after age 75 during the entire study period (19871989 and 2001-2004). Since survival rates for those with dementia have improved since the end of the 1980s, this means that the overall risk of developing the condition has decreased.

This was in direct contrast to what many previously assumed, said researchers from the Aging Research Center, established by the Karolinska Institute and Stockholm University. The project took its data from SNAC-K, an ongoing study on aging and health that started in 1987.

In the recent study, more than 11,000 protein fragments, representing 38 per cent of the protein coding genes, were divided in sets of 384 proteins and printed on 30 protein arrays. A set of 51 proteins was identified as promising autoimmune targets to be used to distinguish MS patient groups as to the severity of disease and how it may develop over time.

103

Focus on Stockholm-Uppsala

Spotting what’s hot

104

Abera Bioscience Stockholm • Biotech • Vaccine Development

Diamyd Medical AB (publ) Stockholm • Drug Development • Diabetes

BinaryBio AB Stockholm • Bio Molecular Simulations and Bioinformatics • Distributed Computing

Episurf Medical (publ) Stockholm • Medtech • Implants

BioLamina AB Stockholm • Biotech • Cell culture tools

Inerventions AB Stockholm • Medtech • Assistive Devices

Biovica International Uppsala • Medtech • Diagnostics

IRRAS AB Stockholm • Medtech • Catheter Systems

Corline Systems AB Uppsala • Medtech • Biomaterials and implants

KeytoLead AB (K2L) Södertälje (Stockholm area) • Preclinical Pharmaceutical Research • Lead Generation and Medicinal Chemistry

Focus on Stockholm-Uppsala

Stockholm Business Region Development, the business development and marketing organisation for Stockholm, has launched a tool to make it easier for foreign investors to find life science partners in Stockholm and Uppsala. The Stockholm-Uppsala Life Science Investment Hotlist, unveiled in March 2013, showcases the region’s most attractive and interesting companies for investors. The list was prepared in collaboration with Swedish consulting firm Avanture and initially includes 20 companies.

ModPro AB Uppsala • Pharmaceuticals • Therapeutic antibody replacement

Q-linea AB Uppsala • Medtech • Human diagnostics, BSI

NeoDynamics Stockholm • Medtech • Diagnostic Technologies

Senzime AB Uppsala • Medtech • Monitoring Devices/Hospital Equipment

NoseLabs AB Stockholm • Medtech and Quality Diagnostics • Cancer Diagnostics

Spiber Technologies AB Uppsala • Life Science • Biomaterial

Oss-Q AB Uppsala • Medtech • Implants for complex bone defects

Xbrane Bioscience Stockholm • Biotech • Protein Expression

Premune Stockholm • Biotechnology • Allergy prevention

XSpray Stockholm • Pharmaceutical dry particle formulation • Protein Kinase Inhibitor formulation

105

Focus on Stockholm-Uppsala

Abera Bioscience AB a novel platform for vaccine development Abera Bioscience (www.aberabio.com) has developed a proprietary platform for the rapid development of multivalent and multistage vaccines. The platform makes use of Outer Membrane Vesicles (OMVs) that display multiple antigens at high density at their surface, and is suitable for the production of combination-vaccines targeting multiple diseases simultaneously.

OMVs are small vesicles that naturally shed from the outer membrane of both harmless and pathogenic bacteria. OMVs are highly promising vaccine candidates because they combine several unique features: • Immunogenicity: they have intrinsic adjuvant activity, similar to the parent bacteria they are derived from, resulting in strong stimulation of both humoral and cellular immune responses.

• Safety: unlike the parent bacteria, OMVs cannot replicate and are thus not subject to the regulatory hurdles that complicate the introduction of live, replicating bacteria as vaccines.

• Compatibility with oral and nasal delivery: ideally suited to induce not only systemic but also local mucosal responses to prevent transmission of pathogens.

Bi ote ch n o l ogy

Of note, OMVs are already used in licensed human vaccines such as the recently approved MenB vaccine.

106

Abera brings the OMV technology to the next level by decorating them with antigens from other (disease causing) bacteria, viruses or parasites. To this end, we have adapted a natural system for bacterial protein secretion (Autotransport) into the most efficient and versatile system for surface display of antigens known today. This way of presenting antigens has the following additional advantages: • Optimal exposure to the immune system.

• Compatible with simultaneous expression of various sizeable antigens to elicit broad protection (even to more than one pathogen) and to prevent immune evasion.

• Acceleration of development: prototype vaccines can be ready in days rather than months.

• Scalable, cost-effective production methods based on a novel hypervesiculating bacterial strain made by Abera.

Prototype vaccines were shown to elicit strong humoral and cellular responses in both mice and cell-based assays and protection against infection in challenge experiments in mice. Other technologies - all based on Abera’s unique expertise in Autotransport - include the display of antigens on the surface of living bacterial cells and the secretion of antigens into bacterial culture medium. These technologies enable the development of antigen selection methods and the construction of live and subunit vaccines for specific (also therapeutic) applications.

Abera technology: antigens are produced inside bacteria and efficiently displayed on the surface of living cells or nonliving OMVs. Alternatively, antigens can be secreted into the extracellular environment for easy recovery.

BIOSCIENCE

Abera Bioscience AB Stureplan 15, SE-111 45 Stockholm Tel.: +46 707 98 36 39 info@aberabio.com www.aberabio.com

Focus on Stockholm-Uppsala

AlphaHelix Technologies AB Development of direct “crude QPCR” instrument AlphaHelix Technologies AB is working in two areas, the development of an instrument based on our patent and to become world leading on small QPCR/PCR set-up and general pipetting robots. Our patented technology for PCR/QPCR, Superconvection, allows for running samples with high volumes faster than other technologies. A newly filed patent will also allow for doing QPCR reading when running non purified samples. The future aim is to develop an instrument allowing running QPCR samples direct without purification steps.

AlphaHelix is also developing a new unit for QPCR/PCR set-up together with Addcare, the leading manufacturer of liquid handling robots in China. The instrument will be launched the first part of 2014. Our aim is to become market leader within the next 3 – 4 years. This will be accomplished by developing a unit with lower cost, simplified running and better performance than existing units.

αAmp thermocycler

Mikael Havsjö, CEO

AlphaHelix Technologies AB Fålhagsleden 53, SE-753 23 Uppsala Tel.: +46 18 12 07 01 sales@alphahelix.com www.alphahelix.com

Li fe Sc i en c e I n st r u m e nt s

“AlphaHelix is an exciting company that will combine development work based on our proprietary technology for running non-purified clinical QPCR samples with sales of QPCR set-up robots that pays for the development“

107

Focus on Stockholm-Uppsala

AlzeCure – Fighting Neurodegenerative Disorders AlzeCure is a hands-on non-profit research foundation developing new therapies, diagnostics and medical technologies for the benefit of patients suffering from Alzheimer’s disease and other neurodegenerative disorders.

AlzeCure is funded by donations and grants, providing long-term stability for continuous evaluation of novel concepts from academic research. The integration of clinical expertise enables the development of novel concept testing approaches and that novel treatment paradigms can be tested in a clinical setting at a very early stage.

Promising projects are spun-out as commercial entities, allowing external partners and investors to buy-in, contribute and collaborate.

AlzeCure has several key projects within two defined strategic drug discovery platforms: • Building the brain - helping the damaged brain to recover from injury • Clearing the brain - removing the misfolded proteins that are common denominators of neurodegenerative disorders AlzeCure is developing an innovative biosensor technology to enable local determination of biomarkers levels with high resolution in various tissue fluids for use in multiple indications.

D r u g D i scove r y

We are interested in: • Donations to AlzeCure Foundation: help us to deliver new effective treatments to the patients!

• Collaborations with academic scientists as well as biotech-, pharma- and med tech companies: join us in the fight against neurodegenerative diseases!

• Investments in our projects: share risks and upsides with us!

108

For enquires and further information, please contact Dr. Jonas Ekstrand, CEO AlzeCure Mail: jonas.ekstrand@alzecure.org Phone: +46 70 302 0896 Visit: AlzeCure Foundation, Karolinska institutet Science Park, Hälsovägen 7, S-141 57 Huddinge, Sweden Web: www.alzecure.org

AlzeCure Karolinska Institutet Science Park Hälsovägen 7, SE-141 57 Huddinge Tel.: +46 70 302 08 96 info@alzecure.org www. alzecure.org

Focus on Stockholm-Uppsala

AroCell AB Develops tests for prognosis, monitoring and follow-up of cancer treatment

In the complicated world of cancer treatment there is one thing you will always want to know – is the tumor growing or not?

AroCell measures what really matters – cell growth.

D i ag n ost i c s

AroCell AB Uppsala Science Park, Generalen Dag Hammarskjölds väg 34A, SE-751 83 Uppsala Tel.: +46 18 50 30 20 info@arocell.com www.arocell.com

109

Focus on Stockholm-Uppsala

110

Focus on Stockholm-Uppsala

Axcentua Pharmaceuticals AB a drug development company

Axcentua Pharmaceuticals is an innovative drug discovery and development company located at the Karolinska Institute Science Park. Axcentua is pioneering a unique strategy, crystal reengineering, for accelerated development of novel therapeutics to the clinic with clear benefits for unmet medical needs.

Axcentua’s lead compound, AXP 107-11, is a multi-targeted crystal re-engineered natural compound, currently in clinical trials for pancreatic cancer. AXP107-11 was developed from bench to clinic in only 2 years showing that crystal re-engineering is a unique strategy for accelerated drug development. IP protection of the crystalline form, the crystallization process, composition of matter, and therapeutic use of AXP107-11 is secured through a recent US patent and a pending PCT. Pipeline expansion through novel formulations of AXP107-11 as well as crystal re-engineering of backup candidates is ongoing.

Our development strategy enables fast proof of principle of candidate drugs in the clinic leading to early value enhancement and commercial opportunities.

Crystal re-engineering Graphite

Diamond

Crystal engineering Name: Carbon Symbol: C Atomic Number: 6 Atomic Mass: 12.0107

Name: Diamond Symbol: C Atomic Number: 6 Atomic Mass: 12.0107

Natural Compound

Drug

Crystal re-engineering Name: Drug Symbol: Atomic Mass: 270

Axcentua Pharmaceuticals AB Alfred Nobels AllĂŠ 10, SE-141 52 Huddinge Tel.: +46 8 524 88 620 www.axcentua.se

D r u g Di s cove r y

Name: Genistein (natural compound) Symbol: C15H10 O5 Atomic Mass: 270

111

Focus on Stockholm-Uppsala

Biomotif AB Capturing the essence of life

Biomotif is a R&D, CRO and instrument sales company with technology for analyzing complex biological samples. We have new powerful tools for modern drug development and validation of new drug candidates.

Operation Biomotif develop new front end instrumentation for mass spectrometry. The multifunctional proprietary HX-IA Instrument™ has been developed for advanced PROTEOMICS & INTERACTOMICSstudies. This technology is based on several new inventions such as ElectroCapture, Memrane assisted H/DX, Compound Fishing-Epitope Imprinting and on-line pI separation of proteins and peptides.

The HX-IA Instrument™ will provide a better understanding of biomarker targets and there structure/conformation, dynamics and molecular interactions with potential drug candidates in the liquid phase.

Fee-for-Service Biomotif offer a contract analysis service in the following areas:

C RO - Cont ra ct Res e a rc h O rga n iz at i on

HDX Studies-Mode-of-Action (MoA) analysis

112

Drug Discovery – Small Molecule and Antibody – • Protein-antibody epitope mapping identification • Protein-protein or protein-peptide interface mapping • Bioequivalence studies • Patent submission/protection information • H/DX screening for structure based drug design Structural Biology • Identification of disordered regions in protein constructs that prevent crystallization • Identifying the effect of mutations on protein stability • Complementary data to x-ray and NMR data Scientific Collaboration Partners We will work with world class scientific partners for technology and method development. Our partners will get access to unique technology for solving complicated analytical tasks as well as copublish with us in high end scientific journals.

Biomotif AB P. O. Box 156, SE-182 12 Danderyd Tel.: +46 8 755 43 90 info@biomotif.com www.biomotif.com

Focus on Stockholm-Uppsala

ZuLa Diagnostics AB Early disease detection ZULA Diagnostics AB, a company located in Täby, Sweden, has the most promising innovation based on unique new substances, arginine derivatives, for research collaboration, project partnering and out-licensing.

More than 25 years of intensive research on the human protein Cystatin C, including identification of its biological active site has lead to production of a large number of small (<600 Dalton) synthetic substances having unique properties suitable for use in cosmetic products, medical device and for pharmaceutical development.

ZULA have potent Antibiotic and Antiviral drug candidates based on the elucidation of the structure of the active site of a human protein, Cystatin C. The mechanism is different compared to all currently available antibiotics, since bacterial strains resistant against all presently available antibiotics still are killed.

Some of our substances show antiviral capability to inhibit the replication of both DNA virus e.g. Herpes simplex and RNA virus e.g. Polio.

We are seeking financial partners for the development and testing of these drug candidates.

ZULA provides high throughput proteomics analyses of clinical samples, first of all blood plasma.

By fast and accurate profiling the relative concentrations of abundant proteins, stratification of patients is performed that is predictive of the progression of Alzheimer’s disease (AD) as well as other severe diseases. Unlike our competitors who search for (often elusive and sometimes non-existent) “golden” molecules uniquely identifying disease status, our approach is to utilize easily accessible information coded in small variations of the levels of abundant proteins. This approach is fast, requires minute amounts of sample, and is potentially scalable to be incorporated in the highthroughput blood analysis pipeline of major hospital centers.

ZULA conducts research related to the action mechanism of novel as well as known anticancer and antibacterial agents. Rapid “in-silico” mechanism prediction algorithm is used to forecast the best complementary drugs for known anticancer agents.

ZULA will initially explore the unique properties of one of the substances in a new cosmetic product, a Lip Balm, for skin and lips in bad condition.

With a special formulation containing exclusive Swedish and Nordic natural ingredients together with Arginine derivative A20, we plan to market our product as a “Swedish Magic Cream”

ZuLa Diagnostics AB P. O. Box 156, SE-182 12 Danderyd Tel.: +46 70 563 89 53 tl@zuladiagnostics.com www.zuladiagnostics.com

D r u g Di s cove r y

The substance library is based upon the active site of the protease inhibitor Cystatin C

113

Focus on Stockholm-Uppsala

BioThema AB We Measure Life BioThema uses its expertise in bioluminescence for the development of assays in a number of applications.

These include: rapid cell counting, cell proliferation and cytotoxicity, immunoassays, measuring enzymes and metabolites, reporter gene expression, hygiene monitoring, biomedicine and HTS in drug discovery.

Our technology The energy currency in all living cells is known as ATP (adenosine triphosphate). Using ATP technology our customers are able to rapidly measure the amount of cells from a single bacterial cell upwards. In addition to the number of cells, we can measure the activity of enzymes, other cell components and gene expression.

Furthermore we produce the best luciferin, which is used, for example, for in vivo imaging.

Customer focus Our assay kits and reagents are used by customers in research institutes, clinical diagnostics, hospital hygiene, and the biotech, food and beverage, water, cleaning and pharmaceutical industries.

Our extensive R&D efforts enable us to launch a constant stream of innovative products in new application areas. We also have a successful OEM business where we cooperate with partners in various fields.

Quality Continued investment in state of the art production facilities ensures the high quality and reliability that BioThema is well known for. Batch to batch variation is very low, and each batch of reagents can be traced via quality assurance records.

International Sales Around 90% of our sales are exported and we supply our products to all the major international markets through direct sales or via our network of distributors.

Bi ote ch n o l ogy

Whatever your requirements, whether direct sales to customers or business to business enterprises, BioThema AB is the company of choice in our selected application areas.

114

BioThema AB Handens stationsv채g 17, SE-136 40 Handen Tel.: +46 8 7770020 info@biothema.com www.biothema.com

Focus on Stockholm-Uppsala

Bluefish Pharmaceuticals AB Quality medicines accessible to more people

Founded in Sweden, with its long tradition of industrial entrepreneurship, Bluefish Pharmaceuticals is one of the most progressive generics pharmaceuticals companies. Since its inception in 2005 Bluefish has acquired the know-how and developed a platform to operate in all the major steps of the value chain of the generic pharmaceuticals business. Driven by our vision of offering high quality pharmaceuticals at prices affordable to all we have worked out new and more cost efficient ways of operating, in areas ranging from product development, quality assurance, pharmacovigilance, IP and supply chain, as well as marketing and sales.

Bluefish has created a strong platform and has a proven business model that is operating on 20 developed generics markets in Europe. Thanks to our experience, flexibility and cost centric mindset, we have developed a lean organization, able to quickly launch new products in markets and rapidly react by adapting to market changes. Bluefish is currently expanding outside Europe and is focused on becoming a global player, bringing the benefits of our vision for medicines to more patients and healthcare systems throughout the world.

Bluefish offers a product portfolio consisting of a broad range of high quality generics for all major therapeutic areas. The company currently has 80 products and a long-term strategy of expanding the product portfolio further, focusing not only on off-patent blockbusters but also offering a broader range of niche products in more narrow disease areas.

P h a rm a ce u t i ca l

Bluefish Pharmaceuticals AB Torsgatan 11, SE-111 23 Stockholm Tel.: +46 8 5191 1600 Fax: +46 8 5191 1690 info-se@bluefishpharma.com www.bluefishpharma.com

115

Focus on Stockholm-Uppsala

CMA Microdialysis Exploring Tissue Chemistry CMA Microdialysis has been the worldâ&#x20AC;&#x2122;s leading microdialysis provider for more than 25 years. Microdialysis is a valuable tool for in vivo evaluation studies on drug delivery, drug metabolism, PK/PD, bioavailability, bioequivalence and pharmacological efficacy.

CMA´s vision is: To substantially shorten the time-to-market of drug and research projects by offering a complete and leading portfolio of Microdialysis products.

The principle of Microdialysis The Microdialysis Probe mimics the function of a blood vessel. The probe is constantly perfused with a physiological solution at a low flow-rate (usually less then 2 Îźl/min).

Once the probe is implanted into the tissue, endogenous substances are filtered by diffusion out of the extracellular fluid into the perfusion medium. By reversing the process the probe can be used to locally infuse exogenous compounds, nutrients and drugs for periods of up to several days. Samples are collected and then analyzed.

The Microdialysis Probe has a semipermeable membrane at its tip. A variety sizes and membranes are available depending on where you like to take samples. The inlet side of the Microdialysis Probe is connected to a CMA syringe pump. The outlet tubing is attached to a CMA Fraction Collector. Microdialysis combined with an appropriate analytical technique is the ultimate solution in the search for a universal, real-time biosensor.

Li fe Sc i en c e I n st r u m e nt s

Examples of where Microdialysis can be applied?

116

Psychopharmacology Mechanisms of drug action on release, uptake and interactions among neurotransmitters and neuromodulators represent the classical application field for Microdialysis.

Neurochemical correlates to different models of mental disorder, behavioral and cognitive functions can be studied in chronically implanted freely moving animals.

Pharmacokinetics and toxicology Microdialysis probes can be implanted simultaneously in several organs (including blood) of the same animal.

Distribution and time course of free drug (toxin) concentrations are measured in vivo. Pharmacokinetic data can be calculated using theoretical compartment models.

Neuropathology and cancer research Microdialysis is an excellent tool for monitoring the compounds proposed as markers of brain injury.

Neurodegenerative diseases, such as ischaemia, hypoglycaemia and epilepsy, as well as, processes related to neuronal plasticity, regeneration, neurotransplantation or tumor growth have been elucidated by Microdialysis.

Physiology Physiological stimuli such as physical exercise, nutrition or stress alter anabolic and catabolic phases of cell biochemistry in peripheral tissues (e.g. muscle, fat). Microdialysis data can serveas a cumulative index of treatment-induced metabolic changes over long time periods in animals or even plants.

CMA Microdialysis AB P. O. Box 7048, SE-164 07 Kista Tel.: +46 8 470 10 00 Fax: +46 8 4701050 cma@microdialysis.se www.microdialysis.com

Focus on Stockholm-Uppsala

Cobra Biologics Contract Manufacturing Excellence Cobra provide a comprehensive biologics and pharmaceuticals service offering, with multi-functional and experienced project teams nurturing customers products from pre-clinical through to clinical and commercial manufacture within three GMP approved facilities.

Expertise Cobra are a Contract Manufacturing Organisation (CMO) supporting the global life sciences industry in the development and manufacture of monoclonal antibodies (mAb), recombinant proteins, DNA, viruses, phage and cell line derived products and pharmaceuticals for clinical trials and commercial supply.

Experience Over 15 years of track record in producing biologics and pharmaceuticals for use in pre-clinical to Phase III clinical trials and commercial supply has given our people a unique knowledge base as both manufacturer and also as service providers for the global life sciences market.

We offer a broad range of integrated and stand-alone development services, stretching from cell line development to the supply of investigational medicinal product for clinical trials and commercial market supply.

Excellence Every program complies with cGMP standards worldwide and is conceived with an unmatched quality derived from the know-how of Cobra’s highly qualified, flexible and dedicated people.

We have three GMP approved facilities; in Sweden our Microbial production and Fill Finish facility in Matfors, and our Mammalian production facility in Södertälje, and in the United Kingdom our Microbial and Virus production facility located in Keele. Our sites offer a comprehensive service to nurture your project from conception to fill and finish.

Cobra take pride in manufacturing excellence, delivering what we promise and helping our customers to develop drugs for the benefit of patients.

Mammalian Production Facility Gärtunavägen 10, SE-152 57 Södertälje, Sweden Tel.: +46 8 552 50500

Microbial Production & Fill Finish Facility Storjordenvägen 2 SE-864 31 Matfors, Sweden Tel.: +46 60 641 670

Microbial & Virus Production Facility Stephenson Building Science Park Keele ST5 5SP UK Tel.: +44 (0)1782 714181

CMO - Cont ra ct Ma n u f ac t u r in g O rga n i z at io n

To take a virtual tour of our Mammalian production facility, or to arrange your own visit to either of our specialised sites, please visit our website www.cobrabio.com

117

Focus on Stockholm-Uppsala

Corline Systems AB The Regenerative Medicine Company

solutions for life

By applying Corline’s unique heparin coating technology CHSTM to your cells and tissue, you will •

•

reduce instant inflammation during cell therapy add pro-healing functionality to the graft

Bi o mate ri a l s & Im pl a nt s

CHSTM increases the survival rate of the cells/tissue and promotes revascularization of the graft.

118

For further information on our products, please visit us at www.corline.com

Corline Systems AB P. O. Box 956, SE-751 09 Uppsala Tel.: +46 18 713090 info@corline.se www.corline.com

Focus on Stockholm-Uppsala

Diamyd Medical AB Fighting Diabetes!

Diamyd Medical is a company dedicated to the fight against diabetes. The diabetes vaccine Diamyd® is the company’s furthest developed drug candidate. It has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes.

Diabetes – a major global problem Diabetes is estimated to affect a total of 371 million people in the world and this figure is expected to rise to 552 million by 2030. Complications from diabetes are already among the most common causes of death in many countries and is afflicting younger and younger people.

Type 1 diabetes, which primarily affects children, is an autoimmune form of the disease, meaning that the body’s own immune system destroys the beta cells in the body that produce insulin and regulate blood sugar. These patients depend upon several insulin injections per day for their survival. But insulin does not address the underlying disease process and even well controlled patients suffer from severe diabetes complications.

Project Portfolio The diabetes vaccine Diamyd® is aimed to prevent, stop or delay the autoimmune process and preserve the endogenous insulin producing capacity in type 1 diabetes.

Large studies show that preservation of at least some of the insulin producing capacity reduces diabetes complications by 60 to 80%. With 80,000 new patients per year in Europe and the US it represents a billion dollar market.

Clinical Trials Two Phase II studies with Diamyd® are ongoing. One study evaluates whether the diabetes vaccine can prevent type 1 diabetes in children who are at high risk of developing the disease, while the other study evaluates whether Diamyd® in combination with relatively high doses of vitamin D and ibuprofen can preserve the body’s own ability to regulate the blood sugar level in children and adolescents newly diagnosed with type 1 diabetes.

Business Development Diamyd Medical is looking to enter alliances with industrial partners for the further development and commercialization of the diabetes vaccine Diamyd® as well as GABA. We also aim to capitalize on our expertise and our global network within diabetes to actively evaluate opportunities for expanding our business in terms of developing and marketing products in the diabetes area. We are looking at both new development projects and fully developed diabetes products and companies.

Diamyd Medical also holds exclusive rights to the use of GABA and GABA receptor agonists for the treatment and prevention of diabetes and other inflammation-related conditions, such as metabolic syndrome, rheumatoid arthritis and allergies.

About Diamyd Medical Diamyd Medical is a Swedish diabetes company. The Company develops the diabetes vaccine Diamyd® for the treatment and prevention of type 1 diabetes. Diamyd Medical also holds exclusive rights to the use of GABA and GABA receptor agonists for the treatment and prevention of diabetes and other inflammation-related conditions.

The Diamyd Medical share is listed on the NASDAQ OMX First North list (ticker: DMYD B).

Please visit www.diamyd.com for more information.

D i a bete s

Diamyd Medical AB Kungsgatan 29 SE-111 56 Stockholm Tel: +46 8 661 00 26 Fax: +46 8 661 63 68 info@diamyd.com www.diamyd.com

119

Focus on Stockholm-Uppsala

Elekta AB

imagine

...advanced technology with the patient in mind

Neuroscience

Oncology

With Elekta, itâ&#x20AC;&#x2122;s reality.

120

4513 371 1128 02:13

Ra di at i on T h era py

Treatment Planning & Information Software

Brachytherapy

Every day, more than 100,000 patients worldwide are diagnosed, treated or receive follow-up with the help of an oncology or neurosurgery solution from Elekta. Through innovation and collaboration, we are advancing patient care.

Human care makes the future possible More at elekta.com

Elekta AB P.O. Box 7593, SE-103 93 Stockholm Tel.: +46 8 587 25 400 Fax: +46 8 587 255 00 info@elekta.com www.elekta.com

Focus on Stockholm-Uppsala

Episurf Medical AB Individually customized joint implants Prosthetic Surgery at a young age means 100 percent probability of reoperation Each year, about 1.2 million knees are replaced with prostheses. The mean age of patients with oa has shifted from 72 years in the 1990´s to 56 years today. The increased need for an interim solution prior to total knee replacement is therefore obvious.

For patients over 55 years of age, knee prostheses work relatively well, at least during the first 20 years. However, among patients who are under 40 years old, assuming an average lifetime, the risk to require another operation to replace the prosthesis is 100 percent. Therefore, in view of the operating costs borne by the society and the life span of the knee protheses, patients offered knee replacement surgeries are usually above the age of 60. The result is that patients who are in their 40s may have to live with the pain for about 20 years before they can undergo the surgery. For those aged 40-60 years, the Episealer Knee® can be a treatment option in the future. In this case treatment of cartilage lesions is done with a less invasive method at an earlier stage, without ruining the possibility of future knee replacement, in case the patient’s condition deteriorates.

Episealer® - customized implants The Episealer® is a small, personalized implant for the treatment of local cartilage damage in human joints. It is a small implant that can easily be deployed with maximum precision, resulting in minimal trauma to surrounding tissue, and requires a less complicated rehabilitation.

Preplanned individualized Surgery provides reproducable results Orthopaedic surgeons are provided with kits that are uniquely tailored to each patient, enabling the possibility of widespread use. The implant can be inserted with very high precision using Episurf’s individualized surgical drill guide, Epiguide®, minimizing the risk of incorrect insertion of implants.

The implants and surgical templates are designed before the surgery, by Episurf’s imaging center, based on patientspecific images (MRI or CT). The implants are designed to replace only the damaged cartilage surface, which is expected to contribute to faster recovery of patients and longer lifetime of the implants. The day surgery is safer and easier compared to current means of inserting implants. Our vision is to be able to treat patients with cartilage injuries at an earlier stage and also to stop further development of osteoarthritis in the knee.

Episurf’s implant concept: • The implants are adapted perfectly to the damaged area • The surgical procedure is minimally invasive • The surgical procedure is performed with high precision • The surgical procedure is easy to implement • The patient can leave the clinic the on the same day.

Clinical trials Episurf’s clinical trials will be conducted with a number of orthopedic clinics from 2012 and onwards. The Episurf Medical’s new implant concept for local cartilage damage is now available for patients in Europe after the CE-approval achieved in july 2013.

Episurf Medical AB Stora Skuggans Väg 11, SE-115 42 Stockholm Tel.: +46 8 6120020 nina.bake@episurf.com www.episurf.com

Me d ic al Dev i ce

We know all patients are unique - therefore we make individually customized implants - perfectly personalized for each patient - in doing so we can improve the outcome for the patient

121

Focus on Stockholm-Uppsala

122

Focus on Stockholm-Uppsala

GE Healthcare Bio-Sciences AB Together we can make the world healthier through imaginative sciences Life Sciences is part of GE Healthcare. Our aim is to provide researchers with innovative technologies that help them to develop new and better ways of treating the diseases and health issues that people all around the world face every day. Since 1950, one of our major sites is located in Uppsala, Sweden. Today we have 1200 employees on site, covering global responsibility for R&D, chemical manufacturing and marketing.

About GE Healthcare GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality and efficiency around the world. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 53,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

The quest for ways to prevent and cure disease has always motivated mankind. The last century, however, saw a phenomenal increase in the rate of progress. One of the most important success stories was the isolation and purification of insulin for the treatment of diabetes. This led eventually to a pharmaceutical industry that develops and manufactures human insulin using recombinant protein technology.

The purification and production of biopharmaceuticals such as insulin on an industrial scale have saved millions of lives worldwide. Today, our products are used in the purification of 90% of all FDA-approved biopharmaceuticals.

production. The ready-to-use and disposable tools deliver process time savings by removing steps such as cleaning and cleaning validation, and thus allow for faster changeover between products.

Uppsala is where GE Healthcare’s ReadyToProcessTM platform is developed and evolved. The ReadyToProcess product portfolio comprises equipment for cell culture, separation and purification, fluid management, and connectivity is designed to help users plug right into today’s challenges by simplifying and accelerating biopharmaceutical manufacturing, reducing time-consuming routines, and ultimately increasing manufacturing agility. Our local presence yet global footprint delivers the benefit of faster and quicker supply of vaccines – at the right time.

The future of bioprocessing Making equipment “smart” by utilizing small, build-in sensors in ready-to-use and single-use equipment with the capability to provide asset tracking and storage of documentation is the next big trend in the bioprocessing arena. Tagging equipment with sensors permits online, real-time verification & validation of production, assembly, storage, shipping, installation and use. GE Healthcare is determined to develop tools that will help biopharmaceutical producers simplify and streamline their processes through utilizing state of the art technologies.

Helping Biopharma producers go flexible Biopharmaceutical development and manufacturing demands scalable processes that can be quickly developed, easily implemented, and smoothly transferred to production.

In today’s environment of fast paced pandemic threats, readyto-use technologies play a crucial role in providing the flexibility to support multiproduct production facilities e.g. for vaccine

Since May 2013, GE Healthcare has combined the Medical Diagnostics and Life Sciences organizations. The new Life Sciences business unites the skills, experience, and technology that will enable customers to make better medical and research decisions, every step of the way from early drug discovery, through biopharmaceutical manufacturing, to diagnosis, therapy selection, and clinical care.

GE Healthcare Bio-Sciences AB Björkgatan 30, SE-751 84 Uppsala Tel.: +46 18 612 00 00 www.gehealthcare.com

He a l t h ca re

In research, GE Life Sciences offers comprehensive technologies and tools for protein purification, protein interaction analysis, electrophoresis, cell assays and imaging, cell therapy and essential lab consumables.

In biopharma manufacturing, we also supply products supporting biopharma manufacturing from cell culture to the final isolated biopharmaceutical product, as well as the capability for building entire facilities.

In the services offering, we can take responsibility for installing and repairing single equipment, to looking after the assets of the entire facility.

123

Focus on Stockholm-Uppsala

Karolinska Development AB Good clinical and commercial progress Karolinska Development is a new type of life science investment company, listed on the NASDAQ OMX Stockholm Stock Exchange (ticker: KDEV). Through a very active ownership, Karolinska Development aims to create value for patients, researchers and investors by developing innovations from world class science into products that can be sold or outlicensed with high returns. The active portfolio (see opposite page) consists of 30 projects with 8 pharmaceutical projects in Phase II clinical trials.

The business model is to select the most commercially attractive medical innovations; develop these innovations to the stage where the greatest return on investment can be achieved; and commercialize the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, such as the Mayo Clinic, delivers a continuous flow of innovations (see illustration below).

Li fe Sc i en c e Com m erci a l iz at i on

The long-term investment philosophy is starting to generate returns The year to date has been very positive for Karolinska Development. In March we announced the closing of a deal where Rosetta Capital acquired a minority share in 13 of Karolinska Developmentâ&#x20AC;&#x2122;s holdings for SEK 220m. In June, Athera Biotechnologies signed an option agreement with Boehringer Ingelheim on the innovative preclinical antibody program PC-mAb for prevention of secondary events in patients with acute coronary syndrome.

124

Recent positive clinical data pave the way for commercialization Several portfolio companies have recently reported clinical data. In April 2013, one of our lead portolio companies, Axelar, reported positive preliminary Phase II-data, which indicate that the lead compound, AXL1717, is effective in second line treatment of patients with non-small cell lung cancer. In June, our portfolio company within wound healing and infection, Pergamum, reported positive follow-up data from a Phase II clinical trial for prevention of post-surgical adhesions after hand surgery, a major medical problem. Given Pergamumâ&#x20AC;&#x2122;s results, we are optimistic that the treatment has the potential to become the first drug approved for this indication. Pergamum also reported positive preliminary efficacy results from a Phase I/II study in patients with venous leg ulcers, an area in great need of new treatment methods. Pergamumâ&#x20AC;&#x2122;s proprietary gel has the potential to be an important treatment in this area. In August, the portfolio company Pharmanest reported that it had met all end points in its Phase II study where its lead product, called SHACT, was tested as pain management in connection with intrauterine device (IUD) insertion. These positive data clearly show that SHACT has the potential to become the first safe and effective pain relief product for millions of women using IUDs.

Focus on Stockholm-Uppsala

Karolinska Development Portfolio Karolinska Development’s Active Portfolio Concept development

Pharmaceuticals

Lead identification

Lead optimization

Preclinical development

Phase I

Phase II

Phase III

Launch

Oncology

Axelar AB AXL1717 Aprea AB APR-246 Akinion Pharmaceuticals AB AKN-028

Infections and Wound Healing

Dilaforette AB Sevuparin, malaria Pergamum AB DPK-060, infected eczema Pergamum AB DPK-060, external otitis Pergamum AB PXL01 Pergamum AB LL-37 Biosergen AS BSG005 Pergamum AB PXL181

Women’s Health

Dilafor AB Tafoxiparin Pharmanest AB SHACT Umecrine Mood AB UC1010 Forendo Pharma Oy Endometriosis

Endocrinology

Forendo Pharma Oy Fispemifene

Cardiovascular

Athera Biotechnologies AB PC-mAb Dilaforette AB Sevuparin, SCD

Ophthalmology

Clanotech AB CLT28643

CNS

BioChromix Pharma AB Umecrine Cognition AB

Inflammation NovaSAID AB

Concept development

Technology

Prototype

Development

Product

Launch

Implants

Promimic AB Hanano Surface™ OssDsign AB Cranio PSI

Diagnostics

Athera Biotechnologies AB Athera CVDefine® BioChromix AB

Pharmaceutical Formulation

Medical Equipment NeoDynamics AB Fourier NeoDynamics AB PRFA

Dark color = completed phase

Light color = ongoing phase

Lead identification means that a number of compounds have been identified (leads) that each bind to the intended molecular target. In the next step (lead optimization), the program seeks to optimize the characteristics of those lead compounds to achieve the desired characteristics of a prospective pharmaceutical, such as increased specificity or solubility. The status of a project is defined as ongoing until it reaches the next milestone. For clinical phases the milestone is defined as when the first patient is dosed. Phase I safety studies conducted in patients, where first signs of efficacy can also be measured, are defined as ongoing in both Phase I and II.

Karolinska Development AB (publ) Tomtebodavägen 23 A, SE-17165 Solna Tel.: +46 8 524 860 70 info@karolinskadevelopment.com www.karolinskadevelopment.com

Li fe S ci e n ce Co mm e rci a l iz at i on

Inhalation Sciences Sweden AB PreciseInhale™ XSpray Microparticles AB RightSize™ Lipidor AB AKVANO™

125

Focus on Stockholm-Uppsala

Karolinska Institutet Science Park A leading arena for innovative life science companies With over 60 companies, Karolinska Institutet Science Park has grown to a leading arena for innovative life science companies.

Based on the vibrant campus sites of Karolinska Institutet in Northern and Southern Stockholm (Solna and Flemingsberg), close to Karolinska University Hospitals, KI Science Park connects research, business and healthcare.

KI Science Parks offers infrastructural services and supporting functions to member companies such as: • Office premises and laboratory facilities • Symposium and networking activities • Mentor program • Investment day • Strategic tool to support efficient drug development Meet the companies in the Park or become one of us!

Companies within the Park comprise anything from start-ups to more mature companies, developing new treatments and methods in various therapeutic areas such as cancer, CNS, women’s health, medical technology. Several projects are in clinical development phases.

S ci e n ce Pa r ks

In April 2013, eight KI Science Park companies were ranked as the hottest biotech companies in Sweden: Akinion, Aprea, Axelar, Dilafor, Index Pharmaceuticals, Pergamum, Pharmanest, Swedish Orphan Biovitrum.

126

Karolinska Institutet Science Park Tomtebodavägen 23 A, SE-171 65 Solna Märit Johansson, CEO Tel: +46 70 872 35 32 Fax +46 8 30 34 23 marit.johansson@kisciencepark.se www.sciencepark.ki.se

Focus on Stockholm-Uppsala

LINK arkitektur AB We create space for better lives LINK arkitektur places great emphasis on the shaping of the most important field of architecture - your everyday environment. Where you work, live, study or seek health care.

We possess extensive knowledge regarding health care environments, and seek to improve and develop continuously to meet future demands on flexibility, efficiency and sustainability in health care architecture. LINK arkitektur strives to be in a leading position within this sector. The search for new knowledge in combination with our long experience forms a stable foundation to build new projects from. We create eventful, exciting architecture, yet streamlined and logic in infrastructure and work flow. We always focus on people - patients, visitors and staff.

Photo: Hundven-Clements Photography

LINK arkitektur is among the leading architectural offices in Scandinavia, regarding turnover, number of employees, and annually completed projects. Our 13 offices in Sweden and Norway work closely together and therefore we always have the capacity to take on both large and small scale projects. Besides the traditional building construction field of architecture we also work within the fields of landscape, interior and maritime architecture, as well as in infrastructure and urban planning.

We dare say that LINK arkitektur is one of the most complete architectural offices in Scandinavia. As a client you will experience a forward looking partner that challenges you through the entire process and shows you possibilities never imagined!

Photo: Hundven-Clements Photography

LINK arkitektur AB Lumaparksv채gen 9, SE-120 31 Stockholm Tel.: +46 10 479 99 00 info@linkarkitektur.se www.linkarkitektur.se

Arch i te ct s

Photo: Hundven-Clements Photography

127

Focus on Stockholm-Uppsala

Medivir The emerging European pharma company Medivir is a collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in the field of hepatitis C. In 2013 registration applications were submitted for a hepatitis C compound, simeprevir - a project being conducted in partnership with Janssen Pharmaceuticals. Medivir also has a broad product portfolio of prescriptions pharmaceuticals that are marketed in the Nordic region.

100 75 50

Research & Development

Pharmaceuticals

Medivir works with the entire development chain, from the early research to the finished pharmaceutical product on the market. Medivirâ&#x20AC;&#x2122;s research focuses on infectious diseases and has cutting edge expertise in the chemistry and biology of the enzyme classes, polymerase and protease.

Medivir markets pharmaceuticals in the Nordic market. The product range comprises approximately 15 prescription pharmaceuticals in a variety of different therapeutic spheres, such as pain, gastro-intestinal, psychiatry and respiratory diseases. The Groupâ&#x20AC;&#x2122;s pharmaceutical sales totalled SEK 165 million in 2012.

The research portfolio comprises approx. nine pharmaceutical projects, five of which are being conducted in collaboration with partners. Seven of the projects focus on the development of antiviral pharmaceuticals, of which four are conducted in the hepatitis C sphere. The protease inhibitor, simeprevir, has been developed by Medivir and Janssen. Positive simeprevir phase III data was reported in December 2012 and togehter with previous phase II data, it formed the basis for the registration applications in the USA, Europe and Japan.

Collaborations Partnerships spread the risks while simultaneously ensuring that our research projects are conducted efficiently and with access to the right skill sets and financial capacity.

Partnerships also broaden the pharmaceutical portfolio.

Ph ar m ac e u t ic al

A strong position in the hepatitis C sphere, coupled with one of the most promising compounds that is currently in the registration phase. A pharmaceutical portfolio that generates stable sales and profitability.

128

Medivir Blasieholmsgatan 2, SE-111 48 Stockholm Tel.: +46 08 407 64 30 Fax: +46 08 407 64 39 info@medivir.com www.medivir.se

Focus on Stockholm-Uppsala

ModPro AB – the ideal partner for the pharmaceutical company ModPro AB is a company based in Uppsala, the biotechnology hotbed of Sweden. ModPro AB has developed a unique and unprecedented proprietary technology with applications ranging from targeted delivery in vivo to target validation in cell based assays and in vitro screening. ModPro has a proven commercial track record in the pharmaceutical field. The ModPro technology offers interesting IP opportunities.

The technology is based on a proprietary set of polypeptides and their conjugation to small molecules or peptides. The conjugates bind to the small molecule protein targets only much ”better”. Typical affinites are 3-4 orders of magnitude higher than those of the small molecules, essentially due to decreased off-rates, and selectivities are dramatically improved. The technology rapidly provides improved performance of lead compounds, candidate drugs, as well as powerful tool compounds for drug discovery and drug development.

Sample applications • Polypeptide conjugation to small organic molecules improves biodistribution in vivo and improves safety.

Candidate drugs failed due to drug related toxicity can be saved!

• Increased affinity due to decreased off-rates increases life time and effect duration of peptide drugs in vivo.

• Polypeptide conjugation to small molecules or peptides enables target validation using non-selective leads, provides ”affinity filter” in screening of libraries. Increased interaction area with proteins provides excellent screening platform for inhibitors of protein-protein interactions.

A large body of results from in vivo and in vitro experiments can be disclosed under CDA.

Contact: Prof Lars Baltzer, Ph D CEO, ModPro AB Email: Lars.Baltzer@modpro.se

L. T. Tegler et al. Angew Chemie Int Ed. 2011, 50, 1823-1827.

L Baltzer. Anal Bioanal Chem, 2011, 400, 1653-1664.

R. Ramapanicker et al. Bioconjugate Chem 2013, 24, 17-25.

ModPro AB P. O. Box 561, Husargatan 3, SE-751 22 Uppsala Tel.: +46 706 482595 info@modpro.se www.modpro.se

P h a rm a ce u t i ca l

References

129

Focus on Stockholm-Uppsala

Premune Revolutionizing the prevention of allergies

10 percent of the dog population suffers from allergy One in five visits to the veterinarian are connected to allergy, making allergy one of the most common diseases in dogs. The prevalence is increasing rapidly and, according to Agria Pet Insurance, allergy diagnoses have doubled over the past eight years. Today, it is estimated that more than ten percent of all dogs, regardless of breed, suffer from allergies. In some breeds, for example among Bull Terriers, Boxers, West highland white terries and German shepherd dogs, the risk is significantly higher. Atopic dermatitis (eczema) and food allergies are the most common allergic diseases, requiring life-long treatment that not only reduces the quality of life for both dog and owner, but also entails high costs for the dog owner.

Developing the worldâ&#x20AC;&#x2122;s first preventive treatment for canine allergies Building on leading research in bacteriology and immunology at University of Gothenburg, Premune is developing the worldâ&#x20AC;&#x2122;s first preventive treatment for canine allergies. The finished product is intended as oral drops, given to the puppy during the first weeks of life to trigger the natural protection of allergies.

Promoting activation of immunological tolerance mechanisms The discovery is based on 15 years of detailed birth cohort studies, where the research team behind Premune has been mapping the gut colonization patterns of Western infants.

From the studies, the research team has identified a naturally occurring bacterial protein, known as superantigen, that has a unique ability to stimulate the early immune system.

Whereas an ordinary bacterium activates <0.1% of all T-lymphocytes, the superantigen has the ability to activate up to 30% of all T-lymphocytes in the body. This massive immune stimulation promotes activation of immunological regulatory mechanisms that protects from allergy development. The research team behind Premune believes that the effect has the potential to recreate a broad immune stimulation that is today lost due to an all too clean lifestyle.

Unique field trial on canine allergy

Ph ar m ac e u t ic al

In May 2013, Premune initiated a unique field trial, aiming to confirm if an early immune activation can be applied to lower the risk of canine allergy development. The trial is performed in collaboration with Agria Pet Insurance, Swedish Kennel Club, Swedish University of Agricultural Science and Royal Canin. The first indications regarding allergy preventive effect of the treatment is expected within 12 to 18 months into the trial.

130

Premune AB Stureplan 15 vĂĽn4, , SE-111 45 Stockholm Tel.: +46 760 265 269 viktor@premune.com www.premune.com

Focus on Stockholm-Uppsala

Q-linea AB Q-linea system overview Every year, approximately 150,000 persons die from sepsis within EU. Currently available techniques for diagnosis take days, and can therefore not be used to guide treatment. For blood stream infections, every hour counts and mortality increases with approximately 7 % per hour.

Q-linea is a Swedish company that develops systems for rapid characterization of blood stream infections, both regarding identity of infectious agent and its susceptibility to different antibiotic substances.

The expected time of the assay will be approximate six hours for identity followed by an additional four hours to determine susceptibility. We believe that this would aid in the guidance of correct treatment at an earlier phase compared to current technologies.

The product will be a fully automated system that handles the samples as they arrive, and with a throughput of up to 100 samples per working day for each instrument. The system is based on proprietary amplified singlemolecule detection’ technology (ASMD), where padlock probes are used for selective identification of few target DNA molecules.

The system will provide a sensitivity of approximate 10 cfu/ml blood and the first pathogen panel will cover >90% of the most common pathogens causing blood stream infections. The system measures true susceptibility and does not rely in genetic markers coding for resistance genes.

The system is developed together with leading professionals within the area of microbiology and medicine in Sweden.

Q-linea also develops systems for rapid identification of Bio Warfare agents, such as bacteria, viruses and toxins.

The proprietary technology enables simultaneous identification on a unified platform, thereby reducing need for multiple systems for nucleic acid and protein detection respectively. The system can be configured as either continuous operation with a sample throughput of a sample every five minutes or batch-based depending on application.

D i ag n ost i c s

Q-linea AB Dag Hammarskjölds väg 54 B, SE-752 37 Uppsala Tel.: +46 18 444 36 10 info@qlinea.com www.qlinea.com

131

Focus on Stockholm-Uppsala

Ridgeview Instruments AB Instruments, software and knowledge for molecular interaction analysis

Follow your drug as it binds to living cells in real-time

Extend end-point assays with time resolved interaction analysis to better understand the biology of a therapeutic protein:

Li fe Sc i en c e I n st r u m e nt s

• time to onset • drug residence time • affinity and kinetics

132

LigandTracer® is a revolutionary simple yet powerful method to monitor protein interactions on living matter. Combine with Interaction Map® analysis from our sister company Ridgeview Diagnostics AB to unravel the heterogeneous biological processes often found on living cells.

Ridgeview Instruments AB Skillsta 4, SE-74020 Vänge Tel.: +46 708 927 856 info@ridgeview.eu www.ridgeview.eu

Focus on Stockholm-Uppsala

Senzime AB Measure and control

Senzime AB is a bio-tech company based in Uppsala, Sweden. The company develops and markets a unique and proprietary enzyme based biosensor technology with a wide applicability throughout different medical and bio/chemical processes and industries. We are already on the market in the biopharma field, for the detection of glucose in cell cultures and fermentation processes.

Senzime focuses on the following application areas: • Biotechnology – Bioreactor control for drug development in biopharma. BioSenz is a unique measuring device specifically developed for analysing glucose in bioreactors.

• Health Care – Continuous glucose monitoring is also needed in health care to improve patient outcomes of complex surgical procedures. Another area where online measurement may be useful is the field of dialysis treatment. For these purposes, Senzime is developing an instrument.

BioSenz is a unique measuring device specifically developed for analysing glucose in bioreactors.

Patented heat-flux technology is used for continuous measurement with high precision and repeatability.

The combination of the BioSenz with a process control system allows accurate control of the glucose levels in a bioreactor to optimize the performance of the bioprocess. The operation of the analyzer can be done through the process control system or via a computer using the BioSenz software.

Senzime AB Vallvägen 4A, SE-756 51 Uppsala Tel.: + 46 18 51 56 40 info@senzime.com www.senzime.com

Bi otec h n ol o gy

BioSenz

133

Focus on Stockholm-Uppsala

SIGOLIS AB We realise your ideas by micro structure replication ABOUT

TECHNOLOGY PLATFORM

Sigolis is a privately held company based in Uppsala, Sweden, and was founded in 2007 focusing on the Life Science Industry.

By using various techniques for micro sculpting silicon or other materials, Sigolis manufactures masters with extreme precision and high complexity. The masters are then transferred into durable molds to fit the CD-injection molding machine in which polymer micro structures are manufactured through a cost-effective replication process.

The technology combines the precision from silicon micromachining with the virtues of thermoplastic injection molding.

Our business concept is to develop customer specific micro structured components, refine existing products and realize proof of concept studies. Sigolis has extensive experience of developing production methods for microsystems in polymers and is dedicated to providing high quality products.

The company has been certified since 2011 according to ISO-EN 13485, the internationally recognized quality management system standard for companies developing and/or producing medical devices. Deloitte have ranked Sigolis numerous times among the fastest growing technology companies in Sweden and EMEA.

Sigolis´ technology can serve many fields of application in need for miniaturization, either as separate components including microstructures for fluidics, optics, mechanics and electronics, or as intricate multifunctional micro systems with several integrated components.

M e di ca l Te ch n o l ogy

Microstructures in polymer

134

Microstructures in nickel Master tool for injection molding

Focus on Stockholm-Uppsala

BENEFITS OF TECHNOLOGY • Cost-effective • High throughput • Extreme precision

• Vast variety of materials • Tool backup

B2B PRODUCTS

Polymer diffractive optical elements, for laser applications.

Micro spike equipped sensor head, for Electronic Impedance Spectroscopy (EIS) in order to detect malignant melanoma.

Nano liter dispenser, used for dispensing of nucleotides in a DNA sequencing application.

M e di c al Te c h n ol og y

Sigolis AB Vallvägen 4B, SE-756 51 Uppsala Tel. +46 18 413 43 00 info@sigolis.com www.sigolis.com

135

Focus on Stockholm-Uppsala

136

Focus on Stockholm-Uppsala

Thurne Teknik AB Specialized in improving your processes within Life Science / Bio Processing

Bi otec h n ol o gy

Thurne Teknik AB Heliosgatan 24, SE-120 30 Stockholm Tel.: +46 8 55 69 31 40 Fax: +46 8 55 69 31 41 info@thurne.se www.thurne.se

137

Focus on Stockholm-Uppsala

Uppsala Cancer Clinic Uppsala Cancer Clinic, UCC, is a private clinic offering leading expertise in cancer treatment The clinic that saves lives Behind every medical prognosis there is a soul. A person with hopes and dreams.

Those of us who work at UCC have spent more than 10 years providing treatment and care to over 750 patients with peritoneal cancer (peritoneal carcinoma). We base our work on the National Board of Health and Welfare’s concept of “Good Care”. The concept represents good health and care with respect for equality of all and the dignity of the individual.

Good care at UCC • Knowledge-based and suited to purpose health care.

• Safe health care.

• Patient-focused health care.

• Effective health care.

• Equal health care.

• Health care provided in a timely manner.

Unique technology saves lives “10 years ago, patients would not be operated by curative surgical intension in Sweden or in most of the places in the world if they were found to have peritoneal cancer”.

There was quite simply nothing that could be done using conventional chemotherapy on peritoneal cancer as the cytotoxin often does not reach the cancer tissue.

However, thanks to the Sugarbaker surgical procedure, which we have used since 2001, many patients can be saved. The purpose of the extensive Cytoreductive surgery is to remove visible cancer tissue. Depending on the diagnosis, the patient is then given heated cytotoxin, so-called HIPEC, for treatment of the invisible cancer cells adjacent to the area that has been operated on. The core of our effective treatment team is Professor and chief physician Haile Mahteme, who has trained with Professor Sugarbaker in the USA and is Sweden’s leading surgeon and expert in the field. Our staff team also includes gynaecological tumour surgeons, liver surgeons, oncologists, urologists, s anaesthesiologist, physiotherapists, a vascular surgeon, and specialist trained nurses. In total there are 40 of us running the clinic with the same mindset: respect for life and a focus on the patient.

I nte r n at i on a l C a re

By focusing on one patient group and providing a well-integrated intermediary/intensive health care, including a ward,safety is further increased. All staff have between five and thirty years of experience.

138

Employees

Professor Doctors of medicine Specialist physicians Nurses Anaesthetic nurses Operating theatre nurse Intensive care nurses Assistant nurses Physiotherapists

Total Women 2 3 1 3 9 8 4 2 5 5 10 5 4 4 1 1

Men 2 2 3 1 2 5

Focus on Stockholm-Uppsala

Contribute to a better tomorrow We want to contribute to a sustainable society and a healthy environmental mindset. The health care environment for the patient, the working environment for staff, and global environmental aspects are all therefore at the centre of all decisions.

We work constantly to reduce the clinic’s environmental impact and energy consumption.

Diagnoses treated with Cytoreductive surgey + HIPEC Appendix cancer One particular form of advanced peritoneal cancer from the appendix is pseudomyxoma peritoneal (PMP).

PMP has been successfully treated using cytoreductive surgery in combination with HIPEC. Colon cancer Colon cancer with peritoneal spread which is treated with extensive surgery in combination with HIPEC has allowed prolonged survival and cured 30-40 per cent.

Peritoneal cancer (abdominal mesothelioma) Disease is treated using cytoreductive surgery in combination with HIPEC. Gynaecological cancer Ovarian cancer In order to achieve good survival outcomes in patients with ovarian cancer and peritoneal cancer spread, all macroscopic tumour tissue should be removed and lymph node evacuation applied through a technically demanding surgical procedure. The treatment is combined with cytotoxin and inserted intravenously. Patients who experience a cancer relapse to the peritoneum after previous surgical and cytotoxic treatment, may be offered extensive cytoreductive surgery in combination with intraperitoneal cytotoxic treatment.

Best treatment regardless of where you live We provide patients with optimal treatment of peritoneal cancer (peritoneal carcinoma) and primary gynaecological tumours with no spread to the peritoneum. With a high quality, safe for the patient, cost effective, and evidence-based treatment, we offer a more accessible treatment option for more patients than has hitherto been possible. Examination initially takes place in your home community and can be done with guidance from UCC. When we have received and reviewed medical records, the patient will be called in for a consultation visit for information and assessment. Patients who have to travel a long way and require overnight accommodation can take advantage of our preferential rates with several hotels in central Uppsala. Naturally, UCC will be happy to help make the booking. Our goal is that a fully examined patient should be treated within 2-4 weeks after they first contact us.

Contact: Professor Haile Mahteme, Medical Officer and Chairman Tel. +46 76 163 08 99 Email: haile.mahteme@uppsalacancerclinic.com

Our goals are that the patient is treated within 4–6 weeks to reduce the clinic’s environmental impact, energy consumption and use of disposable materials.

Uppsala Cancer Clinic Dragarbrunnsgatan 70, SE-753 20 Uppsala Tel.: +46 18 18 56 00 info@uppsalacancerclinic.com www.uppsalacancerclinic.com

I nte rn at i o n al C a re

Susanne Svahn, Surgical nurse and CEO Tel. +46 76 163 67 70 Email: susanne.svahn@uppsalacancerclinic.com

139

Focus on Stockholm-Uppsala

Uppsala Care For foreigners in need of specialist healthcare Welcome to one of the largest hospitals in Sweden â&#x20AC;&#x201C; and the countryâ&#x20AC;&#x2122;s oldest university hospital.

Our specialist healthcare is also available to foreign citizens. We offer diagnosis and treatment by the foremost doctors in the world in a number of fields.

I nte r n at i on a l C a re

Helicopter and Jet Plane transport Uppsala University Hospitalâ&#x20AC;&#x2122;s helicopter is fully equipped to cope with intensive care situations. The crew is adapted to suit the situation, with an intensive care doctor/nurse or a neonatologist/paediatric nurse available as appropriate. We can also offer ECMO (Extra Corporeal Membrane Oxygenation) during transportation.

140

The Department of Endocrine Oncology The Department of Endocrine Oncology is a Center of Excellence and a national and international referral centre for neuroendocrine tumors. We are proud to present new diagnostic tools such as

chromogranins, somatostatin receptor imaging and PET-imaging with specific tracers and new therapies like tumortargeted radioactive treatment (PRRT) and liver embolization.

The Department of Endocrine Surgery has been developed for the treatment of many endocrine tumors, including aggressive resection for some tumors, debulking surgery and radiofrequency ablation.

The Department of Oncology Proton Therapy at The Svedberg Laboratory, Uppsala University Hospital Radio-therapy with protons is increasing worldwide, due to its

better dose distribution compared to conventional radio therapy (X-ray). A high dose can be delivered accurately to the target (tumor) with low or no dose to surrounding normal tissue.

The year of 2015 a new particle facility called the Skandion Clinic will open near the hospital. There will be a culvert connection with the clinics implying bed confined patients to be transported directly from their wards to the proton facility.

The Department of Plastic surgery and burn care At the Department of Plastic surgery, we provide care for children with congenital malformations of the face

Focus on Stockholm-Uppsala

Uppsala University Hospital in Brief: • 1 100 beds • 8 000 employees • 8 000 patients treated for various cancers • 56 000 admissions per year • 300 000 doctor appointments per year • 350 000 treatment procedures per year

of severe burns and intensive care medicine to rehabilitation and reconstructive plastic surgery, making it one of the leading Burn Centers in northern Europe. Telemedicine facilities are used for specialist consultations before transportation which can be handled by our hospital’s own flying ambulance service.

The Department of Gynaecological oncology Three times higher success rate of curing ovarian cancer.

The tumor surgical team at Uppsala University Hospital not only offers you

safe and complete care for all kinds of gynaecological cancer. In many cases we also greatly increase your chances of being cured. For instance, our methods for curing advanced ovarian cancer have a proven success rate of 50 percent, compared to 15 percent, using standard treatment procedures.

At the clinic we have special skills in fertility preservation and nervesparing surgery in treatment of cervical cancer. In other words, where fertility is normally put at risk, we offer you a surgical treatment that allows you to give birth even in the future.

Welcome to a healthier future.

Uppsala Care Uppsala University Hospital SE-751 85 Uppsala Tel.: +46 18 611 22 97 Fax: +46 18 55 15 23 uppsala.care@akademiska.se www.akademiska.se

I nte rn at i o n al C a re

and skull. Our multidisciplinary team gathers experts from plastic surgery, neurosurgery, maxillofacial surgery, pediatric anesthesia, orthodontics, speech pathology, ENT, medical genetics, radiology, ophthalmology and psychology. We offer comprehensive care for a full range of facial and craniofacial malformations, including clefts, hemifacial microcosmic, craniosynostosis and craniofacial tumors.

The Burn Center at Uppsala University Hospital, is one of Sweden’s two national Burn Centers. The Burn Center offers a wide range of clinical competence, from acute treatment

141

Focus on Stockholm-Uppsala

Vironova Providing image analysis services to the Biotechnology and Nanomedicine sectors With technical capabilities, virology- and TEM-expertise, Vironova offers a powerful quality and quantity assessment service invaluable in vaccine, drug delivery or gene-based medicine and important insight into research, development and production.

Vironova’s EM imaging and analysis customers come from many continents with diverse R&D questions. What they have in common is a demand for high quality, project customization, support, as well as fast delivery – all core values at Vironova.

Vironova´s Research and development programme Vironova runs research and development projects in collaboration with world leading scientists. The projects are funded by EU grants through Framework Programme 7 and Eurostars.

Vironova is a Swedish biotechnology company specializing in digital electron microscopy imaging and image analyses of viruses, liposomes and other nanoparticles.

Bi ote ch n o l ogy

With our proprietary software we offer a unique range of objective transmission electron microscopy (TEM) image analysis services to academia, biotech companies and the pharmaceutical industry. The image analysis services include size distribution, circularity, morphology, packaging, aggregation state and presence of debris/contamination.

The level of lamellarity and thickness of the liposomal bilayer of liposomes are also included in our portfolio.

142

Antiviral Portfolio – Medicines of Tomorrow Vironova is developing antiviral drugs against Herpes and Influenza by targeting structural components of the viruses.

By utilizing our own virus analysis technology platform, the effects of the new antiviral drugs can be visualized and analyzed.

The MiniTEM project Vironova aims to co-develop the world’s first portable TEM for automated identification of viruses and characterization of biological nanoparticles.

The TEM technique enables detailed analysis at nano-scale.

We use several techniques to further highlight or distinguish image features. Cryo-TEM is a technique to study delicate and dynamic structures of specimens sensitive to changes from the native environment, where high pressure freezing preparation provides maximum contrast for detailed structure analysis. By labeling antigens using gold particles, the precise identification and localization of proteins exceed any other immune labeling techniques. Moreover, scanning electron microscopy (SEM) provides a topographic image of the specimen with complex details of the surface structure.

Vironova AB Gävlegatan 22, SE-11330 Stockholm Tel.: +46 8 702 67 90 Fax: +46 8 702 67 91 info@vironova.com www.vironova.com

Focus on Stockholm-Uppsala

Vironova Biosafety AB The Scandinavian Center of Excellence in Viral Safety Testing

Viral Clearance Clearing the way for biopharmaceuticals - Adding commercial value

Vironova Biosafety AB, a subsidiary of Vironova AB, and the only of its kind in Scandinavia that is specializing in viral clearance testing of biopharmaceuticals. A careful documentation of viral safety studies is a critical and mandatory element in the overall safety assessment of any manufactured biopharmaceutical that is derived from human or animal components. We offer our clients our expertise and know-how, ensuring optimal viral safety testing and documentations (i.e. data from virus removal and/or inactivation during different steps of the manufacturing process), in accordance with current regulations.

Targeted Biopharmaceuticals Monoclonal antibodies

Recombinant proteins

Vaccines

Plasma-derived products

The Scandinavian Center of Excellence in Viral Safety Testing Based on our unique expertise in viral safety and long experience from work in GLP- and cGMP-certified laboratories at Big Pharma companies, we offer:

• • • • •

Customized virus validation studies Consulting support in the design and implementation of virus-eliminating steps Support in compilation of CMC documentation Expert reports on viral safety Guidance in regulatory-related questions

Located in central Stockholm, Vironova Biosafety AB operates in a new, state-of-the-art testing facility, carefully designed to meet the highest standard, and including a customer’s private laboratory. We perform high quality studies in compliance with GLP, seeking to provide a flexible approach to our customer’s request that may shorten their timelines.

Bi otec h n ol o gy

Vironova Biosafety AB Gävlegatan 22, SE-11330 Stockholm Tel.: +46 8 702 67 90 Fax: +46 8 702 67 91 biosafety@vironova.com www.vironovabiosafety.com

143

Focus on Stockholm-Uppsala

Viscogel AB Enabling improved vaccines, drugs and emulsions Viscogel was founded in 2008 with the objective to continue the development of a novel high quality chitosan. The company was started by professionals with long-term experience from the pharmaceutical industry. At the core of the company is the proprietary chitosan technology and know-how used to develop solutions for improved vaccines and drugs. The vaccine adjuvant project has demonstrated safety and efficacy in a Phase I/II clinical trial.

Chitosan is a derivate obtained from chitin, which is a commonly occurring polysaccharide that can be found in hard structures in nature. Current use of chitosan includes hemostatic products, water purification, cosmetics and food.

Chitosan’s antimicrobial and immuno-stimulating properties make it attractive for medical applications. The utility of standard chitosan is however limited due to issues with low quality and lack of solubility at physiological pH, which is a major hurdle for the use of chitosan in pharmaceutical development. Viscosan® and ViscoGel® have overcome these issues.

Technology Viscogel has developed a technology that provides: -> Viscosan®, a medical-grade chitosan with novel physical and biological properties.

-> ViscoGel®, a viscoelastic hydrogel based on Viscosan® with highly useful properties and potential to improve vaccines and drugs.

-> Viscomulsion®, an emulsion technology enabling efficient drug delivery solutions.

The technology is regulatory uncomplicated and the manufacturing process is well-controlled with low COGS.

Ph ar m ac e u t ic al

Projects

144

Vaccine adjuvants Global health issues tied to vaccines as well as pandemics such as swine flu, keep vaccines a key focal point for the pharma industry. The global humane vaccine market is

estimated at USD 28bn (2010) and expected to grow at rate of 11,5% annually during 2007 - 2017 (GBI Research). Only 4 adjuvants have been licensed in the EU and US combined.

Aluminum hydroxide (alum) is the most commonly used adjuvant worldwide. ViscoGel® is more effective than alum and has the desired properties to become a versatile, safe and effective adjuvant attractive for human and veterinary vaccines.

ViscoGel® as an adjuvant has demonstrated safety and efficacy in a Phase I/II clinical trial using a model vaccine.

Adding ViscoGel® to the vaccine resulted in an increased antibody response and a significantly stronger cellular response compared to the vaccine only.

Several evaluations (under MTA’s) together with vaccine development companies are ongoing in which ViscoGel® is combined with vaccines and evaluated in different animal models.

Drug delivery The drug delivery market is significant and has been identified as of interest to initially develop the company’s proprietary technologies. Properties such as mucoadhesiveness, unique stability, and controlled release features have the potential of adding value to products and patient benefit.

Milestones 2010 -> Start of the ViVac-project through EU research grant (EUR 1.2 million) 2011 -> Pre-clinical Proof–of-Concept for ViscoGel® as an adjuvant published in Vaccine

-> Toxicology studies successfully concluded 2013 -> Proof-of-Concept for ViscoGel® as a vaccine adjuvant in Phase I/II clinical trial.

Viscogel AB Gunnar Asplunds allé 32, SE-17163 Solna Main contact: Peter Singer Tel.: +46 708 555 100 peter.singer@viscogel.se www.viscogel.se

Focus on Stockholm-Uppsala

Xbrane Bioscience Taking protein production in E. coli to the next level Xbrane Bioscience aims to simplify your protein production make it faster and easier. To this end, we have developed two superior, versatile and easy to use systems for the production of proteins in E. coli, the Xbrane Lemo and Rhamex system.

Furthermore, using the Xbrane OptiXpress approach we offer protein production, strain development and optimization services that are tailored around each individual target based on the wishes and needs of the customer.

The Biotechnology market is rapidly growing and proteins are an important component as e.g. therapeutics, industrial catalysts or as a research reagent. The importance of proteins is driving companies to spend both time and money to identify the optimal protein production system for their protein of interest. The optimal system is cost-effective and gives high yields of functional protein. The bacterium E. coli is by far the most widely and successfully used host for the production of recombinant proteins. However, even when using this well-established protein production host, the production of many recombinant proteins is still cumbersome.

Xbraneâ&#x20AC;&#x2122;s Protein Expression systems Both the Xbrane Lemo and Rhamex Systems allow tuning the intensity of expression of the genes encoding recombinant proteins in an unprecedented accurate manner.

Both systems have successfully been used for maximizing the production of both routine and difficult to express proteins. Compared to standard protein production systems,

improvements of production yields of up to 50-fold have been observed. Importantly, both the Xbrane Lemo and Rhamex Systems allow operating in an exceptionally costand time-efficient manner.

The Xbrane Way Xbrane develops protein production strains for target proteins using the Xbrane OptiXpress approach. Based on the wishes and needs of our customers, we carefully design our strain development projects in modules that allow the rapid identification of bottlenecks hampering the production of a particular target so that they can be readily alleviated, thereby maximizing protein production yields.

In the OptiXpress setup we routinely investigate different parameters to improve expressions, e.g. different in-house strains and strain engineering. Xbraneâ&#x20AC;&#x2122;s unique platforms in combination with OptiXpress, ensures high success rates in shorter time for each project.

Higher Yields and Higher Quality - The Xbrane way

CMO - Cont ra ct Ma n u f ac t u r in g O rga n i z at io n

Xbrane Bioscience AB Stureplan 15, SE-111 45 Stockholm Tel: +46 73 434 36 19 info@xbrane.com www.xbrane.com

145

Focus on Stockholm-Uppsala

XSpray XSpray is improving some of the most important modern oral anti-cancer drugs – the protein kinase inhibitors. Our hybrid nanoparticles can improve the solubility and bioavailability of even the most challenging drug substances.

Through licensing deals and partnerships we are able to increase the potential value of PKIs – whether it relates to the formulation of a new PKI drug, a reformulation as part of lifecycle management strategy, differentiation of a generic, or to enable or extend patent protection.

PKIs – a challenging class of drugs Currently, products with sub-optimal formulations are reaching the market.

However, with so many PKIs in clinical development for the same indications it is going to become increasingly important to show a superior product profile and improved patient outcomes in the future.

Ph ar m ac e u t ic al

That means overcoming the problem of absorption variability, where the same treatment can result in a nonefficacious dose for one patient and a life-threatening overdose for another. Better control over bioavailability is needed to reduce risks and allow more efficient dosing regimens.

146

Improving product profiles

Innovators in PKI formulation

XSpray enables formulations with a superior pharmacokinetic profile. Our unique approach combines expertise in PKI formulation together with a proprietary technology platform for formulating PKI compounds as hybrid nano-particles.

We have shown major improvements for all 12 of the marketed PKI compounds that we have reformulated.

What’s more, our approach enables formulations to be optimized more quickly and efficiently than with alternative technologies, helping to reduce time to market.

Find out more and see a video presentation by our CEO, Dr. Per Andersson, “The PKI development challenge and the XSpray solution” at www.xspray.com.

“The PKI market is expected to see a staggering growth with the market valued at USD 15 billion in 2012 and anticipated to reach USD 36 billion in 2018 with a CAGR of 8 to 9 % from 2012 to 2018.” (Transparency Market Research)

Focus on Stockholm-Uppsala

Our approach is unique. Our results to date are unmatched.

P h a rm a ce u t i ca l

XSpray Microparticles AB Fogdevreten 2, SE-171 65 Solna Tel.: +46 8 730 37 00 info@xspray.com www.xspray.com

147

Focus on East Sweden

Focus on East Sweden

148

Focus on East Sweden

149

Focus on East Sweden

Foreword by Peter Larsson, Senior advisor Industrial Development East Sweden Region

Location and main figures The East Sweden Region has 430,000 inhabitants and covers an area of around 10,000 km2. The region is the fourth largest in Sweden, and is located two hours south of Stockholm, three hours northeast of Gothenburg and three hours north of Malmö. The population density is 40 inhabitants per km2, with a concentration of inhabitants in the central areas. The northern and southern areas are less densely populated. The major cities, Linköping and Norrköping, have continued to grow, while the population in the surrounding areas is decreasing. The age structure of the region corresponds to the nation as a whole, facing the same demographic challenges as the rest of Sweden.

foreword

Fourth city region Norrköping and Linköping, with their surrounding smaller towns and villages, are in the process of developing into one coherent, integrated urban region – Sweden’s fourth city region. The structure of the region – with large cities and small towns, surrounded by countryside, all within a relatively compact area – provides numerous opportunities for living within reasonable commuting time from many workplaces.

150

Administrative structure The Swedish public sector has three levels of government: national, regional and local. At local level, the region consists of 13 local authorities. The regional level includes three different authorities: the County Administrative Board, which is the national government’s representative office in the region and also a supervisory authority; the County Council, which is responsible for health and medical care in the region; and the Regional Council, which is in charge of

regional development issues, with political representation from the local authorities and the County Council.

Labour market and business sectors The labour market benefits from the fact that the local economies of Linköping and Norrköping complement each other. Together, the two cities contribute to a large number of different lines of business in the region. The East Sweden Region is becoming a single labour market with extensive commuting to the central parts of the region, also from surrounding regions. The region has well-developed support for business start-ups and new enterprises. There are approximately 40,000 companies in the region, within more than 540 different business sectors. The region possesses extensive and advanced technical know-how in several industries, such as aviation and energy technology.

There are a large number of spin-offs from Linköping University in terms of R&D-intensive companies. A large knowledge base, access to a well-educated workforce, and strong existing and evolving development environments for knowledge-based companies.

The major cities Linköping and Norrköping have been identified as having world-leading competence in the following profile areas: • Energy and Environmental Technology • Advanced Functional Materials • IT and Mobile Communication • Visualisation • Manufacturing Engineering • Health Care and Medical Technology • Logistics

Focus on East Sweden

Both geographical and occupational mobility on the labour market is increasing, but there is still a lack of skilled labour in some industrial areas. Labour shortages combined with a large number of retirements is a future challenge to trade and industry. Generation change among the region’s large number of entrepreneurs and executives is also a challenge.

Infrastructure and communications Infrastructure is a key issue for the East Sweden Region in order to grow, attract new companies and meet labour market demands for skilled people. The region has a well diversified infrastructure when it comes to roads, rail links, airports, ports and the IT network. The physical layout and relative compactness of the region enables good transport and communication solutions. However, the main line rail capacity to the Stockholm region needs to be developed.

The planned high speed railway – the Eastern Link – is important for the future growth of the East Sweden Region.

More than 1,500 foreign students attend courses at the university each year. Besides the growing number of international students, over 100 guest researchers per year take advantage of the stimulating research environment at Linköping University. However, young people from the region do not attend higher education to the same extent as in comparable regions. Overall, the educational level in the region is lower than in other Swedish regions that are successful within the knowledge economy. Skills levels in general need to be raised, and vocational training must be improved. There is a strong need for regional coordination when it comes to matching labour market requirements.

This is one of the main challenges for the East Sweden Region.

fo rewo rd

Culture The region’s cultural infrastructure is well developed, with established institutions, experienced cultural workers, excellent facilities and interesting historical sites. The institutions stand for confidence and continuity and help ensure that cultural production follows in the footsteps of tradition. There is also a great interest in the region for developing cultural life outside the institutions. The region was the first in Sweden to study the creative industry – an initiative which has received much attention both at home and abroad. The creative industry has been recognized as a key driver of the knowledge economy and includes sectors such as media/digital, art/design, cultural heritage, and tourism/recreational/sports.

Education Linköping University, one of Sweden’s larger academic institutions, plays an important role in the East Sweden region. The university is renowned for its innovative educational spirit and its long-standing tradition of interdisciplinary studies and research. The university has four faculties and more than 27,000 students.

151

Focus on East Sweden

Foreword by Mona Jonsson, Managing Director New Tools for Health

A reg i on that inve sts in th e f ut ure

foreword

New Tools for Health (NTfH) is a regional initiative based in Östergötland in the east of Sweden with the objective of creating new products and services that lead to increased independence for older citizens and more effective home based health and social care. NTfH is part of the county of Östergötland’s innovation system and financed by Sweden’s innovation agency, VINNOVA (Swedish Governmental Agency for Innovation Systems), the county council of Östergötland, the municipality of Linköping and Norrköping, Linköping University and some 50 member commercial enterprises. The way NTfH works is characterized by a combined catalysts- and brokers role within the innovation system, to meet the global challenge of the elderly population.

152

The uniqueness of NTfH lays in the partnership constellation in the region. The region has gathered a competence arena focusing elderly citizens, merging academic perspectives, health care and social workers and test environments. This arena forms a base for new products and services supporting loneliness among elder

adults. The municipalities of Linköping and Norrköping contribute with test environments where new solutions may be tested and validated within health and social care.

The region hosts two Science Parks, Mjärdevi SP and Norrköping SP which forms e.g. meeting points for e.g. various workshops within the scope of NTfH’s. Further, two research institutes, within Swedish ICT, Acreo and Interactive Institute, respectively, are part of the innovation system. Partly associated with Acreo is “Printed Electronic Arena” a sister organization to NTfH also supported by VINNOVA. Printed Electronics Arena create strong research and development in the technological field of Printed Electronics which, since 1998, and have been conducted at Linköping University and Acreo. The relationship to NTfH is in the field of developing state of the art mobile – easy to use – biosensors.

Linköping University is another important partner in the innovation system of NTfH’s. A newly established center:

Focus on East Sweden

New Tools for Health

Not often mentioned, medical clinics and staff are intrinsic parts of distributed health care innovations.

The University hospital I Linköping contribute with expertise within their field of duty (e.g. Heart failure, COPD, Degenerative diseases). The county council of Östergötland has initiated a test and innovation center where new medical and care solutions may be demonstrated, validated and tested within the clinics under regulatory advises.

NTfH is organizing one of the largest conferences within Ambient Assisted Living (AAL) in Norrköping 2013. The AAL joint program is a funding activity that aims to create better condition of life for the older adults and to strengthen the industrial opportunities in Europe through the use of information and communication technology (ICT). NTfH is involved in several international constellations working towards innovation within independence for older citizens and more effective home based health and social care.

fo rewo rd

Biosensors - and Bioelectronics Centre – provides world leading competences within biosensor construction for distributed diagnostics and disease monitoring. Other world leading university research competence within NTfH’s area is “lab-on-a-chip” technology to be analyzed with everyday mobile phones and visualization and graphic design. E.g. the “virtual autopsy table”, is a globally acknowledged resource for pathological scrutiny.

The global med tech company SECTRA specialized in medical imaging (headquarters in Linköping), is further developing this innovation. Linköping University hosts an innovation office as part of the regional innovation system and Linköping Initiative for Life Science Technologies (LIST) was initiated by the principal of Linköping University in 2009 to focus on research for future health care solutions.

A sister project, NovaMedTech, focus on development and commercialization of medical technologies for distributed care and personalized medicine.

153

Focus on East Sweden

East Sweden:

A shared focus on innovation

Linköping and Norrköping together represent the powerhouse of the East Sweden region. The county of Östergotland, home to nearly half a million people and 13 municipalities, is Sweden’s fourth largest urban area, some 150 kilometres south of Stockholm. The two cities lie within the Nordic triangle, arguably northern Europe’s most important transport corridor. Besides being the location for well-known international majors, brand new companies are establishing themselves there, primarily in the areas of life science, environmental technology and ICT. The life science cluster is known for its strengths in visualisation, where it is a world leader, medtech and healthcare.

Medieval cathedral city Linköping is the fifth largest city in Sweden, with more than 145,000 inhabitants. Though it has retained the atmosphere of an historic site of learning and culture, over the past 50 years or so it has become a centre for high-tech companies and cutting-edge research. The University of Linköping spans both Linköping and Norrköping, but the majority of its education and research is located in Linköping, at Campus Valla, a few kilometres from the centre, and the University Hospital Campus. Next door to Campus Valla is Mjärdevi Science Park, where many innovative businesses are launched, established and developed.

Former industrial environment The city of Norrköping has a population of about 132,000. Like Linköping, it has a long history, but in recent years many new companies in areas such as IT, media technology and visualisation have established operations there. A total of 9,000 companies are based in Norrköping and the number is steadily increasing. Linköping University’s Campus Norrköping is located right in the city centre, where restored factory and mill buildings now house lecture halls, libraries, research laboratories and cafés. Norrköping Science Park and Visualisation Center C are also sited close to the Campus Norrköping.

Linköping University Linköping University is well-known for encouraging collaboration that crosses traditional subject and faculty boundaries and this innovation-orientated mindset and openness to new ideas has led to a flow of world-class research in areas as varied as materials science, bioelectronics, IT and disability research. With campuses in both cities, Linköping University has 27,000 students, 1,400 research students and 3,900 employees. It is a research-based institution, with Faculties of Arts and Sciences, Educational Sciences, Health Sciences and an Institute of Technology.

It achieved full university status in 1975 and by 1980 had revolutionised research in Sweden by introducing interdisciplinary thematic research at the Faculty of Arts and Sciences. Researchers from different disciplines could find new ways to tackle problems together. In addition, Linköping University has always had an ongoing dialogue with the local business sector and the community, both in terms of research and education. The practical applicability of Linköping’s research has always been a given, making it one of the leading Swedish universities for commercialisation of its innovations. Many local high-tech companies find the university an invaluable research and development partner.

The life science area at Linköping University, including the Faculty of Medicine and the Institute of Technology, has around 800 researchers, among them 140 professors, and some 6,000 students.

154

Characterised by collaborative, cross-border research involving mainly the Faculty of Medicine and the Institute of Technology, strong areas are: Bioinformatics, Biomaterials, Biosensors, Cancer/ stem cells, Diabetes and metabolism, Cardiovascular inflammation, Developmental Biology, Medical Image Science, Organic electronics, and Protein folding, along with Life Science Technologies, Medical Microbiology and Medical Technology.

The University Hospital The university hospital, with 600 beds and about 5,500 employees, provides specialist care for Östergötland, Kalmar and Jönköping counties. It also serves central Östergötland with primary care. The hospital provides top quality healthcare with a number of high competence specialist areas, including burns care where, together with Uppsala University Hospital, it is responsible for national care (rikssjukvård). Its scientific activities are integrated into the Faculty of Health Sciences at Linköping University which makes for an open research environment and active development in healthcare.

The Centre for Teaching and Research in Disaster Medicine and Traumatology is located at Linköping University Hospital. It is independent, directly answerable to Östergötland region and the University of Linköping. It pursues research, development and education in disaster medicine and traumatology at regional, national and international level.

Focus on East Sweden Innovation and collaboration The life science players in the Linkoping and Norrkoping area are a mix of organisations that are part of, or affiliated to, the university or the university hospital, commercial organisations and companies and researchbased state entities. Two keywords sum up the relationships between them: innovation and collaboration.

The East Sweden Business Region organisation is a cooperation between local and regional partners, where growth issues are addressed relating to sustainable development of attractive environments for both businesses and inhabitants of the region. Östsam, the East Sweden Regional Council, is a regional body with political representation from the members – the region’s thirteen local authorities and Östergötland County Council.

Visualisation

Center for Medical Image Science and Visualization (CMIV) is a multidisciplinary research centre initiated by Linköping University, Östergötland region and Sectra AB. It conducts research to develop future methods and tools for image analysis and visualisation for applications within health care and medical research.

Visualisation Center C is a collaboration between the municipality of Norrköping, Linköping University, Norrköping Science Park and the Interactive Institute, is a public visualisation centre.

With the goal of demonstrating and disseminating knowledge about Linköping University worldleading medical visualisation research, it is housed in Norrköping’s historic industrial area.

Medical

Center for Medical Technology Assessment at Linköping University is an independent research institute, involved applied research sponsored by local and state health care providers, basic research and method development funded mainly by scientific councils and other national and international research bodies, and projects externally commissioned by commercial clients.

Linkoping University research centres include: Department of Clinical and Experimental Medicine, Department of Medical and Health Sciences,, the cross-faculty Department of Medical and Health Sciences, Department of Medical Technology, NIMED centre for noninvasive medical measurements, plus the Department of Physics, Chemistry and Biology.

Electronics, digital and nanoscience

ACREO, one of Europe’s top ICT research institutes, providing cutting edge resources and technologies in the fields of sensors and actuators, power electronics, digital communication and life science, has a site in Norrköping.

Santa Anna IT Research Institute carries out applied research in cooperation with industry, universities and the public sector. The Santa Anna Research Faculty includes more than ten professors from Linköping University and Campus Norrköping devoting part of their time on joint research projects with industry.

IT in medicine and home healthcare are research areas of special interest.

Strategic Research Center for Organic Bioelectronics, OBOE center, involves joint research groups from Linköping University, Karolinska Institutet and Acreo. It is funded by the Swedish Foundation for Strategic Research and government innovation agency VINNOVA. Its aim is to combining cutting edge organic electronics with biomedicine to develop groundbreaking life science.

Strategic Research Centre for Materials Science for Nanoscale Surface Engineering is a collaboration between the universities of Linköping and Uppsala. It provides a strong research platform and framework for cooperation between organisations in the area of advanced surface engineering, with a focus on nanotechnology for tools, components, contacts, and sensors.

155

Focus on East Sweden Science parks and high tech environments Mjärdevi Science Park One of the fastest growing science parks in Europe, it is the base for 250 innovative and knowledge-intensive companies together employing more than 6,100 people. Particular strengths there are: mobile broadband, imaging and visualisation and software and systems development. A significant proportion of Mjärdevi-based companies are university spin-offs (27 per cent) and company spin-outs (11 per cent). Berzelius Science Park was merged into Mjärdevi.

Berzelius Clinical Research Center, Linköping, is a site management organisation specialising in clinical conduct of Phase 0/I/II studies working as partner for medical contract research organisations and pharmaceutical companies.

Across the river there are approximately 100 companies in Norrköping Science Park. Its profile areas are visualisation, printed electronics and interactive services. Pronova Science Park forms part of Norrköping Science Park and is the location for a hundred or so knowledge sector companies, in the famous restored former Tuppen spinning mill.

Money talks

Wahlbeck Business Park offers a cluster environment for companies in the healthcare and medical technology sectors. It is situated in Linköping’s Valla district, between Old Linköping and the city centre.

Almi Företagspartner Owned by the state together with the region, it runs programmes to support start-ups and SMEs with advice, loans, venture capital and incubation. As of 1 January 2013 it owns Innovationsbron, the national incubator that provided seed funding to researchers in achieving proof of concept.

Bioventia, life science consultants, works as professional adviser and working partner for universities, companies, venture capital companies and funds. Key competences are general management, project management, business development, R&D and finance.

Innoventus, Swedish venture capital and project management company, specialising in transforming bioscience innovations into successful product launches.

IUC Öst, part of the national network IUC Sweden, with its main focus the implementation of development projects with predominantly small and medium sized businesses.

LiU Innovation aims to create a bridge between the academic and commercial world.

Lead Business Incubator, supports start-ups with high growth potential in the fields of life science, microelectronics, visualisation and digital imaging. LEAD sources its deal flow from Linköping University, governmental and military research institutes as well as the surrounding industries.

156

Focus on East Sweden Recent results demonstrate world-class research • How bacteria ‘communicate’ Bacteria can communicate with each other via special molecules that they produce. A recent study from Linköping University researchers, published in the journal PLOS Pathogens, demonstrates – in a world first – that bacteria also control processes in human cells in the same way.

At the onset of an infection, bacteria gather at the site of the attack and form biofilms, dense structures that can resist both antibiotics and the body’s immune system. Simultaneously they become both more aggressive and more mobile.

The trigger for these changes is when the communication molecules – short fatty acids called AHL – bind to receptors inside the bacterial cells. AHL has the ability to migrate through cell membrane, not only in bacteria but also in human cells, which can be made to change their function.

The Linköping researchers are the first to show how AHL can influence its host cells. The researchers identified a protein known as IQGAP as the recipient of the bacteria’s communications. “The protein can both listen in on the bacteria’s communication and change the functions in its host cells,” said Elena Vikström, researcher in Medical Microbiology.

This discovery may lead to options for treatment where antibiotics are useless, such as designing molecules that bind to the receptor and block the bacteria’s signal path for the bacteria.

• Virtual autopsy tool reveals secrets of the Mummies Using a virtual autopsy tool more usually applied to living patients or the recently deceased, Sweden’s Mediterranean Museum has revealed the secrets of its collection of eight Egyptian mummies. The work was done ahead of a new exhibition to open in 2014.

The project is based on current visualisation and interaction research and technology, which has created the interactive visualisation tool. The Museum’s investment was made in collaboration with the Swedish Interactive Institute ICT, Visualization Center C and CMIV in Norrköping/Linköping.

The museum’s mummies are of great interest to the public, both adults and children. Using the virtual autopsy tool, originally developed for healthcare, museum visitors will be able, for the first time, interactively, to carry out their own detailed study of the mummies. With simple gestures they can explore complex data which is normally only available to researchers.

“Using this tool, we can tell you about an individual’s health and life story, mummification techniques and the ancient Egyptians’ beliefs about the afterlife,” commented Sofia Häggman, Egyptologist, Medelhavsmuseet.

For the exhibition, the mummies and their coffins were fully recorded in 3D using the latest technology in computer tomography, laser scanning and photogrammetry. By combining these different data types a whole new level of realism is achieved.

• New study sheds light on Parkinson’s Recent clinical research at Linköping University has shown why and how electrical brain stimulation for Parkinson’s disease works.

It revealed that electrical shocks increase the release of dopamine, a necessary signal substance.

Peter Zsigmond, consultant and Doctor of Medicine in neurosurgery, performed the first deep brain stimulation at Linköping University Hospital in 1997. This involves electrical stimulation via electrodes from a battery in the collarbone down to the nuclei located deep in the brain’s basal ganglia. However, no one understood how the brain’s signal substances work.

The new clinical study involved five patients with advanced Parkinson’s. A microdialysis technique was used for the first time to observe closely how the flow of substances in the brain was affected by electric stimulation. At the same time as the electrodes were implanted, very small amounts of the substances transported in the cerebrospinal fluid were sampled.

The results, the basis of Dr Zsigmond’s PhD thesis, show that dopamine levels increased when the stimulation took effect.

• High-Fat Diet better for diabetics?

Type 2 diabetes sufferers are traditionally advised to follow a low-fat diet, but research carried out at Linköping University suggests that, a high-fat, low- carbohydrate diet could be beneficial for blood sugar levels and blood lipids. The results of a two-year dietary study led by Hans Guldbrand, general practitioner, and Fredrik Nyström, Linköping professor of Internal Medicine, were published in the prestigious journal Diabetologia.

A total of 61 Type 2 diabetes patients were randomised into two groups, where they followed either a low-carbohydrate (high fat) diet or a low-fat diet. Both groups of patients lost an average of about 4 kg. However, a clear improvement in the glycaemic (blood sugar) control was seen in the low-carbohydrate group after six months.

157

Focus on East Sweden

Center for Medical Image Science and Visualization Visualize the Future

A mission to develop future methods and tools in image analysis and visualization for applications within health care and medical research.

Center for Medical Image Science and Visualization (CMIV) is a multidisciplinary research center initiated by Linköping University, the County Council of Östergötland and Sectra AB. CMIV conducts focused front-line research within multidisciplinary projects providing solutions to tomorrow’s clinical issues.

World Recognized Research

The research at CMIV has rapidly gained wide attention and the unique patient-oriented clinical research attracts researchers and clinicians from around the world. Research ranges from basic to applied health-related. Two of the focus areas are the Brain and Cardio vascular system. CMIV performs numerous clinical patient studies and other examinations such as “virtual autopsies”.

A total of 90 researchers are today affiliated with CMIV and the CMIV doctoral program educates 40 PhD students coming from both technical and medical faculties.

Digital Pathology

Diagnostic pathology is of crucial importance in health care. However, the volumes and demands increase due to an ageing population and more specialized diagnostics.

Digitalization presents a unique possibility to achieve increased efficiency as well as improved quality of care.

Recently, a digital pathology project was initiated by Linköping university (CMIV), Sectra AB and 9 county councils in Sweden. The goal for this project is to achieve shorter turn-around times and higher diagnostic precision.

Partner up with the Technical Front-line

M e di ca l Re s e a rch C e nt re

CMIV has research agreements with several companies (Siemens, Philips, Bayer Schering Pharma, ContextVision etc.) to ensure the very latest technical equipment such as Dual Energy CT scanner and two “state of the art” magnetic resonance imaging. A recurring theme for CMIV is that the medical requirements will govern the technical excellence in a clinical setting.

158

Focus on East Sweden

Ageing Without Disease

Close to the Heart

By lowering radiation doses, using several energies and improving visualization software’s, a new advanced CT scan can be utilized in a quarter of a second. 4D MRI flow adds the functional component!

Learning from the Dead Since the methods we use have been validated on the deceased, they are ready to to be used on patients.

Quantified MRI With synthetic MRI, a software-based technology developed at CMIV, the brain can be scanned in a few minutes. The software improves the analysis and makes it possible to visualize and quantify previously undetected conditions.

Quantification of braun, white and bright fat tissue with new, world leading MRI technology opens up for treatment of obesity.

CMIV Linköpings universitet/US, SE-581 85 Linköping Tel: +046 10 103 86 10 Fax: +46 10 103 70 20 www.cmiv.liu.se

M e di ca l Re s e a rc h C e nt re

Deceased animals helps to validate new technologies that then help patients and living animals.

New rendering technology increases the clinical usefulness.

159

Focus on East Sweden

New Tools For Health Efficient home-based healthcare and community care

New Tools for Health is a regional initiative based in ร stergรถtland in the east of Sweden with the objective of creating new products and services that lead to increased independence for the elderly and more effective health and social care based in the home. Together with other supporters of innovation, we support mobile IT solutions based on information and communications technology. Ideas may come from companies, innovators, researchers, or employees in the field of health and social care.

New Tools for Health has a large network of contacts not just in the region, but also on a national and international scale, and therefore has access to a wide range of expert support. Cooperation within New Tools for Health brings with it, among other things, resources in the form of finance, contacts with potential customers, and unique test and development environments. New Tools for Health supports the whole process from feasibility study and further development to commercialisation of new products and services, which may eventually reach the international market. In this way social benefits and growth are created at the same time.

E -H e al t h

New Tools for Health is convinced that part of the solution lies in more health and social care taking place in the home with the help of, among other things, ICT solutions based on mobile technology, thereby creating more cost efficient health and social care today. Furthermore, preventative measures are also important - solutions should be developed and used to prevent people from becoming ill.

Prevent yourself from feeling old. New Tools for Health believes that the focus needs to shift from reactive measures to preventative and predictive measures. This in turns leads to substantial demand for new applications and services.

160

New Tools for Health

New Tools For Health Platensgatan 29, P. O. Box 1224, SE-581 12 Linkรถping Tel.: +46708919291 info@halsansnyaverktyg.se www.newtoolsforhealth.com

Focus on East Sweden

NovaMedTech innovations for tomorrow’s health care

NovaMedTech is an organization with the aim to support development of new biomedical products and services. We will identify promising ideas and support those so they will reach the care user. By our broad network of participants and continuous stateof-the art investigations, NovaMedTech is a large source of knowledge in biomedical engineering.

We has focus on entrepreneurship and give support by coaching, matching, etc. In this, we contribute to an increasing rate of products that will reach the market.

NovaMedTech (NMT) started in 2008 and has successfully worked with new products in the biomedical area. The network is organized mainly with partners from the care organizations, industry, academy and innovation support organizations. We have developed a structure that covers all steps from the identification of new ideas and tools for support to market entrances.

So far, NMT has resulted in several participating R&D projects that have moved forward in the above described chain of development phases. An increasing amount of knowledge, a large network, an arena with a lot of activities, e.g. seminars, forums and knowledge exchanges. Further, NMT has contributed to establishing new enterprises and creation of employments.

The program is financed by the ERDF and regional funds in Sweden (appr. € 3.1 mill plus € 4,2 mill).

M e di c al Te c h n ol og y

NovaMedTech

NovaMedTech Linköpings universitet, SE-581 85 Linköping Tel.: +46 13 28 67 42 peter.hult@liu.se www.novaMedtech.se

161

Focus on East Sweden

Phil Med Alliance AB The Best of Healthcare from Sweden to the world

About Phil Med Alliance : • Phil Med Alliance is an international export company fully licensed for sales of pharmaceuticals and vaccines worldwide, under control of the Swedish Medical Agency (Läkemedelsverket).

• We are a sales and export channel for leading manufacturers of pharmaceutical and vaccines into areas and countries where the manufacturers are not actively working, and we supply a wide range of Swedish / European FDA Approved vaccines and pharmaceuticals of the highest standards.

• We work from politically independent Sweden and we have contacts with major world help organizations, governments and distributors in specific areas.

Ph ar m ac e u t ic al

Phil Med Alliance : • Is a member of Swecare Foundation, working in close cooperation with the Swedish Government in or- der to in- crease exports of Healthcare products.

• Is a member and sales partner of the exclusive Swedish Life Science Industry Organisation leading or- ganization dedicated to business development.

• Our staff are members of the Swedish Academy of Pharmaceutical Sciences.

162

What it means to be our Customer

What it means to be our Partner

As our customer and local partner, we offer you : • Exclusive access to our portfolio for your market, making you the only reseller of our listed pharmaceuticals in your area, • Guaranteed stocks of pharmaceuticals upon agreed market predictions, as part of the annual production will be made specially for you, • European quality at the highest EMEA standards, as we only offer original, high quality products, • No intermediary, you get your products shipped directly from the producing units, • Guaranteed origin, you will receive the Certificate of Analysis that guarantees that you get what you’re paying for, and not a counterfeit fake product, • Best prices, our partners are the owners of the major brands that already exist in douzains of countries, and guarantee the base price.

As our manufacturing partner, we offer you : • Exclusive partnership with our clients in various market, making you the only producer of your product category/type in our portfolio, • Guaranteed sales of pharmaceuticals upon agreed market predictions, • No intermediary, you send your products directly to the country/client, • Guaranteed destination, our clients are legally obliged to sell your products exclusvely on the agreed markets, in order to avoid any possibility for parallel trade, • Ongoing business, our agreements are set for a minimum period of 5 years, allowing you to plan comfortably in advance for set productions, • Growing potential, we open new markets for your products as we expand our horizons, and offer growing potential for our common business opportunities.

Focus on East Sweden

The Best Swedish companies in the fields of healthcare technologies, pharmaceuticals and equipment have come together to provide complete round-table solutions for all your needs.

Imagined and initiated by PHIL MED ALLIANCE, and in order to promote further the high level of excellence of Swedish healthcare products and services, the Swedish Healthcare Alliance regroups a number of internationally renown Swedish companies that excel in complementary healthcare related specialties. Together, we offer ONE full package of products and services that will answer every need of any market, regardless of its size.

One entity, Thirteen companies global view of the Swedish Healthcare Alliance structure

Building, Planning and Engineering LINK arkitektur, along with its partners form an all-round planning and projecting group, offering 360 degrees consulting, the core competencies being architectural and engineering.

Construction and Equipment After planning, designing and projecting, construction can begin supervised by the projecting team. At this stage equipping can also begin executed by DME Alliance, GETINGE Group, ELEKTA and SECTRA.

Phil Med Alliance AB Teknikringen 10, SE-583 30 Linkรถping Tel.: +46 13 210255 / +46 70 377 9602 info@philmed.se www.philmedalliance.com

Representative for Africa info@philmed.se

P h a rm a ce u t i ca l

Logistics and Supplies Finally Swedish Medical Pharmacy can help developing pharmacy networks, structuring and furnishing pharmacies as well as planning supply logistics and managing stocks.

Furthermore Bluefish Pharmaceuticals, Unimedic and Recipharm can offer High quality Pharmaceutical supply.

163

Focus on East Sweden

164

Focus on East Sweden

Wolfram MathCore Your partner for model design and analysis

Con s u l t a nt s

Wolfram Mathcore Teknikringen 1 F, SE-583 30 Linkรถping Tel.: +46 13 32 85 00 sales@mathcore.com www.wolframmathcore.com

165

Focus on Gothenburg

Focus on Gothenburg

166

Focus on Gothenburg

167

Focus on Gothenburg

Foreword by Iris Öhrn, Investment Manager - Life Science Business Region Göteborg

A region of entrepreneurs and global companies... Let’s Talk Business!!

foreword

Gothenburg (Göteborg) is Sweden’s second largest city and the largest port in the Nordic region. The Gothenburg metropolitan area has around 940,000 inhabitants speaking more than one hundred languages, and has a great quality of life. The Gothenburg region is home to companies from all around the world. There are more than 2900 foreignowned workplaces and about 1700 international headquarters. There is a lot of investment currently going into the Gothenburg region, including into railways, roads and public transportation, as well as into new homes for 30,000 people and commercial space to support 40,000 new jobs in the city itself.

Overall, SEK34 billion will be invested between 2010 and 2028 in the region through what is known as the ‘West Swedish Package’.

168

However, what makes it a hub for the life sciences?

Its academic excellence, the number of innovative biopharma and medtech companies, its well established position as a global centre for biomaterials and implants or the high levels of networking

and collaboration between regional policymakers, industry, hospitals, and academic institutions?

Gothenburg has expertise in a range of field within life sciences and medicine, including cardiovascular, gastrointestinal research, medical imaging, biomaterials, orthopaedics, dental implants, cell therapy, tissue engineering and healthcare IT. The region is at the forefront of clinical and translational medicine and has become the leading centre for clinical trials in Sweden.

This focus on innovation has grown from the skills and expertise from the region’s world-class universities and hospitals including University of Gothenburg, Chalmers University of Technology and Sahlgrenska University Hospital, all located very close to each other.

As a region, Gothenburg has an openness to collaboration between academia and industry, and a great track record of success – it is the region that gave rise to Astra’s (now AstraZeneca’s) blockbuster drugs

Focus on Gothenburg

Losec/Prilosec (omeprazole), Plendil (felodipine) and Seloken/Toprol (metoprolol).

A number of organizations and initiatives such as the Gothia Forum for clinical research and Medtech West serve as a meeting place, and facilitate networking and collaborative research between the health care sector, industry and academia in West Sweden.

Furthermore the region is home to state-of-the-art incubation facilities, laboratory space and commercial properties. This all provides fantastic opportunities for companies from all around the world that are interested in sharing in our success and growing their businesses in a location that really understands life sciences and medicine.

In a few words, Gothenburgâ&#x20AC;&#x2122;s well-established cooperation between industry, academia and the health-care system together with the availability of a well-educated workforce creates a good climate for both small and large companies interested in sharing its success and making Gothenburg a destination for life sciences research and development.

fo rewo rd

Business Region Gothenburg was created to strengthen and develop trade and industry in the Gothenburg region. We focus on business development, promotion and marketing; and provide support and advice for investors and for companies setting up, expanding in or moving to the region.

Business Region Gothenburg can provide advice on a wide range of commercial, financial, recruitment and regulatory issues, including general and industryspecific propositions, help to find suitable commercial properties and locations, and access to a broad network of business partners, qualified advisors and government institutions, including leads for potential partnerships.

169

Focus on Gothenburg

Foreword by Klementina Österberg, CEO GU Holding

Swedish universities are a source of many ideas which have potential to be developed into commercial successes. The University of Gothenburg, one of the largest universities in Europe, employs almost 6,000 people and educates 37,000 students a year. The University of Gothenburg is situated in the center of Gothenburg and has several research stations in the Västra Götaland region in western Sweden. University of Gothenburg researchers collaborate within the region with Sahlgrenska University Hospital and Chalmers University of Technology which is situated close by, as well as globally with researchers, companies and other organizations.

foreword

In 1995 the Swedish Government established holding companies connected to some of the Swedish universities with the goal to facilitate the commercial development of ideas originating from research performed at the universities. GU Holding was established to support the commercialization of ideas from the University of Gothenburg in order to improve the region’s economy and have a positive impact on society. GU Holding’s business and its portfolio are presented in more detail in this publication.

170

The transformation of Swedish universities from being purely focused on research and teaching to also include innovation started earlier, but it has been an exciting journey for us at GU Holding to follow the progress since 1995 and to play an important part of the network of organizations that support researchers and students with financing and commercialization of new ideas, as well as prospering industrial collaborations.

The broad range of research conducted at the University of Gothenburg has proved successful in many contexts including commercial ones. Many researchers have formed internationally successful companies and commercialized products for a global market. The University’s list of world renowned researchers who have also had great commercial success includes the Nobel Prize winner Arvid Carlsson who is commercializing his inventions in his own company as well as within Neurosearch AS; Per-Ingvar Brånemark, a Swedish orthopedic surgeon and professor, touted as the “father of modern dental implantology” as well as the inventor of dental products commercialized by Nobel Biocare; and a group of researchers that have supported AstraZeneca with the invention behind Losec®. GU Holding has also worked with Chalmers Professor Bo Håkansson who has invented the bone anchored hearing aid vibrator, Baha® technology, which is being commercialized by Cochlear; and Professor Jan Holmgren, who is the inventor of the globally utilized cholera vaccine Dukoral®.

The Swedish government is investing heavily in research at Swedish universities and Swedish Universities will receive an extra SEK 4 billion in funding between 2013-2016. The Swedish government is becoming increasingly focused on funding commercially interesting areas of healthcare and technology. Today the University of Gothenburg receives SEK 5,5 billion in revenue and employs 5,890 people. It has 3,220 professors, researchers, teachers and doctoral students, whose expertise spans from developmental biology, physics, logistics and gender studies to design and marine mammals. One of the eight faculties at the University

Focus on Gothenburg

is the Sahlgrenska Academy which is focused on Life Sciences. It has 2,000 researchers and doctoral students and six institutes, pharmacology, children’s health, odontology, cancer, obesity and cardiovascular disease, and personalized health care, which are of the highest international class.

Another of its faculties is the IT University of Gothenburg which is managed together with Chalmers University of Technology. Chalmers is also a major university and has an excellent reputation for commercializing innovations. It has 10,000 students and employs 2,650 of which 1,900 are researchers. These universities represent prosperous and dynamic development partners to industry.

We believe that our expertise and well established processes greatly improve the chances of an idea being successfully commercialized and we have many examples of our past success, and so do our counterparts at Chalmers. Some of the companies started by GU Holding are highly successful with substantial revenues, some have attracted investment capital to be able to expand and some have been listed on a stock exchange while others have been sold to big corporations.

One of the University of Gothenburg’s many strengths is its ability to create innovation and business collaborations that produce attractive and competitive products and services for a global market. We love being involved in the action right from the start. GU Holding works together with innovators from the University and the industry as well as the service sector supporting us to shape a better future by creating companies that deliver these new products and services. Our vision is to help improve the world we live in by commercializing research findings. We live up to our vision every day by being a successful business developer, seed capital investor and a visionary and entrepreneurial part owner in the companies we create. We are passionate about our businesses and eager to always generate the greatest possible return on the resources we invest in these early stage companies – that is what drives us to do our best. It is very rewarding to be able to work with the people involved in our companies, the University, the Swedish government and our financers for the sake of our region and society as well as our many stakeholders.

fo rewo rd

We believe that the University of Gothenburg’s greatest strength is its excellent research within the life and marine sciences and GU Holding’s greatest strength is the commercialization of innovations within these fields. We see many new and interesting key areas for investments, such as vaccines, biomaterials, stem cells, cancer, marine substances in pharmaceuticals aka blue-biotech, information and communication technologies, materials, energy sources

and waste management, as well as social innovation projects within life sciences especially developed for the third world. The University of Gothenburg is well-known in many of these areas and provides GU Holding with the opportunity to present many exciting innovations and businesses to international investors as well as industrial partners.

171

Focus on Gothenburg

Gothenburg:

a leader in three-way collaboration A major characteristic of the life science community in the Gothenburg region is its international triple helix collaboration, in which it is a European leader. Expressed simply, this is co-operation between industry, academia and government – specifically regional government – with industry being responsible for the production, academia as the source of new knowledge and technology and government in charge of regulating contractual relations between all three. The area has 53,000 students at a total of six universities and university colleges. Healthcare accounts for around 90 per cent of its business turnover, while the region has the country’s highest percentage of life science employees with an MD/PhD. Some 1.6 million people live in Västra Götaland, around one-fifth of the population of Sweden.

The development of the life sciences in the region has been fostered by its traditions of trade, co-operation and of strong clinical research, which have resulted in cutting-edge research in biomedicine and the natural sciences and a strong research-based biomaterials industry. The region employs about 20% of Sweden’s life science employees, in 450 companies. It is the base for several world-leading companies, particularly in the field of implants and biomaterials, including AstraZeneca, Nobel Biocare and Cochlear. Other successful life science sector companies include Mölnlycke Healthcare, the Getinge Group and SCA.

The city of Gothenburg Gothenburg lies on the west coast of Sweden and is the second largest city in Sweden, with around 500,000 inhabitants. Founded by Dutch immigrants in the first half of the 17th century, it has always been a cosmopolitan trading centre, helped by its strategic location. Gothenburg is the largest port in Scandinavia and has two international airports. The Gothenburg region was one of the world’s fastest-growing during the first years of the 21st century. Since 2001, the number of company startups per year in the city has doubled. The highest proportion of Gothenburg’s workforce is employed in the human health and social work sectors (14.8 per cent), which reflects its role as the central location for a very active and successful life science cluster, with particular strengths in medtech and biomaterials. The cluster had a total of 8,400 employees in 2012.

172

Focus on Gothenburg The life science cluster players Important elements of the life science education sector in the Gothenburg region owe their founding to charitable benefactors. Chalmers University of Technology, for example, was set up in 1829 following a substantial donation

by Swedish-Scots William Chalmers, a director of the Swedish East India Company. He bequeathed part of his fortune to establish an “industrial school”, partly for poor students.

This was a private institution until 1937, when it became a state-owned university. Today it has two campuses – Campus Johanneberg, Campus Lindholmen – 17 departments, 200 research groups and a total of around 10,000 students.

Chalmers life science researchers are involved in improving nutrition, as well as disease diagnosis and treatment.

The university was one of the first to have a School of Entrepreneurship. Established in 1997, it was founded with the aim of making researchers more business-savvy and of building partnerships between them and entrepreneurs to increase the commercialisation rate of the innovations they produced. It runs a two-year international Master’s Programme called Entrepreneurship and Business Design, during the second year of which the students work on real innovation projects. These are in Bioscience Entrepreneurship, in collaboration with Chalmers’ incubator Encubator, in Technology Entrepreneurship, again with Encubator, and in Intellectual Property Entrepreneurship, mainly in collaboration with Chalmers’ Innovation Office. Chalmers also has a commercial organisation promoting some of its technology and R&D services to industry. Set up in 1984, Chalmers Industriteknik provides: external R&D services for companies; technology scouting; insourcing; technology audits and due diligence; attraction of public funding; and organisation of seminars, workshops and conferences.

University of Gothenburg The University of Gothenburg is the third oldest Swedish university, having achieved full university status in 1954 following the merger of the Göteborgs högskola with the Medicinhögskolan i Göteborg (Gothenburg Medical School).

With 37,000 students in total, plus 5,900 employees, it is one of the largest universities in the Nordic countries. In addition, with eight faculties and more than 170 departments, it offers a very broad range of courses. One of the most popular universities in Sweden, it has the highest number of applicants to many programmes and courses. The university stresses its collaborative tradition. It works in cooperation with Chalmers University of Technology, Sahlgrenska University Hospital, society generally, business and industry – something that has been consistently intensified over recent years, as have international contacts and collaborative projects with partners abroad.

There are around 30 centres of expertise and research at the University of Gothenburg, plus other cross-disciplinary interaction and networking groups. These provide meeting points for students and researchers with representatives from the commercial, industrial and public sectors. The university characterises its tradition in the life science sector as “close ties between health research, clinical work and society”.

Sahlgrenska Academy, the faculty of health sciences at the University of Gothenburg, comprises several strong areas in life science, plus a holding company that manages life science innovations.

Business incubator GU Holding was set up to develop new companies based on University of Gothenburg research. Fullyowned by the Swedish government, it describes its mission as “to ensure that the research and knowledge created at the University of Gothenburg is used to deliver economic, social and cultural benefits both nationally and internationally.” It adds: “Our task is to help scientists commercialise the results of research by offering different forms of cooperation and customised solutions.”

Sahlgrenska University Hospital is the largest hospital in Northern Europe. It was founded in 1782 and, like Chalmers University, also owes its existence to a benefactor: Nicolaus Sahlgren, one of the founders of the Swedish East India Company. Later William Chalmers – the same man who endowed Chalmers – a younger contemporary of Sahlgren, also left half of his fortune to the new hospital. Their intentions were that hospital care should be available for all, rich or poor. Today the original 24 beds have become 2,000 and the staff of 15 has increased to more than 16,000.

Nationally commissioned in certain fields and widely recognised for its outstanding clinical research, Sahlgrenska University Hospital forms the centrepiece of a cluster of related organisations, including Sahlgrenska Academy, Chalmers University of Technology and public and private sector companies. The resulting closeness between research and actual patient care that is possible there represents the hallmark of medical education at the University of Gothenburg. Based on the high quality clinical research carried out at Sahlgrenska, several centres of excellence in highly specialised care have been set up there, jointly funded by the region of Västra Götaland and Sahlgrenska University Hospital. Among these is the only full-scale organ transplant centre in the country, the Transplant Institute, where the first kidney transplant in Sweden was carried out in 1965. Another particular strength at Sahlgrenska is paediatric heart surgery.

The Västra Götaland International Cooperation Model The Gothenburg region has achieved international as well as national recognition for its brand of life science cooperation, triple helix collaboration, which is based on a collaborative environment and notable clinical research. Region Västra Götaland feels that this is transferable as well as successful and is ready and happy to export what it calls the Västra Götaland International Cooperation Model.

The regional authority has backed its idea with financing – establishing a wholly-owned company, Sahlgrenska International Care, to work on exporting quality Swedish healthcare to the international market. One example of the kind of international deals it is involved in is the agreement it signed in 2010 with the Health Insurance Agency of Iceland – Sjúkratryggingar – covering organ donation operations and organ transplant operations. Under the terms of this deal, Icelandic patients can now be treated by leading specialists at Sahlgrenska University Hospital.

173

Focus on Gothenburg Other leading organisations in the collaborative cluster The Gothenburg region life sciences sector is well supported by development and promotional organisations and networking forums.

• Region Västra Götaland The regional authority in charge of healthcare, works in cooperation with academia and the public and private sectors, promoting development of the West Sweden region.

• Business Region Göteborg A non-profit subsidiary of the City of Gothenburg, it promotes growth and employment opportunities in the Gothenburg region and helps both existing and new companies achieve growth.

• MedTech West A network and collaborative platform for research, education, development and evaluation of new biomedical concepts and technologies. It initiates, facilitates and promotes increased research collaboration between the health care sector, industry and academia.

• Gothia Forum for clinical research A meeting place and resource centre for researchers and businesses in the life science sector in the Västra Götaland region, it offers support with major clinical trials, research collaborations and quality training. Gothia Forum is a collaboration between Sahlgrenska Academy, the research industry, Sahlgrenska University Hospital, Chalmers University of Technology and Region Västra Götaland.

Science parks Sahlgrenska Science Park, opened in 2005, serves as the region’s business incubator, providing support for innovators and new companies in launching new life science business ideas. It helps to develop these by means of pre-incubation and incubation services, and also offers laboratories and offices for established life science companies in the park. For example, the Institute for Biomaterials and Cell Therapy rents space at the park’s laboratories, sharing with Nobel prize winner Arvid Carlsson, Professor of Pharmacology. The institute is conducting three research projects, three product development projects and one project related to testing cytotoxicity. Sahlgrenska Science Park is owned by Sahlgrenska Biomedicinska Innovations Centrum and is a cooperative venture between Region Västra Götaland, Business Region Gothenburg, Chalmers University of Technology and the University of Gothenburg. All four stakeholders are represented on the board of the park.

Johanneberg Science Park was established in 2010 by the Chalmers University of Technology Foundation and the City of Gothenburg as an environment which would stimulate collaboration between academia, industry and the public sector, based at Chalmers’ Campus Johanneberg.

A public-private partnership, its other owners are Volvo, Bengt Dahlgren Göteborg, Göteborg Energi, HSB, Riksbyggen and Tyréns. There are two business incubators based in the park: • Chalmers Innovation, which focuses its attention on spin-off companies; and • Encubator, a Chalmers initiative, which develops innovation projects in the area of entrepreneurship education, together with Chalmers School of Entrepreneurship.

Lindholmen Science Park is a public-private partnership, in which the founding players are

174

developer Gothenburg municipality and strategic partners Ericsson, Volvo Group and Volvo Cars. Other stakeholders include: Business Region Göteborg, the region of Västra Götaland, state innovation agency VINNOVA and the Swedish Civil Contingencies Agency. The last of these is the primary funder of projects within Security Arena Lindholmen, a national social safety and security programme. The Security Arena’s other partners include Ericsson and Saab. Over 10 years Lindholmen Science Park has developed into a collaborative environment for business, research and education for transport, ICT and Media. Close by is the Lindholmen campus, where the University of Gothenburg and Chalmers University of Technology have established both independent and joint study and research units. Researchers from Chalmers, Gothenburg University and the IT University of Göteborg – a Chalmers and Gothenburg University joint venture – work there on high tech projects in cooperation with industry.

Gothenburg researchers shed new light

Focus on Gothenburg

Parents can share allergy protection with baby Researchers from Sahlgrenska Academy report in a study published in scientific journal Pediatrics that a child may gain significant protection against allergy development if a parent sucks on its pacifier. They recorded, in a total of 184 cases, how the parents cleaned the pacifier if it had fallen on the floor. Some rinsed it in tap water, while some boiled it, but other parents put it into their mouth and cleaned it by sucking.

It was found that children whose parents habitually sucked the pacifier were three times less likely to suffer from eczema at 1.5 years of age. The researchers decided that this was because parents had exposed their babies to bacteria in their saliva, stimulating babies’ immune systems.

The team was led by Professor Agnes Wold and consisting of paediatricians specialising in allergic diseases, as well as microbiologists and immunologists. They also noted a trend toward a reduction in allergy signs, but by the time babies were three years old, they only had an added protection against eczema.

Altered gut microbiota can predict diabetes In a study published in the journal Nature in May 2013, researchers at Chalmers University of Technology and Sahlgrenska Academy demonstrate that patients with type 2 diabetes have an altered gut microbiota.

Based on these findings, the researchers developed a method of distinguishing between patients with type 2 diabetes and healthy patients by analysis of the metagenome, the microbial content of the gut.

“In this study, we have developed new methods to analyze the metagenomic data and have been able to exploit much more of the ‘unknown’ metagenome, that is, the bacteria that have not been previously mapped,” commented Jens Nielsen, Professor of Systems Biology at Chalmers University of Technology.

Brain infections may result from shingles Shingles, resulting from earlier chickenpox, may be the underlying cause of between150 and 200 cases of infection of the brain in Sweden each year, more than previously believed. Long after suffering from shingles, patients may develop problems with memory and other cognitive problems.

These are conclusions from a PhD dissertation by doctoral student Anna Grahn of Sahlgrenska Academy, which contradicts previous assumptions. She studied 121 patients suffering from meningitis, encephalitis, stroke, or single-sided facial paralysis, and who were found to have chickenpox virus in their spinal fluid.

A total of 24 patients showed signs of neuronal damage associated with infection. Three years later, 14 underwent neuropsychological tests that demonstrated several had a persistent cognitive impairment. Ms Grahn suggested that shingles vaccination can reduce the neurological complications.

175

Focus on Gothenburg

ABIGO Medical AB The proud winner of Swecare´s export award for 2010 ABIGO is a fast expanding family owned Swedish pharmaceutical company, founded, managed and wholly owned by the two brothers Jan G. Smith and Leif Smith.

Apart from the pharmeceutical area ABIGO is also active in the field of medical device products.

ABIGO is a complete company, handling its own R&D, manufacturing and marketing.

The Scandinavian market is covered by our own organization including subsidiaries in Denmark and Norway.

The Sorbact®-method is a Swedish invention based on the results of two leading Swedish professors. This method acts on a natural process that binds and inactivates pathogenic microorganisms without any known side effects. Our ongoing research in this field shows encouraging results that should lead to future new interesting products.

ABIGO´s Sorbact® wound care line, based on the Sorbact®method, is an internationally well documented product for effective and safe treatment of wounds and dermal fungal infection.

Our development program and product range is concentrated on unique and preferably patent covered products with an international potential. ABIGO consequently also holds a number of patents and patent applications. A network and close contacts with researchers at the universities is essential for ABIGO:s R&D success with new innovations and products.

ABIGO is very much internationally oriented. Consequently, we have built up an extensive international distribution network during the last fifteen years.

An area with a high focus is Advanced Wound Healing. The need for Advanced Wound Healing is global and our unique wound-healing products are now available in about 70 countries. The internationalization has taken place with a significant rate of growth and will continue to do so.

Being a dynamic flexible company with a flat organization structure we are able to take fast decisions in identifying emerging opportunities at an early stage and develop the same. We like to establish contact with new competence in exciting new fields and identify new possibilities. this assists ABIGO to develop innovative products that benefit a great number of people.

Advanced wound healing struggles today with microorganisms resistent to antibiotic and antiseptic products. This also creates negative environmental effects in the disposal of these products. As a contrast Sorbact® wound care line offers an effective, safe and environmentally friendly wound healing process. Furthermore, no known side effects and no risk of developing resistant microorganisms, a truly unique combination.

To meet the future ABIGO runs a continuous intensive product development work on Sorbact® and its unique patented mechanism. This will make it possible for patients to have successful treatment and solve wound healing problems without creating new ones, such as, for example, resistant microorganisms.

H ea l t h c are

ABIGO has its head office in Gothenburg, Sweden, where we also have our reserach center. The driving force of all research is curiosity and the desire for knowledge to develop new efficient, unique safe products and treatment methods. This is an important investment for the future ensuring future growth and strength.

176

Candida albicans binds to Sorbact® surface

Focus on Gothenburg

ABIGO´s Swedish plant

ABIGO´s advanced wound healing product range requires specialist compentence including advanced production facilities. This necessitated to manufacture the products in our own manufacturing plant, located in Askersund, Sweden. The plant is unique in many respects and actually Sweden´s only of its kind. Dedicated staff with long and wide experience guarantees the quality of our products. The plant also assists with our product development, including our own design of production equipment. This allows ABIGO to stand in the front line in rational efficient production.

Quality assurance is important to us and ABIGO is of course certified under ISO 9001:2008 (quality), ISO 14001:2004 (environment) and ISO 13485:2012 (medical devices).

Being a pharmaceutical company ABIGO is also regulated by the Swedish Medical Products Agency.

ABIGO participates at many national and international exhibitions, exhibiting our wound care products with special emphasize on Sorbact®. For example ABIGO always participates at EWMA and are since the beginning of 2013 a B-sponsor for EWMA The European Wound Management Association.

The European Wound Management Association was founded in 1991. It works with linking wound management associations across Europe and bringing together individuals and organisations interested in wound treatment. By also being an educational resorce, organising conferences, contributing to international projects related to wounds and provide a wide range of information, ABIGO feels that this is a meaningful sponsorship for the company.

ABIGO Medical is an excellent example of Swedish innovations leading to more jobs and steady growth in turnover for the company. Increased exports lead to greater prosperity, which is well illustrated by ”ABIGO, a very worthy winner of Swecare Export Award 2010”, states the Swedish Secretay of State, Karin Johansson.

ABIGO at EWMA 2013, in Copenhagen, Denmark

He a l t h ca re

ABIGO Medical AB Ekonomivägen 5, SE-436 33 Askim Tel.: +46 31 748 49 50 pharma@abigo.se www.abigo.com

177

Focus on Gothenburg

Bellman & Symfon AB Bellman & Symfon of Sweden is dedicated to improve the quality of life for people with hearing problems. We realize this dedication through continuous development of new and outstanding hearing solutions.

Our people and partners are devoted to this mission and we work closely with hearing healthcare professionals and audiology experts to protect the hearing and make better hearing possible for everyone.

Peter Jungvid, CEO

H ea r i n g

The Bellman & Symfon product portfolio ranges from assistive listening products to complete home notification systems, and are world renown for their clean Scandinavian design, high reliability and ease-of-use.

178

Focus on Gothenburg

Assistive listening products Our assistive listening products complement the hearing aids in noisy environments where they enhance speech further. They are fully digital and work right out of the box.

Alerting systems The Visit system consists of a broad-ranging suit of wireless transmitters and receivers that fully integrates to work as one. Packed with unique features, it is the world leading system today.

Stand-alone products These are easy-to-use, entry level alerting products that help people with hearing loss to notice signals in their homes, like for instance the doorbell or telephone.

He ar i n g

Bellman & Symfon AB S. Långebergsgatan 30, 421 32 SE-Västra Frölunda Tel.: +46 31 682820 Fax: +46 31 682890 info@bellman.se www.bellman.com

179

Focus on Gothenburg

Biognos AB Finding your ligands in chemical space

Find your ligands in chemical space together with

D r u g D i scove r y

www.biognos.se os.se

a provider of computational drug discovery services concerning: ligand-based virtual screening ✔ structure-based virtual screening ✔ lead-optimization ✔ customized solutions ✔

180

We offer: Cost-efficiency State-of-the-art technology High confidentiality Environmental sustainability (”Green Drug Discovery”)

What can we do for you?

Biognos AB is a CRO providing services in computational screening, both structure-based and ligand-based. We have 4 people working in the company and we have a computer cluster with 35 “real” cores. The structure based screening is performed using both commercial and public domain software. The dockings are done with large databases of commercially available compounds. Especially in cases when the structure of the target protein in unknown it is of interest to perform ligand-based screening. We can do this with large libraries also allowing for some flexibility in the ligand. Through ligand-based screening it is possible to achieve scaffold hopping thus allowing reinforcement or circumvention of patents. We can also perform chemoinformatics services e.g. prediction ADME, diversity selection and nearest neighbour analysis.

We work under CDA and we have no claims on IP.

Biognos AB Generatorsgatan 1, P.O. Box 8963, SE-402 74 Göteborg Tel.: +46 31-65 62 40 Fax: +46 31-23 66 44 info@biognos.se www.biognos.se

Focus on Gothenburg

Business Region Göteborg AB FOR LIFE Life Science is one of the main strengths of the Gothenburg region.

For us, this achievement is not a mystery. Several reasons why: • A strong industrial sector • 450 Life Science companies • World-class excellence in scientific research • Long track record of innovation • Significant expertise in CVD and metabolic research; medical imaging, biomaterial, orthopedics, dental implants, stem cell research and transplantation • Meeting-places where participants can interact • State-of-the-art incubation facilities, laboratory spaces and commercial properties Business Region Göteborg creates arenas and networks where science and industry can meet. We convey contacts, make it easier for new players and provide momentum so development can continue. Quite simply, we are your link to a vital region. www.businessregiongoteborg.com

Business Region Göteborg AB Norra Hamngatan 14, SE-411 14 Gothenburg Tel.: +46 31 61 24 02 establishmentservices@businessregion.se www.businessregiongoteborg.com

Bu si n e s s D eve lo pm e nt

For establishment and investment matters, please contact: Petra Sedelius, Head of Investment Service, petra.sedelius@businessregion.se, +46 31 3676130 Iris Öhrn, Investment Manager – Life Science, iris.ohrn@businessregion.se, +46 31 3676128

181

Focus on Gothenburg

CRC medical AB Complete solutions for reducing airborne infection

If you want maximum patient safety, great products are only half the story CRC medical provides complete solutions for optimizing patient safety in clinical environments. Our products and extensive experience allow us to customise the working environment in hospitals and clinics – to meet the toughest demands on hygiene.

Complete solution Patient safety demands 360° thinking. Products only do half the job – insight does the rest.

We can offer: • Analysis • Improvements • Installation • Performance monitoring • Training • Verification

M e di ca l Te ch n o l ogy

• Service

182

Focus on Gothenburg

Wide product range CRC medical provide a wide range of cleanair-products for surgical environments where the demands on air quality are extremely tough.

• Operating theatre ceiling Ideal for surgical procedures with a high risk of infection through airborne contamination.

Very low CFU levels.

Helps to optimize patient safety and the work environment.

• Supplyair filterunit Comes with integrated filter for differing demands. Filtersunits intake supply air in operating rooms, corridors, sterile storage areas and more.

• Exhaust air filter unit Comes with integrated filter for differing demands. Filters exhaust air from the room to prevent the spread of hazardous.

• Airhandling units (clean room design), for operating departments etc Specially designed for operating rooms and sterile spaces where demands on air quality are exceedingly tough. Silent running and hygienic design.

M e di c al Te c h n ol og y

CRC medical AB Industrivägen 55, SE-433 61 Sävedalen Tel.: +46 31 27 70 00 Fax: +46 31 26 41 41 info@crcmed.com www.crcmed.com

183

Focus on Gothenburg

Getinge Infection Control AB Complete Solutions for safe hygiene in research and production

Isocyt Freja: A unique isolation technology system to protect operators from potent compounds during reconstitution of cytotoxic compounds.

The life science industry segment represent a growing proportion of customers for Getinge Infection Control AB, which provides complete solutions for cleaning and sterilization in pharmaceutical and biotech facilities, in the Nordic region and far beyond.

Safety and hygiene are of utmost importance in the life sciences Industry. The repeatability and reliability of cleaning and sterilization processes is crucial to ensure that quality assured production can be carried out in controlled conditions.

I nfe ct i on Cont rol

Regulatory authorities have exacting requirements for processing and documentation to ensure aseptic conditions are maintained. Getinge Infection Control AB, a leading global provider of equipment and systems within healthcare and life sciences, is well placed to meet these demands.

It is a specialist in contamination control and prevention with a growing proportion of its business among life sciences customers, from major pharmaceutical companies and government research institutes to smaller biotech companies.

184

“When a bio-pharmaceutical company produces drugs, those drugs must be produced in an aseptic, controlled environment,” explains Stephen Morley, Business Development Manager in Getinge Infection Control’s Life Science business. “All

Traditional Getinge steam sterilizers, available in many flavors according to application.

the components in the manufacturing of the drugs have to be sterile and all the equipment that comes into contact with the drug must be cleaned and sterilized.

In addition, researchers and investigators who Steam/Air mixture sterilizers with work in bio-medical innovative features to protect packaging research during the during terminal sterilization development phases of a new therapy must ensure that the laboratory animals are kept in clean and sterile conditions, so sterilization of laboratory equipment is another of our specialties.

Getinge AB has a more than 100-year history, starting in the small town of Getinge in the south of Sweden in 1904. It produced its first sterilization equipment in 1932, and is well known in the Nordic area for its expertise with disinfection and sterilization within the healthcare environment. What is perhaps less known, however, says Stephen Morley, is that Getinge also provides complete solutions to the life sciences industry. “Nowadays we supply much more than sterilizers. In the last 15 years we have grown our business, and continue to do so, based on an aggressive growth

Focus on Gothenburg

Getinge GEE Ethylene Oxide sterilizers are used for Terminal Sterilization of heat sensitive Medical Devices.

Getinge GEW Series cGMP WasherDryers provide validatable, repeatable critical cleaning of components and equipment parts.

Getinge’s Closure Processing system (CPS) allows sterile transfer of clean stoppers to a filling line.

strategy of organic growth and acquisitions. We now supply closure processors (for cleaning and sterilization of rubber stoppers used in vials and syringes), and critical cleaning equipment,” says Stephen Morley. “Most recently we acquired La Calhène, a world leader in isolation technology, based in France.

Getinge Infection Control AB P.O. Box 69, SE-305 05 Getinge Tel.: +46 10 335 00 00 www.getinge.com

I nfec t i on Co nt rol

Having this wide ranging portfolio mean we can now supply complete systems and application solutions to our customers in the life sciences arena.” The vision is to continuously integrate complementary core competences in order to ensure the company’s continuing success in a highly competitive marketplace. “Our goal is to sell not only a piece of innovative equipment but a complete system that offers greater efficiency and significant economic advantages for our customers,” says Stephen Morley.

The growth strategy via organic growth and acquisitions is complemented by geographical expansion, says Stephen Morley, where Getinge is going into areas where it has previously not been so active, such as India and Turkey, and expanding its presence in other markets, like Germany, that present growth areas. This is important in life sciences, characterized by companies that act globally. In addition, he notes that the R&D market is booming in the field of bio-containment. In the USA this is related to the Homeland Security programme prompted by the terrorist attacks of 9/11, which has prompted the need for a coordinated plan against the threat of bio-terrorism. Getinge is developing systems for use in all types of biocontainment facilities, but in particular within the highest risk agent groups, BSL3 and BSL4. “We see life sciences as a clear growth opportunity for Getinge, one that we intend to seize in parallel with the strong growth of the life sciences and biotech industry in the Nordic region.”

185

Focus on Gothenburg

186

Focus on Gothenburg

GU Holding AB GU Holding is a Gothenburg based holding company wholly owned by the Swedish Government. The company’s overall objective is to create growth and improve the world we live in by commercializing the cutting edge research performed at the University. The company builds, finances, develops and sells new businesses with high growth commercial potential founded on the basis of research and know-how from the University of Gothenburg and its affiliations. It is one of the strongest incubators in Sweden and is participating in the national incubator program with many other incubators for sharing experiences and best practice.

GU Holding invests seed capital together with the founders, as well as recruit new investors to the start-ups. We take an active part in the business development to ensure that technology, know-how and IPR are appropriately protected and to recruit a suitable team to drive the business. We empower the selling processes by working closely with potential customers to develop the invention into a minimum viable product or service - or grant licenses, and establish relationships with both future customers and investors. We offer individuals within the portfolio tailored training in professional sales, business development and many other areas to help them develop the skills necessary to meet the needs of the business and improve their business acumen. We also offer office facilities, IT solutions and administration services, and access to our network of IP consultants, accountants, lawyers, marketing and communication agencies and other support organizations. The incubation, which is a certified and structured development process, is focused on value creation in the starting phases and on securing and flourishing the business potential of each idea.

GU Holding has a constant flow of new ideas from researchers.

We also work together with the internal Innovation Office at the University to identify research that may come to use and that have commercial potential. We also support researchers by verifying their ideas concerning its business potential and customer need, IP and commercial risks, etc. All new proposals go through GU Holding’s due diligence processes after that, which ensure that GU Holding owns solid companies and constantly expands and becomes stronger.

Facts and figures • 111 ideas financed and launched since 1995 • 82 of them in operation today • 33 projects and companies developed in the incubator and 20 projects in the pre-incubator • 300 people employed by companies created by GU Holding • SEK 296 million in revenue generated in total by these companies • SEK 732 million of external investment has been attracted, of which SEK 67 million invested by GU Holding • SEK 56 million generated in exits already.

GU Holding’s portfolio is diverse and reflecting 50 excellent research findings in a wide range of areas. Ideas from medicine and other life sciences make up the vast majority of our dealflow and portfolio, followed by clean-tech and ICT. They are also at various stages of development, from start to pre-expansion.

The foremost goal of GU Holding is to generate new businesses and make good long-term investments that benefit our society and result in profitable exits. Our mission is to invest early and by that, we are taking high risks – often nobody else is investing so early, neither capital nor manpower. We exit earlier than most investors, to be able to reinvest our investment money in new ideas. Exit opportunities are ‘few and far between’ though, why we take advantage of every opportunity we have to make a partial of full exit to enable us to make good use of our seed capital – and we have a good success rate. To date, we have earned a fair return on our investments and we still have many interesting and unrealized holdings that are worth millions. We have contributed to our region’s renewal, improving growth figures and healthier economy by enhancing the competitiveness of the region. We have also made people’s lives easier, healthier and happier.

I n c u bato rs

GU Holding AB Erik Dahlbergsgatan 11A, SE-411 26 Göteborg Tel.: +46 31 786 5163 Fax: +46 31 786 5150 information@holding.gu.se www.holding.gu.se

187

Focus on Gothenburg

Medfield Diagnostics Enabling faster treatment for stroke patients Time is of greatest importance when someone gets a stroke. Millions of brain cells die each minute during the first hours. It is today possible to get acute treatment for most strokes. But the treatment cannot be given without a diagnostic step and plenty of time is lost before the diagnosis is set at the hospital.

Medfield’s instrument will be located inside the ambulance or in the emergency room. This will cut the time to treatment substantially resulting in that many more stroke victims can keep their speech and mobility after a stroke attack, as well as ensuring huge cost savings for the healthcare system.

M e di ca l Te ch n o l ogy

Medfield’s diagnostic instruments (called Strokefinder) are based on microwave technology. Microwaves scatter compared to x-rays, which sets a high demand on data interpretation and algorithms, the core of Medfield’s technology. A clinical study has been completed with Sahlgrenska University Hospital, which also resulted in a first reference sale of a Strokefinder R10. The next generation Strokefinder (M100) is now being prepared for launch. The goal is to have the product commercially available for both monitoring and diagnosis applications during 2014.

188

Strokefinder R10 in a clinical trial at Sahlgrenska Hospital.

Clot or bleeding? Diagnosis is required before treatment can be initiated.

Microwaves scatter, setting high demand on robust algorithms, the core of Medfield’s technology.

Strokefinder for use in ambulances.

Medfield Diagnostics Medicinaregatan 8 A, SE413 46 Göteborg Tel.: +46 31 741 17 53 info@medfielddiagnostics.com www.medfielddiagnostics.com

Focus on Gothenburg

Meducati AB Delivering medical education since 2010 Meducati specializes in medical education and the staff has experience from interacting with both the healthcare and IT industries for more than ten years. The company is specialized in delivering software solutions for many different training situations, including leading assessments for clinical studies, training investigators, and providing e-learning activities on the web.

DESIGN In order to succeed with educational activities, it is important to define objectives and expectations that can be targeted. We are certified project managers that can support you through the development of a communication strategy and during the carry-through of your training projects.

PRODUCTION We package your information; as interactive training courses, simulators, games, documents, and webcasts. We can supply graphics, provide existing or develop new tools, and produce videos.

DELIVERY We can deliver your documents and software through our own LMS (Learning Management System) and MMS (Media Management System). We utilize fast and reliable cloud-servers and have a global coverage.

FOLLOW-THROUGH Our platforms are designed to enable extensive progress tracking. If you choose to work with Meducati, you will be able to define and track performance indicators.

You will understand the usage and impact of your documents, videos and courses and be able to use this information to adapt communication. You will be able to control quality in your project by correlating organizational requirements to training advancements.

WHY WORK WITH US? We are a small dedicated enterprise that wants to deliver excellent results to satisfied clients. We stay agile and are able to take on small and large projects. We have a long history and extensive experience from the healthcare-, learning-, and IT-sectors and have clients from both the pharmaceutical industry and international research organizations. If you are interested in using us for your next educational activity or only want to know more about us and what we have accomplished already, please get in contact!

Meducati AB Åvägen 24, SE-41251 Göteborg Tel.: +46 708 205052 bjorn.haman@meducati.com www.meducati.com

E d u cat io n & Re s e a rc h

Bjorn Haman, M.Sc. Founder and CEO of Meducati

189

Focus on Gothenburg

Unfors RaySafe - maximum safety in the X-ray room The Swedish medical engineering company Unfors RaySafe is one of the many Northern European technology leaders which are hardly known outside their respective industries. In 1994, Tomas Unfors founded the company with the objective to make the quality assurance of diagnostic X-ray machines more user-friendly. Following the guiding mission to help people avoid unnecessary radiation and to establish a better radiation safety culture wherever technicians, medical staff and patients encounter radiation, the company has developed into an international market leader. It is supplier to major X-ray manufacturers such as Philips and Siemens, as well as direct distributor to independent service and maintenance providers. Unfors Raysafe is currently the only company that provides a comprehensive solution for the X-ray room, consisting of devices for quality assurance of diagnostic X-ray equipment, real-time dose monitoring devices to measure radiation exposure of medical staff and dose monitoring and tracking solutions for patients. It is best known for the high measuring accuracy and simple handling of its devices.

“X-ray cannot be detected by the human senses. Even experts who know how they can protect themselves are frequently exposed to higher radiation doses than they expect.”

Magnus Kristoferson, CEO of Unfors RaySafe.

In addition to the Equipment Division, Unfors RaySafe established a Staff Division in 2011 and became the first medical engineering company to introduce the real-time measurement of the radiation to which medical staff is exposed in X-ray rooms: For the first time, doctors and nurses can reduce their radiation exposure dose and actively influence it by changing their behavior during interventional procedures. To complete Unfors RaySafe’s radiation safety concept, the company started to focus on the patient in 2012 within the newly founded Patient Division: Each year approximately 3.6 billion diagnostic X-ray exams are performed globally and the use of CT scans is increasing around 10% yearly due to its low cost and high image quality. With each exposure a patient has to radiation, it increases the risk of developing cancer later in life. Unfors RaySafe therefore developed a solution that helps reduce unnecessary examinations, facilitates dose tracking and avoids wasted radiation events, thus helping to increase patient safety and cutting hospital costs through improved process quality.

“The medical application of X-ray has constantly increased in the past years and with it also the concerns about their health impact. With our solutions, we want to help people avoid unnecessary radiation and keep the necessary exposure as low as possible.”

M e di ca l Te ch n o l ogy

Magnus Kristoferson, CEO of Unfors RaySafe.

190

Focus on Gothenburg

THE CANARY BIRD To emphasize its focus on a better radiation safety culture for all groups exposed, Unfors RaySafe has changed its name from Unfors Instruments to Unfors RaySafe in 2012 - and with this step added a small canary bird to its company logo. It symbolizes the canary bird miners used to bring into the coal mine: In the early days, coal miners brought canary birds into the mines as an early warning system for dangerous – yet undetectable – gases. As long as the little yellow bird kept singing, the air in the mine was safe. When the singing stopped, the miners knew something was wrong and could leave the area in time.

For Unfors RaySafe, it is the perfect symbol because the company has made it its mission to help people avoid unnecessary radiation that cannot be detected by the human senses.

• Founded in 1994 by Tomas Unfors • Headquartered in Billdal, Sweden • 3 Company divisions: Equipment, Staff, Patient • 163 staff worldwide • 7 subsidiaries in the USA, Germany, Singapore, Great Britain, Japan, China and India

M e di c al Te c h n ol og y

Unfors RaySafe Uggledalsvägen 29, SE-427 40 Billdal Tel.: +46 31 719 97 00 Fax: +46 31 910 950 info.se@raysafe.com www.raysafe.com

191

Focus on Sk책ne

Focus on Sk책ne

192

Focus on Sk책ne

193

Focus on Skåne

Foreword by Anna Chérouvrier Hansson, Head of Life Sciences Invest in Skåne

Skå ne – whe re innovation g row s

foreword

Skåne is the southernmost region of Sweden, close to Denmark and Germany. In this part of the country it is easy to find the work-life balance many people are looking for; the distance between larger cities and relaxing post-card beautiful countryside is short. The combination of being close to the continent but still “in the countryside” has laid the ground for curiosity and perseverance.

194

The spirit of innovation burns bright in Skåne, so you will find enthusiasm, entrepreneurship and excellence typify our life science cluster.

The region has an exceptional talent pool of scientists, world-class research facilities, and over 350 R&D companies, focusing on biotech and medtech, within the Medicon Valley cluster (Skåne and Greater Copenhagen area).

Groundbreaking science is in our blood. Skåne has an excellent track record of innovative achievements, which brought the MAX IV Laboratory and the European Spallation Source (ESS) to Lund. These two facilities will form one of the foremost materials science research hubs in the world when completed, offering state of the art scientific analysis.

Our success is achieved through a highly collaborative environment represented by the so called “quadruple helix” model comprising businesses, research institutes (universities & hospitals), government and investors. It nurtures our dynamic knowledge-based cluster, fosters a synergy of innovation and creates profitable business with continuous growth.

Focus on Skåne

Medicon Valley offers you a unique blend of close collaboration, a specialist talent pool and a complete value chain that allows you

to invest, discover and grow with confidence.

Our experienced investment team, at Invest in Skåne, will help you find the right opportunities, business partners, talents and facilities to allow your life science ideas to flourish in this unique environment.

Welcome to Skåne!

fo rewo rd

In Skåne we look at the positive side of changes to make new exciting possibilities arise. When AstraZeneca left their R&D facilities in Lund the science park Medicon Village was formed instead. It is now the base for several AstraZeneca spin-off companies, making it possible to support the inhalation expertise to prosper. The informatics giant Intel has also chosen Skåne and will locate its new R&D facility in Lund to retain the software competence being released from former ST Ericsson. This also makes our region a natural place to develop digital health, as we have solid experience of working cross-disciplinary.

195

Focus on Skåne

Foreword by Professor Gunilla Westergren-Thorsson Dean of Faculty of Medicine Lund University

To un d erstand, explain an d im prove h um a n h e a lt h

foreword

Staying power and development over the long term are strengths. Since 1666, we have been a University on the move. Through the centuries, we have researched our way to new knowledge and we have educated leaders, problem-solvers and knowledge developers to improve human health and quality of life. Many important breakthroughs – such as the medical application of ultrasound and the artificial kidney – originate from the Faculty of Medicine at Lund University.

196

At the Faculty of Medicine, we work actively to ensure that the knowledge generated here benefits society, in the form of better diagnostics, new drugs and improved treatments. This is achieved above all through very close collaboration with healthcare services in our region and cooperation with successful researchers all over the world. Since 1999, Lund University’s innovation activities have

invested in over 60 new research companies, which together have generated more than 2 300 workyears and over SEK 635 million in tax revenue.

We have companies here working with new ideas within life science, food science, nanotechnology, social innovations and engineering.

The depth and breadth of subjects represented at Lund University create endless opportunities for interdisciplinary research. In many research projects, medics, biologists, engineers, social scientists, chemists, economists, behavioural scientists, ethicists and humanists meet to solve complex social problems. The global challenges that we are facing today must be met with boundary-crossing cooperation.

Globalisation entails the change, weakening or disappearance of boundaries. Humanity is facing

Focus on Skåne

enormous challenges, not least with regard to the major health issues. Fortunately, the frontiers of research and technology are moving forward at lightning speed. With this development, our location at the centre of one of Europe’s most dynamic border regions – the Öresund region – is a strength.

We are now intensifying our work on contributing to the solution of major health problems. We are taking on the challenge by investing in new, creative research environments with young researchers from various research fields, improving support for the international researchers who choose to come here and expanding our global cooperation. These are some important steps towards living up to our vision: to be a Faculty of Medicine that understands, explains and improves our world and human health.

fo rewo rd

Lund University is Sweden’s most international university. We attract the largest number of international students and our research environment is an international creative meeting-place. Sweden’s population registry and biobanks, unique in the world, combine with creative meeting-places, outstanding equipment and technical platforms to contribute to the creation of strong research environments that attract researchers from all over the world. Universities abroad, researchers in other countries and international networks regard us as

an attractive partner. We reach out into the world and it comes to us.

197

Focus on Skåne

Foreword by Ulf G Andersson, CEO Det Medicinska Malmö

foreword

Wel come to the south !

198

Southern Scandinavia, with the city-axis Copenhagen – Malmö – Lund, has always been a strong region within Life Sciences.

held together by the world wide known cluster organization Medicon Valley Alliance. This region is built on strong cities and committed people.

This strong position has been continuously developed through a natural and effective collaboration between health care, universities, industry, society and capital.

In order to maintain this strong position it will be increasingly important to be capable of attracting skilled people, world class research and innovation projects and companies with significant growth potential. All the above is necessary to attract sufficient amount of capital for investments into this area.

During the last two decades this unique “ecosystem” has been further improved through the creation of Medicon Valley, a bi-national region hosting big pharmaceutical companies, hundreds of small and medium sized enterprises, more than 10 universities hosting 150,000 students and more than 4,000 scientists within Life Sciences all

Furthermore, the establishments of the giant research facilities ESS and MAX IV will be of vital importance in attracting international investments.

Focus on Skåne

For the development of the next generation of technologies and products co-operative interactions will have to be even further intensified. New arenas for open innovation and multidisciplinary initiatives will be increasingly important. Last but not least an increased interaction between the health care system, with its providers and hospitals, and research, innovation and industry will be absolutely essential in bringing new technologies and products forward.

Medical Malmö offers professional collaboration opportunities for and together with private and public organizations.

Welcome !

Ulf G Andersson CEO

fo rewo rd

Medical Malmö of Sweden – Det Medicinska Malmö was founded in 2010 by Region Skåne, the University of Malmö, the University of Lund and the City of Malmö. Medical Malmö is thus

an active common forum within Life Science and Health for its four principals with a definite focus on unique events, establishments, new initiatives and engagements.

199

Focus on Skåne

Foreword by Anette Orheim, Communications Director Medicon Village AB

Streng t h in dive r s ity - re s h a ping bo unda rie s to g et h e r

foreword

Imagine that you are thinking about the Solution. The thing that will be most effective and profitable for your project.

Then you take a break, go for lunch in Restaurant Inspira at Medicon Village. And on the spur of the moment, you sit at a table with a nice group of people that you met at a seminar the other day. You talk about your ideas. They nod enthusiastically and share their experiences. Things you hadn’t thought of.

200

Just a normal day at Medicon Village. This is where researchers, innovators, and entrepreneurs meet. Today, there are members from the Academy and innovation teams as well as from the industry, medical device, biotechnology and pharmaceutical companies. They work on health and wellbeing projects, products, or services in prevention, diagnosis, care or treatment. Our strength lies in our differences. This triple-helix environment takes what you thought was the Solution, and develops into the Solution 2.0. Medicon Village is a platform for knowledge collaboration and business benefits, for people’s health and wellbeing. Through participation in the big things – a supportive environment -we create the conditions for the small things. That is the essence of what we want to offer our members at Medicon Village.

New opportunities are created by interfacing and cooperation between regional players, universities, and industry. The prospect of cross-disciplinary cooperation and meetings creating value was the basis for the formation of Medicon Village. Mr. Allan Larsson - Chairman of the Board of Lund University, ESS negotiator, and a well-known name on the political stage - was the driving force behind establishing a new life science village in the wake of AstraZeneca’s relocation from Lund to Gothenburg. Mr. Larsson worked onbehalf of the Research and Innovation Council in Skåne (FIRS) consisting of Lund University, Region Skåne, as well as the municipalities of Lund and Malmö. Another participant on this fascinating conceptual journey, from the very beginning, was the serial entrepreneur Mats Paulsson, one of the founders of the construction company Peab. By personally donating SEK 100 million to the foundation, Mats Paulsson laid the foundations of Medicon Village. The life science village, which first saw the light of day in January 2012, is now home to almost as many jobs as on the day when AstraZeneca announced its move - over 800.

Both public and private innovator organisations are to be found in our diverse environment, e g Lund Life Science Incubator. With consideration for the small things, it is

Focus on Skåne

important for Medicon Village to create a great environment for innovation and to help companies grow. Small and medium sized companies are the future engines of growth in life sciences. We want to strengthen those companies that are successful and willing to develop within health and wellbeing with a view to stimulating their growth and development.

At Medicon Village, companies are close to research in areas such as cancer and diabetes and have access to clinics. Not least there are the high quality laboratories. At the same time, Medicon Village also offers participation in a larger structure, with proximity to knowledge intensive service companies and service companies offering cutting edge expertise.

Our strength is that we are all different - but together. If you are working on a project, a product, or a service in health and better life, you’re welcome to join us as a member and take advantage of our offers. By being a member of Medicon Village and cooperating with other companies and operators, your visibility in the market can increase. Maybe you’ll even find a new path to follow - a Solution 2.0.

fo rewo rd

To be part of Medicon Village is to be part of a collaborative community. Here there are arenas for meeting to exchange ideas, with the clear objective of creating growth. It is also close to other important organisations like Skåne University Hospital, Lund Bio Imaging Centre, Clinical Research Centre (CRC), and the Biomedical Center (BMC). Together with the future research facilities, MAX IV and ESS, Medicon Village is creating a world class infrastructure. This offers a big lift for the entire Öresund Region, and establishes broad and growing opportunities for research and entrepreneurship in life sciences in the region.

There is a commitment from members of Medicon Village to cooperate and support each other. We all know that the path from research to innovation and growth, before becoming a robust company is a long one for any company in life sciences. The Swedish side of Medicon Valley has changed character and become an arena for SMEs and true triple helix collaborations.

201

Focus on Skåne

Skåne:

Unique international cross-border cluster The centre of life science excellence that has grown up in the Öresund region is unique in that it not only includes three administrative regions but two different countries. Known as Medicon Valley because of its life science credentials, the cluster spans the regions of Greater Copenhagen and Zealand in Denmark and Skåne in southern Sweden, which since 2000 have been linked by the Öresund bridge. A total of 12 universities –five of which provide life science-related education – 11 university hospitals and over 350 R&D companies, focusing on biotech and medtech, are based in the whole of Medicon Valley.

In the mid-1990s, the idea was born that became Medicon Valley. The concept then gained backing and funding from the EU. It was further strengthened when, in 1997, Danish and Swedish universities established a permanent forum for cross-border cooperation in the Öresund region, creating a consortium known as Öresund University that encompassed all the region’s universities. The two biggest and best known are Lund University and the University of Copenhagen. In the Medicon Valley region there are more than 150,000 university students, of whom at least 45,000 study life science and around 2,600 are doctoral students in the life sciences.

The life science research being carried out at the Medicon Valley universities is of the highest international standard and the cluster is one of the strongest in Europe, as well as the largest in Scandinavia. In this chapter we shall be looking at the rapidly expanding life science sector on the Swedish side of the Öresund bridge.

Malmö is the third largest city in Sweden and the administrative centre of Skåne County. It is the commercial centre of southern Sweden, with international links through its port and airport. Road and rail infrastructure are also good. Malmö is currently moving from being an industrial city to becoming a knowledge-based environment. Older industries have been replaced by investments in new technology and high quality training programmes. Malmö University, established in 1998, is Sweden’s most recently opened and has some 15,000 students. There are a number of well-known companies in the fields of biotechnology and medical technology based in Malmö and there is close cooperation between academia, science parks and industry. Lund University has a satellite campus in Malmö and another in Helsingborg. Malmö is also the location for part of Skåne University Hospital – the other site is in Lund – where Lund University has its Clinical Research Centre. And since 2011, det Medicinska Malmö has provided an common forum for its four principals: Region Skåne, Lund University, Malmö University and City of Malmö.

Lund, which is only 15 km from Malmö, is a historic cathedral city founded in the late tenth century, when the area was still ruled by Denmark. Lund University, which was founded in 1666, is Sweden’s largest, and arguably the oldest in Scandinavia. It has around 47,000 students altogether, including those attending Lund Institute of Technology, which is to a degree independent. Since the middle of the last century, Lund University has seen its numbers expand considerably and, at the same time, companies involved in the chemical, medical, electronics and – towards the end of the century – the IT sectors have based themselves in Lund.

Research at Lund University has produced discoveries and innovations that are justly world famous, including: diagnostic ultrasound and the artificial kidney for dialysis patients.

202

Lund University has eight faculties, with more than 280 different programmes, offering a total of about 2,250 separate courses. It works cooperatively with 680 partner universities in over 50 countries. The Lund campus is centred on Lundagård park, next to Lund Cathedral. The university is rightly proud of its research and in recent years has received more research funding than any other comparable Swedish institution. With 2,500 researchers, and a research budget of SEK 3.8 billion, the university attributes its success to its high quality inter-disciplinary research and the wide range of subject areas covered. It describes its research as internationally renowned in several fields, including nanotechnology, stem cell biology, diabetes and neurodegenerative diseases, such as Parkinson’s disease. Its research in nano science, stem cells and endocrinology has been judged to be excellent or outstanding.

Focus on Skåne Strategic research funding In 2009 the government awarded Lund University strategic research funding of SEK 715 million to lead and develop world-leading research in six life science areas for the following five years: epidemiology, diabetes, neuroscience, stem cells and regenerative medicine and cancer, plus an interdisciplinary research project in nanoscience.

• EpiHealth (epidemiology) This joint project (Lund 60 per cent, Uppsala 40 per cent) aims to promote national and international excellence in epidemiological research, including areas such as gene–environment interactions, databases, biobanks, quality in healthcare, patient databases and health economics.

• EXODIAB (diabetes) This collaboration (Lund 70 per cent, Uppsala 30 per cent) will work on developing tools for prevention and successful treatment of diabetes and to create a national resource for Swedish diabetes research.

• MultiPark This multidisciplinary neuroscience research focuses on Parkinson’s disease and relies on cooperation between Lund University and Skåne University Hospital, Lund, with support from the University of Gothenburg (Lund 97 per cent, Gothenburg 3 per cent).

• Stem therapy The aim of this joint project (Lund 80 per cent, Uppsala 20 per cent) is to demonstrate, within the next 10 years, that stem cell-based cell replacement therapy is effective and safe for diabetes treatment. It is part of a national initiative on stem cells for regenerative therapy.

• BioCARE (cancer) This collaborative project on biomarkers in cancer medicine (Lund 70 per cent, Gothenburg 30 per cent) is aimed at developing strategies to strengthen cancer research at the two universities and so achieve the greatest possible international effectiveness and translational effect.

• Nanometer Structure Consortium This 100 per cent Lund University project in nanoscience and nanotechnology recognises that for the past 20 years Lund has hosted a major interdisciplinary research environment in nanoscience, with more than 100 scientists working on research in areas including the life sciences.

The Faculty of Medicine at Lund University collaborates with Skåne University Hospital at its facilities in Lund and in Malmö, with the intention of creating an environment with productive communication between basic research and the healthcare system. Among the products of this collaboration are the Biomedical Centre, a research and education centre in Lund which houses 800 researchers and scientists, and the newly established Clinical Research Centre in Malmö, where more than 400 clinical and preclinical researchers are based. These are affiliated to Skåne University Hospital.

The international companies The presence of a relatively high number of mature role models in the form of internationally-focused pharmaceutical companies has provided critical mass for Medicon Valley’s life science cluster. For example, Malmö is an operations base for Ferring Pharmaceuticals. It is a US-owned research-driven bio-pharmaceutical company, focused on identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and osteoarthritis. Also located in Malmö is LEO Pharma, a Danish-owned international company working on treatments in the areas of dermatology – psoriasis, actinic keratosis and non-melanoma skin cancer, eczema and skin infections – and thrombosis. Lundbeck, a Danish-owned global pharmaceutical company specialising in neuroscience research, has a site in Helsingborg, while Novo Nordisk, the Danish-headquartered global healthcare company, has a Swedish operation in Malmö. It is a leader in diabetes and haemophilia care, growth hormone therapy and hormone replacement therapy.

Global pharmaceuticals major AstraZeneca, which previously ran a research facility in Lund, closed it and in 2012 formally handed the site over to become Medicon Village, a new centre for life science research, innovation and entrepreneurship.

203

Science parks

Focus on Skåne There are a large number of science parks in the region. The main ones with a strong life science focus are: Ideon Science Park in Lund is Sweden’s first and biggest science park. Founded in 1983, its aim was to create new companies from the ideas, research and innovations of Lund University researchers. Several global leaders in the fields of ITC, life science and cleantech started their operations at Ideon Science Park. Today there are around 260 companies together employing some 2,000 people based in the park.

Medicon Village, in the former AstraZeneca research centre in Lund, will house up to 1,000 people working in medical research, pharmaceuticals, medical technology and biotechnology when it is fully up and running. Its operator describes its mission as “to create an environment where research, innovation and enterprise interact to create value for human health and wellbeing”.

Medeon Science Park in Malmö is solely for life science companies. It offers office space and conference facilities, participation in competence networks, incubator support for newly established companies, together with service functions.

It can provide a centrally located starting point for research exchange, business contacts and recruitment. Medeon Science Park also houses the incubator Medeon Incubator.

LU Bio (Lund University Bioscience) was founded in May 2007 and forms part of Lund University’s innovation system. It is a holding company part-owned by Lund University (20 per cent), a consortium of private investors (48 per cent) and additional investors (32 per cent), which supports life science research spin-offs with early financing. The companies in its portfolio cover areas including cancer, sepsis, muscular dystrophy and hair loss.

LUIS, LU Innovation is the Lund University technology transfer office. It supports the start-up of around 10 research-based companies annually. It can provide researchers with support and resources in the commercialisation process, including advice with patents, design of business concept and financing.

Organisations

Medeon Incubator focuses entirely on life science sector start-up companies. It offers a growth environment with access to industry-specific coaching, business counselling, training and other services to new ventures in the areas of medical technology, biotechnology, pharmaceuticals and healthcare.

Medicon Valley Alliance is a Danish-Swedish network organisation representing the life sciences in Medicon Valley.

A not-for-profit membership organisation, it describes its role as “raising the international recognition of Medicon Valley with the aim of attracting labour, investments, and partners.”

Members include biotech, medtech and pharma companies of all sizes, CROs and CMOs, as well as public organisations, universities, science parks, investors, and various business service providers. MVA runs Medicon Valley Online, an online portal that provides an overview of the Medicon Valley life science cluster.

There are several marketing and business development organisations in the area. Region Skåne is the regional marketing organisation. Its affiliate Business Region Skåne is responsible for promoting business and industry in the region. Invest in Skåne is the inward investment agency for Southern Sweden. It is also part of Business Region Skåne.

The experienced investment team at Invest in Skåne can help anyone with life science ideas to find the right opportunities, business partners, talents and facilities to allow the ideas to flourish.

204

A case study of the kind of assistance Invest in Skåne can offer, and the success that can result, is Medicon Valley Inhalation Consortium (MVIC). Most of the scientists and researchers now involved in MVIC had previously worked for AstraZeneca in the field of inhalation until the company closed down its Lund R&D. At that point things had seemed

Venture capital and incubators

Ideon Bioincubator has been based at BMC (Biomedical Centre) at Lund University since 2007. It offers advanced laboratory premises for carrying out proof-of-concept studies, plus business development services, coaching and access to various networks. It supports selected companies for up to three years through subsidised rent of facilities.

uncertain for them as inhalation is a niche area, though an important part of the pharmaceutical industry. However, Orest Lastow, now president of MVIC, saw an opportunity to retain their expertise and build Skåne’s worldwide reputation as a centre of inhalation excellence.

He suggested collecting together several companies set up by former AstraZeneca colleagues and forming a consortium, creating a higher profile internationally and a more secure business platform. As he explained: “Our consortium can offer the full value chain in inhalation from development through to delivered product. That is very attractive to large pharmaceutical companies, who are out-sourcing non-core areas of business to gain more flexibility to take on more projects.”

MVIC started with 10 companies and has grown to 18 in just under a year. Orest went on: “We have 60 experts in inhalation, with 800 years of relevant experience, and 25 of them are PhDs. This level of competence combined with our ability to provide a complete value chain makes us unique in Scandinavia.”

The next step for MVIC after establishing the parent company is to broaden its international appeal to the many mid-sized pharmaceutical companies across Europe. Orest said: “We really value Invest in Skåne’s support and we also realise it can play a vital role in helping us to find, reach and meet midsized companies.”

Focus on Skåne Lund University Researchers point way to breakthrough • Can single antibody hold key to blood cancer?

A single antibody may hold the key to treatment for multiple myeloma, or cancer of the blood, which is currently incurable, research from Lund University suggests.

“We tested the antibody in various ways, including on tumour cells from myeloma patients that have been transplanted into mice. The tests showed that the antibody is able to destroy myeloma cells,” said researcher Markus Hansson.

The research team selected antibody BI-505, shown to be effective on tumour cells in both cell studies and animal experiments, from a ‘biological library’ of thousands of antibodies from the company BioInvent in Lund.

The antibody had also been tested in an previous safety study on seriously ill patients. Now a study of its treatment on less ill patients has started. “This study will include patients who have just been diagnosed and therefore still feel fairly well. We want to test the antibody treatment before the patients are treated with any other drugs,” said Hansson.

The Lund treatment study will involve 15 patients and is expected to be completed this year. If the results are good, the team plan to continue testing BI-505 in larger-scale studies.

• Insulin reactions depend on ethnicity People’s differing abilities to release and react to insulin depend on their ethnicity, a new joint research study from Lund University, Stanford University, California, and Kitasato University, Tokyo. The results show that healthy subjects of all ethnicities could maintain a normal glucose level, but in different ways.

“Africans tend to have lower insulin sensitivity. However, they appear to compensate for this by releasing larger quantities of insulin. Among those of East Asian origin, the reverse appears to be the case. They have very good insulin sensitivity, but appear to have a poorer ability to release more insulin if it is needed.

“Caucasians fall somewhere between the two extremes. Both insulin release and insulin sensitivity are affected,” commented Damon Tojjar, a doctoral student at the Lund University Diabetes Centre.

• Whooping cough may have lifelong effects Whooping cough, or pertussis, was thought to have been almost eradicated in developed countries until recently, but there have been serious outbreaks of the disease over the past two years.

And research at Lund University has shown the childhood disease can have a lifelong impact on health. People born during whooping cough outbreaks are more likely to die prematurely, even if they survive into adulthood, the research found.

Women had a 20% higher risk of an early death, and men a staggering 40%. Women also suffered more complications during and after pregnancy, with an increased risk of miscarriage and of neonatal death.

“The results show the importance of following up patients with exposure to whooping cough in childhood, particularly pregnant women,” says Luciana Quaranta, the PhD student at Lund University whose findings these are.

Her study used the Scanian Economic Demographic Database, based on data from Sweden’s extensive population registers, between 1813 and 1968, to examine how conditions at birth, such as socioeconomic status and exposure to infectious diseases, affect people later in life.

205

Focus on Skåne

Aventure – from market to science to market

Aventure is a research-based company in the field of food - nutrition - biotechnology. Our core activity is the development of scientifically verified products and processes for functional foods and adjacent spheres. Our competence stretches all the way from research to finished products.

Our business idea is to develop unique, scientifically validated food/nutrition and biotech concepts (incl. products and patents) with large national and international market potential and to generate stand alone companies with high rated IP. Our company builds on a high level of in-house competence and our understanding of the needs of the market, combined with close cooperation with a network of qualified resources in some of the world’s leading research institutes in the fields of food and biotechnology. This network gives us access to cutting edge competence within many different areas, and enables us, for example, to conduct clinical studies.

Aventure is geographically located in Lund - the heart of the Öresund Region, one of the world´s most expansive areas for research and business within food/biotech. Lund university, the leading university of Scandinavia, with it´s Chemical Center is only a stones throw away from our office.

Aventure’s patent portfolio today encompasses an impressive number of patented products and processes that are organised in different fully or partial owned companies. Some of these companies are on the verge to launch their products nationally and/or internationally.

Fo o d & N u t ri t i on

We have a proven track record as developers of both nutritious and commercially successful products. Examples of this are the oat-based products internationally marketed by Oatly AB (www.oatly.com), shelf stable, liquid batter marketed by United Pancakes AB (www.united-pancakes.com) as Pancake & Friends, different B2B products based on oats with a result of enzymatic frontline technologies presented by Glucanova AB (www.glucanova.com) and a concept-winning way to develop and distribute the new generation of organic baby food products from Otto Barnmat AB (www.otto.se). Aventure is also involved in a new, nutritious way to produce yoghurt-based smoothies via the company Berries by Astrid AB (www.berriesbyastrid.com).

206

Aventure AB Scheelevägen 22, P. O. Box 719, SE-220 07 LUND Tel.: +46 46 16 39 40 info@aventureab.com www.aventureab.com

Focus on Skåne

Det Medicinska Malmö

Medical Malmö of Sweden life science and health new initiatives in motion Copenhagen

Unique events

Lund Malmö

Establishments

DRIVE

Facilitator

INFLUENCE SUPPORT

Det Medicinska Malmö SE-205 12 Malmö Tel.: +46 40 650 17 52 Tel.: +46 721 827 583 (mobile) ulf.g.andersson@malmo.se www.medicinskamalmo.se

No n -p rofi t S u ppo r t O rga n i z at i o n

www.medicinskamalmo.se

207

Focus on Sk책ne

208

Focus on Skåne

Fagerström Pharma Systems AB Your Life Science Engineering Contractor Fagerström Pharma Systems AB is part of Fagerström Industrikonsult AB. The company offers consultancy services within machine design and turn-key deliveries together with a range of solutions for improving the efficiency of different production lines, analytical equipments and machine design in the aim to assist companies in the pharmaceutical industry in the development of their competitiveness through finding new solutions. The company also offers advanced simulation services for production flow.

Machine design Fagerström Pharma Systems AB is frequently commissioned for developing unique specialized machines in compliance with GMP. We realize long-term development projects; one example is the close cooperation with the Swedish pharmaceutical industry, where we interact with its organizations while conducting turn-key projects and engineering services.

As an evidence of our technical expertise, we also carry out extensive external training activities in areas such as advanced CAD systems and Finite Element Analysis software.

Manufacturing The Fagerström group has since many years close cooperation with various manufacturing subcontractors which meet the same high level of quality standards as our own. Naturally, we are quality and environmentally certified according to ISO 9001:2008 and ISO 14001:2004.

Simulation For optimizing processes we assist our customers using simulation software for creating digital models of logistic production systems, for fine tuning of material flow, resource utilization and logistics for all levels of plant planning from global production facilities, through local plants, to specific lines.

Validation Naturally, all machines, production lines, analysis equipment etc. must fulfill codes, standards and regulatory requirements. Fagerström Pharma systems have experience, also from CEmarking and risk asserment.

Fagerström Pharma Systems AB La Cours gata 4, SE-252 31 Helsingborg Tel.: +46 042 20 88 00 Fax: +46 042 14 93 05 lennart.astrom@fagerstrom.se www.fagerstrom.se

CMO - Cont ra ct Ma n u f ac t u r in g O rga n i z at io n

Automation A good process automation technology, control systems and supporting data and infrastructure means improved productivity.

Process automation and control is at the core of our machine/line turn-key business. We have experience from most PLC and HMI systems available. We design your process infrastructure through implementing automation solutions for your manufacturing and processing needs.

209

Focus on Skåne

Genovis AB Enzymes that accelerate pharmaceutical research

Genovis and the wholly owned subsidiary GeccoDots share a vision; To help create conditions for better pharmaceuticals through new technology that saves resources and provides improved individual care for everyone.

Genovis has introduced new products in the segment for development and production of biologics, where it has found a unique and focused niche for commercialization of its products.

Technology and Products Genovis has focused on design and production of products to analyze and characterize pharmaceutical substances using unique enzymes and various production formats. The product portfolio consists of three enzymes FabRICATOR®, IgGZERO™ and FabULOUS™ and Genovis has several other unique enzyme products under development.

Benefits of Genovis products An antibody is a very large molecule and several different analyses are required to characterize an antibody. Characterization is essential for all processes in the development of a new medication, from early discovery through clinical trials to commercial product. Once in production, the analyses are used to monitor the quality of the medication. Genovis’ products enable customers to work with completely new analytical methods. They can use the enzymes to carry out faster analyses with higher quality than competing technology can offer.

Bi ote ch n o l ogy

Using FabRICATOR, researchers can detect errors in the development process in less than one hour compared with other methods.

210

GeccoDots AB GeccoDots provides unique multimodal contrast agents and biomarkers for medical imaging. By combining contrast agents, optical probes, radionuclides and nanotechnology, GeccoDots products offer a new toolbox for multipurpose imaging (www.geccodots.com)

Focus on Skåne

Customers Today 90% of the customers are industrial, primarily pharmaceutical companies and biotech companies, as well as companies that offer contract manufacturing of biologics. One common denominator for the customers is that they all work with antibody-based drugs. Over the past two years customers from companies and organizations including Pfizer, the FDA, Pierre Fabre, Novartis, LFB, Genentech and Amgen have published scientific articles demonstrating new analyses and the potential of Genovis products. This achievement represents good technical and commercial feedback to the company and also provides effective marketing of the products.

Business Model The business model is based on the sale of consumables. All products are designed as single-use materials and Genovis focuses development of new product formats on technologies that facilitate sample preparation, are easy and robust to use and that facilitate upscaling of customer processes. When the pharmaceutical industry registers production processes and analytical methods for a new drug, changes in the protocol are avoided during the life cycle of the product since it is an expensive process. This is strategically important for Genovis since sales could substantially rise if customers integrate FabRICATOR and the other products into clinical development and ultimately in production of drugs, which would represent a major boost in consumption. Establishing Genovis’ enzymes in routine processes will lead to long-term customer relationships. Genovis’ products do not require any regulatory authorization.

Sales Genovis launched the enzyme products in the European and North American markets in 2009 and 2010. Over the past years, the enzymes have shown consistent sales growth of over 100% annually. Sales are carried out both directly to end customers and in cooperation with distributors, who in turn market the products to customers on different regional markets. Distributors are currently represented in the US, Europe, South America and Asia. The largest market for Genovis’ products is the US, which accounts for about 60 percent of sales.

Collaborations and partners Genovis and its subsidiary GeccoDots has well-established relationships with several academic partners. The strategy is to involve customers, companies and academic research groups in R&D to build a valuable pipeline and sustainable development of new products with a focus on market needs.

For preclinical marketing, Genovis and GeccoDots are always willing to collaborate in initiatives such as co-marketing, sales and distribution. For clinical development, GeccoDots is actively seeking partners to work with at an early phase.

Company information Genovis is a biotech enterprise headquartered in Lund, Sweden and listed on the NASDAQ OMX First North stock exchange since 2006. The group consists of Genovis AB and the wholly owned subsidiary GeccoDots AB.

Genovis AB P.O. Box 790, SE-220 07 Lund Phone.: +46 46 10 12 30 Fax: +46 46 12 80 20 info@genovis.com www.genovis.com

Bi otec h n ol o gy

Sarah Fredriksson, CEO

211

Focus on Skåne

ImaGene-iT AB a company that performs full CRO imaging services for Academy and Industry customers.

ImaGene-iT provides imaging services to research and discovery in health-care, pharma- and biotechnology.

Our deliverables range from the setup and performance of complex research projects to recommendations for product development.

We provide a panel of services for molecular detection and tissue analyses from histological to intracellular levels: • Discovery assignments – Solutions with performance of experiments, imaging and data analysis, evaluation and report.

• Discovery projects – Supervision for experimental set-up, imaging and analysis.

• System Support – In-house support for optimized performance of advanced equipment.

• Education – Courses and training in optical microscopy, experimental and equipment, brightfield, fluorescence, live cell – super resolution imaging.

“To be able to provide the best results for customers we prefer to get in early in the process, providing strategies for the best performance of all steps leading to a successful imaging!”

The company was founded in 2005 (by Bo Holmqvist, ass. prof.) and has developed into a strong organization that can take on complete development or research projects.

ImaGene-iT sets up the project strategy, decides experimental methods, prepares the samples, performs the labeling, collects image data, and performs the analysis.

Bo: “When I started I was mainly committed to support the Academy but also did projects for pharmaceutical and biotechnology industries.

I think the fact that we combined academy and industry assignments made it possible to pursue new opportunities and obtain synergy effects.”

Our services include the following deliverables of combined experimental and imaging resources: • Sample preparation – Cell culture for live and fixed samples, tissues for paraffin and frozen sections, whole mounts and for transmission electron microscopy.

• Histology and histopathology – Samples for brightfield microscopy – Histochemistry and immunohistochemistry.

• Fluorescence – Samples for epi- and confocal microscopy Immunofluorescence multilabelling and organelles.

• Image capturing – Data and Scientific analysis and Recommendations • Courses - Basic and Advanced microscopy • System support – Services to optimize customers’ use of imaging equipment.

In 2012 ImaGene-iT was re-organized and expanded together with the cofounders Peter Ekström (prof.) and Anders Brinte (MSci tech.), establishing its headquarter at Medicon Village, Lund, Sweden.

Bo: “The creation of Medicon Village emerged as an excellent opportunity to develop the company. From molecule to microscope, and beyond – ImaGene-iT now provides a complete imaging service, from initial sample preparations, experimental set-up, image data collection and analysis, to reports.”

ImaGene-iT’s strong academic basis is reflected in more than 150 scientific publications and experiences from a variety of research fields ranging from cancer research to biology.

C RO - Cont ra ct Res e a rc h O rga n iz at i on

Peter: “ We have always considered quality to be the key! Every step in experiments and analysis has to be secured.”

212

ImaGene-iT’s main expertise is in confocal, fluorescence and live cell imaging technologies. To provide imaging equipment adapted for the individual project, we also cooperate with microscope suppliers, and academic institutions.

With the headquarter at Medicon Village, ImaGene-iT is currently engaged in several important research projects and discovery assignments, for pharmaceutical companies and academic institutions.

Bo: “Our decision to establish our company at Medicon Village has proven to be right. We see increasing demands for our services in this region, and Medicon Village is a great environment to work and expand within.”

Peter: “We appreciate the possibility to share ideas and projects with our companion companies at Medicon Village. This interaction provides keys to our mutual success.”

Anders: “Development of computer imaging software has increased the possibilities to analyze image raw data. We have the skills to exploit that.”

Immunofluorescence with three different markers on a histological (paraffin) section of mammary gland tissue.

Immunohistochemical labeling of a cryosection of kidney tissue.

Differential interference contrast microcopy reveals unlabeled cells.

Confocal microscopic image of a cultured muscle cell, with nuclear label (blue) and cytoskeletal label (red).

3D-rendering of a series of confocal microscopic images (z-stack) of a fish embryo, showing the spinal nerves.

ImaGene-iT AB Medicon Village, SE-223 81 Lund www.imagene-it.se

Focus on SkĂĽne

ImmuneBiotech AB Connecting immunology research with public health At ImmuneBiotech AB, we focus on therapeutic bioactive pharmaceutical products including innovative combinations of probiotics, prebiotics and proteins, in order to confront a range of inflammatory disorders, putting us at the forefront of immunological research and development.

There is growing evidence indicating a major influence of changes in the gastrointestinal tract, with its microorganisms, immune cells and barrier function, on many acute and chronic diseases.

ImmuneBiotech AB represents new therapeutic strategies aiming at reducing or eliminating causative factors targeting our gutâ&#x20AC;&#x2122;s mucosal immune system.

Turning knowledge and innovation into action The company aims to develop, market, and sell innovative products independently, or with partners. As a part of the financing strategies, ImmuneBiotech AB provides contract research and consulting services in the area of pre-clinical development, evaluation of pharmaceutical drug/diagnostic tool effectiveness, and optimizing R&D, based on its long experience of in vivo pre-clinical models for some common human diseases including multiple sclerosis, rheumatoid arthritis, type 1 diabetes mellitus, sepsis, inflammatory bowel diseases (IBD) and cancer. The company promotes a collaborative environment by leveraging its industry and academic associations to ensure accurate, cost-effective and timely solutions with the highest standard of quality.

A new way of thinking ImmuneBiotech AB is a team driven by innovative spirit, calculated risk taking, and sense of communal responsibility. Its vision is to achieve international recognition for excellence of research, and to be at the forefront in generating and using new knowledge for creating cost-efficient advancements that have a true impact on health.

P h a rm a ce u t i ca l

ImmuneBiotech AB Medicon Village Scheelevägen 2, SE-223 81 Lund Tel.: +46 707 40 86 61 info@immunebiotech.com www.immunebiotech.com

213

Focus on Sk책ne

C l u ster s & N et wo rk s

Invest in Sk책ne

214

Focus on Skåne

C l u ste rs & N et wor k s

Invest in Skåne Dockplatsen 26, SE-211 19 Malmö, Sweden Tel.: +46 675 30 01 lifescience.invest@skane.com investinskane.com

215

Focus on SkĂĽne

Labjoy AB Gain experience and competence immediately! ::Labjoy is your competence and development partner with many years of experience of laboratory work from preclinical and clinical research, mainly from the biotechnology and pharmaceuticals industry plus universities and county councils.

We also offer help and support during the planning and design of laboratories to create a safe, modern and competitive laboratory environment.

Our consultants, registered Biomedical Analysts, Biologists and Chemists, have solid and genuine knowledge of cellular and molecular biology, biochemistry, histology and analytical chemistry. Of course we have access to all instruments needed.

We also have substantial experience of the planning and design of laboratory environments so that they fulfil the requirements that apply with regard to safety, health and the environment.

Lab support We have long experience of Assay Development and of executing Screening Assays in Vitro (both primary cells and cell lines), Flow Cytometry (FCS), High Content Screening (HCS), ELISA, Multiplex analysis (MSD, Luminex), Biacore, High Pressure Liquid Chromatography (HPLC), Histology techniques, Immunohistochemistry and Protein Chemistry such as PCR, sequencing, cloning and expression of recombinant proteins.

Lab design We plan and design laboratory environments. The planning process is executed along with all parties concerned and takes place in accordance with Lean Six Sigma and selected sections of the DMAIC model: Define, Measure, Analyse, Improve and Control.

Laboratory fixtures are designed and produced in cooperation with LabRum AB. Lab documentation All laboratory work is carefully documented in Laboratory notebooks. We have many years of experience of setting up method descriptions, risk assessments, checklists and work instructions and Standard Operating Procedures (SOP).

Co n s u lt a nt s

Lab safety We have substantial competence as regards safety, health and the environment in the laboratory and the activity being run. We offer advice and assistance at the time of internal inspections to ensure that the laboratory work is executed in accordance with the Work Environment Agencyâ&#x20AC;&#x2122;s rules and laws.

216

Lab education We offer custom-made educations, e.g. best practice how to perform in Vitro work in a sterile way and environment.

Labjoy AB Medicon Village, SE-223 81 Lund Tel.: +46 702 83 03 73 info@labjoy.se www.labjoy.se

Focus on Skåne

LifeAssays AB Complete Point-of-care System LifeAssays® is a Swedish diagnostic company focused on providing accurate and affordable point-of-care diagnostic testing for veterinarians, community health centers and primary physicians based on our unique patented point-of-care technology platform.

LifeAssays® AB was founded in 2000 and listed on the Nordic Growth Market stock exchange in Stockholm, Sweden since 2003. LifeAssays is committed to helping people and their pets to live longer and healthier lives by providing innovative solutions to help with early disease detection and prevention. Our mission is to accomplish this by providing a system that is Rapid, Easy to use, Accurate and Convenient.

The LifeAssays® Complete Point-of-care solution offers a new alternative for POC testing utilizing the unique and patented magnet immunoassay (MIA) technique. The system is based on small, nano-size magnetic particles and composes of two parts; a wet chemistry reagent in the assays vial where the immunoreactions takes place and an analytical instrument, the Reader, for quantification and measuring. The two are connected with a disposable algorithm chip the “one computer chip” containing all analytic specific data, as well as, a self-executable calculation algorithm. The “one computer chip” is the key of the LifeAssays® POC system and locks the LifeAssays® Reader to the LifeAssays® reagents. The chip is inserted into the reader when a new reagent kit is opened and remains in the reader until the last reagent vial in the kit is disposed of. Upgrades are easily provided with each new reagent kit.

This point-of- care platform is the foundation of LifeAssays® and the technology is developed at Lund University, Sweden.

Today LifeAssays® is a growing diagnostic company with in-house development, manufacturing and market & sales. Sales of LifeAssays products are done trough distribution networks where strong partners are identified and signed in order to ensure a fast and effective instrument placement and market penetration. Currently LifeAssays is established in, among others, Scandinavia, Asia, UK, Spain, France and are actively working on expanding the sales area.

The aim is to become a market leading POC manufacturer and the focus is on continuous market growth and to develop more point-ofcare tests to be used on the unique platform to offer the veterinary and human diagnostic market state-of-the-art products and make early treatment decisions possible.

D i ag n ost i c s

LifeAssays AB Scheelevägen 19, SE-223 70 Lund Tel.: +46 46 286 54 00 info@lifeassays.com www.lifeassays.com

217

Focus on Skåne

Medeon AB You can reach the entire world from Medeon Science Park in Malmö

A creative environment with the right people can make the difference between winning and losing.

The science park is located in Malmö, right at the centre of the Öresund region and bang in the middle of Medicon Valley.

Medeon Science Park offers an inspiring innovative environment for activities within life science. It has everything you need for your company to develop such as strong network functions and incubator. Medeon also has close cooperation with health care and the university and you gain access to good service with reception, switchboard, travel agency and restaurant.

S ci e n ce Pa r ks

As an entrepreneur at Medeon you become a part of Medicon Valley, one of Europe’s leading clusters within life science. We have a tight-knit cooperation and network with researchers and businesses on both the Swedish and Danish side.

218

Our creative environment is designed for both established and emerging companies. The premises can be adapted, according to need – from single offices to entire new buildings in the park. The incubator is the perfect environment to evolve for those of you have a company in the early stages of development.

Medeon AB Medeon Science Park, Per Albin Hanssons v.41 SE-205 12 Malmö Tel.: +46 040 32 10 00 medeon@medeon.se www.medeon.se

Focus on Skåne

Medicon Village The whole value chain for the whole person:

Photo: Precious People

Medicon Village increases the pulse of Swedish life science

Medicon Village in Lund is designed to foster unique and innovative collaborations among academy, innovators and the broad and diverse commercial life science industry. We also want to speed the translation of promising new life science discoveries “from idea to market.” Medicon Village offers a unique environment for life science organisations; integrating research, innovation and enterprise and thereby creating the conditions for improved health and a better life. Today Medicon Village is home to hundreds of researchers and experts within life science.

At Medicon Village, SMEs benefit from the advantages ordinarily enjoyed by large companies - there are laboratories such as cell labs and advanced instrumentation labs, that make it possible for a start-up company in life sciences to launch their business without costly investments in premises and instruments. This forms the conditions for the development of new medical devices and diagnostics to drugs.

From idea to commercial product. There are more than 1000 instruments available to hire, and Medicon Village has 30,000 m2 of laboratories. We provide a meeting place that creates growth and drives opinion.

Alongside Lund’s future research facilities, MAX IV and ESS, Medicon Village is part of a world class infrastructure of today and tomorrow. This offers a big lift not just to the Öresund Region, but also nationally, and creates an expanse of opportunities for growth in research and entrepreneurship in life sciences.

Medicon Village AB is owned by the Mats Paulsson Foundation for Research, Innovation, and societal development. The Foundation’s profits are reinvested into research and innovation.

Medicon Village AB Scheelev. 2, SE-223 81 Lund Tel.: +46 46 275 60 00 info@mediconvillage.se www.mediconvillage.se

C l u ste rs & N et wor k s

So far, medical technology companies such as Airsonett ORI, and biotechnology companies such as Alligator Bioscience and NeuroVive Pharmaceutical, have taken up residence- along with some 20 other companies. Many of these companies are located in the Lund Life Science Incubator, which is housed at Medicon Village. If you need specialist advice or assistance with a project, there are highly trained professionals. Today more than 50 service providers at Medicon Village offer consultancy services from contract research companies (CRO), to IP, finance-, economy-, law- or technical experience firms that specialize in the life sciences. Institutes such as the newly established Life Science Foresight Institute and SP Technical Research Institute of Sweden are also a part of Medicon Village.

Apart from the companies, there are also a number of other operators at Medicon Village. Region Skåne is represented

by Regional Cancer Centre South, Epicentrum, Primary Care Centres Skåne, Labmedicin Skåne - Biobank, Skåne Care, Innovator Skåne, and ClinTrials Skåne. Lund University is established and present at Medicon Village with working groups in various areas including cancer and diabetic research.

Lund and Medicon Village is home to the headquarters of ESS, European Spallation Source, a planned pan-European research facility, which is due to be built.

219

Focus on Skåne

Mercan AB Mertex® surgical fabrics meeting the highest requirements.

Mertex® reusable surgical fabrics Mertex® reusable surgical textiles are developed to meet the demands in today’s infection- and surgical wards. The risk of transmitting infections is a vital concern and to protect both patients and the medical staff surgical garments are used to minimize the spread of infective agents. Mercan AB offers a full range of high and standard performance reusable surgical textiles designed and optimized for surgical garments with excellent comfort and durability.

High performance laminates Mertex® surgical 3-layer laminates with either absorbent or repellent finish are impermeable to liquids and provide a 100% barrier against viruses and bacteria.

Mertex® laminates have a lifespan of 100 WDA cycles. The laminates comply with European standard EN13795 and have passed ASTM F 1670/1671 and biocompatibility tests according to EN/ISO 10993 after 100 WDA cycles.

Mertex laminates are soft, light, elastic and extremely comfortable, ideally used for surgical drapes and high performance barrier gowns. Mertex surgical barrier gowns with Mertex seam seal system meet with AAMI PB70:2003 Level 4 requirements and has passed the ASTM F 1671 viral penetration test even after 100 WDA cycles.

Single layer Mertex® single layer textiles are ideal for scrub suits/clean air suits and surgical gown non-critical areas. Mertex® single layer textiles are available in 100% polyester or our patented PALPA polycotton. Due to the special PALPA construction Mertex® PALPA polycotton provides exceptional comfort with 100% cotton against the skin.

All Mertex® textiles include carbon yarn and comply with the European EN13795 standard after 100 WDA cycles.

M e di ca l D ev ice

Environmental benefits

220

Within the healthcare sector large quantities of disposable products are consumed every day producing a huge volume of medical waste and negative environmental impact. The environmental impact of medical garments in the main relates to the production process. This means that reusable medical garments offer tremendous environmental benefits compared to single-use programs since reusable medical textiles can be reprocessed and use many times.

Mercan AB Mellangatan 66, SE-239 30 Skanör Tel.: +46 40 47 52 30 Fax: +46 40 47 41 82 kleine@mercan.se www.mercan.se

Focus on Skåne

Ori Medical The final link to success We all come into contact with lots of packaging in our day-to-day lives. Often, we do not even give it a thought – after all, packaging is very much something we see all the time. But a fantastic amount of work goes into successful packaging. It has to perform lots of different functions.

It has to protect the product, inform people about its contents, provide advice and instructions on how to use the product and at the same time create a profile and add value from a brand perspective. Special demands are made of packaging for pharmaceuticals and medical devices. Ori Medical in Ystad is a company which has plenty of experience of this. It packages all kinds of things, from antidepressants to catheters.

Ori Medical works with both primary and secondary packing and is often involved in the process early on in order to assist its clients with finding the most effective packaging solutions. We focus strongly on streamlining and quality work in everything we do.

Primary packing takes place in cleanrooms, and there are lots of different options to choose from. There can be different kinds of bottles, blister packs or deep blister packs. Functional aspects are important: packaging have to be easy to open while at the same

time remaining sealed, tamper proof and ensuring that the contents have the required shelf life. Ori Medical is a committed partner that frequently helps its clients to develop packaging solutions from the ground up.

As far as secondary packing is concerned, the company has a number of production lines with integral control systems which keep manual handling to a minimum.

This builds safety into the process.

Parallel-imported pharmaceuticals that have to be repackaged are checked on arrival by an automatic system in order to ensure that the batch number is correct.

The production lines are also used for labelling, printing with inkjet bar or 2D codes. 2D codes are becoming more and more important. European countries are already demanding that these should replace the EAN codes.

For many clients, the fact that Ori Medical keeps bulk pharmaceuticals in stock and ships them to various markets on a justin-time basis is a major advantage. “A lot of companies choose us because we are flexible and have extremely short lead times. We can switch quickly from one product to another,” says Birgitta Olsson, Head of Marketing and Sales at Ori Medical.

Ori Medical also offers a range of related services. It develops packaging from the ground up, manufacture necessary tools, carries out various tests, and validates, documents and reports. As far as medical devices are concerned, packaging is a part of the product which may be of crucial significance to its function. Ori Medical has many years of experience of various technical solutions, and this is a growing client segment.

The company holds accreditation to EU GMP and ISO 13485. During the latest inspection by the Medical Products Agency, MPA, Ori Medical was also granted a licence to release pharmaceuticals from a third country (outside the EU). The US Food and Drug Administration, FDA, has inspected the company’s facilities and submitted its approval for the handling of both pharmaceuticals and medical devices.

The company is compliant with the FDA’s 21CFR 820 rules and has been granted a licence to handle drugs. The company also has years of experience and established procedures relating to chilled products.

P h a rm a ce u t i ca l

Orifice Medical AB Aktergatan 2, SE-271 55 Ystad Tel.: +46 411 79 660 Fax: +46 411 79 669 info@orimedical.com www.orimedical.com

221

Focus on Sk책ne

222

Focus on Skåne

PolyPeptide Group

The PolyPeptide Group is a privately held company focused primarily on the manufacture of GMP peptides for the human and veterinary pharmaceutical markets. The Group employs 450 trained staff at six separate manufacturing sites across three continents: Denmark (Hillerød), France (Strasbourg), India (Mumbai), Sweden (Malmö) and the USA (San Diego and Torrance). With more than 50 years of experience producing therapeutic peptides the Group is one of the world’s leading peptide manufacturing organizations.

The PolyPeptide Group also offers a full spectrum of complementary services for peptide projects, including a comprehensive catalogue of more than 1,250 bioactive peptides; a dedicated catalogue section includes more than 750 special amino acids and derivatives, building blocks and turn mimics, all available from stock. Other services include manufacture of research grade peptides, stable and radio isotope-labeled peptides, and production of anti-peptide antibodies. Custom synthesis of non-peptidic molecules from grams to several hundreds of grams as well as cGMP manufacturing at the kilogram scale can also be provided.

With its exclusive focus on peptides, a solid financial base, multiple manufacturing sites and a proven and established track record with regulatory agencies, the PolyPeptide Group offers an almost unique security of supply to its customers.

PolyPeptide Laboratories (Sweden) AB Limhamnsvägen 108 P.O. Box 30089, SE-200 61 Limhamn Tel.: +46 40 36 62 00 Fax: +46 40 36 63 86 ppl@polypeptide.com www.polypeptide.com

M an u f a ct u re r s

Peptide manufacturing services range from small-scale nonGMP custom synthesis for basic research and lead discovery, through support for pre-clinical studies and on to pre-GMP development of large-scale manufacturing proc es. The range of peptide structures manufactured at the PolyPeptide Group according to GMP extends from dipeptides up to the most complex structures being developed in today’s therapeutic market. These include conjugates with PEG, lipids, and nonpeptidic components as well as peptides with multi-cyclic, branched, and substituted sequences. Exotic amino acids and other organic chemicals can be developed in-house.

By rigorous integration of analytical development into all aspects of R&D, the Group ensures that all products are of the highest purity. GMP manufacturing scale ranges from gram lots through to multi-10 kg quantities. By careful and ongoing harmonization of procedures and technology across the individual sites, the Group can offer local development of manufacturing processes with the potential to transfer the identical process to a second site as requirements grow.

The Group has a long history of cGMP-compliant manufacture and has successfully undergone more than 15 FDA PreApproval and Site Inspections. Altogether, the Group has more than 20 approved drug substances worldwide. The generic portfolio of the PolyPeptide Group includes established drug substances such as Calcitonin, Desmopressin, Leuprolide and Octreotide, as well as a continually expanding range of new products including Eptifibatide, Bivalirudin, Exenatide and hPTH (1-34). GMP services include support for all regulatory and approval processes, and full documentation is provided for all products.

223

Focus on Sk책ne

Promech Lab AB

Co n s u lt a nt s

Customized research equipment

224

Focus on Sk책ne

Con s u l t a nt s

Promech Lab AB Almviksv. 41, SE-218 45 Vintrie Tel.: +46 40 154490 info@promech.se www.promech.se

225

Focus on Sk책ne

Redoxis AB Preclinical In Vivo models of Autoimmunity Redoxis AB is a research focused CRO with long experience of preclinical efficacy models of autoimmunity. Preclinical models of autoimmune inflammatory diseases resemble complex human diseases and are affected by both genetic and environmental factors. Different models represent different phases and characteristics of the human diseases. Therefore, the most critical aspects of preclinical drug efficacy studies are the choice of a proper model and study design.

Redoxis main expertise and knowledge is within the area of rheumatoid arthritis (RA), multiple sclerosis (MS) and chronic inflammation. We offer services regarding evaluation of novel drugs and therapeutic targets both in vitro, ex vivo and in vivo. In addition to efficacy studies of treatment in vivo, we offer analytical services of immunological characterisation and bioavailability analyses. Redoxis senior scientists have many years of experience in the area of drug development and inflammatory experimental models with a deep understanding of the immunological processes underlying autoimmune diseases. Our goal is to provide high cost value studies and efficient service delivery.

Preclinical efficacy studies of autoimmune diseases Redoxis have a strong portfolio of arthritis models including the most commonly used models Collagen induced arthritis (CIA) and collagen antibody induced arthritis (CAIA). Redoxis also provide models of arthritis in rats including CIA and the more T cell specific models of arthritis pristane induced arthritis (PIA) and adjuvant induced arthritis (AIA).

Redoxis provides models of inflammatory induced EAE (Experimental Autoimmune Encephalomyelitis, models for MS) in both rats and mice, induced with proteins or peptides derived from the CNS.

C RO - Cont ra ct Res e a rc h O rga n iz at i on

Redoxis also provides ex vivo systems for early drug validation. These models are based on analysis of the test compound directly on autoreactive primary cells and are useful for early drug characterization and lead compound selection.

226

We tailor-make studies for preclinical drug validation in models of Arthritis and MS. In addition, Redoxis develop and optimise more specific preclinical efficacy models of chronic inflammation. Please find a more detailed description of the models we provide at our updated homepage (www.redoxis.com).

redoxis

Redoxis AB Medicon Village, SE-223 81 Lund Tel.: +46 709 164608 service@redoxis.com www.redoxis.com

Focus on Skåne Consultants

Science and Innovation placing intelligence Science and Innovation

placing intelligence

Science and Innovation AB is a company that provides your business with Medical Advisors. We also help you to plan and carry out clinical studies, as well as writing your applications (IRB, MPA, FDA).

Medical Advisors We can provide you with a vast network of highly experienced and scientifically qualified physicians, from Key Opinion Leaders in various fields, to Physicians in Hospital based specialties as well as in Primary Care.

Let us help you to get accurate and useful data on medical conditions or specific cases or facilitate you with your study plans and projects. We can also review the medical information that is provided by your company´s web page, packet inserts, sales representatives and brochures, so that it is correct and up-to-date.

Let us assemble and manage key opinion leader advisory groups for your products or projects.

Clinical Studies We will provide you with the expert advice you need to plan and execute your clinical studies, producing everything from study designs, protocols to study reports and publications.

Our staff has expertise in conducting studies from early proof-of-concept studies to larger scale projects.

We can arrange study sites in Sweden, Europe, and in the US.

We will assist you in writing various applications where a correct medical input is crucial, from your local ethics committee or medical products agency, to obtaining FDA approval for clinical trials of devices or 510(k) clearances.

Science and Innovation AB Medicon Village, Scheelevägen 2 223 81 Lund

Science and Innovation AB Medicon Village, Scheelevägen 2, SE-223 81 Lund Phone +46 703 262627 Tel.: +46 703 262627 info@scienceandinnovation.se info@scienceandinnovation.se www.scienceandinnovation.se

www.scienceandinnovation.se

CRO - Co nt ra ct Re se arch O rga n i z at io n

Applications and Correspondence

227

Focus on Skåne

Skåne Care AB University Medical Care with Excellence Skåne Care based in the south of Sweden offers well renowned healthcare services to the international market since 2008. We are part of the public Swedish healthcare sector and are organized directly under the regional council of Skåne, with the first governor of Skåne as our principal. Our vision “to be a leading health care provider on the international market that makes a strong contribution to people’s improved health” is reflected in all our business.

Skåne Care represents all public hospitals in the region. We can deliver tailor-made care to patients, expertise support on location, to international clients.

Our strength and our offer to international customers: • Professional public healthcare • Medical city with comprehensive services • Swedish leadership and process mind-set The medical city, positioned close to both Copenhagen and Malmö with international airports, offer easy access to comprehensive and competitive healthcare services performed by 30 000 employees.

I nte r n at i on a l C a re

The Department of Plastic and Reconstructive Surgery has to date performed 250 successful treatments using an innovative method to completely reduce chronic large lymphoedemas following cancer treatment or congenital. The same department is also a leading institution in ear reconstruction. Our Cardiothoracic Centre and Endocrinology Centre both represent two internationally renowned areas of expertise in our portfolio.

228

Focus on Skåne

Our services range from catering to the individual or groups of patient(s) who desires to travel to Sweden for treatment, to education programs as well as consultancy services in a broad range of areas such as research, management and organisation. Our portfolio is perhaps best demonstrated through a selected number of reference cases: Libyan war wounded patients Skåne Care and our Regional hospital of Hässleholm provided care for 39 war wounded patients from Libya between 2011 and 2013. Skåne Care was awarded the business directly from the Libyan council in international competition. The program was successfully closed with positive remarks from patients and Libyan representatives.

Icelandic children with heart disease Skåne Care collaborates with an Icelandic health Insurance organisation and Skåne University hospital regarding pediatric cardiac surgery of 8-10 children each year. This is highly specialised care in an area where Skåne is positioned as one of the two national centres.

Advanced diabetic training for nurses in the UAE Skåne Care, Lund University and Malmö University collaborate in producing an extensive program for registered nurses in the United Arab Emirates. The education program will start in January 2014 at the Fatima College of Health Sciences.

Diabetes prevalence in the region is over 20% and the need to strengthen the local competence is high. We offer services to the highest international standards in this area.

Consultation to diabetic clinic in Ajman, UAE Skåne Care, Skåne University hospital and Global Health Partner collaborate with a local unit to improve care for diabetic patients in Ajman. Our services include audits and advice on how to implement the best standards for diabetic care in the local setting by providing expertise in areas of management, training and research.

I nte rn at i o n al C a re

Skåne Care AB Medicon Village, SE-223 81 Lund Tel.: +46 46 275 2283 skanecare@skane.se www.skanecare.com

229

Focus on Sk책ne

SPAGO Imaging AB

Bi ote ch n o l ogy

SPAGO Imaging performs research and development in the nanomedicine field with focus on cancer diagnostics and treatment

230

Focus on Skåne

SPAGO Imaging performs research and development in the nanomedicine field with focus on cancer diagnostics and treatment SPAGO Imaging is a public company performing research and development in the nanomedicine field with focus on cancer diagnostics and treatment.

The development is based on SPAGO´s platform technologies, IonXgel and 3PEG. The company’s lead project SPAGO Pix, targets the need for significantly improved soft tissue tumor imaging.

Platform Technologies IonXgel is a unique nanomaterial and the basis for SPAGO’s novel cancer selective MRI contrast agent, SPAGO Pix. The SPAGO Pix portfolio also includes opportunities within cancer selective drug delivery for improved cancer treatment, as well as additional MRI indications.

SPAGO Imaging is developing a cancer selective MRI contrast agent, SPAGO Pix, with unique properties providing potential for visualization of smaller cancer lesions and metastases with increased specificity (fewer false positive findings).

It is a nanoparticle based contrast agent which selectively accumulates in cancer tissue through the EPR effect and has exceptionally high relaxivity (enhancement of the MRIsignal). This combination provides excellent contrast between tumors and surrounding tissue in preclinical PoC studies, which indicate good clinical potential.

Spago Imaging AB Medicon Village, Scheelevägen 2, SE-223 81 Lund Tel.: +46 (0)46 275 6160 info@spagoimaging.se www.spagoimaging.com

Bi otec h n ol o gy

3PEG is a proprietary PEGylation platform with competitive advantages. 3PEG can improve critical drug properties of small molecules, peptides and proteins, and provide e.g. increased efficacy and reduced side effects.

Novel Cancer Selective MRI Contrast Agent Early and correct diagnosis is vital to ensure treatment efficiency and increase long term patient survival.

231

Focus on Skåne

The Faculty of Medicine at Lund University After over 300 years of medical research in Lund, the Faculty of Medicine is now one of the most research-intensive university environments in Europe. Our researchers have made discoveries and innovations of great significance for human health, for example the medical ultrasound by Helmut Hertz & Inge Edler in 1953 and the artificial kidney in 1946 by Nils Alwall. The mechanical heart massage machine by Stig Steen and treatment of pre-eclampsia by Bo Åkerström & Stefan Hansson are examples of discoveries made in the 21st century. Research spans across a broad area from basic experimental research to applied research, in order to answer questions related to clinical practice, the health sciences and society.

Researchers from the Faculty of Medicine are involved in six of the Swedish Government’s strategic research areas for the period of 2009-2014; Epidemiology, Diabetes, Neuroscience, Stem cells and regenerative medicine, Cancer and Nanoscience. Also, several of the Faculty´s research groups are participating in EU-financed Networks for Excellent Research, and the collaboration with research colleagues across the world is extensive.

Lund University Lund University was founded in 1666. Today, the University is ranked as one of the world’s top 100 and is Sweden’s most international higher education institution. The University has 47 000 students and 7 200 staff based in Lund, Helsingborg and Malmö. We are united in our efforts to understand, explain and improve our world and the human condition.

Lund is Sweden’s most attractive study destination. The University offers one of the broadest ranges of programmes and courses in Scandinavia, based on cross-disciplinary and cutting-edge research. A degree from Lund University is a hallmark of quality both in Sweden and abroad. The compact university campus encourages networking and creates the conditions for scientific breakthroughs and innovations.

Lund is in a period of rapid development. We are intensifying our work to provide answers to the major questions and challenges facing mankind. ESS and the MAX IV Laboratory are under construction in the city, and these research facilities will change our view of the world and the world’s view of us.

E d u cat i on & Re se a rch

The Faculty of Medicine at Lund University offers a wealth of research, postgraduate and undergraduate education programmes in medicine, nursing and health.

232

The Faculty of Medicine at Lund University P. O. Box 117, SE-221 00 Lund Tel.: +46 46 222 0000 info@med.lu.se www.med.lu.se/english

Focus on Skåne

Truly Translational Sweden AB CRO with a focus on translational science

Truly Translational Sweden AB offers consultancy combined with specialized experimental services within translational science. Our mission is to help our customers to translate preclinical project ideas into efficient experimental plans delivering successful clinical trials.

Strategic project plans

Biomarkers in animal and man

We believe pharmacology is the core of drug development. A better understanding of the relationship between the pharmacokinetic (PK) properties and the pharmacodynamic (PD) effects of your compound will provide key information for successful pre-clinical development and clinical design.

Strategic plans from hypothesis to patient are crucial in our concept for successful pre-clinical development and clinical design. We provide strategic consultancy including planning, leadership and evaluation of your projects, and will help you develop sharp strategic plans with a focus on the end goal and clear milestones along the way.

Biomarkers are becoming increasingly important in drug development, and integrated with PK/PD data they provide important links between preclinical and clinical research. We can help you identify and implement the use of biomarkers in your projects to support decisions about efficacy, dose selection, safety and personalized medicine.

We support you with • Preclinical project plans • Target product profiles (TPP) • Differentiation & market strategies • Strategic & operational project leadership • Second opinion

We provide consultancy on biomarkers regarding • Context of use • Biomarkers for efficacy/patient stratification • Regulatory vs. exploratory use • Clinical and analytical validation • Linking PK/PD to biomarker strategy

We offer specialized experimental services combined with consultancy including • Identification and design of key experiments • PK studies using optimized formulation/administration conditions • Customized PD animal models • Modeling of PK/PD relationships and dose predictions • Data evaluation

©Photos by fotolia.com and Ebba von Wachenfeldt

Truly Translational Sweden AB Medicon Village, SE-223 81 Lund Tel.: +46 46 460 21 00 info@trulytranslational.com www.trulytranslational.com

CRO - Co nt ra ct Re se arch O rga n i z at io n

Pre-clinical pharmacology

233

Focus on Sk책ne

234

Focus on Sk책ne

Zelmic AB We solve delivery problems Zelmic is a pharmaceutical contract research organization with the ability to take projects from start to clinical testing including transfer to a commercial manufacturing unit at low cost and high speed. We are focused on topical delivery and on local delivery of proteins and peptides.

In the development process we use in vitro techniques of various types in order to increase the success ratio of the project and to decrease time and costs. We have extensive experience regarding penetration of drugs into and through skin as well as distribution of drugs in tissue. We use both static and dynamic methods and the results may be used as evidence for effect of drug products as well as of medical devices.

Zelmic has long experience of running pharmaceutical projects and we can therefore contribute to the success of your project by working with your organization.

We perform analytical development in the form of development of assay methods for actives and excipients including peptides and proteins well as development and validation of stability indicating methods.

The pharmaceutical work includes formulation work, stability screening and transfer to a CMO. We do studies of drug delivery and the results can be used for selection of product candidates or for registration of generic products, provided the active is already on the market.

We can provide expert advice regarding optimization of drug development process in order to quickly reach pre-clinical testing or proof of concept studies of biological nature. We can also offer valuation of projects and generation of project plans for investment decisions Zelmic is a privately held limited company and has no marketing facility and no intention to market products.

CRO - Co nt ra ct Re se arch O rga n i z at io n

Zelmic AB Sankt Lars v채g 45 B, SE-222 70 Lund Tel.: +46 46 161240 info@zelmic.se www.zelmic.se

235

Focus on Europe

Focus on Europe

236

Focus on Europe

237

Focus on Europe

Foreword by EBD Group

Pa r t n e ri n g i s t h e key to s uc c essfu l st rategic d evel o p ment in b iotech Today, collaboration — industry term “partnering” — is the defining strategy for business development in life science.

The reasons for this are well understood; drying pharma drug pipelines and looming patent expiry of blockbuster drugs are creating a worrisome income gap expected to reach USD 30 billion over the next five years. Filling that pipeline with new drugs from biotech firms promises to be the quickest and surest way of keeping innovation alive and pharma balance sheets in the black.

For example, based on our internal data we have determined that companies participating in the partnering events we produce, such as BIO-Europe, represent a significant percentage of the deal volume in a given year – USD 21 billion in 2012.

Industry partnering in the form of in-licensing has come to the fore over the past decade. According to industry data, in 1995 drugs based on deals accounted for just over 20% of revenue, but by 2012 that figure spiked to over 50% of big pharma’s revenue coming from in-licensed deals.

Commenting on the value of EBD Group partnering events, Susan Galbraith, Vice President and Head of Oncology iMed, AstraZeneca, said, “AstraZeneca is continually searching for partnerships that will help speed up the delivery of highquality, targeted medicines that make a meaningful difference to patients. BIO-Europe allows us to connect with companies who have demonstrated real potential to complement our efforts as a global, innovation-driven biopharmaceutical business.”

foreword

Now, partnering is on the cusp of becoming even more essential to the industry. Powerful diagnostic technologies and the move to a personalized medicine system are inviting new entrants to the bio-pharmaceutical value chain. As a result, companies operating in life science will need to develop new strategies for collaborations and alliances to remain both competitive and relevant in a rapidly evolving healthcare market.

238

This is why events like BIO-Europe 2013 in Vienna, Austria are more important than ever to the industry. BIO-Europe provides a platform where high-level industry executives and dealmakers can identify and meet with numerous potential partners. In fact, many industry deals are conceived at BIO-Europe, or at one of our other EBD Group partnering events.

Swedish biotech companies have increased their engagement with the industry at large – companies attending our partnering events from Sweden have grown 83 percent from 2008 to 2012.

It is productive outcomes such as this that compel companies to participate in EBD Group partnering events. The upcoming BIO-Europe event in Vienna will attract approximately 3,000 executives from 1,700 companies representing over 40 countries. These executives will engage in upwards of 16,000 one-to-one partnering meetings.

Leading pharmaceutical companies are also supporting the event and are sending teams of scouts to BIO-Europe Spring to engage with new and innovative products, ideas and

Focus on Europe

companies. Abbvie, Amgen, AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, Janssen, Lilly, MSD, Merck & Co. Inc., Merck Serono, Novartis, Nycomed, Pfizer, Roche, Shire, Sanofi, Takeda, and many other large drug development firms will be in attendance and ready to partner.

BIO-Europe, like all EBD Group partnering events, facilitates networking with its partneringONE速 web-based partnering system. Using the advanced partneringONE system delegates of the event are able to quickly identify and arrange meetings with potential partners from across the life science value chain, from large biotech and pharma companies to financiers and innovative start-ups.

Over the course of a three-day conference, delegates are able to meet with dozens of potential partners from around the world, thereby measurably advancing their business strategy and goals.

This dynamic has developed more quickly in the biotech industry because of significant structural problems.

Big pharmaceutical companies desperately need to bridge this income gap, yet they have severely cut internal research and development (R&D) teams that proved inefficient in filling pipelines and too expensive to maintain.

Today no company can stand alone and partnering presents a proven model for finding a way forward.

This has given rise to a host of events and the application of new technologies to help partnerships get started. For example, our firm, EBD Group, supports partnering with a powerful process that combines a virtual-world search for qualified partners with real-world, face-to-face meetings at events.

It may seem too obvious, yet it needs to be said: to successfully collaborate, you will need to come out into the world and meet with people.

I can promise you that after your first 10 partnering meetings you will know far more about your own business than you can guess sitting behind your desk.

fo rewo rd

For example, over the past 10 years partnering has demonstrated its value as an effective approach to business development that allows smaller biotechnology companies to move innovative ideas to market, while helping large pharmaceutical companies at the other end of the table meet a continual demand for growth.

For example, over the next five years pharma companies will lose USD 100 billion in sales as patents expire. New products coming on line are expected to only generate USD 30 billion of new income.

239

Focus on Europe

Foreword by Patrik Frei, CEO Venture Valuation

F ut u re of Life S c ie nc e s Fina ncing in Euro pe Financing of Life Science companies is a key success factor within this research intensive industry. It is one of the few industries where large investment sizes are required and possible returns far away. Any investment in a Biotechnology company involves high risk, but the possibility of return for it’s investor can be vast. So in this respect, the valuation of life science companies and reaching value creating milestones becomes essential. It provides information on what the expected return to the investor can look like, and simultaneously helps companies to elicit a dialogue with their potential future investors.

foreword

Investors nowadays are extremely careful with what they are funding. Each project is reviewed very diligently and only the high value projects (most favorable risk / return ratio) will be funded. For a company it is essential to know the value of its products/projects and to be able to discuss with potential investors what the risk / reward benefits are.

240

An analysis based on Venture Valuations proprietary Biotechgate database shows that even though the total amount of financing in Europe and Scandinavia has remained stable in recent years, the number of financing rounds completed by private biotechnology companies focused on therapeutics has decreased. We also noted that the overall number of newly formed companies has declined in the past five years. These are certainly alarming signs for the industry.

A key question for Pharmas, VCs as well as biotechnology companies is this: “Where will the needed funds come from?” For VCs this question is now more pressing than ever, as during the last 3 to 4 years, institutional investors have been increasingly hesitant to provide capital for biotech investments. Aside from the uncertain financial environment (a biotech investment almost seems to carry the same risk as an investment in government bonds, prompting investors to look for safer bets), the “perceived” poor performance in the biotechnology sector continues to pose a problem. Additional obstacles include the changes in the regulatory environment that has led to increased costs and time to market, as well as prolonged times to strategic exit. A recent analysis by BIO shows that between 2010 and 2012 the average IPO in the US was below the amount raised by the companies. This implies that investors have lost substantial amounts of money. However, in 2013, for the first time since 3 years, the average amount raised versus filed is positive.

Even though this is an optimistic sign, the question remains, how will Biotech companies finance their research and development, especially small private companies?

For VCs this means that they have to be able to convince their investors why biotechnology is still an attractive investment, as compared to other options such as for example cleantech or ICT investments. VCs more than ever now have to employ creative and innovative strategies to ensure continued satisfactory ROI’s for their investors. And

Focus on Europe

we can actually see such deveopments in the market where VCs are trending toward new “forms” of investments, for example the financing of individual projects instead of investing in a company (the “American Idol” model). This approach reduces the unspecific risk, while allowing the VCs to diversify on a “project portfolio” basis, rather than leaving it to an individual company to invest in several projects. Furthermore, we see partnerships between Big Pharmas and VCs to create new collaborative funds. This is certainly a very promising model to address current funding shortages. Given the challenges faced by the VCs, Biotechnology companies are nowadays less able to rely on traditional VC funds and are forced to think outside the box to find alternative ways to finance continued growth.

Important sources of finances here include funds generated from the early stage licensing of products in development, but also from investments by corporate venture funds.

Conclusively, closer collaboration between Pharma, Biotechs and VCs, as well as Academia and Governments will be key for the future success of the Biotechnology industry in Europe. There is still a large potential to increase efficiency in coordinating the efforts and resources among the different stakeholders and to move toward a more collaborative model. “Connecting the dots” is more important than ever to eliminate inefficiencies and to provide all key players with an advantage and associated return on investment.

Thus, transparency (who does what), personal meetings (partnering / investors meetings) and knowing how to provide value to investors will be key success factors for European Biotechnology companies to keep the investment money rolling.

fo rewo rd

High net worth individuals and family offices have also become increasingly active in providing financing to Biotech companies, although such funds are more difficult to come by. Philanthropy investors and foundations, especially in the US, belong to this category, and we believe we will see more of this in the near future in Europe. One other important source of capital are government grants and funding. In the EU this is the Horizon 2020 program, which allows companies to fund their research through grants by teaming up with other European companies.

The Pharma industry in turn faces a lack of suitable projects to fuel their product pipelines. This has raised the question- where will all the required new projects be coming from in the future? The strategies to address this issue range from strengthening internal R&D efforts, and increasing in-licensing from Biotechs to a renewed focus on early stage collaborations with Academia. Pharma has realized that without a functional VC – Biotech – Pharma “eco system”, problems will only mount in the future. The integration of Government and Academia as additional critical stakeholders in this model is one way of allowing the overall system to survive.

241

Focus on Europe

Foreword by Alasdair Stamps, Executive Director BioPartner UK

M asters of Innovation – the U K a nd Swe de n

foreword

Britain’s life sciences industry continues to maintain its position as the largest in Europe, and second only to the US. Innovation is the driver of the UK’s life sciences sector.

British inventions are behind therapies and devices that have immeasurably improved the quality of life of billions of individuals across the planet. Today, the UK is at the forefront in regenerative and personalized medicine, genebased therapeutics and vaccines, bioanalytical devices, medical imaging and robotics, with emerging strengths in the new areas of bionanotechnology and synthetic biology.

The UK is also a global destination for life sciences research, attracting investment, businesses and innovative talent from abroad.

242

The Nordic life sciences cluster is a substantial force in European life sciences. Sometimes referred to as ‘Europe’s best kept secret’, nevertheless it has strong links with the UK bioscience community, from academia through to global pharma. Historically, the strongest of these connections have been in Sweden. For example, the Karolinska Institutet – the ‘Medical University’ – ranking in the top twenty life sciences research institutions and a pioneer in oncology, neuroscience, endocrinology and surgical research, is a natural research partner for UK academics and companies.

AstraZeneca, one of the world’s top ten pharmaceutical

companies, was formed just over 14 years ago through the merger of ICI offshoot Zeneca plc in the UK, and Astra AB in Sweden. Sweden possesses a culture of innovation that is familiar to UK researchers and entrepreneurs and more than 20 British academics have made the trip to Stockholm to receive the Nobel Prize for their contribution to biomedical discoveries.

The UK’s growth companies also take advantage of the opportunities offered by the Swedish life sciences sector.

Excellent transport communications make it easy to visit Stockholm or Lund and return to London the same day. A number of targeted events and UK trade missions have grown up around these opportunities, accessing the broader Scandinavian biocluster. The annual Anglonordic Biotech and Medtech Conference, from small beginnings at the Swedish Trade Council in London, has built up over ten years a unique forum for venture capital investment. Trade missions have been initiated and supported by UK Trade & Investment, the government agency that works with UKbased businesses to ensure their success in international markets. These missions have opened up the dialogue in collaborative and commercial research for UK companies looking for opportunities in Sweden. The first major international biopartnering event in Sweden, Nordic Life

Focus on Europe

Science Days was established in 2013, bringing together a wide cross section of the sector to do business in Stockholm, and is a prime opportunity for UK life science companies.

These events and missions have played a significant part in creating a long-term relationship between the UK and Swedish life science sectors, through innovative collaborations, venture investment and trade in research services.

As the commercial life sciences sector emerges from a challenging time of decreased funding, restricted exit options and declining drug approval rates, growth companies in the UK and Sweden are well placed to take first pick of new sources of funding and the re-focus by their governments on biomedical therapies and technologies as economic drivers. We hope the relationships built up between researchers and entrepreneurs in both countries continue to help them to seize the advantage through collaboration, expansion and trade.

fo rewo rd

The last couple of years have seen a major re-focus on support for the commercialisation of life sciences in the UK and Sweden. The British government views the sector as a key driver of economic regeneration and foreign companies â&#x20AC;&#x201C; including SMEs â&#x20AC;&#x201C; are being encouraged to set up shop in the UK to become part of a virtuous circle of growth and investment. A range of new sources of finance have become available in the UK, from specialised government grant packages for commercial development of medical biotechnology, through funding of specialised disciplines such as stratified medicine and cell therapies; creation of the National Biologics Manufacturing Centre; technology transfer cash for academic commercialisation units, to innovation funds from charities, foundations and corporate entities. The sums are significant, designed

both to rejuvenate a post-recession life sciences sector and to attract investment. At the same time, changes to tax and regulation have made the UK more attractive to business. Bioscience companies entering clinical phase research in the UK are now guided by NOCRI, the Office of Clinical Research Infrastructure to access the worldâ&#x20AC;&#x2122;s most integrated health research system, the UK National Institute of Health Research (NIHR).

243

Focus on Europe

244

Focus on Europe

Almac Contract Pharmaceutical Development Services Almac provides a comprehensive range of integrated services from research through to commercialisation. They are a financially stable, privately owned organisation with over 3,300 employees located within the UK and US. Over 95% of work is repeat business, testament itself to the quality, innovation, efficiency and high level of customer satisfaction provided.

Services Offered: Biomarker Discovery & Development • Companion Diagnostic Development • Genomic Services • Bioinformatics Consultancy • Proprietary Discovery Arrays API Services & Chemical Development: • API Development & Manufacture • Peptide & Protein Technology • Accelerated First in Man Solution • Solid State Services • Isotope Chemistry • Biocatalysis Pharmaceutical Development: • Preformulation & Early Stage Development • Scale-Up and Late Stage Development • Clinical Trial Manufacture • Contained Development & Manufacture

Clinical Trial Supply • Comparator Blinding • Packaging & Labelling • QP Release • Global Distribution & Supply Chain Management Clinical Technologies • IVR / Web Systems • ePRO • Statistical Services Commercial Services • Manufacturing & Packaging • Product Launch & Distribution

Almac EU Tel: +44 (0) 2838 332200 US Tel: +1 (215) 660 8500 info@almacgroup.com www.almacgroup.com

CMO - Cont ra ct Ma n u f ac t u r in g O rga n i z at io n

Analytical Services • Physical & Chemical Characterisation • Method Development & Validation • API & Drug Product Testing • Stability Testing

245

Focus on Europe

Aqua Bio Technology ASA Aqua Bio Technology ASA (ABT) is a Norwegian biotechnology company that develops ingredients for the cosmetics industry.

Imagine that you possess a unique technology that is in demand, filling an unmet need, in the fastest-growing segment, in a rapidly expanding industry. For most companies, this will never be more than a dream. For us at ABT, this dream is starting to come true.

Growth in the international cosmetics industry has continued despite of the uncertain economic times. Skin care is the fastest-growing segment of the cosmetics industry. In addition, face care products account for an increasing share of the skin care segment. In the face care segment, products with anti-ageing effects are still experiencing rapid growth.

The consumers increasingly desire natural and gentle products, and the industry will have to adapt to this over time. ABT finds itself in a good position within this trend.

Our unique technology does not only meet the growth trends in the industry, it is also an answer to the consumersâ&#x20AC;&#x2122; desire for more natural and sustainable ingredients.

Bi ote ch n o l ogy

It has been a long and challenging journey, from when it was first discovered that the hands of the fish farming workers, who manually handled the hatching fluid in the fjords of Western Norway, were smooth as silk, and that this was caused by a very special enzyme, until ABT achieved its first international and commercial breakthrough in 2012.

A journey we call from Fusa in Hordaland to Fifth Avenue in New York.

246

It is no coincidence that it is in the USA that ABT has gained its first foothold. American women (and men) represent the largest cosmetics market in the world, and they use more than NOK 320 billion on cosmetic products every year. Antiageing products represent the most popular segment.

Aqua Bio Technologyâ&#x20AC;&#x2122;s proprietary ingredients have two key characteristics: a) reverse the signs of ageing in a gentle manner, and b) remove dead skin cells without harming the living cells, being a perfect exfoliator. Extensive studies have documented that our ingredients are at least as effective as alternative products even at low concentrations with no undesired effects reported. In addition, our ingredients are completely natural, as opposed to the traditional oil-based ingredients.

Even though the USA is the largest cosmetics market in the world, the strongest growth is found in Asia. Countries such as China, South Korea and Japan represent countries with enormous growth in this industry. The desire for well being and looking young is strong among Asian consumers and the population is experiencing growth in prosperity and purchasing power. Therefore, ABT is also looking towards Asia. In recent years, we have proven what our technology can do in laboratories. In 2012, we showed that our products have a place in the worldâ&#x20AC;&#x2122;s toughest cosmetics market by proving the cosmetic benefits of our products in cosmetic studies. Our journey into the world has just started.

Focus on Europe

We have also taken our technology one step further by launching two new ingredients in 2012; Beauty Propellineâ&#x201E;˘ and Dermaclarineâ&#x201E;˘. Both these ingredients have demonstrated great cosmetic benefits with no undesired effects reported. We have great confidence in the potential of these ingredients.

ABT is also focusing on helping other companies to develop their technology and enter into collaborations within skin care research with the prime goal of launching new cosmetic ingredients to the market. Our long journey has given us broader competence, especially in the commercialization of new technology aimed at the cosmetics and personal care industry.

Therefore, we are looking to develop collaborations with other companies.

In other words, the future looks positive.

Our journey has just started, and we have not yet reached our cruising altitude.

However, we are well on our way, and we have had a positive boost this past year. We have celebrated that 2012 was the first year in the history of the company with positive earnings, and with great enthusiasm we look forward and continue our journey to further grow Aqua Bio Technology ASA.

Bi otec h n ol o gy

Aqua Bio Technology ASA Thormøhlensgate 55, NO-5008 Bergen Tel.: +47 982 45 410 / +47 916 28 092 info@aquabiotech.no www.aquabiotechnology.com

247

Focus on Europe

beòcarta Ltd Skottland: from uisge beatha to metabolic clarity…

OK, you have a microbe – a “microbial cell factory” – capable of synthesizing quantities of a commercially viable product with a market and customers. But you want to expand production or reduce production costs or use the fermentation inputs more efficiently, and there is a competitor on the horizon.

You may have a complete sequenced genome that informs you that 50% or more of the open reading frames are “unassigned” or of unknown function. The application of transcriptomics gives a confusing picture but some genes are clearly up-regulated or downregulated in response to the onset of product synthesis or to differentiation events – the result being a lot of head scratching but little illumination beyond the obvious biological requirement to activate a pathway when cells enter the production phase, after which a strange assortment of genes play parts in a stage play of Shakespearian complexity.

I n du st ri a l Bi ote ch n o l og y

R&D suggest metabolomics but which of the thousands of molecules in the metabolome are relevant when the immediate need is to boost productivity (Figure 1)? Preliminary analysis tells you that the broad brushstrokes point to a partition of batched and fed carbon (or nitrogen) into various compartments that are or may appear to be competing (Figure 2). Sometimes

248

Figure 1: Typical production titre curves for an initial platform bioprocess and an evolved variant with faster kinetics and higher yield.

known coproducts of defined molecular structures are known or identifiable and these may be precursors of the commercial product or compete at other levels of biochemical organization. What then?

An action plan is to follow what has been done with bioprocesses from secondary metabolites to enzymes, from vitamins to biopharmaceuticals: only 10% of the metabolome may be essential to the yield-defining steps – define those steps, find what accumulates and when, and understand reasons for the decline in productivity 24 or 48 or 100 or 200 hours into the bioprocess at scales of production from 1 x103 to 1 x106 L. What is limiting then and can it be averted or overcome? The answer may be another compromise – few bioprocesses can be truly “optimized” for yield – but a new and better platform can be evolved to serve as the beginning of another cycle of development.

“Mapping bioprocess metabolism” is a route successfully used by beòcarta since the 1980s to improve industrial biomanufacturing for yield, space-time yield or process economics, from amino acids to acyltransferases and novel bioactives.

Visit www.beocarta.com and find out more.

Figure 2: Metabolic fate (percentage distribution at harvest) of supplied carbon to microbial fermentations with and without known coproducts being formed.

beòcarta Ltd Registered office: 76 Dumbarton Road, Glasgow G81 1UG Tel.: +44 7510 297388 Fax: +44 1698 374501 dmousdale@beocarta.com www.beocarta.com

Focus on Europe

Biolink Group AS Life science R&D A well-established Biotech Life Science company dedicated to the scientific research, development and manufacturing of prophylactic, therapeutic and health-improving nutraceuticals, including anthocyanins and other polyphenols, since 1998.

Mission: Keep people healthier, longer. Counteract the increasing health challenges caused by a sharp rise in life expectancy and a dramatic increase in life-style diseases, all together burdening communities with unsustainable healthcare costs.

Means: Our anthocyanin nutraceutical Medox速 and our catechol-structured anthocyanins have been subject to clinical studies. This includes sizeable, humane, randomized, double-blind, placebo-controlled studies conducted at universities and university hospitals in Norway, EU, China and USA since the year 2000. In addition, we have the world`s only scaled-up production of synthetic anthocyanins. Anthocyanins possess sensational health improvement possibilities.

Documentation: Studies on Medox速, published in internationally recognized nutrition/medical journals, document a wide specter of decisive health-promoting effects. Important examples include: Lowering Chronic Inflammation; Elevating HDL and lowering LDL cholesterol, the CETP-pathway significantly reducing the risk of coronary heart diseases; Stimulating insulin production and thereby reducing complications related to diabetes 2, and more.

Results: Keeping people healthier, longer will significantly reduce unsustainable health care costs, and most importantly improve the quality of life for older people/seniors.

Biolink`s R&D laboratory for natural Anthocyanins

Biolink Group AS Hanaveien 4-6, NO-4327 Sandnes Tel.: +47 4695 2900 Fax: +47 5162 5182 mail@biolink.no www.biolink.no / www.medox.no

Re s e a rch & D eve l op me nt

Biolink`s R&D laboratory for synthetic Anthocyanins

249

Focus on Europe

Biotechpharma Contract Service Provider for Biopharmaceuticals Biotechpharma UAB is a contract development and manufacturing company for biopharmaceuticals. Company’s expertise lies in a biotechnological drug substance and drug product development and cGMP compliant manufacturing as well as process characterisation and validation activities. In its state-of-the-art facility company is capable of taking any therapeutic protein “from gene to protein”.

Biotechpharma owns a brand new laboratory complex and stateof-the-art production facility (constructed and validated in 2012).

Biotechpharma is led by an experienced team of professionals with advanced scientific degrees (e.g. M.Sc. or Ph.D.) in their area of expertise and extensive industry experience. The team ensures timely and quality execution of every project.

Areas of expertise: • cell line development and cell banking; • high productivity biosynthesis process development; • efficient protein refolding and downstream processes development; • technology transfer; • cGMP compliant analytical services ; • stability studies; • stable protein formulation development; • drug substance and drug product cGMP manufacturing; • project management.

C M O - Co nt rac t M an u f a ct u r in g O rga ni z ati on

Utilising one-stop-shop concept the company provides full range of services including, but not limited to: production strain development; upstream and downstream process development and optimization; manufacturing of drug substance and drug product (Proof-of-concept, preclinical, Phase I-III and commercial).

250

Biotechpharma UAB Mokslininku str. 4, LT-08412 Vilnius, Lithuania Tel.: +370 5255 9140 Fax: +370 5278 9305 info@biotechpharma.lt www.biotechpharma.lt

Focus on Europe

CytoVac A/S Cell-based cancer therapy

CytoVac is a biotechnology company developing new cancer therapies based on the patient’s own cellular immune system. A new adoptive cell therapy technology ALECSAT is the basis for the development of potent therapeutic cancer vaccines. Vast experience in immunology and cell biology research has enabled the development of this novel technology, which offers a range of advantages over existing cancer vaccines.

Technology Specific cells from the immune system are isolated from a blood donation; these cells are then activated and cultivated outside the body. These autologous cytotoxic T-cells (CTL) and Natural Killer (NK) cells are then returned to the cancer patient where they attach cancer cells and help the patient’s immune system to win the battle against cancer.

Clinical Development CytoVac is clinically developing its cell based cancer therapy – it is shown in clinical trials that the treatment is safe and well tolerated. In clinical phase Ia and Ib trials for both Prostate cancer and Glioblastoma patients, there are clear indications that the treatment may be clinically effective. Clinical phase I studies in pancreatic cancer have started and phase II studies in Glioblastoma will start shortly.

CytoVac has “state of the art” research and production facilities. The dedicated GMP production facilities are approved by the Danish authorities for pharmaceutical production and handling human cells and tissue.

CytoVac A/S Scion-DTU Research Park, Venlighedsvej 6, DK-2970 Hørsholm, Denmark Tel.: +45 45 57 22 45 info@cytovac.dk www.cytovac.dk

Bi otec h n ol o gy

Good clinical data: “In the prostate cancer trials we are able to lower or stabilize Prostate Specific Antigen (PSA) levels (a validated indicator of prostate cancer development) and see reductions in bone metastasis. In the Glioblastoma trial data indicates that patients treated with ALECSAT may experience disease stabilization and other responses such as tumor size reductions and improved quality of life, and there are even indications for prolonged survival.”

251

Focus on Europe

Dako Denmark A/S With a heritage of over 45 years, Dako is a leading global provider of high-quality cancer diagnostic reagents and instruments used by pathologists, hospital labs and researchers around the world.

Dako was established in 1966, when Danish medical doctor Niels Harboe founded the company and played a pioneering role in the standardizing antibodies for clinical use; since then the company has grown into a global business with a leading position in the pathology segment of the in vitro diagnostics industry.

Dako’s strong focus on anatomic pathology and its relentless fight against cancer is accompanied by a separate and focused business division targeting retail and OEM customers – Dako Reagent Partnership Division.

Today, Dako is headquartered in Denmark with manufacturing and research sites in Denmark and the United States and more than 1,200 committed employees. Dako’s reagents, instruments and software are sold in more than 100 markets.

DAKO REAGENT PARTNERSHIP DIVISION Reagent Partnership offers a comprehensive product portfolio as well as a large, world-wide network of distributors to ensure prompt access and support to partners and customers around the globe.

In 2012, Dako became part of Agilent Technologies – the world’s premier measurement company. Agilent has a global footprint of more than 20,000 employees in more than 100 countries – a global reach that is now benefiting Dako.

Reagent Partnership has two major product categories: Specific Proteins and Flow Cytometry.

SPECIFIC PROTEINS Within the field of clinical immunochemistry, Reagent Partnership possesses long-standing experience at producing reagents for measuring proteins in body fluids. These reagents have been developed in particular for turbidimetry, nephelometry and ELISA, techniques which exploit the fast and specific reaction between antibody and antigen.

Reagent Partnership’s major product categories within Specific Proteins: • Turbidimetry and Nephelometry • Calibrators and Controls • Test Systems • Chromogranin A ELISA Kit • Kits/Reagents • Diabetes, ELISA Kits • Antibodies • Accessory products for ELISA Kits • Buffers • Multipurpose Antibodies for Clinical Chemistry

D ia g n ost ic s

FLOW CYTOMETRY Flow cytometric immunophenotyping is becoming an important tool for diagnosing acute and chronic leukemia. Reagent Partnership offers a broad panel of high-quality products for this area which are widely used in hospitals as well as in research laboratories.

252

Reagent Partnership’s major product categories within Flow Cytometry: • Conjugated Control Reagents • FITC/RPE/APC Reagent Line • FITC/RPE/RPE-Cy5 Reagent Line • Single-Color Mouse Isotype Reagents • Single-Color Rabbit Ig Reagents • Secondary Antibody Conjugates • CD34+ Cells, Enumeration Kit and Count Kit • MultiMix™ Dual and Triple-Color Reagents • Lysing, Fixation and Permeabilization Reagents • MultiMix™ Dual and Triple-Color Isotype Reagents • Calibration Beads • Primary Single-Color Reagents

Dako Denmark A/S Produktionsvej 42, DK-2600 Glostrup, Denmark Tel.: +45 44 85 95 00 rpsupport@dako.com www.dako.com

Focus on Europe

Ergolet

Me d ic al Dev i ce

Ergolet Taarnborgvej 12C, DK-4220 Korsoer, Denmark Tel.: +45 70 27 37 20 Fax: +45 70 27 37 19 ergolet@ergolet.dk www.ergolet.com

253

Focus on Europe

254

Focus on Europe

Iduron The Glycosaminoglycan Company

Bi otec h n ol o gy

Iduron Paterson Institute for Cancer Research, Manchester M20 4BX UK Tel.: +44 (0) 161 446 3205 Fax: +44 (0) 161 918 7030 info@iduron.co.uk www.iduron.co.uk

255

Focus on Europe

Niels Clauson-Kaas A/S Chemical Research Laboratory

APIs & INTERMEDIATES 57 Years of experience in synthetic organic chemistry  Process development  Route discovery / Up-scaling  Lab / Pilot synthesis from mg to kg scale  Production of APIs under cGMP  Technology transfer 

PILOT PLANT Five production lines (40–280 L reactors)  Temperature range from –100°C to +200°C  Centrifuges  Pressure filters  Preparative HPLC  Flash chromatography  Separate drying / final handling rooms 

ACCUMULATED EXPERIENCE SINCE 1956 8,300 Different reactions carried out  69,000 Isolated samples  1,400 Projects for more than 180 customers  1,528 CK products

C RO - Cont ra ct Res e a rc h O rga n iz at i on



256

GMP CUSTOM SYNTHESIS

Focus on Europe

Niels Clauson-Kaas A/S Rugmarken 28, DK-3520 Farum, Denmark Tel.: +45 4495 1881 Fax: +45 4495 1855 info@clauson-kaas.dk www.clauson-kaas.com

CRO - Co nt ra ct Re se arch O rga n i z at io n

ANALYTICAL SERVICES

ANALYTICAL SERVICES  Fast HPLC development (3–5 days)  Method development (GC, LC-MS, IC)  Impurity profiling  Genotoxic impurities  Quantification of salts by IC  Accurate mass determination  Stress testing  Early phase / full ICH validation  Method transfer  Drug substance ICH stability testing

257

Focus on Europe

258

Focus on Europe

Scottish Development International

Scotland.

Home to the bionic hand and investment support.

Financial assistance and sector expertise at your fingertips.

We’ve a wealth of financial backing for life sciences companies and our life sciences cluster has the highest level of start-ups in the UK. In fact, over 100 businesses have been established over the last five years with help from the Scottish Investment Bank.

Our support has also helped Mölnlycke Heath Care to establish a subsidiary at Edinburgh BioQuarter to

develop products for point-of-care diagnostic testing.

But financial support would be nothing without the drive, passion and entrepreneurialism of the Scottish life sciences sector. Scotland has already attracted global companies like GlaxoSmithKline and Charles River Laboratories. So why not join us? You’ll be in good company.

SCOTLAND. SUCCESS LIKES IT HERE. Scottish Development International Tel.: +44 141 228 2828 mette.bach-dyremose@scotent.co.uk www.sdi.co.uk

Bu si n e s s D eve lo pm e nt

To find out about opportunities in Scotland for your business, contact our Nordic representative – mette.bach-dyremose@scotent.co.uk or visit sdi.co.uk/lifesciences

259

Focus on Europe

260

Focus on Europe

Scottish Development International

HYPODERMIC SYRINGE

INSULIN

1853

1923

MRI BODY SCANNER 1974-1980

YOUR NEXT BREAKTHROUGH?

Scotland.

The home of scientific innovation.

From the world’s first genetically-engineered vaccine to the first cloned mammal, Scotland is renowned for medical innovation. It’s a reputation that continues to grow. We have one of the largest life sciences clusters in Europe, home to over 640 organisations employing over 32,000 staff, worldclass academic institutions and purpose-built science parks

with some of the finest research facilities in the world. We’re renowned internationally for pre-clinical testing, clinical trials and some of the fastest median times to R&D approval anywhere. Our people have a passion for success and a hunger to win. All of which makes Scotland the perfect place to make your breakthrough.

SCOTLAND. SUCCESS LIKES IT HERE. Scottish Development International Tel.: +44 141 228 2828 mette.bach-dyremose@scotent.co.uk www.sdi.co.uk

Bu si n e s s D eve lo pm e nt

To find out about opportunities in Scotland for your business, contact our Nordic representative – mette.bach-dyremose@scotent.co.uk or visit sdi.co.uk/lifesciences

261

Focus on Europe

262

Focus on Europe

SIRION Biotech GmbH State of the art service provider for preclinical target research SIRION Biotech GmbH has been operating for 7 years as a specialized service provider for preclinical target research. Using proprietary viral vector and RNAi technologies SIRION`s customized assay cell models offer access to in depth functional gene analysis, thereby improving target identification/ validation and compound screening in a variety of industries.

Their technologies have also been successfully used for primary cell immortalizations.

Moreover, novel viral vectors for gene therapy and vaccine applications are under development.

SIRION`s business model focuses on 3 areas 1. Access to sophisticated and proprietary platforms • Customized Viral Vectors – Adenovirus (AV), Lentivirus (LV) and Adeno-Associated Virus (AAV) • RNAiONETM – for reaching nearly 100% gene knockdown - guaranteed 2. Cells by Design • Tailor made cell models • SenCELLTM - next generation assay cell models with built-in reporter genes (e.g. Hypoxia, actin cytoskeleton) • VariCHECKTM – functional analysis of protein variants and RNAi ON-target control • Primary cell immortalization 3. Partnering & Licensing • TET technology for inducible gene regulation • Reporter genes with licenses from Promega and Evrogen • Novel Adenovirus serotypes for vaccination / Ad19a • 3D cell culture for oncology drug discovery SIRION’s track record is supported and validated by over 300 commercial projects with more than 70 clients worldwide.

SIRION`s expertise offers faster end points, improved reliability, enhanced predictability and significant cost savings.

Located at one of Europe`s most attractive hot spots in the Biotech industries, the “Innovation and Startup Center for Biotechnology” (IZB) near Munich/ Bavaria, SIRION drives leading scientific collaboration to refine technologies.

SIRION’s competitive advantage a. FASTER for shortened time to market with customized cell models in just 6 weeks b. RELIABLE with confirmed phenotypes and guaranteed functionality d. PREDICTIVE with near quantitative KNOCKDOWN to minimize risk of target failure e. FLEXIBLE with INDIVIDUAL working models

S er v i ce s

SIRION Biotech GmbH Am Klopferspitz 19, 82152 Martinsried Contact Dr. Kathrin Schmitt Tel.: +49 89 700 961 99 13 schmitt@sirion-biotech.com www.sirion-biotech.com

263

Focus on Europe

Vetter Development Service Supporting your compound´s success

Filling your clinical development needs in Chicago Vetter Development Service supports your drug-development projects, from inception to market launch. Our Chicago facility, along with our existing sites, provides clinical manufacturing from preclinical development through Phase II, with scale-up and transfer to our commercial manufacturing facilities. The Chicago site is designed specifically for supporting the development of your early-stage, high-value biopharmaceuticals. Vetter Development Service fills clinical trial materials under strict aseptic and GMP standards. Thanks to state-of-the-art technology and innovative processes, we help increase your API yield.

C D MO - Cont ra ct D eve l op me nt an d Manufacturi ng Organi z ati on

Vetter Development Service provides you with:

264

Formulation Support In early clinical development, preformulated compounds may sometimes require a higher level of support prior to process development. Vetter can work side by side with your development team to optimize preformulated API for clinical trial â&#x20AC;&#x201C; as well as identify the strongest of several prequalified candidate drug formulations through compounding and filtration studies, API/material compatibility analysis, and lyophilization cycle testing. Transfer, optimization of analytical methods, and validation is also provided.

Process development The goal of process development is to enable fast, smooth transfer of your project to commercial manufacturing.

Tailored to your productâ&#x20AC;&#x2122;s specific requirements, process development services include: siliconization methods studies for the appropriate drug delivery system; filter compatibility testing; lyophilization cycle development if required; feasibility studies; engineering batches; stability batches; validation batches; method transfer and scale-up for commercial manufacturing.

Clinical trial manufacturing Following confirmation of successful process scale-up, clinical production begins. Key steps include compounding, filtration, preparation of primary packaging materials, and filling. Additional steps may include lyophilization, terminal sterilization, and visual inspection. Precise indicators are also generated for the master batch record.

Focus on Europe

Analytical service Validation of all raw materials, bulk solutions, in-process materials, and finished product is determined by sophisticated analytical techniques. Vetter’s analytical quality control staff also provides expert support for the critical transfer of analytical methods. All instruments and methods are aligned with current international requirements.

Regulatory support Vetter supports you through all phases of regulatory submission. Expert technical writing and dossier preparation begins in parallel with clinical production to streamline the regulatory submission process, supported by our in-depth knowledge of global regulatory requirements, including FDA, EMA, PMDA (Japan), and RP (Germany).

Vetter is a leading independent contract development and manufacturing organization (CDMO) that specializes in the aseptic filling of syringes, cartridges and vials. The company has extensive experience with biologics and other complex compounds, including monoclonal antibodies, peptides, interferons and vaccines. Collaborating with the world’s top 10 pharma/biotech firms and emerging companies alike, Vetter supports your products from preclinical development through global market supply. The company offers state-of-the-art technology and innovative processes to increase product quality and maximize API yield.

Vetter’s international success arises from its three interdependent divisions: • Vetter Development Service specializes in taking complex compounds from preclinical development through Phase lll.

• Vetter Commercial Manufacturing provides Phase lll clinical manufacturing through global market supply.

• Vetter Packaging Solutions helps clients match their drug substance with the appropriate drugdelivery system for a product’s life cycle.

Corporate Headquarters: Vetter Pharma International GmbH Eywiesenstrasse 5, 88212 Ravensburg, Germany Tel.: +49 751 3700-0 info@vetter-pharma.com www.vetter-pharma.com

For US Inquiries: Vetter Pharma International USA Inc. 4901 Searle Parkway, Suite 300A, Skokie, IL 60077 Tel.: +1-847-581-6888 infoUS@vetter-pharma.com

CDMO - Contract Devel opment an d M a n u fa ct u r i n g O rg a n iz at i on

Vetter at a glance

265

Alphabetical Index Abera Bioscience AB Biotechnology Vaccine & Infectious Diseases

106

ABIGO Medical AB Healthcare

176

Aqua Bio Technology ASA Biotechnology Healthcare Health & Nutrition Suppliers & Distributors

246

109

32

Agilent Technologies Sweden AB Biotechnology

34

AkzoNobel Biotechnology Industrial Biotechnology Pharmaceutical Diagnostics

36

AroCell AB Diagnostics Oncology

40

Alkit Communications E-Health Medical Technology Healthcare Life Science Instruments

38

Arthur D. Little AB Consultants Pharmaceutical Medical Technology Healthcare AstraZeneca Pharmaceutical

41

Avena Partners Consultants

42

AlphaHelix Technologies AB Life Science Instruments Manufacturers Diagnostics

A l p ha b eti c al I n d ex

108

Addtech AB Life Science Commercialization Diagnostics

Almac 245 CMO - Contract Manufacturing Organizations

266

AlzeCure Drug Discovery Medical Technology Life Science Commercialization Non-governmental Organization

107

Aventure AB Food & Nutrition Health & Nutrition Business Development Biotechnology

206

Axcentua Pharmaceuticals AB Drug Discovery

111

Bellman & Symfon AB Hearing

178

beòcarta Ltd Industrial Biotechnology Business Development Consultants Pharmaceutical

248

Biognos AB Drug Discovery Consultants Pharmaceutical

180

Biolink Group AS Research & Development

249

Biomotif AB 112 CRO - Contract Research Organization Drug Discovery Diagnostics Life Science Instruments Biotechpharma UAB 250 CMO - Contract Manufacturing Organization Biotechnology Pharmaceutical CRO - Contract Research Organization

BioThema AB Biotechnology Diagnostics Drug Discovery Healthcare

114

Bluefish Pharmaceuticals AB Pharmaceutical Business Development

115

Brann AB Intellectual Property & Legal Services Business Development Life Science Commercialization Consultants

44

Business Region GĂśteborg AB Business Development

181

CMA Microdialysis AB Life Science Instruments Suppliers & Distributors Drug Discovery Manufacturers

116

CMIV Medical Research Centre Visualization Radiology Medical Imaging

158

A l p ha b eti c al I nd ex 267

A l p ha b eti c al I n d ex 268

Cobra Biologics 117 CMO - Contract Manufacturing Organization Pharmaceutical Manufacturers Biotechnology

Elekta AB Radiation Therapy Neurosurgery Brachytherapy Software

120

Corline Systems AB Biomaterials & Implants Medical Device Manufacturers

118

Episurf Medical AB Medical Device

121

253

CRC medical AB Medical Technology Healthcare

182

Ergolet Medical Device Healthcare Rehabilitation Medical Technology

CytoVac A/S Biotechnology Medical Technology Pharmaceutical Oncology

251

Dako Denmark A/S Diagnostics Medical Device Manufacturers Biotechnology

252

Det Medicinska Malmรถ Non-profit Support Organization Public Partner Organization Events

207

Diamyd Medical AB Diabetes Pharmaceutical Biotechnology

119

Etteplan Consultants

45

Fagerstrรถm Pharma Systems AB 209 CMO - Contract Manufacturing Organization Engineering Contractor FOI Swedish Defence Research Agency 47 CRO - Contract Research Organization GE Healthcare Bio-Sciences AB Healthcare Biotechnology Life Science Instruments Life Science Commercialization

123

Genovis AB Biotechnology

210

Getinge Infection Control AB Infection Control Healthcare Medical Device Contamination Prevention

184

GU Holding AB Incubators Life Science Commercialization Business Development

187

Iduron Biotechnology Education & Research Drug Discovery Biomaterials & Implants

255

KOMMUNICERA COMMUNICATIONS Translation Services Pharmaceutical Medical Device Biotechnology

48

Labjoy AB 216 Consultants CRO - Contract Research Organization Biotechnology Services

ImaGene-iT AB 212 CRO - Contract Research Organization Drug Discovery Life Science Instruments Oncology

Late Phase Solutions Europe AB Consultants CRO - Clinical Research Organization Pharmaceutical Services

ImmuneBiotech AB Pharmaceutical Health & Nutrition

213

Invest in Sk책ne Clusters & Networks

214

Karolinska Development Life Science Commercialization Pharmaceutical Medical Technology Business Development

124

Linde Healthcare Pharmaceutical Medical Technology Services Medical Device

Karolinska Institutet Science Park Science Parks Incubators Clusters & Networks

126

LINK arkitektur AB Architects Hospitals Pharmacies

LifeAssays AB Diagnostics Healthcare Medical Device Biotechnology

50

217

52

127

A l p ha b eti c al I nd ex 269

A l p ha b eti c al I n d ex 270

Medeon AB Science Parks Incubators Clusters & Networks

218

Medfield Diagnostics Medical Technology Diagnostics Life Science Instruments Medical Device

188

Medicon Village AB Clusters & Networks Science Parks

219

Medicvent AB Medical Device Medical Technology

86

Milton Medtech AB Medical Device Consultants Engineering Contractor Manufacturers ModPro AB Pharmaceutical Drug Discovery Diagnostics Biotechnology

Medivir Pharmaceutical Drug Discovery Research & Development Business Development

128

Meducati AB Education & Research E-Health Business Development CRO - Clinical Research Organization

189

Mercan AB Medical Device Healthcare Manufacturers Suppliers & Distributors

220

53

129

Nanomed North Non-profit Support Organization Nanomedicine Member Organization Clusters & Networks

55

NDA Group Consultants Services

56

New Tools For Health E-Health Cardiology Healthcare Rehabilitation

160

Niels Clauson-Kaas A/S 256 CRO - Contract Research Organization CMO - Contract Manufacturing Organization Pharmaceutical NovaMedTech Medical Technology Healthcare Clusters & Networks Business Development

161

Ori Medical Pharmaceutical Manufacturers Medical Device Pall Norden AB Biotechnology Pharmaceutical Drug Discovery Suppliers & Distributors Phil Med Alliance AB Pharmaceutical

221

Redoxis AB 226 CRO - Contract Research Organization Biotechnology Drug Discovery Services 162 Ridgeview Instruments AB Life Science Instruments

130

Proffice Life Science AB Staffing & Recruitment

60

Promech Lab AB Consultants Engineering Contractor Biotechnology

224

QIAGEN AB Diagnostics Life Science Instruments Medical Technology Biotechnology

131

58

PolyPeptide Laboratories (Sweden) AB 223 Manufacturers CRO - Contract Research Organization Pharmaceutical Premune Pharmaceutical Biotechnology Health & Nutrition Life Science Commercialization

Q-linea AB Life Science Instruments Diagnostics Medical Device Oncology

62

132

Science And Innovation AB 227 CRO - Contract Research Organization Consultants Pharmaceutical Medical Device Scottish Development International 259/261 Business Development Biotechnology Clusters & Networks Medical Technology Senzime AB Biotechnology Medical Device Life Science Instruments Medical Technology

133

Sigolis AB Medical Technology Medical Device Manufacturers

134

A l p ha b eti c al I nd ex 271

A l p ha b eti c al I n d ex

Silentia AB Interior

272

65

SIRION Biotech GmbH Services CBA - Cell Based Assays Drug Discovery Oncology

263

The Faculty of Medicine at Lund University 232 Education & Research Diagnostics Drug Discovery

Sk책ne Care AB International Care Healthcare Consultants Education & Research

228

Thurne Teknik AB Biotechnology Engineering Contractor Suppliers & Distributors Services

SPAGO Imaging AB Biotechnology

230

Truly Translational Sweden AB 233 CRO - Contract Research Organization Business Development Drug Discovery Pharmaceutical

137

Umetrics AB Software Biotechnology Pharmaceutical Services

89

87

Ume책 Care International Care Oncology Radiation Therapy Cardiology Healthcare

90

68

Unfors Raysafe Medical Technology

190

Symbioteq Kvalitet AB Consultants Medical Device Education & Research

66

Techtum Lab AB Life Science Instruments Biotechnology Services Manufacturers Diagnostics TFS Trial Form Support CRO - Clinical Research Organization Pharmaceutical Medical Device Health & Nutrition

Unimedic AB 71 Pharmaceutical CMO - Contract Manufacturing Organization Life Science Commercialization Suppliers & Distributors

Wolfram MathCore Consultants Drug Discovery Pharmaceutical World Courier Specialized Transport Services

165

72

Uppsala Cancer Clinic International Care

138

Uppsala Care International Care Healthcare Oncology

140

Xbrane Bioscience AB 145 CMO - Contract Manufacturing Organization Biotechnology Services

Vetter Pharma International CDMO - Contract Development and Manufacturing Organization Biotechnology Pharmaceutical Injectables Manufacturing

264

XSpray Microparticles AB Pharmaceutical Oncology Manufacturers

Vironova AB 142 Biotechnology CRO - Contract Research Organization Vironova Biosafety AB Biotechnology CRO - Contract Research Organization

143

Viscogel AB Pharmaceutical

144

146

Zelmic AB 235 CRO - Contract Research Organization Pharmaceutical Biotechnology Zula Diagnostics AB 113 Drug Discovery CRO - Contract Research Organization Diagnostics Oncology

A l p ha b eti c al I nd ex 273

Categorical Index Architects

Corline Systems AB............................................ 118 Iduron................................................................. 255

Umetrics AB......................................................... 89 Vetter Pharma International............................. 264 Vironova AB....................................................... 142 Vironova Biosafety AB....................................... 143 Xbrane Bioscience AB........................................ 145 Zelmic AB........................................................... 235

Biotechnology

Brachytherapy

Abera Bioscience AB.......................................... 106 Agilent Technologies Sweden AB....................... 34 AkzoNobel............................................................ 36 Aqua Bio Technology ASA................................. 246 Aventure AB....................................................... 206 Biotechpharma UAB.......................................... 250 BioThema AB..................................................... 114 Cobra Biologics.................................................. 117 CytoVac A/S....................................................... 251 Dako Denmark A/S........................................... 252 Diamyd Medical AB........................................... 119 GE Healthcare Bio-Sciences AB......................... 123 Genovis AB......................................................... 210 Iduron................................................................. 255 KOMMUNICERA COMMUNICATIONS...................... 48 Labjoy AB........................................................... 216 LifeAssays AB..................................................... 217 ModPro AB......................................................... 129 Pall Norden AB.................................................... 58 Premune............................................................ 130 Promech Lab AB................................................ 224 QIAGEN AB........................................................... 62 Redoxis AB......................................................... 226 Scottish Development International.........259/261 Senzime AB........................................................ 133 SPAGO Imaging AB............................................ 230 Techtum Lab AB................................................... 87 Thurne Teknik AB............................................... 137

Elekta AB............................................................ 120

LINK arkitektur AB............................................. 127

C ateg o r i c a l I n d ex

Biomaterials & Implants

274

Business Development Aventure AB....................................................... 206 beòcarta Ltd....................................................... 248 Bluefish Pharmaceuticals AB............................ 115 Brann AB.............................................................. 44 Business Region Göteborg AB........................... 181 GU Holding AB................................................... 187 Karolinska Development .................................. 124 Medivir............................................................... 128 Meducati AB....................................................... 189 NovaMedTech.................................................... 161 Scottish Development International.........259/261 Truly Translational Sweden AB.......................... 233

Cardiology New Tools For Health........................................ 160 Umeå Care........................................................... 90

CBA - Cell Based Assays SIRION Biotech GmbH........................................ 263

CDMO Contract Development and Manufacturing Organization Vetter Pharma International............................. 264

Clusters & Networks

CRO - Clinical Research Organization

Invest in Skåne.................................................. 214 Karolinska Institutet Science Park..................... 126 Medeon AB........................................................ 218 Medicon Village AB........................................... 219 Nanomed North................................................... 55 NovaMedTech.................................................... 161 Scottish Development International.........259/261

Late Phase Solutions Europe AB......................... 50 Meducati AB....................................................... 189 TFS Trial Form Support......................................... 68

CMO - Contract Manufacturing Organization Almac................................................................. 245 Biotechpharma UAB.......................................... 250 Cobra Biologics.................................................. 117 Fagerström Pharma Systems AB....................... 209 Niels Clauson-Kaas A/S..................................... 256 Unimedic AB........................................................ 71 Xbrane Bioscience AB........................................ 145

Consultants Arthur D. Little AB................................................ 40 Avena Partners.................................................... 42 beòcarta Ltd....................................................... 248 Biognos AB......................................................... 180 Brann AB.............................................................. 44 Etteplan . ............................................................. 45 Labjoy AB........................................................... 216 Late Phase Solutions Europe AB......................... 50 Milton Medtech AB.............................................. 53 NDA Group........................................................... 56 Promech Lab AB................................................ 224 Science And Innovation AB............................... 227 Skåne Care AB................................................... 228 Symbioteq Kvalitet AB......................................... 66 Wolfram MathCore .......................................... 165

Contamination Prevention

Biomotif AB........................................................ 112 Biotechpharma UAB.......................................... 250 ImaGene-iT AB................................................... 212 Labjoy AB........................................................... 216 Niels Clauson-Kaas A/S..................................... 256 PolyPeptide Laboratories (Sweden) AB........... 223 Redoxis AB......................................................... 226 Science And Innovation AB............................... 227 Truly Translational Sweden AB.......................... 233 Vironova AB....................................................... 142 Vironova Biosafety AB....................................... 143 Zelmic AB........................................................... 235 Zula Diagnostics AB ......................................... 113

Diabetes Diamyd Medical AB........................................... 119

Diagnostics AkzoNobel............................................................ 36 Addtech AB.......................................................... 32 AlphaHelix Technologies AB............................. 107 AroCell AB.......................................................... 109 Biomotif AB........................................................ 112 BioThema AB..................................................... 114 Dako Denmark A/S........................................... 252 LifeAssays AB..................................................... 217 Medfield Diagnostics ........................................ 188 ModPro AB......................................................... 129 QIAGEN AB........................................................... 62 Q-linea AB.......................................................... 131 Techtum Lab AB................................................... 87

C ateg o r i c al I nd ex

Getinge Infection Control AB............................ 184

CRO - Contract Research Organization

275

The Faculty of Medicine at Lund University..... 232 Zula Diagnostics AB ......................................... 113

Events

Drug Discovery

Food & Nutrition

AlzeCure............................................................. 108 Axcentua Pharmaceuticals AB.......................... 111 Biognos AB......................................................... 180 Biomotif AB........................................................ 112 BioThema AB..................................................... 114 CMA Microdialysis AB........................................ 116 Iduron................................................................. 255 ImaGene-iT AB................................................... 212 Medivir............................................................... 128 ModPro AB......................................................... 129 Pall Norden AB.................................................... 58 Redoxis AB......................................................... 226 SIRION Biotech GmbH........................................ 263 The Faculty of Medicine at Lund University..... 232 Truly Translational Sweden AB.......................... 233 Wolfram MathCore .......................................... 165 Zula Diagnostics AB ......................................... 113

Aventure AB....................................................... 206

Education & Research Iduron................................................................. 255 Meducati AB....................................................... 189 Skåne Care AB................................................... 228 Symbioteq Kvalitet AB......................................... 66 The Faculty of Medicine at Lund University..... 232

C ateg o r i c a l I n d ex

E-Health

276

Det Medicinska Malmö..................................... 207

Health & Nutrition Aqua Bio Technology ASA................................. 246 Aventure AB....................................................... 206 ImmuneBiotech AB........................................... 213 Premune............................................................ 130 TFS Trial Form Support......................................... 68

Healthcare ABIGO Medical AB............................................. 176 Alkit Communications......................................... 38 Aqua Bio Technology ASA................................. 246 Arthur D. Little AB................................................ 40 BioThema AB..................................................... 114 CRC medical AB.................................................. 182 Ergolet . ............................................................. 253 GE Healthcare Bio-Sciences AB......................... 123 Getinge Infection Control AB............................ 184 LifeAssays AB..................................................... 217 Mercan AB.......................................................... 220 New Tools For Health........................................ 160 NovaMedTech.................................................... 161 Skåne Care AB................................................... 228 Umeå Care........................................................... 90 Uppsala Care...................................................... 140

Alkit Communications......................................... 38 Meducati AB....................................................... 189 New Tools For Health........................................ 160

Hearing

Engineering Contractor

Hospitals

Fagerström Pharma Systems AB....................... 209 Milton Medtech AB.............................................. 53 Promech Lab AB................................................ 224 Thurne Teknik AB............................................... 137

LINK arkitektur AB............................................. 127

Bellman & Symfon AB....................................... 178

Incubators GU Holding AB................................................... 187 Karolinska Institutet Science Park..................... 126 Medeon AB........................................................ 218

Industrial Biotechnology AkzoNobel............................................................ 36 beòcarta Ltd....................................................... 248

Infection Control Getinge Infection Control AB............................ 184

Injectables Manufacturing Vetter Pharma International............................. 264

Intellectual Property & Legal Services Brann AB.............................................................. 44

Interior Silentia AB............................................................ 65

International Care Skåne Care AB................................................... 228 Umeå Care........................................................... 90 Uppsala Cancer Clinic......................................... 138 Uppsala Care...................................................... 140

Life Science Commercialization Addtech AB.......................................................... 32 AlzeCure............................................................. 108 Brann AB.............................................................. 44 GE Healthcare Bio-Sciences AB......................... 123 GU Holding AB................................................... 187 Karolinska Development .................................. 124 Premune............................................................ 130 Unimedic AB........................................................ 71

Life Science Instruments

Manufacturers AlphaHelix Technologies AB............................. 107 CMA Microdialysis AB........................................ 116 Cobra Biologics.................................................. 117 Corline Systems AB............................................ 118 Dako Denmark A/S........................................... 252 Mercan AB.......................................................... 220 Milton Medtech AB.............................................. 53 Ori Medical......................................................... 221 PolyPeptide Laboratories (Sweden) AB........... 223 Sigolis AB........................................................... 134 Techtum Lab AB................................................... 87 XSpray Microparticles AB ................................ 146

Medical Device Corline Systems AB............................................ 118 Dako Denmark A/S........................................... 252 Episurf Medical AB............................................. 121 Ergolet . ............................................................. 253 Getinge Infection Control AB............................ 184 KOMMUNICERA COMMUNICATIONS...................... 48 LifeAssays AB..................................................... 217 Linde Healthcare.................................................. 52 Medfield Diagnostics ........................................ 188 Medicvent AB...................................................... 86 Mercan AB.......................................................... 220 Milton Medtech AB.............................................. 53 Ori Medical......................................................... 221 Q-linea AB.......................................................... 131

C ateg o r i c al I nd ex

Alkit Communications......................................... 38 AlphaHelix Technologies AB............................. 107

Biomotif AB........................................................ 112 CMA Microdialysis AB........................................ 116 GE Healthcare Bio-Sciences AB......................... 123 ImaGene-iT AB................................................... 212 Medfield Diagnostics ........................................ 188 QIAGEN AB........................................................... 62 Q-linea AB.......................................................... 131 Ridgeview Instruments AB............................... 132 Senzime AB........................................................ 133 Techtum Lab AB................................................... 87.

277

Science And Innovation AB............................... 227 Senzime AB........................................................ 133 Sigolis AB........................................................... 134 Symbioteq Kvalitet AB......................................... 66 TFS Trial Form Support......................................... 68

Medical Imaging CMIV ................................................................. 158

Medical Research Centre CMIV ................................................................. 158

Medical Technology Alkit Communications......................................... 38 AlzeCure............................................................. 108 Arthur D. Little AB................................................ 40 CRC medical AB.................................................. 182 CytoVac A/S....................................................... 251 Ergolet . ............................................................. 253 Karolinska Development .................................. 124 Linde Healthcare.................................................. 52 Medfield Diagnostics ........................................ 188 Medicvent AB...................................................... 86 NovaMedTech.................................................... 161 QIAGEN AB........................................................... 62 Scottish Development International.........259/261 Senzime AB........................................................ 133 Sigolis AB........................................................... 134 Unfors Raysafe................................................... 190

Member Organization Nanomed North................................................... 55

Nanomedicine Nanomed North................................................... 55

Neurosurgery

C ateg o r i c a l I n d ex

Elekta AB............................................................ 120

278

Non-governmental Organization AlzeCure............................................................. 108

Non-profit Support Organization Det Medicinska Malmö..................................... 207 Nanomed North................................................... 55

Oncology AroCell AB.......................................................... 109 CytoVac A/S....................................................... 251 ImaGene-iT AB................................................... 212 Q-linea AB.......................................................... 131 SIRION Biotech GmbH........................................ 263 Umeå Care........................................................... 90 Uppsala Care...................................................... 140 XSpray Microparticles AB ................................ 146 Zula Diagnostics AB ......................................... 113

Pharmaceutical AkzoNobel............................................................ 36 Arthur D. Little AB................................................ 40 AstraZeneca ........................................................ 41 beòcarta Ltd....................................................... 248 Biognos AB......................................................... 180 Biotechpharma UAB.......................................... 250 Bluefish Pharmaceuticals AB............................ 115 Cobra Biologics.................................................. 117 CytoVac A/S....................................................... 251 Diamyd Medical AB........................................... 119 ImmuneBiotech AB........................................... 213 Karolinska Development .................................. 124 KOMMUNICERA COMMUNICATIONS...................... 48 Late Phase Solutions Europe AB......................... 50 Linde Healthcare.................................................. 52 Medivir............................................................... 128 ModPro AB......................................................... 129 Niels Clauson-Kaas A/S..................................... 256 Ori Medical......................................................... 221 Pall Norden AB.................................................... 58

Phil Med Alliance AB......................................... 162 PolyPeptide Laboratories (Sweden) AB........... 223 Premune............................................................ 130 Science And Innovation AB............................... 227 TFS Trial Form Support......................................... 68 Truly Translational Sweden AB.......................... 233 Umetrics AB......................................................... 89 Unimedic AB........................................................ 71 Vetter Pharma International............................. 264 Viscogel AB........................................................ 144 Wolfram MathCore .......................................... 165 XSpray Microparticles AB ................................ 146 Zelmic AB........................................................... 235

Pharmacies

Services Labjoy AB........................................................... 216 Late Phase Solutions Europe AB......................... 50 Linde Healthcare.................................................. 52 NDA Group........................................................... 56 Redoxis AB......................................................... 226 SIRION Biotech GmbH........................................ 263 Techtum Lab AB................................................... 87 Thurne Teknik AB............................................... 137 Umetrics AB......................................................... 89 World Courier ..................................................... 72 Xbrane Bioscience AB........................................ 145

Software

LINK arkitektur AB............................................. 127

Elekta AB............................................................ 120 Umetrics AB......................................................... 89

Public Partner Organization

Specialized Transport

Det Medicinska Malmรถ..................................... 207

World Courier ..................................................... 72

Radiation Therapy

Staffing & Recruitment

Elekta AB............................................................ 120 Umeรฅ Care........................................................... 90

Proffice Life Science AB....................................... 60

Radiology

Suppliers & Distributors

Ergolet . ............................................................. 253 New Tools For Health........................................ 160

Aqua Bio Technology ASA................................. 246 CMA Microdialysis AB........................................ 116 Mercan AB.......................................................... 220 Pall Norden AB.................................................... 58 Thurne Teknik AB............................................... 137 Unimedic AB........................................................ 71

Research & Development

Translation Services

Biolink Group AS................................................ 249 Medivir............................................................... 128

KOMMUNICERA COMMUNICATIONS...................... 48

CMIV ................................................................. 158

Rehabilitation

Science Parks Karolinska Institutet Science Park..................... 126 Medeon AB........................................................ 218 Medicon Village AB........................................... 219

Vaccine & Infectious Diseases Abera Bioscience AB.......................................... 106

Visualization CMIV ................................................................. 158

C ateg o r i c al I nd ex 279

d i st r i b u te d f re e of c h a rg e wo r l d w i d e

Profilmanual engelsk log

Hoved font: ITC Av Tilleggsfont: Tele-M

CMYK: 10

Gradient: